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LAY SUMMARY OF THESIS 
The pancreas gland sits behind the stomach and helps with the digestion of food. Acute 
pancreatitis occurs when the pancreas becomes inflamed, usually after irritation by bile stones 
from the gallbladder, or excessive consumption of strong alcohol. It is a common reason to be 
admitted to hospital with abdominal pain. One in five patients will experience a serious attack 
which involves damage to vital organs, characterised by a dangerous response by the body’s 
immune system. The treatment for those with severe pancreatitis usually consists of supportive 
therapy in critical care, with intravenous fluids and strong pain killers, but there is currently no 
specific treatment that can improve the body’s response to pancreatitis. The burden on 
healthcare resources from pancreatitis is substantial and expensive. Despite modern medical 
practice, at least one in twenty patients die from an attack of acute pancreatitis. Those who 
are sickest have been shown to have increased blood levels of a potentially harmful bodily 
chemical called ‘3HK’, which stands for 3-hydroxykynurenine, a breakdown product 
tryptophan, which is an essential dietary nutrient. The chemical 3HK is made by an enzyme 
called ‘KMO’, which stands for kynurenine-3-monooxygenase. 
Before starting my project, our research group discovered that blocking the enzyme 
activity of KMO reduced the harmful effects in a laboratory test model of severe pancreatitis. 
This potential breakthrough had only been studied at an early stage in the disease, and it was 
unknown whether KMO blockade could improve recovery beyond 24 hours, and reduced the 
risk of death.  
My research, therefore, focussed on the early disease recovery phase from 24 hours 
to 7 days. Using experimental models of pancreatitis, I found that artificially increasing blood 
levels of the 3HK increased susceptibility to critical illness but that blocking the KMO enzyme 
which produces 3HK, critical illness could be delayed and potentialy reduced. When working 
with cells in the test tube, bodily inflammation signalling molecules increased cell death when 
tested with 3HK, but not so with other chemicals related to 3HK. This information supports the 
theory that 3HK is most toxic during severe inflammation, such as acute pancreatitis. Together 
these results support the concept that blocking KMO enzyme would reduce the sensitivity of 
bodily vital organs to inflammation in acute pancreatitis and may improve recovery by reducing 
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ABSTRACT OF THESIS 
Acute pancreatitis (AP) is a common inflammatory disease with multiple aetiological 
triggers, most commonly gallstones and alcohol consumption, but with no specific treatment. 
One in four patients with AP develop organ dysfunction, requiring critical care support and 
have a high risk of death. During systemic inflammation, and specifically during AP, there is 
increased flux through the kynurenine pathway of tryptophan metabolism due to induction of 
rate-limiting enzymes by inflammatory mediators, leading to elevated circulating 3-
hydroxykynurenine (3HK) levels. In clinical AP in humans, plasma 3HK levels correlate with 
clinical severity. 3HK is hazardous to many cell types, principally through the generation of 
reactive oxygen species. Production of 3HK can be blocked by inhibiting kynurenine 3-
monooxygenase (KMO), the enzyme which catalyses kynurenine hydroxylation. KMO has a 
prominent role in regulating the systemic inflammatory response during severe AP, but the 
mechanisms that link metabolism through KMO and systemic inflammation have eluded 
discovery, until now.  
In this thesis, I firstly show that the KMO blockade in genetically-altered mice protects 
against critical illness and improves recovery in an experimental model of severe AP. This 
more severe model consisted of 2% sodium taurocholate retrograde ductal infusion along with 
simultaneous implantation of a moderately invasive telemeter device with chest leads, which 
monitored heart rate, locomotor activity and body temperature. The telemetry system was 
required to continuously monitor for clinical signs of recovery and deterioration in this 
potentially lethal model, and because the pancreatic ductal infusion after the device 
implantation would not be technically feasible, the device had to be implanted at the same time 
as pancreatitis induction. I discovered a hepatocyte-restricted role for KMO, where mice 
generated to lack Kmo solely in hepatocytes (Kmoalb-cre) showed elevated plasma kynurenine 
and 3HK levels, reduced 13C6-3-hydroxykynurenine tracer clearance, and transcriptomic 
alterations in key innate immunity pathways in liver tissue, specifically modulating expression 
of canonical toll-like receptor pathway signalling genes. Although Kmoalb-cre mice with elevated 
3HK did not significantly differ in pancreas injury metrics, multiple-organ neutrophilia infiltrate 
or routine biochemistry at an early timepoint (24-hr) using, these mice succumbed fatally earlier 
and more readily to experimental AP over 7-days using a less severe recovery telemetered 
model of AP, thus indicating an impaired recovery and increased susceptibility for critical 
illness. The less severe, recovery model, also utilised 2% sodium taurocholate infusion, but 
the telemeter device was smaller, lighter and faster to implant and only measured locomotor 
activity and temperature. Therapeutically reducing 3HK to undetectable levels through 
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systemic blockade using a highly-specific KMO inhibitor rescued the phenotype, protecting 
against critical illness and early mortality in the 7-day recovery telemetered model of AP. In 
vitro, interleukin-1β was found to synergise with 3HK to cause cellular apoptosis, a mode of 
cell death previously shown to occur in multiple organ failure during experimental severe AP 
by our research group, thereby demonstrating a cytotoxic effect by 3HK and innate immune 
mediators. 
Together, these findings establish the KMO product 3HK as a modulator of innate 
immunity that exhibits a complex interaction with inflammatory cytokines during critical illness 
to promote excess morbidity and death from multiple organ failure that may be rescued by 
systemic KMO blockade.  
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1. INTRODUCTION 
1.1. Acute pancreatitis 
1.1.1. History of the pancreas gland and pancreatitis 
1.1.1.1. Ancient observations of the pancreas 
The term ‘pancreas’, originates from the ancient Greek term ‘πᾶν’ (meaning ‘pan’, or 
‘all’ in English) and κρέας (‘kreas’, or ‘flesh’) meaning ‘all flesh’, on account of the absence of 
hard matter such as bone or cartilage (1, 2). The term was in use during Aristotle’s era (384-
322 B.C.), who referred to the gland as the ‘so-called pancreas’ in his pioneering zoology 
writings ‘Historia Animālium’ (3). The earliest detailed anatomical description of the pancreas 
is attributed to another Greek scholar, the anatomist Herophilus of Chalceodon (c. 335-280 
B.C.), who studied many human and animal organs and is accredited with naming of the 
duodenum which means ‘twelve fingers long’. The pancreas is common to all vertebrates, but 
the form by which it takes in different species is variable, and can consist of anatomically 
separate pancreata. The human pancreas is a relatively distinct elongated gland located in the 
retroperitoneal region of the upper abdomen, with distinct parts referred to as the head, body, 
and tail. The pancreatic head is in direct contact with the duodenum, whilst the tail abuts the 
hilum of the spleen (Figure 1). For centuries after its identification, the functions of the 
pancreas remained mysterious, with theories relating to its proximity to the stomach; as a 
cushion function for the stomach, or that it served to close the pyloric sphincter. 
 
1.1.1.2. Modern-day understanding of the pancreas gland 
Under the microscope, the pancreas can be seen to be structurally arranged into 
distinct lobules composed primarily of the digestive enzyme-producing cells of the exocrine 
pancreas, named ‘acinar cells’; there are also ducts which transmit digestive enzymes into the 
intestines; and distinct clusters of endocrine cells can also be seen, described as ‘islets of 
Langerhans’ (P. Langerhans 1869), that secrete many important hormones including insulin 
by beta cells. The acinar cells produce pancreatic amylase and an array of lipases and 
proteases (4). Pancreatic amylase and lipases and are synthesized as active enzymes which 
catalyse the initial breakdown of carbohydrates and triglycerides, respectively duodenum (5). 
Trypsinogen is the most important of the protease enzymes because of its central role in 
regulating all of the others. There are 3 well defined forms of this enzyme: cationic trypsinogen 
(encoded by PRSS1 gene), anionic trypsinogen (encoded by PRSS2 gene), and 
mesotrypsinogen (encoded by PRSS3 gene) (4). Cationic and anionic trypsinogens are the 
major forms with respect to trypsin activity, and these are co-synthesised with pancreatic 
secretory trypsin inhibitor (PSTI), also known as serine protease inhibitor, Kazal-type 1 
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Figure 1. The human pancreas and its anatomical relations  
The majority of the stomach has been removed in this illustration to give a view of the pancreas gland (centre of 
image). The duodenal loop surrounds the head of the pancreas and the spleen is adjacent to the tail of the 
gland. The gallbladder and the proximal part of the common bile duct can be seen below the liver. The plentiful 
blood supply to the pancreas, spleen and liver is well illustrated in this image from Sabiston Textbook of Surgery, 
20th Edition: Chapter 55 ‘Exocrine pancreas’, Figure 55-1 (5). The image was originally from Netter illustration, 
www.netterimages.com Elsevier Inc. 
 
(SPINK1) (4). Trypsinogens are normally activated in the duodenum thereby producing trypsin, 
a process which was traditionally thought to be performed by enterokinase (also called 
enteropeptidase), but controversy exists (4). Activation occurs by cleavage of the trypsinogen 
activation peptide which then alters the molecular structure and stabilises the trypsin active 
site; a process that is regulated by feedback control mechanisms and biochemical conditions 
- principally pH and [Ca2+] (4). Once activated, trypsin catalyses the activation of protease 
zymogens (i.e. chymotrypsinogen, proelastase, carboxypeptidase) within the duodenum and 
jejunum by engaging its activation site with the zymogen activation peptide sequence (4). 
Pancreatic lipase, more precisely known as pancreatic triglyceride lipase (PTL), is also 
indirectly controlled by trypsin because an enzyme which promotes PTL activity within the 
duodenum, called ‘colipase’, is thought to be secreted as a pro-enzyme and converted by 
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trypsin to its active form in the duodenum. The pancreas also contains connective tissue, 
derived from the embryonic mesenchyme, which forms the septa that separate the many 
lobules of the organ and the gland is surrounded by a very thin connective tissue capsule.  
Acinar cells are pyramidal in shape, which allows them to cluster around drainage acini 
and ducts. The acinar cells are responsible for the synthesis, storage and secretion of 
pancreatic digestive zymogens into the ductal lumen, along with chloride and these cells 
comprise the majority of the pancreas parenchyma (6). Acinar cells have a high secretory 
turnover heavily dependent on mitochondrial production of adenosine triphosphate (ATP). The 
ductal cells produce bicarbonate-rich fluid which help transport the enzymes through the ductal 
system and into the duodenum (5). The primary functions of the pancreatic ductal cells are to 
provide the water (H2O) and electrolytes, including bicarbonate (HCO3-), required to dilute the 
pancreatic digestive enzymes and deliver these into the duodenum (5). Intracellular carbonic 
anhydrase catalyses the conversion of H2O and CO2 into HCO3- and H+ within pancreatic ductal 
cells, and from the apical membrane of the ductal cells HCO3- is secreted into the ductal lumen 
(5). The delivery of bicarbonate into the duodenum is important for neutralisation of 
hydrochloric acid secreted by gastric parietal cells, because the pancreatic digestive enzymes 
require an alkaline environment for catalytic activity (5). The complex neurohormonal 
mechanisms which control activity of the exocrine pancreas starts with the cephalic phase, 
whereby upon sight and smell of food the brainstem stimulates the pancreas to secrete, which 
is followed by stimuli from gastric distension and duodenal stimulation from secretin and 
cholecystokinin release. 
 
1.1.1.3. Historical descriptions of the inflamed pancreas 
The earliest surviving description of an acutely inflamed pancreas is often attributed to 
a Huguenot doctor, Iacobo A Vindone, who when living in Basel, Switzerland in 1579 reported 
his post-mortem findings in an alcoholic with pancreatic necrosis (7). Much later, the famous 
Dutch surgeon, anatomist, writer and politician, Nicolaes P Tulp, published in 1652 in his 
‘Observationes medicae’ a clinicopathological report of a pancreatic abscess (7). In 1815, G 
Fleischmann reported his autopsy findings linking pancreatitis and alcohol. In 1887, Reginald 
Fitz from Boston, USA delivered a lecture reporting the systematic review of 53 patients with 
pathologically documented acute pancreatitis, entitled “A consideration of Pancreatic 
Hemorrhage, Hemorrhagic, Suppurative, and Gangrenous Pancreatitis, and of Disseminated 
Fat-Necrosis” (2). W. Korte (1899), was the first to consider gallstones as a trigger of 
pancreatitis, although EL Opie (1901), a pathologist at Johns Hopkins Hospital in Baltimore, 
proposed the that reflux of bile into the pancreatic duct induced AP (7). 
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1.1.2. Pathobiology of acute pancreatitis (AP) 
Investigation into the initial molecular events which lead to human AP is inherently 
problematic, but nonetheless several noteworthy discoveries have been made. Evidence of 
pathological events are based upon data derived from in-vitro cell-based studies (mostly 
investigating acinar physiological mechanisms), models of the disease in laboratory animals 
(mostly rodents), which are informed by clinical observations. 
 
1.1.2.1. Experimental AP 
The four most frequently used acute pancreatitis model-types in rodents comprise: i) 
secretagogue hyperstimulation; ii) retrograde pancreatic ductal infusion; iii) nutrient-induced 
pancreatitis and; iv) the amino acid induction models (e.g. L-arginine) (8-10). The intra-ductal 
infusion models commonly consist of a dilute bile acid infusate containing taurolithocholate, 
taurodeoxycholate or taurocholate (11-14). The commonly utilised experimental models of AP 
are listed in Table 1. The choice of AP model for any given study will not only depend on 
scientific issues, but any given laboratory group may have preferences influenced on prior 
experience and indeed by animal licencing regulations. The severity of each model can be 
quite variable depending on the animal species used, any genetic alteration in the host animal, 
the dosing protocol and the use of adjunct sensitizer treatments. There is a catalogue of 
genetically engineered mouse models which can produce inflammatory changes targeted to 
the pancreas, using various genetic engineering systems, but which lack the systemic 
proinflammatory effects that are more commonly seen in the above four listed AP model-types 
(15). With the retrograde pancreatic ductal infusion models, increased concentrations of 
 




Cerulein injections (CCK analogue) +/- 
alcohol, LPS, obesity, GDOC, duct 
obstruction 
Mild to lethal depending on 
cerulein and sensitizer dosing (16) 
Bile acid infusion of 
pancreatic duct 
Glycodeoxycholic acid (GDOC) 
Sodium taurocholic acid (NaTCA) Potentially lethal* (11-14, 17) 
Diet-induced AP Choline-deficient ethionine (CDE) diet Potentially lethal* (17) 
Amino acid-induced AP L-arginine, L-lysine, L-ornithine Potentially lethal* (9, 10) 
Pancreatic duct obstruction 
+/- secretagogue 
Ligation of common biliopancreatic duct 
+/- caerulin 
Mild to moderate - variable 
due to species used & duration 
of ligation 
(17) 
Table 1: Commonly used experimental AP rodent models 
*potentially lethal at high doses. 
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infused bile acids and flow rates are associated with increased pancreatic and extra-pancreatic 
organ injury which can produce severe disease with multiple-organ injury and lethality. Given 
Professor Mole group’s considerable experience with the intraductal infusion model, with its 
capacity to induce extra-pancreatic organ injury but with the option to adjust the severity of the 
model, this was the chosen model for my work. 
 
1.1.2.2. Acinar cell events in physiology and disease 
During the past half-century, many fascinating discoveries have been made which give 
mechanistic insights into the physiological workings of the pancreas. Whilst pancreatic ductal 
cells have a recognised contributory role in AP (see Hegyi et al. (6)), here I focus upon the 
acinar cells, as these are the dominant cell-type in the pathogenesis of AP. 
 
1.1.2.2.1. Acinar cell physiology 
Other than the transport of chloride into the ductal system, the biological activity of 
acinar cells is to synthesise and secrete digestive enzymes and pro-enzymes. In eukaryotic 
cells, exocytosis is generally activated by a spike in cytosolic Ca2+ concentrations ([Ca2+]i). 
Because pancreatic acinar cells do not possess voltage-gated plasma membrane channels, 
such as those on neural and endocrine cells, the large and rapid Ca2+ cytosolic concentration 
spikes required for stimulus-secretion coupling is mostly delivered from cytoplasmic Ca2+ 
storage compartments (Figure 2). Additionally, one research group have recently reported 
their novel and very interesting findings of a plasma membrane mechanoreceptor, Piezo1, 
which upon mechanical stimulation forms a pore that facilitates acinar cell Ca2+ influx (18). The 
initial stimulatory response spike in [Ca2+]i is independent of extracellular Ca2+, but as 
intracellular stores are depleted, and cytosolic Ca2+ having been extruded (in order to avoid 
cytotoxic levels) extracellular Ca2+ supply becomes increasingly critical in order to sustain 
secretion (19). Acinar cells have a special type of store-operated channel (SOC) called a Ca2+ 
release-activated Ca2+ (CRAC) channel which allows Ca2+ entry into the cells to replenish 
cytoplasmic stores (20). [Ca2+]i also regulates chloride channel opening and repeated Ca2+ 
spikes are important for efficient mitochondrial generation of ATP (21). Both chloride transport 
and zymogen granule exocytosis occur through the apical plasma membrane where they are 
secreted into the acinar lumen and ductal system. 
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Figure 2: Overview of calcium signalling in pancreatic acinar cells  
Movement of Ca2+ is indicated by dotted arrows. Abbreviations: ACh: acetylcholine; ADP: adenosine 
diphosphate; ATPase: adenosine triphosphate; CCK1R: cholecystokinin 1A receptor; CRAC: Ca2+ release-
activated Ca2+; mAChR: muscarinic acetylcholine receptor; PLC: phospholipase C; PMCA: plasma membrane 
Ca2+-activated ATPase. Copyright © 2020 AJ Hayes. 
 
The main site of cytoplasmic Ca2+ storage is the endoplasmic reticulum (ER), but other 
organelles, such as zymogen granules (ZGs), also contribute Ca2+ to the cytosol (Figure 2) 
(22). Although the ER is mostly located in the basolateral area of the acinar cells, it has long, 
thin extensions which extend into apex where the secretory ZGs are located. There are two 
well characterised Ca2+ channels which mediate Ca2+ release from cytoplasmic stores (e.g. 
ER) into the apical area of the acinar cell – inositol triphosphate receptor (IP3R) (23) and the 
ryanodine receptor (RYR) channel (24). Nicotinic acid adenine dinucleotide phosphate 
(NAADP) from NADP and cyclic ADP-ribose (cADPR) from NAD activate RYR channels, and 
this is typically initiated by the hormone cholecystokinin binding the CCK1 receptor on the 
acinar plasma membrane (25). Inositol triphosphate (IP3) is a water-soluble messenger 
compound generated by receptor-activated phospholipase C that binds the IP3R, and this is 
typically initiated by the neurotransmitter acetylcholine (ACh), from vagal stimulation, which 
binds the plasma membrane muscarinic ACh receptor (23, 26). 
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Acinar cells contain high numbers of mitochondria, which supply ATP for critical 
functions including secretory processes and for the plasma membrane Ca2+-activated ATPase 
(PMCA) pumps which allow acinar cells to extrude toxic levels of Ca2+. Importantly, acinar 
mitochondria are distributed in a very specific ‘belt-like’ manner that creates a diffusion barrier 
between the apex where the cytosolic Ca2+ concentrates spike, and the basal part of the cell 
that contains the nucleus. Another noteworthy factor which protects against cytotoxic Ca2+ 
levels is Calmodulin, which is a protein that binds calcium and organelle release of Ca2+ 
through its inhibitor effect on calcium releasing channel, the aforementioned IP3R (20, 26, 27). 
The human pancreas secretes three isoforms of trypsinogen, encoded by the serine 
protease (PRSS) genes 1, 2 and 3 (28). Trypsinogen is normally inactive until it is cleaved by 
enterokinase in the intestinal lumen to make active trypsin in the duodenum by proteolysis of 
its 8 amino acid-long N-terminal activation peptide (29). Acinar cells have a number of inbuilt 
protective mechanisms to avoid excessive intracellular trypsin activity; namely: i) Synthesis of 
trypsin in the inactivated form (trypsinogen); ii) Compartmentalisation of trypsinogen in 
zymogen granules (ZGs); iii) Autolysis of activated trypsin; iv) Synthesis of specific trypsin 
inhibitors which delay trypsinogen autoactivation (e.g. serine protease inhibitor Kazal type 1: 
encoded by SPINK1 gene) or can catalyse trypsinogen breakdown (e.g. chymotrypsin C) (29); 
and v) Prevention of globally elevated cytosolic Ca2+ concentrations which promote 
trypsinogen activation. The second of these, isolation of trypsinogen in ZGs, protects 
trypsinogen from Cathepsin B which is a lysosomal enzyme that can activate trypsinogen to 
trypsin (30). With respect to iv), active chymotrypsin C (CTRC) (activated by trypsin from 
chymotrypsinogen C) and trypsin can act in concert to irreversibly degrade trypsinogen thereby 
mitigating the development of trypsin activity, but paradoxically they can both also activate 
trypsinogen to trypsin depending on the particular peptide bonds which are cleaved (29, 31). 
 
1.1.2.2.2. Acinar cell injury 
Before considering the he earliest molecular events that are specific to various 
aetiologies, it is helpful to review the core biological acinar features which appear to be 
common to all initiating causes of AP. There are three key pancreatic acinar cell mechanisms 
implicated in the pathogenesis of AP, which consist of: 
i) Abnormal elevations in cytosolic Ca2+ concentrations 
ii) Mitochondrial dysfunction 
iii) Intra-acinar conversion of digestive proteases from inactive zymogens into their active 
forms (32, 33). 
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As discussed above (1.1.2.2.1.), spikes in the concentrations of cytosolic Ca2+ within 
the apical area of the acinar cell are physiological, but Ca2+ overload results in cellular 
dysfunction which may lead to cell death. The generation of excessive [Ca2+]i signalling has 
been shown to be elicited by unphysiologically elevated concentrations of ACh or CCK, by 
long-chain fatty acids (FAs) or fatty acid ethyl esters (FAEEs), or by bile acids (34). The central 
importance of Ca2+ in the pathogenesis of AP has been demonstrated by treatment with a 
selective Ca2+ chelator agent which prevents many of the features of AP (26, 35-38). 
Additionally, pharmacological inhibition of plasma membrane Ca2+ entry channel, CRAC, has 
been demonstrated to be cytoprotective for acinar cells exposed to experimental AP stimuli 
(39). Mitochondrial Ca2+ overload reduces ATP production, the energy substrate for Ca2+ pump 
activity at the ER and plasma membrane (i.e. PMCA pumps), thereby disarming the protective 
defences and further elevating [Ca2+]i (6). The vicious cycle of increasing [Ca2+]i leads to acinar 
cell toxicity, large endocytic vacuolization, intracellular trypsinogen activation and cell necrosis 
(6, 32). 
Secondly, mitochondria play at least 2 vital physiological roles for the acinar cells 
(detailed in 1.1.2.2.1.); i) The biosynthesis of ATP and ii) As a chain, the mitochondria act as 
a Ca2+ diffusion barrier ‘fire-wall’ preventing cytotoxic global cytoplasmic elevations in Ca2+. A 
non-specific mitochondrial channel that traverses the outer and inner mitochondrial 
membranes, called the mitochondrial permeability transition pore (MPTP), is known to open 
during high [Ca2+]i, especially when accompanied by oxidative stress, which causes loss of 
mitochondrial membrane potential, termed ‘depolarisation’, which causes ATP depletion and 
necrosis (33, 40-43) . MPTP opening promotes cleavage of phosphoglycerate mutase family 
member 5 (PGAM5) from the inner mitochondrial membrane which also activates necrosis 
(40). Additionally, a heme protein normally located between the inner and outer mitochondrial 
membranes that functions in the electron transport chain, called Cytochrome c, is also released 
in response to elevated [Ca2+]i and activates a series of caspases which induce apoptosis. 
MPTP inhibitors such as cyclosporin A, are able to prevent cytochrome c release thus inhibiting 
caspase activation and apoptosis (44). 
Cyclophilin D is a mitochondria-specific peptidyl-prolyl isomerase plays a negative role 
in the production and efficient transmission of mitochondrial energy to the cytoplasm, though 
a number of mechanisms, including MPTP regulation (45, 46). Although mitochondrial 
dysfunction results from unphysiologically elevated [Ca2+]i, this is not the sole mechanism in 
AP, however, and cyclophilin D is another important factor. The formation of a complex 
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between cyclophilin D and ATP synthase, a mechanism that does not require [Ca2+] overload, 
has also been observed in AP (47). Impaired autophagy, endoplasmic reticulum (ER) stress 
and deregulated acinar lipid metabolism which are all found in acinar cells in AP are all 
mediated by mitochondrial dysfunction and can be normalised by cyclophilin D knockout (47). 
Cyclophilin D inhibitors have shown promise as a potential pancreatitis drug target to reduce 
acinar cell damage by mitochondrial protection (40, 46). Trypsin-mediated trypsinogen 
activation within the pancreas is referred to as ‘autoactivation’ and increases acinar trypsin 
activity. Inappropriately high levels of trypsinogen autoactivation within the acinar cell can 
precipitate activation of several enzyme types, as well as the complement and kinin pathways, 
resulting localised acute inflammatory changes (48). Intra-pancreatic trypsin activity is highly 
regulated and failure of the various protective mechanisms contribute of the development of 
AP.  
Starting with trypsinogen, the strongest disease-causing mutations are in the cationic 
trypsinogen gene (PRSS1) and are more typically associated with chronic pancreatitis than 
AP, as autosomal dominant hereditary pancreatitis (28, 49). Briefly, functional mutations in 
PRSS1 are known to give rise to acinar cell injury and pancreatitis by increasing intracellular 
trypsin activity in 3 ways (Table 2). In light of CTRC’s important role in trypsin activity 
regulation, it is not surprising that loss-of-function CTRC gene mutations may increase risk of 
pancreatic inflammation (52). Such mutations have one of three functional defects in CTRC 
activity: i) impaired CTRC protein secretion (and causing ER stress); ii) impaired catalytic 
activity; and iii) impaired proteolytic stability (50). The CTRC-independent mechanism was 
discovered most recently, and has been re-created as a genetically-altered mouse model with 
mutant D23A of the murine T7 gene, which is analogous to the D22G mutation in human 
PRSS1 (51). Although trypsinogen-trypsin dynamics are more relevant to chronic AP, there is 
likely a contributory role in acute inflammation given that protection is observed in experim- 
 
Primary 
mechanism CTRC Effect of mutations Mutant examples* Refs. 
Increase 
trypsinogen Involved 
Block CTRC-dependent trypsinogen 
degradation 
N29I, N29T, V39A, 
R112C, R122H (31) 
Increase trypsin Involved 
Increase autoactivation by CTRC-
mediated cleavage of the trypsinogen 
activation peptide (at the N terminus) 
A16V, N29I (31, 51) 
Increase trypsin Independent Directly stimulate autoactivation independent of CTRC 
D19A, D20A, D22G, 
K23R (52) 
Table 2: Functional genetic mutations in PRSS1 which increase trypsin activity 
*human mutations 
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-ental AP with absent trypsinogen isoform-7 gene (mouse cationic trypsinogen) from 
supramaximal caerulein-induced acinar injury (53). SPINK1 binds trypsin and thereby prevents 
the latter from interacting and potentially activating further trypsinogen (although trypsin also 
contributes to trypsinogen degradation). Trypsinogen autoactivation is thereby delayed until 
the SPINK1 is saturated and newly formed trypsin is free to potentially autoactivate 
trypsinogen. Functional mutations in the SPINK1 gene have also been found to impair SP|NK1 
function leading to increased intra-acinar trypsin activity and such mutations are well known 
for their prevalence in hereditary forms of chronic pancreatitis (see section 1.1.4.3.) 
Additionally, impaired autophagy, ER stress and dysregulated acinar cell lipid 
metabolism are also known to contribute to acinar cell stress and promote the three key 
pathological hallmarks described above (47, 54). Beyond these recognised acinar hallmarks, 
other harmful features have been observed in AP, most notably the autodigestive dysfunctional 
processing of secretory granules with the release of endocytic vacuole content into the cytosol 
or abnormal basolateral membrane exocytosis (into the gland!), as opposed to physiological 
secretion through the apical membrane and onwards into the ducts and duodenum (55). 
 
 
1.1.3. Epidemiology and demographics of acute pancreatitis 
The estimated worldwide incidence of acute pancreatitis (AP) has been calculated to 
be 34 cases [95% confidence interval (CI) 23-49] per 100,000 general population per year (56). 
The disease predominantly affects middle-aged or older people. Amongst children, the 
incidence stands at 3-13 cases per 100,000 population per year (57). Pooled analyses of global 
data found equivalent incidence of AP between adult men and women (56). However, with 
increase age, there is an increasing preponderance towards males (58). Across the globe 
differences exist in regard to incidence of AP, with North America and Western Pacific regions 
having a higher incidence (58). Europe has a relatively low incidence (29 cases per 100,000 
general population per year), but Northern and Eastern parts of Europe have higher rates (58). 
In the United Kingdom, the reported incidence of AP has ranged from 5 to 42 cases per 
100,000 general population, and has been slowly increasing over recent decades (59-62). 
Similar to other countries, the overall gender distribution for AP is approximately equal (47% 
female) in Scotland, but there is slight male preponderance for those with severe AP (63). As 
with other diseases provoked by an array of inducers, the population’s epidemiological 
characteristics are defined by the aetiological factors (63). 
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1.1.4. Aetiology of acute pancreatitis 
There are great number of published clinical reports that allege possible causes of AP. 
The identification and isolation of aetiology, particularly in humans, has many challenges and 
studies often have many limitations. Moreover, the distinction between inducers of AP, as 
opposed to risk factors becomes increasingly less distinct where aetiological factors are rare. 
A mnemonic frequently cited in undergraduate textbooks (e.g. The Oxford Handbook of Clinical 
Medicine, 5th edition) or other educational materials which serves as memory-recall aid for the 
aetiological factors in AP is ‘I GET SMASHED’. I have adopted this mnemonic here for two 
reasons. Primarily it is easily remembered, and will best help the reader recall the details which 
follow. Secondly, I have used this mnemonic in a modified fashion, with the addition ‘& Smoke’ 
(Table 3) to underline the contribution of cigarette smoking as a modifiable aetiological factor 
for recurrent AP, and the synergistic effect between smoking and alcohol for non-gallstone AP. 
Prior to reviewing the individual aetiological factors sequentially using the mnemonic as a 
framework, the descriptive epidemiological factors (i.e. age, sex, ethnicity and geographical 





G: Gallstones (especially calculi £ 5 mm) & Genetic mutations (64) 
E: Ethanol/ alcohol (especially spirits) (65) 
T: Trauma (66) & obstructing Tumours of the pancreas 
 
S: Surgery & Steroids (67) 
M: Mumps & other infectious triggers (68-70) 
A: Autoimmune 
S: Scorpion stings 
H: Hypercalcaemia / Hyperlipidaemia (metabolic) (71) 
E: ERCP-induced pancreatitis 
D: Drug side-effect (69, 70, 72) 
& 
Smoke (duration of cigarette smoking associated with increased non-gallstone AP risk) (73) 
Table 3. Aetiology of acute pancreatitis – I GET SMASHED & Smoke 
A popular mnemonic often cited in undergraduate textbooks (e.g. The Oxford Handbook of Clinical Medicine, 5th 
Edition; pg 466) to recall the causes of acute pancreatitis is ‘I GET SMASHED’. This is extend here to include ‘& 
Smoke’ to highlight the aetiological importance of cigarette smoking with regards to AP, recurrent AP and chronic 
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1.1.4.1. Descriptive epidemiology of AP 
In adult populations, the most frequent triggers of AP are gallstones or alcohol 
consumption, whilst amongst children non-malignant biliary tract diseases are the most 
frequent cause of AP, accounting for ~1/3rd of cases (57, 75). Unlike adults, alcohol is rarely 
reported as a trigger in paediatrics (57, 75). Blunt abdominal trauma, systemic diseases (e.g. 
autoimmune), infections, drugs, and genetic causes are other frequent causes within the 
paediatric population which are described in the relevant sections below (57).  
Most studies report an increased proportion of gallstone aetiology amongst females, 
and a higher proportion of alcohol-related AP amongst males (63, 76). Females also appear 
to be at slightly increased risk of AP after ERCP compared to males (77). There does not 
appear to be sex preponderance in drug-induced AP or genetic causes (78). However, primary 
hyperparathyroidism (pHPT) is more prevalent amongst females, and there is considerable 
evidence that pHPT is a risk factor for AP (79). 
With regards to ethnicity, a large (n = 70,231 hospitalised AP patients) observational 
epidemiological study from California, USA showed statistically significant differences between 
ethnic groups (76). After data standardisation, African Americans had a higher incidence of 
alcohol-related AP, and a lower biliary AP rate compared to white Americans (76). Asians had 
a very low standardized incidence rate of alcohol-related AP, and Hispanics had the highest 
rates of biliary AP (76). 
Geographical differences in AP aetiology relate to complex interactions between many 
aetiological factors including population demographics, alcohol consumption, ethnicity, 
immunisation programs (e.g. Mumps), and local prevalence of AP-related infectious diseases 
(particularly parasitic causes) (68, 80). Limitations in access to diagnostic services, such as 
radiological and endoscopic ultrasound technologies, in some parts of the world likely bias the 
aetiological classifications reported.  
 
1.1.4.2. Gallstone-related AP 
Across Europe, ~10% adult males and ~20% adult females have calculi in the 
gallbladder or biliary tract (81). For those with asymptomatic gallstones, it has been estimated 
that over a 30-year period, the risk of biliary pancreatitis would be no more than 2% (82). The 
prevalence of gallstones increases with age, and is higher in women than in men across all 
age groups (81). There are many recognised risk factors for gallstone disease besides sex 
and ethnicity, include genetic risk factors, metabolic syndrome, physical inactivity, rapid weight 
loss, dietary factors, gallbladder hypomotility, drugs, liver cirrhosis, Crohn’s disease (81, 83). 
The accessibly of surgical services to removal of the gallbladder (cholecystectomy) or 
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endoscopically extract ductal stones by endoscopic retrograde cholangiopancreatography 
(ERCP), is an important factor for reducing the incidence of biliary AP, particularly rates of 
recurrent biliary AP. Gallstones may be asymptomatic but can be complicated by biliary colic, 
cholecystitis, jaundice and AP. Despite the higher female : male ratio of gallstone prevalence 
(~2-fold), the rate of biliary pancreatitis amongst patients at risk of biliary pancreatitis (i.e. non-
cholecystectomy cohort with gallstones) was 20% higher for males than females (82). Small 
gallstones (i.e. <5 mm) pose an increased risk of AP (84), as large stones which form within 
the gallbladder may be too big to pass through the cystic duct and into the common bile duct. 
Reported in 1974, Acosta et al. tested his hypothesis that calculi migrating through the ampulla 
induced AP by systematically examining the faeces of AP and acute biliary patients, looking 
for gallstones (85). 34 pancreatitis patients had faecal gallstones (94%), as compared to only 
three biliary controls (8%) (85). The proportion of AP cases attributable to gallstones reported 
in European national studies has been just less than half of all pancreatitis patients (44% in 
Sweden, Hungary and Scotland) (63, 65, 86). Large-scale AP studies often do not specify what 
proportion of gallstone-related pancreatitis patients were or were not induced by ERCP, which 
is a well-recognised complication of the procedure. AP complicates 5-10% of ERCP 
procedures, but there are recognised risk factors related to the procedure or patient, such as 
difficult cannulation, multiple injections; patients who are young, female or have previously had 
pancreatitis (8, 87). 
It is widely accepted that biliary pancreatitis is initiated by the migration of stones 
through the ampulla of Vater (85), but the underlying mechanism has been heavily debated. 
Since the presence and passage of bile duct stones, without pancreatitis, is not an uncommon 
clinical situation there must be specific requirements, or additional factors, necessary to 
potentiate acinar cell injury sufficient to cause clinical pancreatitis (e.g. stone/duct features, 
duct occlusion time, sphincter of Oddi function, pancreas health, smoking etc). The three 
configurations by which a migrating gallstone could theoretically induce pancreatic injury are 
well-illustrated in a review by Lerch and Gorelick (reproduced in Figure 3) which shows:  
A. Isolated pancreatic duct obstruction  
B. Common channel theory 
C. Dual ductal obstruction (9) 
It has been shown that in addition to passive diffusion, bile acids can be taken up by 
acinar cells via bile acid transporters or G-protein-coupled, cell surface bile acid receptor 
(Gpbar1) (88). With the presumption that refluxing bile acids reach the ductal and acinar cells, 
investigators have reported several interesting mechanisms demonstrating how bile-acids can  
Metabolic regulators of inflammation in acute pancreatitis                                                         S0897427 
Alastair J Hayes 
  - 14 -  
 
induce pancreatic cellular damage (6). Low dose 
luminal administration of bile acids can stimulate a 
protective bicarbonate and fluid secretion effect, which 
is calcium dependent (38). High concentrations of 
luminal bile acid inhibit ductal secretion and induce 
toxic elevations in Ca2+ concentrations (38). On 
reaching acinar cells, bile acids mobilise Ca2+ from 
endoplasmic reticulum (36, 90), and apical acidic Ca2+ 
stores (91) increasing cytosolic Ca2+ concentrations.  
There are notable objections to the simplistic 
assertion that contaminating biliary reflux up the 
pancreatic ductal system induces pancreatitis when 
considering the real-life human situation. Specifically, 
because the pancreatic secretory pressure is 
physiologically higher than that of the bile duct, 
pancreatic secretions would preferentially enter the 
biliary tree, and not the other way around, at least for 
the first few hours after ampullary obstruction should a 
common biliopancreatic channel exist (92, 93). 
Any bile that would enter the pancreatic ductal 
tree must overcome the stimulatory ‘flushing away’ 
effect which bile acids are known to induce in ductal 
cells (at low but not high concentrations) (38), before 
the bile acids can reach the acinar cells (6, 11). It has 
been shown that elevated pancreatic ductal pressures 
can cause upstream impaired acinar cell zymogen 
granule exocytosis resulting in granules to coalesce 
with intracellular lysosomes resulting in autodigestive 
pancreatic injury (94). After prolonged obstruction at 
the ampulla, pancreatic ductal pressures begin to fall 
and by 24 hours may be equivalent to biliary 
pressures. By which time, the obstructed bile-
pancreatic juice mixture may become activated (i.e. 
bile salts activation of trypsinogen) with enhanced toxicity to the pancreas (93). 
 
 
Figure 3. Theoretical mechanisms by 
which gallstone migration might induce 
acute pancreatitis  
A) Pancreatic duct outflow obstruction.  
B) Common channel theory with a channel 
between the common bile duct and the 
pancreatic duct.  
C) Calculus obstructing both ducts.  
The literature favours theories A & C, as 
there is compelling evidence that 
undermines the requirement for a common 
channel as shown in B. Figure is from 
Lerch and Gorelick Gastroenterology, 2013 
[Figure 4] (89). 
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1.1.4.3. Genetic-related AP 
Known genetic mutations which increase the rise of pancreatitis arise in genes which 
code for digestive proteases or trypsin inhibitor proteins. Patients with such mutations typically 
present to paediatric services with early onset of recurrent AP which progress to chronic 
pancreatitis by adulthood. Genetic mutations in PRSS1 gene have been discussed in relation 
to acinar cell physiology and give rise to increased intracellular trypsin activity by impaired 
trypsinogen degradation, or increased trypsin formation by CTRC-dependent, or (rarely) by 
CTRC-independent mechanisms (see section 2.2.1.1.1. and Table 2) (29, 31). The clinically 
most frequent mutations involve R122H (~70%), and N291 (~20%) sites (31). Such mutations 
have a high penetrance, of up to 80%, and are associated with recurrent AP from a young age 
(31, 95). Additionally, a genome-wide association study (GWAS) found that two common 
genetic variants in PRSS1, at CLDN2 and PRSS1-PRSS2 loci, significantly increase the risk 
for alcohol-related pancreatitis (96).  
Unlike PRSS1 mutations, known functional mutations in the CTRC gene are all loss-
of-function in nature. CTRC mutations are classified as impairing either secretion, catalytic 
activity, or proteolytic stability (29). These were also discussed in some detail above (section 
2.2.1.1.1.), and are of particular relevance to chronic pancreatitis. Mutations in CTRC alone 
are not thought to be sufficient to cause pancreatitic inflammation without additional genetic 
predisposition or other risk factors (97).  
During inflammation of the pancreas, SPINK1 gene expression is increased to 
minimize the presence of active trypsin (97). Therefore, loss-of-function mutations in SPINK1 
reduce the effectiveness of this protective mechanism increasing susceptibility to recurrent AP 
and progression to chronic pancreatitis (97). Indeed, mutations in SPINK1 (typically N34S, 
which is common, affecting ~2% of people in populations across the world) can present with 
AP, but similar to PRSS1- and CTRC-related AP, cases present at a young age (median ~20 
yrs old in SPINK1) (97, 98). SPINK1 mutations are not a risk factor for an initial attack of AP, 
and it is very infrequently associated with organ failure, however, it is strongly associated with 
recurrent AP (Odds ratio = 19) (98, 99).  
Cystic fibrosis transmembrane conductance regulator (CFTR) is a cyclic adenosine 
monophosphate-regulated chloride-bicarbonate channel which is localised to the apical 
plasma membrane of epithelial cells such as pancreatic ductal cells (100). CFTR gene 
mutations disrupt activity of the channel with variable phenotypes. Such mutations are typically 
associated with chronic pancreatitis. Lastly, mutations in the calcium-sensing receptor gene, 
CASR, are rare and are more typically related to chronic pancreatitis (100). 
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1.1.4.4. Ethanol / Alcohol-related AP 
Alcohol consumption behaviour varies widely across the world for cultural, religious, 
and socioeconomic reasons, as well as reasons related to farming and production. Considering 
that heavy alcohol consumption (e.g. >60 g/day) is far more common in any given population 
than the incidence of alcohol-related AP, with <10% of heavy drinkers developing clinically 
relevant AP, this suggests that there are undetermined environmental or genetic factors which 
may be protective for many heavy drinkers, or else factors which increase susceptibility for the 
subgroup who develop alcoholic pancreatitis (33, 101). Indeed, as mentioned above (section 
1.1.4.3.), a recent GWAS study found two common genetic variants in PRSS1 gene to 
significantly increase the risk for alcohol-related pancreatitis (96). It is important, therefore, not 
to overlook other causes of AP simply because a patient consumes alcohol (102). Different 
types of alcoholic drink are likely to differ with respect to pancreas toxicity, as the risk of AP is 
increased by the amount of spirits consumed on single occasion (65). The amount of wine, 
beer or average amount of monthly alcohol ingestion was not significant (65). Smoking is 
associated with a younger age of first episode of AP in both alcohol drinkers and non-alcohol 
drinkers, and is associated with recurrence of non-gallstone-related AP (73, 103). 
The main difficulty in studying the underlying mechanisms of alcohol-induced 
pancreatitis in rodents has been that alcohol consumption alone (i.e. alcohol diet +/- gastric 
infusion) does not reliably cause AP (8). This has been the experience of researchers using 
wildtype mice, but genetically altered mice [e.g. nuclear factor erythroid 2 like factor 2 (NRF2) 
gene knockout mice] have been shown to develop pancreatic (and liver) injury with alcohol 
ingestion (104).  
Researchers have found that chronic alcohol ingestion primes the rodent pancreas to 
sensitizer co-treatments (e.g. cholecystokinin analogue cerulein) which can be given at very 
low, physiological doses to induce AP (8). Lipopolysaccharide (LPS) is a component of the 
gram-negative bacterial cell membrane which can induce AP when co-administered to rats 
with prolonged ethanol feeding (8). Because alcohol is known to increase gut permeability, 
and increased serum LPS levels are found in humans with high chronic alcohol consumption 
due to translocation of enteric gram-negative bacteria, this is a clinically relevant model (105). 
Furthermore, gut barrier failure has been observed in experimental AP, with increased gut 
mucus oxidative stress which is thought to promote the development of multiple organ failure 
(106). 
Alcohol is metabolised by both oxidative and non-oxidative pathways in humans and 
rodents (107). With oxidative metabolism, ethanol is converted to acetaldehyde and acetate, 
principally by alcohol dehydrogenase and also by cytochrome P450 family 2 subtype E 
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member 1 (CYP2E1), with generation of reactive oxygen species as a by-product which can 
cause oxidant stress. Fatty acid ethyl esters (FAEEs) are formed by non-oxidative metabolism, 
the products of alcohol and fatty acids catalysed by fatty acid ethyl ester synthases (FAEE 
synthases) (107). Oxidative metabolism of ethanol mostly occurs in the liver, and in the 
pancreas metabolism is dominantly by non-oxidative pathways (6, 107). The toxic effects of 
FAEEs on pancreatic acinar cells include toxic Ca2+ signalling, mitochondrial dysfunction, 
trypsinogen activation, induction of transcription factors nuclear factor kappa B (NF-κB) and 
activator protein 1 (AP-1), leading to apoptosis and necrosis (22, 107-111). Additionally, 
alcohol has harmful effects upon ductal and pancreatic stellate cells (94). 
 
1.1.4.5. Trauma- and Tumour-related AP 
Injuries to the pancreas following abdominal trauma are relatively rare, particularly after 
blunt injury, but are more frequent with penetrating injuries. Elevations in serum amylase after 
major trauma, however, are relatively common, particularly involving severe craniofacial 
injuries due to circulating salivary gland-type α-amylase. In abdominal trauma specifically, 
hyperamylasaemia is associated with pancreatic injuries and can serve as a screening test, 
particularly in children where a large radiation dose from CT scanning may seem unjustifiable. 
However, hyperamylasaemia can also result from an injury to the small bowel due to systemic 
absorption of α-amylase from an intestinal perforation (112). Additionally, hyperamylasaemia 
has been found to be unreliable in excluding pancreatic injuries within 6-hrs from the time injury 
(112). Therefore, considered interpretation of amylase results in trauma patients is required in 
light of the pancreatic specificity of the α-amylase assay, the injury pattern and the time interval 
since the injury. Pancreatic trauma is associated with significant morbidity and mortality 
particularly especially when the duct is damaged (AAST grades III to V), and the American 
Association for the Surgery of Trauma (AAST) have produced a pancreatic injury grading 
system which guides assessment (by CT/MRI, ERCP or operative), management, 
prognostication and trauma research (113, 114). Besides the in increasingly severe grades of 
haematoma and laceration describe by AAST with gland injury, abdominal trauma can also 
induce acute pancreatitis which is thought result from ischaemia or activation of acinar cell 
mechanical stress sensors, Piezo1 ion channels, which are described in more detail in the 
above section ‘acinar cell physiology’ (see 1.1.2.2.1) (18). Whilst some classifications 
incorporate post-ERCP pancreatitis within ‘trauma’, it is addressed separately bellow (see 
1.1.4.11). 
The other ‘T’ in this mnemonic represents pancreaticobiliary ‘Tumours’. It is thought 
that AP arises in these patients because of elevated ductal pressures resulting from 
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obstructing. It has been estimated that 5-14% of patients with pancreaticobiliary mass lesions 
(malignant or benign) present with idiopathic AP (115). For this reason, it has been 
recommended that a pancreaticobiliary mass be excluded in any patient over 40 years old with 
idiopathic AP by contrast-enhanced CT, MRI or endoscopic ultrasound (115). 
 
1.1.4.6. Surgery- and Steroid-related AP 
Following on from pancreatic tumours is major ‘Surgery’. Indeed, the most frequently 
cited surgical inducer of AP has been surgery pancreatic surgery, which can be understood in 
mechanistic terms when considering the tissue damage and ischaemia involved, and activation 
of the acinar cell mechanoreceptors, Piezo1 ion channels, which allow Ca2+ influx into acinar 
cells [Piezo1 channels have been discussed above (sections 1.1.2.2.1 and 1.1.4.5)]. Other 
major operations, particularly aortic, cardiopulmonary bypass and liver transplantation have 
been recognised as an inducers of AP, likely due to pancreatic ischaemia (67, 116).  
The other ‘S’ in this mnemonic stands for ‘Steroids’ – which have been recognised as 
potential inducers of AP since the 1950s (117). However, cases of steroid-induced AP in the 
literature do not meet the criteria for class 1a level of evidence described by for drug-induced 
AP Badalov et al. (see section 1.1.4.12 and Table 4, below), so it must be highlighted that 
whilst steroids are considered separately from other medications in this aetiological mnemonic 
system, the evidence for AP-induction is not higher for steroids than other drugs (78). That 
said, cases of steroid-related AP that have been published do show a particularly severe 
disease course with high lethality (78). 
 
1.1.4.7. Mumps & other infectious triggers of AP 
Infectious agents are rare but potentially preventable and curative inducers of AP. 
Aetiologically, the best understood are parasitic causes which appear to trigger AP through 
obstruction of the ductal system and may require decompressive endoscopic sphincterotomy 
in addition to anti-parasitic therapy (118). Of these, the best recognised are the nematode 
Ascaris lumbricoides and the trematode Clonorchis senensis (popularly known as the Chinese 
liver fluke) (68, 118).  
The mechanisms by which viral infections induce AP are less clear despite the 
induction of pancreatic inflammation in laboratory mice using single stranded-RNA 
picornavirus, Coxsackievirus type B, having been first demonstrated 70-years ago (119). The 
other viruses which have reportedly induced AP have all been DNA viruses, and are supported 
by case report level evidence only. Specifically, single stranded-DNA viruses: paramyovirus 
Mumps orthorubulavirus (which causes Mumps), and orthohepadnavirus Hepatitis B virus. 
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Double-stranded-DNA viruses include: herpesviridae Cytomegalovirus (CMV) and Herpes 
simplex virus (HSV), as well as alphaherpesvirus Varicella-zoster virus (VZV). AP is not 
uncommon in HIV/AIDS since immuno-compromised patients are susceptible to opportunistic 
infections which may trigger AP and anti-retroviral drugs can induce AP (80).  
The body of evidence to support the aetiology of bacterial infections in AP is less than 
that for viral infections and there is also no established pathological mechanism to support this 
possible cause. Even if such micro-organisms are cultured directly from sampling th pancreas, 
a critic could reasonably suggest that such infections could be secondary rather than a primary 
aetiological factor. Those bacterial which are cited in the literature as potential inducers of AP 
by more than one case report include Mycoplasma pneumoniae, Salmonella typhi (68, 80).  
Lastly, whilst fungal infections can arise within the pancreas parenchyma as micro- or 
macro-abscesses, these generally do not cause AP (68, 80). The relevance of fungal infections 
in AP is that they arise as a complication by causing infection of necrotic pancreatic tissue (e.g. 
Candida) (80). 
 
1.1.4.8. Autoimmune-related AP 
Disease of the adaptive immune system which involves the pancreas is termed auto-
immune pancreatitis (AIP). It is a pancreatic manifestation of a multi-organ inflammatory 
disease which is now termed IgG4-related disease (120). It is a chronic fibroinflammatory 
disease which is distinct from classical chronic pancreatitis. Current classifications distinguish 
two subtypes which have several opposing features, but for simplicity Type 1 can be 
remembered as having elevated serum IgG4 levels, whilst Type 2 patients have levels within 
normal limits (121). Type 1 typically involves extra-pancreatic organs, whilst Type 2 is more 
confined to the pancreas. Both types response well to steroid challenge. Histologically there 
are lymphoplasmacytic infiltration with fibrotic changes which are very different to chronic 
pancreatitis and AP. Systemic lupus erythematous (SLE), which is characterised by immune 
complex deposition in multiple organ systems, is also associated with AP, albeit rarely, and 
authors often report a favourable response to steroids in these patients (122). Another 
autoimmune disease with upregulation of interferon type-1 inducible genes which has an 
increased risk of AP is Sjogren’s syndrome, although pathobiological connections between AP 
and Sjogren’s are not currently defined (123). 
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1.1.4.9. Scorpion sting-induced AP 
 Venomous stings can induce a wide array of acute critical illness. Besides the few 
cases of snake bite-induced AP, scorpion stings are the main venomous inducers of AP. 
Scorpions are predatory arachnids with >1000 species. The genera, Tityus, are a subgroup of 
scorpions with thick-tails. The species Tityus trinitatis (Figure 4), which is endemic to Trinidad 
and Tobago, possess an especially pancreatotoxic venom that induces AP, which was first 
highlighted in 1970 by C Bartholomew who reported 
24 cases of scorpion-induced AP encountered in just 
a 2-month period (125)! AP is not the only effect on 
humans from this venom, as is has cardiotoxic 
effects too. Additionally, other scorpions of this 
genus also have pancreaticotoxic effects, such as 
the venom of the Tityus serrulatus, which can be 
found in Brazil (126). Mechanistically, such Tityus 
venom has been shown to profoundly induce 
exocrine secretion and contraction of the sphincter 
of Oddi, which is likely mediated by muscarinic 
cholinergic mechanisms (127-129). 
 
1.1.4.10. Hypercalcaemia, hyperlipidaemia and metabolism-related AP 
There are two main chronic metabolic associated with the occurrence and recurrence 
of AP; namely hypercalcaemia (which is often the result of primary hyperparathyroidism) and 
hyperlipidaemia.  
Several observational studies from many groups around the world have found a 
significant association between hypercalcaemia and AP (79). There are notable exceptions, 
however, which allow for ongoing debate. In particular, the JAMA 1980 paper from Mayo Clinic 
denounced this association based on a large dataset of >1000 cases of surgically confirmed 
hyperparathyroidism with only 1.5% having had evidence of pancreatitis, and of these, more 
than half had other more compelling aetiological factors, such as high alcohol intake or 
gallstones (130). However, given the central role of calcium signalling in both acinar cell 
physiology and in AP pathogenesis (26), it seems biologically plausible that there would be a 
causal association to some degree as the data overall appears to suggest. Interestingly, it 
should be noted that severe AP and admission to critical care, as opposed to mild disease, is 
associated the use of calcium-altering drugs, previous parathyroid surgery as well as 
hypocalcaemia found on admission bloods (63). 
 
Figure 4: Tityus trinitatis scorpion (male) 
Picture is from textbook ‘Scorpion Venoms’ 
Springer Science, 2015 [Chapter 10, pg 224, 
Figure 2 B]. Photograph taken by Jan Ove 
Rein. (124) 
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Another chronic metabolic disorder associated with the occurrence of AP is 
hyperlipidaemia. Required serum levels are thought to be very high, however, with guidelines 
suggesting an arbitrary cut-off of serum triglyceride >1000 mg/dl (11.2 mmol/l) (115). The 
condition may be primary, such as inherited disorders of lipoprotein metabolism which may be 
detected in childhood, or secondary disorders of lipoprotein metabolism (e.g. diabetes mellitus, 
obesity, hypothyroidism) which may also require an additional underlying mild form of genetic 
dyslipidaemia (48). The treatment is with standard supportive measures, anti-lipid drugs and 
the consideration of plasma electrophoresis and heparin (131, 132). Mechanistically, fatty acid 
esters are known to contribute to dysregulated Ca2+ signalling within acinar cells so there is a 
plausible association between elevated lipids and the induction of AP.  
 
1.1.4.11. ERCP-related AP 
Whilst the pathogenesis of acute pancreatitis has mostly focussed upon gallstone and 
alcohol-induced aetiologies, post-ERCP pancreatitis presents the opportunity to administer 
drugs prophylactically or very early in the disease course, which would not be feasible with 
other aetiologies. Experimental ERCP-pancreatitis models using rodents consist of pressure-
controlled pancreatic ductal infusion (133). The pressure effect of ductal infusion has been 
shown to induce transient pancreatitis changes in rats, where saline was used as the infusate 
at high pressures (134). In the human therapeutic ERCP situation, luminal pressures are a 
likely contributing factor for post-ERCP pancreatitis, which is the rationale for inserting a plastic 
stent into the pancreatic duct in challenging cases (135). However, additional factors, such as 
luminal acidity, are also known to be important in the pathogenesis of post-ERCP AP (133), 
with the supporting evidence that release of inflammatory mediators can be induced by low pH 
stimulus of transient receptor potential neuronal ion channels (133). Whilst understanding of 
the specific molecular events which trigger acinar cell injury and pancreatitis by animal models 
would seem important, it is noteworthy that use of rectal NSAIDs, as evidenced by clinical 
studies, has not undergone confirmation animal study (8, 136, 137).  
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1.1.4.12. Drug induced-AP (other than steroids) 
The diagnosis of drug-induced AP is not easily established but a thorough review of 
this topic was published in 2007 by Badalov et al. (78). Herein the authors classify alleged 
pharmacological inducers of AP by levels of evidence from Class I to IV (Table 4), with the 
strongest evidence being Class Ia in which ‘at least 1 case report is that of a positive challenge, 
excluding all other causes, such as alcohol, hypertriglyceridaemia, gallstones and other drugs’ 
(78). 
 
Class Definition Drug 
1a • At least 1 case report 
with positive re-challenge 
test, excluding all other 
causes 
Methyldopa, Azodisalicylate, Bezafibrate, Cannabis, Carbimazole, 
Codeine, Cytosine, Dapsone, Enalapril, Furosemide, Isoniazid, Mesalazine, 
Metronidazole, Pentamidine, Pravastatin, Procainamide, Pyritinol, 
Simvastatin, Stibogluconate, Sulfamethoxazole, Sulindac, Tetracycline, 
Valproic acid  
1b • At least 1 case report 
with positive re-challenge 
test; however other 
causes were not ruled 
out 
Tretinoin, Amiodarone, Azathioprine, Clomiphene, Dexamethasone, 
Ifosfamide, Lamivudine, Losartan, Lynesterol, 6-mercaptopurine, 
Meglumine, Methimazole, Nelfinavir, Norethindronate/Mestranol, 
Omeprazole, Premarin, Co-Trimoxazole  
II • At least 4 cases in the 
literature 
• Consistent latency 
(³75% of cases)  
Paracetamol, Chlorthiazide, Clozapine, Didanosine, Erythromycin, 
Estrogen, Asparaginase, Pegasparagase, Propofol, Tamoxifen 
III • At least 2 cases in the 
literature 
• No consistent latency 
among cases 
• No re-challenge test  
Alendronate, Atorvastatin, Carbamazepine, Captopril, Ceftriaxone, 
Chlorthalidone, Cimetidine, Clarithromycin, Cyclosporin, Gold, 
Hydrochlorothiazide, Indomethacin, Interferon/ribavirin, Irbesartan, 
Isotretinoin, Ketorolac, Lisinopril, Metolazone, Metformin, Minocycline, 
Mirtazapine, Naproxen, Paclitaxel, Prednisone, Prednisolone 
IV • Drugs not fitting into the 
earlier-described classes, 
single case report 




Adrenocorticotropic hormone, Ampicillin, Bendroflumethiazide, Benazepril, 
Betamethasone, Capecitabine, Cisplatin, Colchicine, Cyclophosphamide, 
Cyproheptadine, Danazol, Diazoxide, Diclofenac, Diphenoxylate, 
Doxorubicin, Ethacrynic acid, Famciclovir, Finasteride, 5-fluorouracil, 
Fluvastatin, Gemfibrozil, Interleukin-2, Ketoprofen, Lovastatin, Mefenamic 
acid, Nitrofurantoin, Octreotide, Oxyphenbutazone, Penicillin, 
Phenolphthalein, Propoxyphene, Ramipril, Ranitidine, Rifampin, 
Risperidone, Ritonavir, Roxithromycin, Rosuvastatin, Sertraline, 
Strychnine, Tacrolimus, Vigabatrin/lamotrigine, Vincristine 
Table 4: Drug-induced AP based on drug classes (78). 
 
 
1.1.4.13. Smoking-related AP 
Whilst cigarette smoking is a recognised risk factor for both acute and chronic 
pancreatitis, experimental animal models of cigarette-smoke toxicity are lacking (8). Liquid 
extracts of cigarette tobacco, especially nicotine metabolite nicotine-derived nitrosamine 
ketone (NNK), have been demonstrated to cause mild pancreatic injury. In vivo, NNK was 
found to activate trypsinogen and vacuolization, whereas NNK pre-treatment prior to induction 
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of acute pancreatitis with cerulein heightened its effects upon the pancreas (138). Chronic 
nicotine exposure (as well as NNK exposure) impairs thiamine (vitamin B1) uptake from the 
circulation by decreasing expression of cell thiamine transporters. Deficiency of thiamine 
results in mitochondrial dysfunction, a hallmark of pancreatitis pathogenesis (139, 140). 
Chronic alcohol use is frequently associated with inadequate thiamine absorption from the diet, 
which likely compounds acinar cell thiamine depletion amongst smokers. 
 
 
1.1.5. Clinical definitions and scoring systems for acute pancreatitis 
1.1.5.1. Diagnostic criteria for acute pancreatitis 
The internationally agreed diagnostic features for AP require at least two of the 
following criteria (115, 141):  
1) Characteristic abdominal pain  
2) Serum pancreatic enzyme levels (i.e. amylase or lipase) 3-fold greater than the 
upper limit of normal range values  
3) Radiological evidence of AP. 
Plasma pancreatic enzyme levels (i.e. amylase) are useful for diagnostic purposes, but a 
higher plasma concentration does not reliably correlate with worse disease severity (142). The 
diagnosis is usually reached without the need for radiological imaging, but where it is required, 
contrast-enhanced computed tomography (CT), magnetic resonance 
cholangiopancreatography (MRCP) or transabdominal ultrasonography have been 
recommended (141, 143).  
 
1.1.5.2. Fatal acute pancreatitis 
The clinical outcomes in AP are remarkably heterogenous, ranging from mild and self-
limiting to multiple organ failure and death. Deaths are typically due to extra-pancreatic organ 
failure and usually arise in the first 2 weeks, as evidenced by national studies consisting of 
>1000 AP deaths (59, 144) (Figure 5). Indeed, the median duration from hospital admission 
to death amongst AP patients admitted to critical care was found in one national study to be 
just 82-hrs (n = 54 AP deaths) (63). Prior to these reports, smaller studies (<20 AP deaths) 
advocated a theory that there is a second peak of deaths from AP that arise later (>3 weeks) 
due to infected pancreatitis necrosis. This debunked theory highlights the limitations of 
conclusions drawn from small data series from specialist units, rather than taking a broad 
population-based approach (145, 146). This distinction is important when directing finite  
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research resources with the aim of 
reducing lethality in AP. These larger, 
population-based studies support the 
concept that deaths typically arise in 
the first 2 weeks and are due to 
overwhelming multiple organ failure, 
rather than from septic complications 
thereafter. Additionally, studies from 
specialist units typically overlook 
prehospital AP fatalities which were 
found to comprise 17% of nation-wide 
deaths from AP in Sweden at that 
time (147). The proportion of fatal 
prehospital cases for any given 
country will differ depending upon the 
availability of access to emergency 
medical services, social care systems, levels of societal levels of alcohol dependence and the 
size of homeless populations. Better characterised are the inpatient fatal AP cases amongst 
adults, which most large series report this figure at approximately 4% [of 70231 in California, 
USA (76)] to 5% amongst adults [of 2053 in Scotland (63)]. Mortality amongst paediatric 
populations has been reported between 0-11% (75). This broad range in mortality reflects the 
small sample size of each study. However, taken together, from available reports, the collective 
paediatric AP mortality was 4.7% (43 of 922) (148-153). The key interventions to reduce AP 
fatalities apart from prevention strategies, are rapid access to diagnostics and effective 
treatments which ameliorate the systemic inflammatory response and organ failure. 
 
1.1.5.3. Nature and duration of organ dysfunction in acute pancreatitis 
Acute inflammation which leads to the systemic inflammatory response syndrome 
(SIRS) can be caused by other non-infective conditions besides AP, such as major burns, 
trauma, surgery, ischaemia-reperfusion and haemorrhagic shock. All of these conditions can 
be complicated by multiple organ dysfunction syndrome (MODS), which commonly involves 
severe pulmonary, cardiovascular, or renal function compromise. These bodily systems in 
particular typically struggle to meet the physiological requirements during a severe acute 
systemic inflammatory condition, and therefore malfunction to the point of ‘critical illness’; the 
latter has been defined as ‘life-threatening organ dysfunction which requires mechanical or 
 
Figure 5: Deaths arise early in AP, no delayed second 
peak from sepsis 
Histogram depicts right-skewed data with the majority of 
deaths arising early in AP (<3 weeks) from a large, national 
population-based study (n = 1024 AP deaths). Notably, there is 
no large delayed second peak after 3 weeks, a notion that has 
been advocated by smaller studies from specialist units. Figure 
is from Mole et al. HPB, 2009 [Figure 1] (144). 
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pharmacological support to prevent imminent death’ (154). In severe AP, pulmonary, 
cardiovascular, renal, haematological and hepatic systems are the most commonly affected 
(63, 144, 155). Failure of the more frequently affected organ systems (respiratory, 
cardiovascular, renal), are discussed in more details. 
The duration of organ dysfunction in the first week of AP was the focus of UK clinical 
research groups at the start of the 20th century (156, 157), with the description of terms 
‘transient’ (<48-hrs) and ‘persistent’ (>48-hrs) which are now ingrained in the international AP 
severity nomenclature (158). It has been firmly established that transient organ dysfunction 
has a distinctly better prognosis than persistent organ dysfunction (158).  
 
1.1.5.3.1. Respiratory failure in AP 
Acute respiratory distress syndrome (ARDS) is defined by a constellation of clinical and 
physiological criteria characterised by an acute, diffuse, inflammatory lung injury, leading to 
increased alveolar capillary permeability, increase lung weight, and loss of aerated lung tissue 
(Figure 6) (159). The term ‘acute lung injury’ (ALI) has dropped out of favour within the 
scientific community, and ARDS is now subclassified as mild, moderate and severe, with the 
2012 Berlin definition having been widely endorsed by esteemed thoracic and critical care 
societies (159). Histologically, ARDS is characterized by an acute, exudative phase, combining 
diffuse alveolar damage and noncardiogenic oedema, followed later (amongst survivors) by a 
fibroproliferative phase (160). The injury process in ARDS involves diffuse alveolar damage 
with alarmin and proinflammatory mediator release, PRR activation, transcription of genes 
under NF-κB and activator protein-1 (AP-1) control, infiltration of activated macrophages and 
neutrophils, proliferation of fibroblasts all of which impair gas exchange and lung mechanics 
(160). A comprehensive review of the 
inflammatory and cellular components of ARDS in 
AP by Akbarshahi et al. is recommended for 
interested readers (161). ARDS is not the only 
thoracic complication of AP, however, and other 
potentially serious intrathoracic complications can 
give rise to cardiopulmonary failure, such as 
pleural, pericardial and mediastinal collections 
(effusion, pseudocyst, empyema), pneumonia, 
venous thromboembolism, pseudoaneurysm and 
cardiac arrhythmia (162). 
 
Figure 6. Chest radiograph of a patient with 
acute respiratory distress syndrome (ARDS)  
Chest radiographic features demonstrating 
diffuse bilateral pulmonary infiltrates. Acute 
respiratory distress syndrome (ARDS) is a 
common complication in severe AP. Image from 
Fan et al. JAMA, 2018 [Figure 1A] (159). 
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1.1.5.3.2. Cardiovascular failure in AP 
Cardiovascular dysfunction requiring inotrope or vasopressor support  is very common 
in severe AP, affecting ~60% of patients (63).  Bleeding in the context of AP (e.g. haemorrhagic 
pancreatitis) is exceptionally rare, and therefore cardiovascular dysfunction is typically due to 
‘vasoplegia’; a syndrome of pathologically low systemic vascular resistance (SVR), that is 
manifest as hypotension or the requirement for therapies to avoid this, in the presence of a 
normal or increased cardiac output (163). The contractile state of the vascular smooth muscle 
cells within the tunica media controls the arteriolar diameter and thereby modulates the 
systemic vascular resistance along with cardiac output (163). 
As vasoplegia progresses to the point of tissue hypoperfusion and cellular hypoxia it is 
termed ‘shock’. This form of shock is known by a few terms in the literature; namely, 
vasodilatory, distributive or vasoplegic shock. Treatment often requires vasopressor infusion, 
usually with catecholamines, with invasive blood pressure monitoring. Physiological regulators 
of arterial tone include endothelial secretions (e.g. nitric oxide, prostacyclin, endothelin), 
vasoactive metabolites (e.g. acidosis, hydrogen peroxide) and other autocoids (e.g. serotonin, 
prostaglandins, thromboxane A2) (163). Extrinsic regulation of vascular resistance is largely 
mediated by neural sympathetic control and vasoactive hormones (e.g. adrenaline, 
angiotensin II and vasopressin) (163). In AP, circulating DAMPs and other proinflammatory 
mediators, together with altered neuro-endocrine hormone axes, disrupt the vascular tone by 
their effects on endovascular smooth muscle and endothelial cells. 
 
1.1.5.3.3. Acute kidney injury in AP 
Acute kidney injury (AKI) is a collection of extremely heterogenous clinical syndromes 
united by a sudden decrease in estimated glomerular filtration rate (164). AKI may manifest as 
changes in only serum creatinine, or just urine output, or both (164). The overall prevalence 
of acute kidney injury (AKI) in AP is not well defined, but appears to be in the region of 8-
15% (165). From a detailed case-by-case review of AP clinical records (n = 2053 cohort), 
which included 0.3% patients already on renal dialysis prior to hospitalization, 4.8% of AP 
patients required renal replacement therapy during their admission (63). AKI typically 
develops late in the course of AP, usually after failure of other systems, with <10% of AP-
MODS patients first developing AKI (155, 165). This explains why the mortality amongst AP 
patients who require renal replacement therapy is so very high (>75%), as it is a late 
occurrence in the sequence of failing organ systems (165). The pathophysiology of AKI in AP 
has received less attention than pulmonary complications in severe AP. From available 
studies, there is evidence that mediators absorbed into the circulation from necrotic acinar cells 
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and pancreatic ascites are pathogenic. Circulating proinflammatory cytokines, such as TNFα, 
are thought to have cytotoxic effects on glomeruli, tubular capillaries and endothelial cells, 
potentially leading to ischaemia, apoptosis and necrosis (165). Collectively AKI in AP appears 
to arise from the culmination of hypovolaemia from increased vascular permeability, 
inflammatory signalling, vasoconstriction, intravascular coagulation and the direct nephrotoxic 
effects of circulating endogenous mediators and DAMPs (165). For interested readers, a 
focussed review of AKI in AP by Nassar and Qunibi is recommended (165). 
 
1.1.5.4. Severity predictor scoring systems in acute pancreatitis 
There are many clinical scoring systems which have been designed to act as tools in 
the assessment of AP patients or else generic critical care tools which have been adopted by 
the pancreatitis scientific community. Table 5 lists, in chronological order, the main scoring 
systems used to prognosticate AP severity. The output result for each score is listed is a 
separate column. 
 
Score Country (Year) Factors Disease Tests Output Ref(s) 
Ranson 
NY, USA  
(1974 & 1977) 




Glasgow UK (1978) 9 AP-specific Single 
Number (0-8) 
Mild (0-2) or Severe (³3) 
(168-170)  
Balthazar NY, USA (1985) 1 AP-specific Single CT grade of AP severity (A-E) (171) 
APACHE II 
DC, USA  
(1985 & 1989) 
12 Generic Single 
Number (0-71) 
Severe (³10)  
or >8 in AP (143) 
(172, 173) 
Hong Kong Hong Kong (1993) 2 AP-specific Single 
Severe (Urea >7.4 
mmol/L and/or Glucose 
>100 mmol/L) 
(174) 




Panc 3  MA, USA (2007) 3 AP-specific Single 
Number (0-3) 
Mild (0) or Severe (³1) 
(176) 
POP UK (2007) 6 AP-specific Single Number (0-54) (177) 
BISAP MA, USA (2008) 5 AP-specific Single 
Number (0-5) 
Mild (0-2) Severe (³3) 
(178) 
HAPS Germany (2009) 3  AP-specific Single 
Number (0-3) 
Mild (0) Severe (³1) 
(179) 
Table 5: Severity prognosticator scores  
APACHE II: Acute physiology and chronic health examination II; BISAP: Bedside index for severity in AP; HAPS: 
Harmless acute pancreatitis score; PASS: Pancreatitis activity scoring system; POP: pancreatitis outcome prediction. 
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1.1.5.4.1. The original AP severity prediction scores – Ranson & Imrie 
 The original scoring system by John Ranson and colleagues in New York, USA in the 
mid to late 1970s (166, 167), described 13 variables, which became 11 (having dropped the 
serum ‘amylase’ result and ‘previous AP episodes’). Six of the 11 required a repeat 
assessment within 48-hrs: The decrease in haematocrit, increase in urea, the lowest serum 
calcium and arterial oxygen tension, and highest base deficit and estimated fluid deficit (166). 
The need for repeated tests, an estimation of fluid deficit and 48-hrs delay were practical 
limitations that other scoring system since have all avoided. Around the same time, across the 
Atlantic Ocean in Scotland, the surgical department in Glasgow produced their own scoring 
system for pancreatitis in 1978 using 8 factors, with the only new parameter being serum 
Albumin which was missing from Ranson’s system. Professor Imrie and his Glasgow 
colleagues did not include haematocrit decrease or estimation of fluid sequestration, nor did 
they include acidaemia by way of base excess which Ranson had included (168, 169). 
 
1.1.5.4.2. New AP scores between 1980-2000  
In 1985, a New York radiologist Emil J Balthazar produced a CT-based 5-level scoring 
system to grade the severity of AP-related radiological changes (171). During the same year, 
a team of intensive care academics in Washington DC published the national validation results 
of a revised version of their original APACHE score, simply rebranded as APACHE II, which 
was found to be a robust prognosticator tool in for critical illness in general (173). APACHE II 
has 12 factors with graded scoring with a maximum of 71 points, and a score over 10 being 
considered as severe. The APACHE II score was found to be useful for AP patients in particular 
when tested in an UK population (172), and has since been adopted by into UK guidelines as 
a quantifier of severity, but using a slightly lower cut-off of >8 for severe AP (143). In 1992, a 
group from Hong Kong sought to focus severity prediction down to only 2 factors on admission 
for predicting severe AP; using elevated blood urea and glucose, but this system was criticised 
and not widely adopted (174).  
 
1.1.5.4.3. The 21st century AP prediction scores 
After the turn of the 21st century, in the 2000s, there was a global flurry of new AP 
scoring systems. A decade after the Hong Kong score, and in stark contrast, the Japanese 
developed the most sophisticate system employing 18 factors, which is more than any AP 
severity system before or since (175). Then in 2007, in line with the Hong Kong efforts to 
produce a rapid and simple score, a group from Harvard, Boston in the USA produced the 3-
point Panc 3 score. In keeping with the origin American score by Ranson, Panc 3 also used 
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haematocrit, but used two novel parameters: body mass index (BMI) and evidence of pleural 
effusion on chest radiograph (176). At the same time, a group in London developed a new 
predictive score, called the Pancreatitis Outcome Prediction (POP) score for severe AP with 
the premise that a new AP-specific score was worthy of investigation given the considerable 
advances in critical care medicine over the 30 years since the Glasgow and Ranson scores 
were developed (177). The POP score utilised 6 parameters, of which 4 were largely 
unchanged: Age, urea, calcium and arterial oxygenation. As in Ranson’s score, POP quantified 
acidaemia, using arterial pH as opposed to base excess. The only new factor not included in 
either the Glasgow or Ranson scores was mean arterial blood pressure (177). Curiously, less 
than a year after the Panc 3 score was published a separate group of authors also affiliated 
with Harvard, Boston published the Bedside Index Severity in Acute Pancreatitis (BISAP) score 
(178). This was an easy-to-use 5-factor score which for the first time incorporated impaired 
mental status as a prognostic indicator. As with the other Harvard score (i.e. Panc 3), the 
BISAP also scored pleural effusion on chest radiograph. In 2009, a group from Germany with 
the collaborations of Italian clinical epidemiologist P Mainsoneuve and pancreatologist AB 
Lowenfels from New York, took a refreshing and novel approach to AP severity scoring by 
producing the Harmless Acute Pancreatitis Score which used just three factors to exclude a 
severe episode; namely: Absence of rebound tenderness, normal haematocrit, and normal 
serum creatinine (Table 5, above) (179). 
Whilst APACHE II is not disease-specific, it has the unique advantage in that it is 
designed to be repeatedly recalculated during intensive care therapy and given that the linear 
range is from 0 to 71, it can be used as a daily, dynamic surrogate marker of clinical 
improvement, in a similar fashion to the organ failure severity scores. 
 
1.1.5.4.4. Organ failure scores 
The scoring systems listed above are used to prognostically stratify acutely ill patients, 
which is subtly different from quantifying actual severity. The risk of fatal AP relate to the 
duration of organ failure in the first week, and the most widely utilised tool for assessing organ 
failure is the Marshall score which is a generic critical care tool which measures 6 factors (180):   
- Respiratory: PO2/FiO2 ratio 
- Renal: Serum creatinine 
- Hepatic: Serum bilirubin 
- Cardiovascular: P ressure adjusted heart rate 
- Haematologic: Platelet count 
- Neurologic: Glasgow coma score (GCS). 
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When studying patients with AP in particular, the hepatic dysfunction component is 
omitted to avoid confounding effects of biliary obstruction, and even the haematological and 
neurological components were dropped by the 2012 revised Atlanta classification, which is 
interesting in light of the 2008 BISAP score that incorporates mental status. Another system 
used to score organ failure which is very similar to the Marshall system is the sepsis-related 
organ failure assessment (SOFA) tool which also uses a 6-factor score: PO2/FiO2 ratio, 
creatinine, bilirubin, hypotension, platelet count, and GCS (Table 6). Thus, the only difference 
between Marshall and SOFA is the cardiovascular quantification, with the Marshall system 
using a pressure-adjusted heart rate [PAR = (Heart rate x central venous pressure) / mean 
blood pressure], whilst the SOFA uses mean arterial pressure (with or without increasing 
quantities of vasopressors). The preference of 2012 revised Atlanta is the modified Marshall 
score (141). 
System Country (Year) Factors Disease Detail Ref(s) 
Marshall OF Canada (1995) 6 Generic Number (0-24). Clinicobiochemical markers of OF (180) 
SOFA International (1996) 6 Generic Number (0-24). Clinicobiochemical markers of OF (181) 
Table 6: Organ failure severity systems 
OF: Organ failure; SOFA: Sepsis-related organ failure assessment 
 
1.1.5.4.5. Actual severity AP assessment systems 
During the early 1990s, as multiple organ failure scoring tools were being developed, 
the need for clearer definitions in the literature for AP was met by an international consortium 
who assembled in Atlanta, USA. This was the start of improved uniformity in definitions in AP, 
to help with the development of international guidelines and in conducting clinical research. 
Table 7 shows a chronological catalogue of publications which describe actual AP disease 
severity, which includes a column detailing definitions of severity groups. The evolution of 
expert opinion can be seen with the introduction of ‘duration of organ failure’ in 2005 from the 
UK guideline, to the inclusion of a moderate group from 2012 onwards.  
More recently a more functional scoring system has been introduced by the Southern 
California Pancreas Study Group, called the Pancreatitis Activity Scoring System (PASS) (182, 
183). PASS differs from the others in Table 7 in that it can be used to monitor a patient’s 
condition during AP and chart progress, in a similar way that APACHE II can be used to chart 
physiological progress. The factors which comprise the PASS score are: i) organ failure 
(modified Marshall ³2), ii) SIRS (³2), iii) abdominal pain, iv) opiate requirement over 12-hrs, v) 
tolerance of oral intake over 12-hrs (182). 
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System Country (Year) Severity groups  Ref. 
1992 Atlanta International (1992) 
Mild (no OF or complications) 
Severe (OF and/or complications) 
(184) 
Japanese Japan (2002) 
Number (0-27). Stage (0-4) 
Clinicobiochemical markers of OF. 
(175) 
UK  UK (2005) 
Mild (OF lasting <48-hrs) 
Severe (OF >48-hrs, otherwise as per ‘92 Atlanta) 
(143) 
2012 Atlanta International (2012) 
Mild: No OF or complications 
Moderate: OF <48-hrs, local complications or 
exacerbated co-morbidities 
Severe: OF >48-hrs 
(141) 
Determinant-
based International (2012) 
Mild: No OF and no (P)P necrosis* 
Moderate: OF <48-hrs and/or sterile (P)P necrosis* 
Severe: OF >48-hrs or infected (P)P necrosis* 
Critical: OF >48-hrs and infected (P)P necrosis* 
(158) 
ACG USA (2013) 
Mild: no OF and/or pancreatic necrosis 
Moderate:  OF <48-hrs or complications (local or 
systematic) 
Severe: OF >48-hrs and/or death 
(115) 
PASS CA, USA (2017) 
5 factors: SIRS (x25 points/ criteria), mod Marshall (x100/ 
system of 3 – respiratory, cardiovascular, renal), Abdo 
pain (0-10 score x5), Morphine equivalent dose (number 
of mg x5), Tolerating diet (yes=0, no=1, x40). 
Number (0-450). Mild (<140) 
(182, 
183) 
AAST EGS USA (2018) 
Grades 1 to 5 (guides to management) 
1: Acute oedematous AP; 2: Pancreatic phlegmon or 
peripancreatic fluids collection or haemorrhage; 
3: Sterile pancreatic necrosis  
4: Infected pancreatic necrosis or abscess 
5: Extrapancreatic extension of pancreatic necrosis (e.g. 
colonic necrosis) 
(185) 
Table 7: System of actual AP severity 
AAST EGS: American association for the surgery of trauma emergency general surgery; ACG: American 
college of gastroenterology; IAP: International association of pancreatology; OF: Organ failure; SOFA: 
Sepsis-related organ failure assessment. *(P)P necrosis: (peri)pancreatic necrosis 
 
1.1.5.4.6. Application of human AP severity systems to my experimental AP research 
In the murine model of AP used in this PhD work, which is discussed later, I sought to 
apply the principles of AP scoring systems by using implantable telemetry to continuously 
monitor physiological changes, and I developed and used an experimental AP-specific cage-
side clinical scoring sheet. This cage-side tool incorporated clinical signs of pain in rodents 
with analgesia administration protocols, and the parenteral administration and oral 
consumption of analgesia was monitored throughout these AP recovery studies. The total body 
weight loss was also recorded. All these measures were taken in an effort to monitor 
experimental AP disease activity under laboratory conditions. 
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1.1.5.5. Adverse risk factors for a severe episode of AP 
The simplest surrogate clinical endpoints for an adverse outcome in AP are all 
physiologically based: i) organ dysfunction; ii) critical care admission; and iii) fatality. Published 
observational studies employing multivariate statistical analysis tools have can highlight 
adverse and protective factors of AP-MODS. Table 8 outlines the main factors associated with 
critical illness in AP. 
Adverse pre-existing factors for critical illness 
Aged over 80 years (63) 
Alcohol dependency (63, 147) 
Calcium-altering medication use (63) 
Chronic kidney disease (63) 
COPD (63) 
Coronary artery stent placement in previous 1 year (63) 
Diabetes in the young (aged 30-39 years) (63) 
Hyperlipidaemia (86) 
IHD or hypertension (63) 
Morbid obesity (186-188) 
Smoking (63) 
Thyroid or parathyroid surgical history (63) 
Type 2 diabetes mellitus (if not taking insulin) (63) 
Adverse factors on admission for critical illness 
Organ dysfunction: Respiratory; Cardiovascular; Renal (63, 144, 158, 165) 
Hypocalcaemia (63) 
(Peri)pancreatic necrosis or infection on CT/MRI scan (158) 
Protective pre-existing factors against critical illness 
Previous hospitalization for AP (less likely to need CC admission) (63) 
Table 8. Clinical features associated with critical illness in acute pancreatitis  
Adverse and protective factors associate with critical care admission, organ support or death in acute 
pancreatitis. The adverse factors are shaded above in green with distinction between pre-existing 
factors and those on admission. Protective factors for multiple organ failure in AP are highlighted 
below in blue. This is not an exhaustive list, but covers the main factors evidenced by the literature.  
 
Some findings by different studies have shown conflicting results, such as the 
protection or risk conferred by statin use prior to AP, which may relate to heterogenous statin 
prescribing practices across the world (63, 189). Some risk factors can be identified in one 
study, but found to be statistically insignificant in another, which may be explained by a number 
of factors such as the complex nature of the risk factor of interest with occult confounders, the 
study size, demographics or definitions. One example of this, is the increased risk of critical 
illness in AP associated with (morbid) obesity (186, 187), which is not seen in all studies (63, 
190). However, there are good biological reasons to support the assertion that obesity is not 
only associated with the development of AP (i.e. cholesterol cholelithiasis), but contributes to  
the  severity  of  AP  by  contributing  to  proinflammatory  mediator  production [e.g. damage-
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associated molecular patterns (DAMPs) and adipokines (188, 191, 192)], and impairs 
inflammation resolution (193). Interestingly, a previous hospitalisation for AP is protective 
against the need for critical care support, which may relate to local pancreatic changes 
following a previous pancreatitis episode (i.e. fibrosis).  
 
 
1.1.6. Systemic inflammatory response in acute pancreatitis 
The clinical course of AP has been described in terms of the ‘early’ and late’ phases. 
The ‘early phase’ (<2 weeks) is widely considered as a sterile inflammatory response, because 
activation of the innate immune system is driven by host cellular injury products [i.e. damage- 
(or danger-) associated molecular pattern molecules (DAMPs)] which engage many of the 
same receptors and signalling cascades that exogenous infectious agents activate [i.e. 
pathogen-associated molecular patterns (PAMPS)]. AP is frequently complicated by a 
systemic inflammatory response syndrome (SIRS), and clinical biochemical markers, most 
notably C-reactive protein (CRP) which is produced by hepatocytes in response to 
proinflammatory cytokines (e.g. interleukin-6), can aid clinicians in biochemically monitoring 
progression or resolution of the systemic inflammatory response. The term ‘SIRS’ has been in 
use for over 25 years as a non-specific human pathophysiological response, and is widely 
utilised in AP literature (194). The most common cause of SIRS is infection, which is termed 
‘sepsis’, but there are other non-microbial drivers of SIRS besides AP; with major burns, 
trauma and major surgery being common examples in clinical practice. In adults, the criteria 
for SIRS are met when 2 or more of the following abnormal clinical features are met: 
i) Abnormal body temperature >38oC or <36oC;  
ii) Tachycardia, with heart rate greater than 90 beats per minute;  
iii) Tachypnoea, with >20 breaths per minute and/or hyperventilation indicated by a blood 
partial pressure of carbon dioxide <32 mmHg (<4.27 kPa); 
iv) Abnormal total white blood cell count >12,000 cells/mm3 or <4,000 cells/mm3 (194). 
There is evidence to support impaired gut integrity in AP related to increased reactive oxygen 
species and reactive nitrogen intermediate-mediated mucous damage, which can exacerbate 
SIRS (106, 195). At its worst, SIRS can progress into functional failure of multiple organ 
systems – a state of affairs that was unsurvivable before the modern era of intensive care 
medicine. AP multiple organ failure (AP-MOF) often arises from a hyperinflammatory ‘sterile’ 
response, but may signify an overt septic complication, with common sources being infected 
pancreatic necrosis, cholangitis, or pneumonia. For those that survive the ‘early phase’ and 
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transition into the ‘late phase’, the SIRS is replaced by a prolonged hypo-inflammatory 
derangement of the immune system, which has been termed as the ‘compensatory, anti-
inflammatory response syndrome’ (CARS) or ‘persistent inflammation, immunosuppression 
and catabolism syndrome’ (PICS). This can increase susceptibility to an array of diseases on 
account of a poorly functioning immune system for weeks or months. The altered immune 
function relates to changes in the innate and adaptive systems, including consumption of 
complement (196-199). 
  
1.1.6.1. The innate immune system 
The cellular components of the immune system are broadly divided into two 
complementary groups; the adaptive system (comprising T and B lymphocytes), and the innate 
cells (including macrophages, dendritic cells, neutrophils and mast cells). The innate immune 
system is characterized by its ability to quickly recognise and react to a wide array of stimuli, 
which activates a multitude of signalling pathways (e.g. induction of inflammatory genes, 
complement cascade activation), produces pro-inflammatory mediators (e.g. cytokines), 
stimulates leucocyte recruitment to the site of injury (e.g. chemokines and adhesion 
molecules), and is key to the acute phase response in inflammation (200). Regardless of the 
nature of pancreatic injury, the immune system response is initially activated by abnormal 
movement of intra-cellular contents (i.e. DAMPs) by dead, dying and injured pancreatic cells, 
predominantly acinar cells (43). The local and systemic production of proinflammatory 
mediators (e.g. inflammasomes, cytokines) is a key part of the systemic inflammatory 
response. Inflammasomes are innate immune complexes comprising nucleotide-binding 
oligomerization domain-like receptors (NLRs) or absent in melanoma 2 (AIM2) which can 
activate caspase-1, and can subsequently cleave pro-cytokines to secrete IL-1β and IL-18, 
and in-so-doing communicate inflammatory signalling to neighbouring cells (201). 
Consequently, the activation, recruitment and infiltration of leukocyte subsets proceeds with a 
neuro-endocrine stress response. Here I lay out some of the key factors which activate the 
host immune response in AP. 
 
1.1.6.2. Damage-associated molecular pattern molecules (DAMPs) 
1.1.6.2.1. Description and examples of DAMPs 
DAMPs (also termed ‘alarmins’, originally by Dr. Joost J. Oppenheim) comprises a 
growing list of endogenous host molecules which can act as receptor agonists when they are 
released into intra- or extra-cellular compartments in which they do not normally traffic, where 
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they engage receptors which would otherwise bind microbe components, pathogen-associated 
molecular patterns (PAMPs), and thereby activate the innate immune signalling by ‘sterile’ 
means. Post-translational modification of DAMPs can affect their ability to bind receptors (43). 
The DAMPs best characterised include: high mobility group box 1 (HMGB1), histones, nucleic 
acids, adenosine triphosphate (ATP), oxidised-low density lipoprotein (LDL), amyloid-β, 
calcium-binding proteins of the S100 protein family, oxidised-phospholipid, degradation 
products of extra-cellular matrix (ECM) and heat shock proteins (e.g. Hsp60) (202). This 
assorted group of molecules is recognised as an important driver of SIRS and multiple organ 
dysfunction syndrome (MODS) (43, 202-205). 
HMGB1 is one particular DAMP which has been the focus of considerable research 
activity, including in relation to AP. HMGB1 functions in the nucleus as a non-histone 
architectural chromatin-binding protein that bends DNA and promotes protein assembly on 
specific DNA targets, but it also has an extracellular role as an alarmin (206). It can be secreted 
by activated monocytes and macrophages, and passively released by necrotic cells (less so 
by apoptotic cells) and is recognised as an early mediator in sterile injuries (in contrast to a 
late mediator in sepsis) (202, 206-209). Circulating HMGB1 levels have been shown to be 
elevated in patients with AP, particularly in severe disease, and HMGB1 co-culture with select 
proinflammatory mediators, in particular IL-1β and LPS, causes a strong proinflammatory 
synergist effect, detected through highly elevated IL-6 synthesis (210, 211). Systemic HMGB1 
blockage, by intraperitoneal anti-HMGB1 antibody, attenuates severe experimental AP (212). 
Interestingly, intra-acinar HMGB1 appears to protect against acinar damage in experimental 
AP, with loss of HMGB1 in the acinar cells substantially worsening the severity of experimental 
AP in terms of the pancreas injury and lung injury (213). This is in stark contrast to extracellular 
HMGB1 which acts as a pro-inflammatory cytokine (213).   
 
1.1.6.2.2. Pattern recognition receptors (PRRs) 
The detection and response to DAMPs is first mediated by membrane-bound as well 
as cytosolic pattern recognition receptors (PRRs) expressed by resident and circulating 
immune cells (e.g. monocytes), endothelial and epithelial cells (200). Additionally, DAMPs are 
also potent activators of complement, leading to rapid C3a and C5a generation (198, 214). 
PRRs are classified into several groups: AIM2-like receptors (ALRs), c-type lectin receptors 
(CLRs), NOD-like receptors (NLRs), purinergic receptor 2X ligand-gated ion channel 7 
(P2RX7), receptor for advanced glycation end products (RAGE), RIG-like receptors (RLRs), 
Toll-like receptors (TLRs). Some PRRs reside on the cell surface (e.g. TLRs-1,-2,-4,-5,-6,  
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PRR Example PRR site Ligands include Functions include Refs 
ALRs AIM2 Cytosol dsDNA Caspase-1-activating inflammasome assembly (215) 
CLRs Dectin-1 Cell surface (DCs) Fungal 
Antifungal immunity by lymphocyte function. 
IRF-1 activation, Ras/Raf-1, 
Ca2+/calcineurin/NFAR, NLRP3/caspase-1 
(216) 
NLRs NLRP3 Cytosol DAMPs, PAMPs NOD1/2 RIP2, NF-κB, AP-1 (202) 
P2XR7 P2XR7 Cell surface Extracellular ATP Proinflammatory mediator release, proliferation, cell death (217) 
RAGE RAGE Cell surface HMGB1, S100s HMGB1 uptake (43) 
RLRs RIG-I Cytosol Viral PAMPs, other RNAs 
Anti-viral IFN induction, caspase activation, 
IPS-1-dependent NF-κB (218) 
TLRs TLR2 
Cell surface or 
intracellular 
vesicles 
DAMPs, PAMPs  Downstream transcription factor activation (e.g. MyD88-dependent NF-κB activation) (202) 
Table 9: Pattern recognition receptors (PRRs) 
Abbreviations: ALRs: Absent in melanoma 2-like receptors; CLRs: C-type lectin receptor; NLRs: Nucleotide-binding 
oligomerization domain-like receptor; P2XR7s: Purinergic receptor 2X ligand-gated ion channel 7; RAGE: Receptor for 
advanced glycation end products; RLRs: Retinoic acid-inducible gene (RIG)-I-like receptors; RIG-I: Retinoic acid 
inducible gene-I; TLRs: Toll-like receptors. 
 
P2RX7), or on intracellular vesicles, such as the endoplasmic reticulum (e.g. TLRs-3,-7,-8,-9), 
whilst others are less constrained and found in the cytosol (e.g. NLRs) (Table 9) (202, 203). 
 
1.1.6.2.3. PRR activation by location: Cell surface, Intracellular organelle, & Cytosolic  
After DAMP ligand engagement of a PRR, various proinflammatory downstream 
signalling pathways are activated. For example, TLRs are known to recruit a variety of adaptor 
proteins such as Myeloid differentiation primary response protein 88 (MyD88), Toll/interleukin-
1 receptor domain-containing adapter protein (TIRAP), TIR-domain-containing adapter-
inducing interferon-beta (TRIF), TRIF-related adaptor molecule (TRAM) (207). MyD88 is used 
by all TLRs, except intracellular TLR3, and activates transcription factor NF-κB and mitogen-
activated protein kinase (MAPK) pathways, releasing NF-κB for nuclear translocation and 
induction of proinflammatory cytokines and other mediators of inflammation (202).  
Cell surface PRRs TLR2 and TLR4 are activated by HMGB1, heat shock proteins 
(HSPs) and histones (43, 219). Investigators have demonstrated that TLR4 signalling 
contributes to severity in experimental AP, in terms of injury to the pancreas and lung, by 
ameliorating pro-inflammatory signalling in TLR4-knockout mice with AP (220) or in wild-type 
mice with AP which are engrafted TLR4-deficient hematopoietic cells (221). Another important 
surface PRR is RAGE, which is known for RAGE-dependent uptake of HMGB1 by 
macrophages (43), and the ‘HMGB1-self DNA’ complex is internalised by RAGE and is 
recognised by TLR9 (202). In experimental AP, RAGE has been found to modulate 
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inflammasome activation in macrophages, by activating the immune sensor AIM2 which 
initiates AIM2-inflammasome assembly (222). 
TLR9 is found on ER membrane, and can bind to histones and plays a role in DNA 
recognition which may be important in inflammation where self-DNA is incompletely digested 
during apoptosis (43, 201, 202). In AP, activation of TLR9 is known to induce expression of 
genes which encode pro-cytokines and mediates the innate immune responses to nuclear and 
mitochondrial DNAs, histone and HMGB1 (201, 223).  
Cytosolic PRRs, nucleotide-binding oligomerization domain-like receptors (NLRs) and 
retinoic acid-inducible gene-I-like receptors (RLRs) perform cytosolic DAMP/PAMP 
surveillance in many cell types, not only immune cells (43, 202). The NLRs are noteworthy as 
they include NOD-like receptor protein 3 (NLRP3) which resides in the cytosol and can form 
the NLRP3-inflammasome (201). ATP-induced NLRP3/caspase-1 inflammasome activation is 
mediated via the plasma membrane purinergic receptor P2RX7 and has been shown to have 
a contributory role in experimental AP (43, 201). 
 
1.1.6.3. Cytokines and proinflammatory intracellular signaling 
Cytokines are small protein signalling molecules (usually 16 to 25 kDa) produced by a 
wide variety of cells including leucocytes, endothelial cells, fibroblasts and stromal cells, which 
trigger a plethora of inflammatory effects. Chemokines are a subclass of the latter, which 
induce chemotaxis in nearby responsive cells. Several circulating cytokines are robustly 
elevated in the plasma of AP patients and positively correlate with disease severity; most 
notably cytokines tumour necrosis factor α (TNFα), interleukins 1β (IL-1β) and 6 (IL-6), 
interferon γ (IFNγ) and chemokines interleukin 8 (IL-8) and monocyte chemoattractant protein 
(MCP-1) (94, 224-230). These mediators are secreted by injured acinar cells and peripheral 
blood mononuclear cells (PBMCs) (227, 231). 
TNFα is released from many cell types including activated monocytes/macrophages, 
endothelial cells and pancreatic acinar cells (48, 225, 228, 230-233). The precursor protein, 
pro-TNFα, is a transmembrane protein that requires cleavage by TNFα converting enzyme 
(TACE; also known as ADAM17) to allow extracellular release of soluble TNFα. TNF (~20 
types known) binds TNF receptors (~30 types known) and activates important signalling 
pathways, which include NF-κB translocation to the nucleus, as well as c-Jun N-terminal kinase 
(JNK), and p38 MAPK signalling (231, 233). NF-κB plays an important role in various stages 
of AP by mediating the expression of many genes involved in inflammation, including 
intercellular adhesion molecule 1 (ICAM-1) adhesion molecule expression in acinar cells (234, 
235). TNF can induce cell death by apoptosis or necroptosis, both of which depend on the 
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non-ubiquitinatylated status of receptor-interacting serine/threonine protein kinase 1 (RIPK1) 
and recruitment of caspase 8 by the death effector domain of Fas associated via death domain 
(FADD) (233). 
Another robustly elevated circulating cytokine in AP is IL-6, which binds to its receptors 
which are membrane bound (IL-6R) or soluble (sIL-6R) (236). The membrane-bound receptors 
are mainly found on hepatocytes and leukocytes (236). IL-6 bound to its receptor activates 
Jak-2-dependent STAT3 pathway (236). STAT3 is involved in regulation of apoptosis, 
inflammation, and the acute phase response, which includes CRP expression in hepatocytes 
(236). 
The orchestrated induction of cytokines is a highly complex process, and is not well 
characterised in AP principally because the disease course and severity are so variable from 
person-to-person and there is cross-talk between pathways depending upon the involved cell 
types (237). Cytokine knockout mice can throw up unexpected results, for instance IFNy which 
is elevated in AP, particularly in severe disease, was found to be protective against pancreatic 
injury and neutrophil recruitment in cerulein-induced AP by repressing NF-κB activation (238).  
Furthermore, the gut microbiota can have profound effects on the circulating cytokine 
profile and systemic inflammatory response, even in sterile DAMP-driven inflammatory 
conditions (239). One notable function of circulating inflammatory cytokines is to activate the 
endothelium which becomes more porous, allowing mediators to gain access to the 
intercellular space and promote infiltration of leucocytes, which in the case of AP is mostly 
neutrophil infiltration into the pancreas (43, 198). 
 
1.1.6.4. Endothelium, leukocytes and platelets 
1.1.6.4.1. Endothelial cells 
Endothelial cells are the interface between the inflamed pancreas and the circulation, 
which play an important role in inflammation (240). Several adhesion molecules are required 
to facilitate leucocyte recruitment which is a critical step in the inflammatory response: These 
include vascular cell adhesion molecule-1 (VCAM-1), intracellular cellular adhesion molecule-
1 (ICAM-1), endothelial leukocyte adhesion molecule-1 (ELAM-1), and E-selectin are 
expressed on endothelial cells, smooth muscle cells and tissue macrophages (240). These 
adhesion molecules, together with other mediators (e.g. proinflammatory lipid mediators), 
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1.1.6.4.2. Leukocytes - Neutrophils 
The dominant leucocyte in AP in terms of peripheral blood counts during the initial 
stages of AP with and infiltration into the pancreas, is the neutrophil. In humans, neutrophils 
are the most abundant circulating leucocyte, with ~60% of bone marrow dedicated to neutrophil 
production. These phagocytic cells are highly motile, terminally differentiated, and short-lived 
(191). Circulating neutrophils are quiescent, but can be primed and activated, with IL8 an 
important neutrophil-activating CXC chemokine (191). Neutrophils express a vast array of 
PRRs, particularly TLRs, and are thus able recognised and react to PAMPs and DAMPs (191, 
242). Neutrophils are highly effective pathogen killers during the early phase of infection due 
to their capacity to rapidly recruit at sites of infection (e.g. by MIP2) where they provide the first 
line of defence by phagocytosing, killing, and digesting bacteria and fungi. A hallmark of AP is 
the accumulation of neutrophils in the pancreas, which have been shown to modulate the 
severity of both the local changes (e.g. by trypsin activation through NADPH oxidase) as well 
as the systemic manifestations of pancreatitis (44, 243, 244). Necrotic cell death, such as 
acinar necrosis in AP, can generate a profound local inflammatory reaction characterised by 
accumulation of neutrophils which leak proteases and other noxious agents that can damage 
the surrounding viable tissue (245). Such responses are classically considered as ‘wound 
healing’ homeostatic reactions to tissue injury, in which the phagocytic functions of neutrophils 
contribute to the clearance of debris (245). However, neutrophils are capable of causing 
profound collateral tissue injury in the process of debris clearance, and this overexuberant 
neutrophil activity contributes to tissue damage in sterile inflammatory stimuli (246). With 
regard to other granulocytes, eosinophils have been shown to accumulate and degranulate in 
the pancreas and promote inflammation and fibrosis during experimental AP (247). Mast cells 
appear to contribute to pancreatic and lung injury in experimental AP, as demonstrated by the 
amelioration of AP using a mast cell stabilizer (248). 
 
1.1.6.4.3. Leukocytes - Macrophages 
Macrophages are the major resident immune cell in the normal pancreas (249, 250). 
However, in pancreatitis, there is an influx of monocytes/macrophages from the bone marrow 
(249, 251). In mice, these infiltrative monocyte/macrophages highly express cell surface 
lymphocyte antigen 6 complex locus C protein (Ly6Chi) (249, 252), become activated (249), 
and release cytokines and HMGB1 (213, 251). Infiltrative macrophages also help with tissue 
healing by promoting DNA damage repair by making high levels of heparin-binding epidermal 
growth factor receptor-like growth factor (HB-EGF) (253). In general terms, dendritic cells 
(DCs) function as instructors for the T-cell response by antigen presentation. DCs are also 
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normally present in the pancreas, but in contrast to macrophages, DCs do not appear to be 
harmful, but have a protective role when examined in experimental AP, with protection from 
pancreatic injury and reduction in circulating proinflammatory cytokines (254). Besides the 
observed depletion of circulating natural killer (NK) cell numbers in severe AP in humans (255), 
investigators have not found any significant role in clinical or experimental AP for NK cells 
(197, 249). 
 
1.1.6.4.4. Leukocytes - Lymphocytes 
RAG2 knockout mice, lacking both B and T cells, are partially protected against 
pancreatic injury in cerulein-induced AP (249). In clinical studies, there is a decrease in total 
circulating lymphocyte (T & B cell) counts in AP, particularly with severe AP, which is likely due 
to increased apoptosis as well as migration to the site of inflammation, but does not appear to 
have been thoroughly investigated (197, 199, 255-257). This pattern of repressed lymphocyte 
counts is also seen in non-pancreatitis critical illness (258).   
With regard to B cells, whilst there is an overall decrease in CD19+ B cell number (256, 
257), there is a relative increase in CD19+ B cells amongst a pure lymphocyte population, 
particularly with severe AP (259, 260). This at first appears contradictory, but reflects the 
composition of the parent population pool from which the percentages are calculated. Anti-
inflammatory IL-10 producing B cell subset populations are quantitively smaller in severe AP, 
as compared with mild AP (256). 
With regard to T cells (CD4+ and CD8+), these known to be present in small numbers 
in the normal pancreas, but have been shown to be recruited into the pancreas in experimental 
AP (250). It is unknown to what extent T cell activity contributes to SIRS in pancreatitis but 
circulating concentrations of inflammatory mediators made by T cells (and other cells) are 
robustly elevated in the plasma (250). The CD4+ (helper) T cell subgroup contributes to 
pancreatic injury in experimental pancreatitis, whereas the cytotoxic (CD8+) subgroup do not 
(250). It is unclear how CD4+ cells induce acinar cell injury, particularly since the most likely 
culprit, the macrophage activator IFNγ, has surprisingly been found to be protective with 
regards pancreatic injury in experimental pancreatitis using a global IFNγ knockout (238). It 
might be postulated that HIV-induced CD4 cell depletion could clarify the importance of CD4+ 
lymphocytes in AP, but the clinical data are confounded by the use of anti-HIV medications 
which are known to be associated with AP and hypertriglyceridemia (70). Whilst there are 
increased circulating concentrations of CD4+ T helper cell type 1 (Th1) cytokines (ie. IFNγ, 
TNFα) as well as CD4+ Th2 cytokines (i.e. IL-4, IL-5, IL-10) in AP, there appears to be a robust 
asymmetrical suppression of CD4+ subgroup populations. Specifically, the Th1 subpopulation 
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seems to be more diminished than the Th2 subgroup and have altered inflammatory signalling 
profiles (199, 257, 261). It seems likely that altered lymphocyte transcriptome following and 




Circulating platelets are known to be activated in AP patients (262). Platelet integrin 
glycoprotein IIb/IIIa (GPIIb/IIIa) is a receptor for fibrinogen and von Williebrand factor and 
contributes to platelet activation. Activated platelets typically secrete the arachidonic acid 
metabolite thromboxane A2, as well as an array of immunomodulatory mediators (e.g. 
histamine and serotonin), and undergo morphological changes. Activated platelets are known 
to engage with, and activate, neutrophils by forming platelet-leukocyte aggregates (PLAs). A 
platelet-activating factor antagonist, Lexipifant, was tested in a large-scale multi-centred 
double-blinded randomized trial in the UK examining its clinical effect on reducing SIRS and 
AP-MODS in acute pancreatitis (263). The treatment arm was associated with repression of 
circulating proinflammatory inflammatory mediators, inferring an immunological benefit, but did 
not demonstrate improvements in preventing organ dysfunction, which was the main study 
outcome. This was in part due to the unexpectedly high proportion of included participants with 
established organ dysfunction prior to drug delivery (263). It is most likely that platelet 
activation does contribute to SIRS/MODS given some of the improvements in soft end-points 
in the Lexipifant study and from experimental data showing that platelets promotes neutrophil 
accumulation in pancreas and lung in pancreatitis, which is in part mediated by platelet 
production of MIP-2 and CXC chemokines (264-266). 
 
1.1.6.5. Neuro-endocrine stress response 
Critical illness is characterized by alterations in the hypothalamic—anterior pituitary—
peripheral hormone axes, which profile changes between the ‘acute’, ‘chronic’ and ‘recovery’ 
phases of critical illness survivors (267). In contrast to cytokines which are produced by a 
variety of cells and have effects on a large spectrum of effector cell types, hormones are 
distinctly produced by select specialist cells and have more restricted target effects. The early 
acute phase response (first hours to a few days) involves increased systemic cortisol 
availability, elevations in catecholamines, growth hormone, and altered thyroid axis function, 
due to complex mechanisms involving increased pituitary secretion, altered peripheral 
endocrine organ sensitivity and activity, altered plasma protein binding, and reduced hormone 
clearance (154, 267-269). There is activation of the sympathetic nervous system, and other 
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neuro-hormones vasopressin and dopamine are also elevated in critical illness and AP (154, 
267, 269, 270). 
The situation is complicated by target tissue resistance to circulating hormones, in part 
due to proinflammatory cytokine effects on hormone receptor expression (267). The stress-
induced hypercortisolism observed in critically ill patients has many profound physiological 
effects from stimulating catabolism, supporting cardiovascular function and 
immunomodulatory effects. All of the aforementioned acute phase hormones, plus glucagon 
from the pancreas, collectively help maintain tissue perfusion and release rapid provision of 
energy substrates (e.g. glucose, fatty acids, and amino acids) from body stores (271). The 
stress hormone profiles change substantially, however, over the duration of the disease 
course. The most dramatic clinical presentation of this change is the onset of adrenal 
insufficiency, which may require therapeutic supplementation with catecholamines and 
hydrocortisone infusions in the critical care department. In experimental AP in rats, 
hydrocortisone showed beneficial effects in relation to reduced early mortality and suppression 
of cytokines and arachidonic acid breakdown products (272). Dopamine, which is often used 
in critical care for its vasopressor effects, appears to have anti-inflammatory effects in the 
context of experimental AP (270). Other important hormone systems may dysregulate during 
critical illness, such as insulin resistance and sick euthyroid syndrome (271). 
Additionally, heavy alcohol consumption, a frequent inducer of AP, has complicated 
effects upon the hypothalamic and extrahypothalamic stress regulation pathways, with acute 
binge intoxication driving blood cortisol and norepinephrine levels, whilst chronic consumption 
causes neuroendocrine tolerance and blunted stress responses (273). Finally, heavy alcohol 
consumption can give rise to sympathetic dominance and repressed parasympathetic activity 
with altered cardiovascular effects (274). 
 
1.1.6.6. Resolution of the systemic inflammatory response and organ failure in AP 
1.1.6.6.1. The proinflammatory response in microbial invasion versus sterile inflammation 
The acute inflammatory response is an important protective mechanism against host 
attack, such as infection or injury, but must be switched off to avoid the ill effects from 
nonresolving inflammation when the offending insult is neutralized (275). The need for a local 
inflammatory response is most apparent in cases of microbial invasion, as opposed to a sterile 
insult, and the SIRS response, particularly multiple organ dysfunction, appears to be have no 
clear benefit in sterile inflammation. 
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1.1.6.6.2. Resolution of inflammation 
Uncontrolled inflammation, in terms of magnitude and duration, is potentially very 
damaging for the host, and to avoid excessive inflammation there exists inbuilt endogenous 
control mechanisms (276). In self-limiting inflammation, the host inflammatory response 
actively participates in successful resolution, which requires more than simply passive dilution 
of proinflammatory mediators (276). Resolution is a complex orchestrated process which 
involves actions by leukocytes, cytokines, hormones and specialised proresolving mediators. 
Anti-inflammatory lipid mediators include eicosanoids and ‘specialized pro-resolving lipid 
mediators’ (SPMs), which are known to be key signalling molecules in the resolution of 
inflammation, play a pivotal role in regulating the inflammatory profile and return to 
homeostasis. SPMs thwart inflammation by chemokine sequestering and eliminating 
chemoattractant gradients thereby inhibiting neutrophil chemotaxis, promoting leukocyte 
engulfment, and stimulating resolution through the recruitment and differentiation of 
macrophages to clear cell debris and apoptotic neutrophils from inflamed tissue (241). SPM 
comprise lipoxins, resolvins, protectins, and maresins which are biosynthesized from 
arachidonic acid and omega-3 fatty acids (241, 277). 
 
1.1.6.6.3. Resolution in acute pancreatitis 
Failure to resolve inflammation can lead to excess tissue damage, such as persistent 
multiple organ dysfunction in AP, or the development of chronic inflammation in the form of 
chronic pancreatitis. It is known that neutrophil extracellular traps (NETs) are used to degrade 
cytokines and chemokines, thereby disrupting neutrophil recruitment and activation (278). And 
together with macrophages, neutrophils also appear to have a regulatory role in pancreatic 
regeneration (279). With regard to systemic inflammation and proresolving lipid mediators, 
observational studies have shown that impaired clinical recovery amongst major trauma 
patients is associated with higher ratios of proinflammatory leukotriene pathway gene 
expression to resolvin pathway genes, which begs the question as to whether this balance 
could be pharmacologically tipped in favour of proresolution, and if doing so could expedite 
recovery (241). Indeed, manipulation of resolution-regulating lipid mediators might be of benefit 
to patients of all-cause critical illness and lipid mediator resolution therapies may become part 
of a multimodal immunomodulatory approach (277). Whilst SPMs have received little clinical 
study in AP, there has been encouraging research activity with SPMs in experimental AP, 
which have shown to ameliorate injury to both pancreas and lung (280, 281). 
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1.1.7. Long-term sequelae of acute pancreatitis 
Of those who survive an attack of AP, there are potential sequelae which may arise 
long after apparent clinical resolution (282). Transition from AP to clear-cut chronic pancreatitis 
occurs in ~4% of cases (282), and transition to recurrent episodes of AP in ~20% (58). Those 
who get recurrent AP are then at higher risk of subsequently developing chronic pancreatitis 
(58, 282). Endocrine and exocrine and dysfunction are far more common after AP than in the 
general population (87). With regard to the former, newly diagnosed diabetes mellitus (DM) is 
much higher after AP (23%) than in the general population (4-9%) (283). Following discharge 
from hospital after AP, the prevalence of DM is two-fold at 5 years compared with rates at 12 
months (283). Post-pancreatitis diabetes mellitus is more common amongst those who had 
severe AP and in alcohol-related pancreatitis (58, 284). Steatorrhoea, the main symptom of 
exocrine dysfunction, is common after substantial pancreatic necrosis (58). Pancreatic 
exocrine insufficiency can lead to maldigestion and malabsorption and there is an increased 
risk of developing osteoporosis years after AP, particularly amongst females aged 50-64 years 
old, and with recurrent AP (58, 285).  
Following AP, cross sectional imaging may reveal anatomical abnormalities of the 
gland such as pseudocysts and peripancreatic vascular complications (e.g. splenic vein 
thrombosis or splenic artery aneurysm). In the longer term, pancreatic atrophy, ductal changes 
or parenchymal calcification are well recognised. There is little clinical evidence that AP, unlike 
chronic pancreatitis, is a risk factor for pancreatic cancer, however occult pancreatic cancer 
should be considered as a possible trigger of AP in patients aged over 50 years old if no 
aetiology factor is identified (286). 
As is generic amongst surviving critical care patients, AP hospital survivors with 
persistent early organ dysfunction, as compared to those who had mild disease, have been 
shown to have a reduced life expectancy upon hospital discharge (287). Severe AP patients 
were more likely than match controls to develop cardiovascular, gastrointestinal, pulmonary 
and neoplastic disease (288). More specifically, these consisted of myocardial infarction, 
congestive cardiac failure, DM, liver disease, peptic ulcer disease, peripheral vascular disease, 
pulmonary disease, cancers and renal disease (288). As for actual cause of death amongst 
AP hospital survivors, the most common fatal conditions were neoplasia, vascular, 
digestive/metabolic and respiratory causes (288). The biggest difference between the general 
population and was the 3-fold increase in proportion of digestive/metabolic deaths in ccAP 
survivors, classified by the 10th revision of the international statistical classification of diseases 
and related health problems (ICD-10) chapters III, IV, XI, XVIII (288). 
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1.1.8. Potential treatments for acute pancreatitis 
1.1.8.1. Previously tested targeted AP drugs have failed  
A high-quality systematic review of pharmacological interventions for AP tested in 
randomised controlled trials has been published by the Cochrane Library in 2017 (289). The 
investigators analysed 78 trials which met inclusion criteria, to assess the effects firstly on 
short-term mortality for a vast array of treatments in AP patients: antibiotics, antioxidants, 
aprotinin, atropine, calcitonin, cimetidine, EDTA, gabexate, glucagon, iniprol, platelet activating 
factor receptor antagonist (Lexipafant), NSAIDs, octreotide, oxyphenonium, probiotics, 
activated protein C, somatostatin, somatostatin plus omeprazole, somatostatin plus ulinastatin, 
thymosin, ulinastatin, and inactive control (289). This extensive list included protease inhibitors 
(gabexate, aprotinin and ulinastatin), an anticholinergic drug (oxyphenonium), hormones 
(thymosin, calcitonin, octreotide) and acid suppressants (cimetidine and omeprazole). The 
authors had several other outcomes of interest besides short term mortality, including as 
‘serious adverse events’, ‘adverse events’, ‘organ failure’ and ‘sepsis’; please see publication 
for definitions on ‘adverse’ and ‘serious adverse’ events (289). The authors summarised their 
findings by concluding that there: 
“was no evidence of difference in short-term mortality between the groups in 
any of the comparisons. However, the confidence intervals were wide and consistent with 
significant benefits or harms of interventions”. 
Of all the interventions, Lexipafant appeared to be the most promising agent. The last 
clinical trial by Johnson et al. was hoped to demonstrate an improved short-term mortality but 
the results were not consistent with survival benefit (263). An independent critical appraisal of 
the Lexipafant AP studies has been published and is recommended for interested readers 
(290). 
 
1.1.8.2. Benefits of organ support  
However, there are many therapies and interventions offered by modern critical care 
departments which have been shown to optimize organ function (e.g. low tidal volume 
ventilation and prone positioning in moderate/severe ARDS) which likely extend to AP-MODS 
patients, and offer a survival advantage. In particular, a critical review of the evidence of certain 
pulmonary interventions (which is the most frequent extra-pancreatic organ to fail in AP-
MODS) can be can be sourced from the Intensive Care society website <www.ics.ac.uk> (e.g. 
Guidelines on the management of acute respiratory distress syndrome, V1, 2018).  
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1.1.8.3. Potential new AP-specific pharmacological therapies 
Despite the concerns that AP research is dramatically on the decline relative to 
research activity in other areas of gastroenterology (291), there is a raft of exciting new 
possibilities on the horizon, and interested readers can interrogate ClinicalTrials.gov or the 
ISRCTN registry websites for the latest registered trials. Some of the upcoming 
pharmacological therapies entering clinical trials have been captured by PJ Lee and GI 
Papachristou in a recent review published in Nat Rev Gastroenterol Hepatol., with diverse drug 
targets such as: calcium release-activated channel (CRAC), mitochondrial permeability 
transition pore (MPTP), HMG-CoA, G protein-couples receptor 81 (GPR81), TNF synthesis, 
unsaturated free fatty acids and IL-6 (292). Additionally, new technologies have emerged from 
the pharmaceutical industry, such as the CytoSorb® which aims to remove cytokines from the 
circulation by extracorporeal cytokine adsorption (293). Meanwhile some investigators have 
adopted a different approach to organ dysfunction and are focussed on the restoration of 
cellular ATP levels with the hope of enhancing the functional recovery of tissues, akin to 
recharging ‘flat batteries’, with restoration of cellular ATP levels by nutrition, to protect acinar 
cells and vital organ function (294-296).  
One novel avenue for modulating the systemic inflammatory response and multiple 
organ dysfunction in AP is the kynurenine pathway of tryptophan metabolism (297) which has 
been the focus of this PhD thesis. 
 
 
1.2. The kynurenine pathway of tryptophan metabolism 
1.2.1. Essential nutrients, including B-vitamins and amino acids 
All organisms, not least humans, require micronutrients for healthy metabolic 
functioning. Essential micronutrients are particularly important biochemical compounds which 
cannot be synthesized at sufficient quantities within an organism, if at all, and therefore must 
be externally sourced from the diet to maintain health. In disease states, such as acute 
inflammation and critical illness, concentrations of many micronutrients alter, having many 
systemic repercussions on metabolism and inflammation (298). 
 
1.2.1.1. Vitamins 
Essential micronutrients for human health fall into four categories: minerals, essential 
fatty acids, essential amino acids and vitamins. The latter group was originally termed 
‘vitamine’, by Polish chemist Casimir Funk (1884-1967), because they were ‘vital’ for health 
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and, on account of their nitrogenous content, were mistakenly thought to include an amine 
group, which is of course true of amino acids (299). However, the term was popularised and 
remains today as ‘vitamin’. There are 13 vitamins required by humans for metabolic functions, 
which comprise the four fat-soluble vitamins A, D, E, K, as well as water-soluble vitamin C and 
the 8 B-vitamins (B1, B2, B3, B5, B6, B7, B9, B12). The term ‘vitamer’ refers to a chemical 
compound which has a similar molecular structure to a particular vitamin and shows vitamin 
activity in a biological system. With regard to the metabolism of amino acid tryptophan, which 
is discussed later, there are three notable B-vitamins which play important roles in the oxidat- 
 -ive kynurenine pathway: these are B2 (riboflavin and associated vitamers), B3 (niacin and 
nicotinamide) and B6 (pyridoxine and vitamers) (Figure 7). The numbers within the B-vitamin 
category are not sequential as others have come and gone, having been debunked as vitamins 
and lost their status. These include, choline/adenine (formally B4), adenosine monophosphate 
(formally B8), para-aminobenzoic acid (formally B10), pteryl-hepta-glutamic acid (formally B11). 
B6 comprises of six vitamers: pyridoxal (PL), 
pyridoxamine (PM), pyridoxine (PN), and 
their corresponding phosphorylated forms 
(300). Pyridoxal 5’-phosphate (PLP) is the 
active coenzyme form of vitamin B6, which 
is an important cofactor for many metabolic 
enzymes, including those which metabolise 
amino acids. Further details can be found 
below regarding particular vitamers: PLP 
(section 1.2.6.2.) and FAD (section 1.2.7.2). 
 
1.2.1.2. Amino acids 
Amino acids are defined as structural organic units, or monomers, that contain basic 
amine (-NH2) and acidic carboxyl (-COOH) groups, 
centralised on a carbon atom. By way of comparison, 
ketoacids similarly contain a carboxyl (-COOH) group but 
contain a ketone (RC(=O)R1) group, rather than an amine. 
Integral to their function, each amino acid possesses a 
unique organic R group (or side chain) appendage (Figure 
8). When the latter is an aryl group, also called an aromatic 
ring, such amino acids are termed ‘aromatic’. Aromatic 









Figure 7. B-vitamins necessary in the kynurenine 
pathway  
Left: Flavin adenine dinucleotide (B2 vitamer). Top right: 
Nicotinic acid (B3). Bottom right: Pyridoxal 5-phosphate 
(B6 vitamer). Images from Wikipedia. 
 
Figure 8. Amino acid structure 
Each amino acid has an -NH2 amine 
group, and a -COOH carboxyl group, 
and an individual -R side chain. 
Image from Wikipedia. 
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chemically very stable. With the exception of glycine (because of its structural simplicity), all 
amino acids have L- (laevorotatory) and D- (dextrorotatory) stereochemical isoforms, with a 
mirror-image structural orientation, akin to the similarities between left and right feet. This 
structural distinction is important, since the difference of L- or D-isomeric configuration can 
have functional biological implications. For example, L-tryptophan, which has a strong bitter 
flavour has a 100-fold greater affinity to bind albumin than D-tryptophan, which cannot easily 
cross the blood brain barrier and is sweeter than sucrose to taste (301, 302). However, across 
all the kingdoms of life, cells predominantly use L-amino acids (303).   
There are over 140 known amino acids which are component residues of naturally 
occurring proteins (304, 305). Few amino acids independently enact biological activities, rather 
they tend to function as proteins by forming peptide chains (‘polypeptides’). There are 22 amino 
acids that are naturally incorporated into polypeptides, and therefore described as natural, or 
‘proteinogenic’, amino acids (304). Two of these, selenocysteine and pyrrolysine, are 
incorporated into proteins by unique synthetic mechanisms, whilst 20 amino acids are encoded 
by genetic codes of living organisms and are called ‘canonical’ amino acids. Of these 20 
protein-forming amino acids, nine are commonly termed ‘essential’ with regard to human 
health (i.e. His, Ile, Leu, Lys, Met, Phe, Thr, Trp and Val). Because the human body cannot 
synthesize them de novo, they must be externally sourced, normally by dietary ingestion. 
Additionally, other amino acids are described as semi-essential depending on the stage of 
growth and development. In mammals, skeletal muscle is the largest reservoir of both peptide-
bound and free amino acids (306). 
 
1.2.1.2.1. An overview of amino acid functions 
Amino acids have diverse roles which include cellular fuel, signalling, regulators of 
gene expression, precursors for synthesis of hormones and small-molecule nitrogenous 
substances with enormous biological importance. Plasma amino acid concentrations are 
maintained at relatively constant levels in the post-absorptive state in health, but can alter with 
pathophysiological conditions such as disease, lactation and pregnancy (304). Altered levels 
of amino acids and their products can have pathological consequences (304). Interestingly 
intra-peritoneal dosing of rodents with arginine, ornithine and lysine have been shown to 
induce experimental acute pancreatitis, but the primary biological mechanism is unclear (10). 
There are a small number of amino acids which have profound neurophysiological effects; 
some are inhibitory neurotransmitters (e.g. GABA) whilst others are excitatory (e.g. 
Glutamine/Glutamate). 
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Genes encoding enzymes to metabolise arginine and tryptophan are known to respond 
to pro-inflammatory mediators, a key feature that distinguishes them from other amino acids. 
Inflammatory cues induce expression of inducible nitric oxide synthase (iNOS) and two 
arginase isoforms (ARG1, ARG2) which metabolise the former, whilst isoforms of indoleamine 




1.2.2.1. L-tryptophan overview 
The aromatic amino acid L-tryptophan (tryptophan), is required by all forms of life for 
protein synthesis and is a precursor for several bioactive compounds that are known to be 
important for mammalian physiology, such as the neurotransmitter serotonin (5-
hydroxytryptamine), the hormone melatonin, the immune-modulatory kynurenines, and 
nicotinamide adenine dinucleotide (NAD+). Tryptophan has vitamin-like properties through its 
ability to replace pellagra-preventing dietary factor niacin (vitamin B3) at times of dietary niacin 
shortage. In the plant kingdom, where tryptophan is biosynthesised, tryptophan has several 
important biological roles in pollination, development, and plant-pathogen interactions. 
Tryptophan is incorporated into polypeptides or metabolized into auxin, glucosinolates, 
phytoalexins, alkaloids, and other important indolic compounds (308, 309). Polypeptide amino 
acids translated from human genes are exclusively in the L-isomer configuration. In recent 
years it has been established that D-amino acids can in rare instances be post-translationally 
introduced into polypeptides, however D-tryptophan occurs exceptionally rarely amongst the 
appearance of D-amino acids (303, 310, 311). Indeed, only the L-isomer (i.e. L-tryptophan) 
can cross the blood-to-brain barrier (306).  
 
1.2.2.2. Discovery and naming of tryptophan 
Tryptophan was first isolated in the early 1900s by British biochemists FG Hopkins and 
SW Cole (312). Hopkins, along with Christiaan Eijkman of Holland, was later a recipient of the 
1929 Nobel Prize in Physiology or Medicine for the discovery of vitamins. Hopkins and Cole 
digested the phosphoprotein milk extract, casein, with pancreatic secretions [liquor 
pancreaticus (Benger)] in the presence of glyoxylic acid. The name tryptophan, appears to 
have come from the fact that it is ‘revealed by tryptic digestion of a protein’ (302). Additionally, 
the term ‘tryp-’, seems to have originated from Greek ‘τρῖψις’ (‘trîpsis’, or ‘rubbing’) referring 
to the yield of digestive fluid released from rubbing of the pancreas. Of the 20 canonical amino 
acids, tryptophan is the largest by molecular weight, but is the least chemically abundant 
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canonical amino acid in proteins and cells. As with the other aromatic amino acids (tyrosine 
and phenylalanine), tryptophan is naturally fluorescent (313), but possesses some unique 
features which include the possession of an indole structure, and the ability to bind serum 
albumin. Other amino acids, such as glutamine or cysteine are naturally linked in plasma to 
metals, such as copper (314, 315). Indeed only ~10% of tryptophan is freely diffusible, ensuring 
that there is a storage pool of circulating tryptophan awaiting release (301, 302, 316). Non-
esterified fatty acids, and a small number of drugs, are known to be able to displace circulating 
tryptophan from its bond with albumin (302, 314). 
 
1.2.2.3. Biosynthesis of tryptophan 
Humans lack the biochemical pathways to produce tryptophan, the costliest amino acid 
to synthesise, it is therefore derived from the diet and microbiome. Tryptophan biosynthesis is 
performed by lower organisms including most plants, algae, bacteria, and fungi, as well as 
some parasitic protozoans, utilising the shikimate pathway in the initial steps. This pathway is 
also responsible for the synthesis of other aromatic amino acids; namely phenylalanine and 
tyrosine (317). The shikimate-chorsimate pathway is a seven-step biosynthetic metabolic route  
 
Figure 9. Tryptophan biosynthesis by the shikimate and the tryptophan pathways 
Tryptophan biosynthesis starts through the seven-step shikimate pathway. The shikimate pathway produces 
chorismate, a common precursor for aromatic amino acids, at which point the biosynthesis of tryptophan 
diverges from that of tyrosine and phenylalanine. The tryptophan pathway converts chorismite to tryptophan 
via six enzymatic steps. These pathways are present in lower organisms e.g. plants, bacteria. Abbreviations: 
ATP: adenosine triphosphate; DAHP: 3-deoxy-D-arabiono-heptulosonate-7-phosphate; G3P: glyceraldehyde 
3-phosphate; PEP: phosphoenolpyruvate; 5-PRPP: 5-phosphoribosyl pyrophosphate; Pi: inorganic 
phosphate; PPi: inorganic pyrophosphate; NADP: nicotinamide adenine dinucleotide phosphate; TSα: 
tryptophan synthase α subunit; TSβ: tryptophan synthase β subunit.  Copyright © 2020 AJ Hayes. 
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which starts with intermediates from glycolysis and the pentose-phosphate pathway, the 3-
carbon phosphoenolpyruvate (PEP), and the 4-carbon erythrose-4-phosphate (E4P), 
respectively, which are condensed into the 7-carbon compound, 3-deoxy-D-arabino-
heptulosonate-7-phosphate (DAHP) (Figure 9, above). The end product of the shikimate 
pathway is chorismite, which requires an ATP-dependent phosphorylation step (shikimate to 
shikimate 3-phosphate) (318, 319). 
After the formation of chorismite, tryptophan synthesis diverges from that of 
phenylalanine and tyrosine: The initial enzymatic step converts chorismite to anthranilate. 
Three mores intermediate steps are involved, before the final two steps which are both 
catalysed by the a2b2 tetramer bi-enzyme complex, called tryptophan synthase. The α-subunit 
cleaves indole glycerol-3-phosphate into separate indole and glyceraldehyde-3-phosphate, 
and transports the indole through a molecular tunnel before the β-subunit can complete a 
condensation reaction by coupling of serine with indole, resulting in tryptophan formation (317, 
320-322). 
A group of genes called the trp operon encode a cluster of enzymes for the biosynthesis 
of tryptophan in organisms that can make tryptophan. Regulation of the trp operon is interesting 
and complex, with different mechanisms amongst bacterial genera (323). High and low 
intracellular tryptophan concentrations modulate trp operon transcription through a complex 
gene regulatory negative feedback loop. A trp repressor reduces expression of the trp operon, 
whilst attenuation promotes termination of trp operon transcription (324). Because tryptophan 
biosynthesis is costly process in terms of energy consumption, many gut-commensal bacteria 
(e.g. E. Coli) preferentially transport tryptophan intra-cellularly from their environment by way 
of specialised permeases transmembrane transport proteins for nitrogenous and tryptophan 
metabolites needs and resort to de novo biosynthesis only when the environment is tryptophan 
deficient (325, 326). 
 
1.2.2.4. The fate of dietary tryptophan 
Besides aforementioned milk as a source of tryptophan, other natural food types rich 
in this amino acid include poultry, egg, soy, bean, tuna fish, oats, bananas, dried prunes, rice, 
cheese, bread, peanuts and chocolate (327, 328). The World Health Organisation (WHO) 
report in 2007, set the recommended tryptophan intake at 4 mg kg-1 day-1 for healthy 
metabolism (329), supported by original work from Lazaris-Brunner et al. (330). The necessary 
quantity of tryptophan is less than the other eight essential amino acids which ranges from 10 
mg kg-1 day-1 (Histidine and Methionine) to 39 mg kg-1 day-1 (Leucine) (329). 
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After a meal, proteins are digested into di- and tri-peptides, referred to as oligopeptides, 
as well as single amino acids, by the action of pancreatic proteases (trypsin, chymotrypsin, 
elastase, and carboxypeptidases) (4, 331). Oligopeptides absorbed from the intestinal lumen 
do so along the brush border via oligopeptide transporters, and are cleaved by intracellular 
peptidases into single amino acids (331). There are general ubiquitously expressed neutral 
amino acid transporters, as well as high-affinity and highly-selective transporters which are 
important for efficient uptake when concentrations are low (332, 333). Local mediators such 
as cytokine IFNγ can induce tryptophan-selective uptake which is important since IFNγ 
regulates indoleamine 2,3-dioxygenase (IDO) activity and depletes intracellular tryptophan 
levels (334). Tryptophan and other aromatic amino acids that are not immediately metabolised, 
are transported through intestinal enterocytes by amino acid transporter SLC6A19 (B0AT1), 
and exit the basolateral side via SLC16A10 (TAT1) towards the portal blood (331). Recently 
tryptophanyl-tRNA synthetase has also been found to play an important role in high-affinity 
intra-cellular transport of tryptophan, possibly by secretion of TrpRS into the extracellular 
space where it binds tryptophan and re-enters the cell (335). Mutations in genes encoding 
specialised transporters can result in systemic disorders, for example Hartnup disease results 
from functional mutations in SLC6A19 (331, 336). Not all dietary tryptophan directly absorbed 
by the human host, but is instead metabolised within the gut by three major pathways (328):  
i) Gut microbiota can directly metabolise tryptophan to indole, indicant, tryptamine, and 
skatole, and indole derivatives (337). These are ligands of the aryl hydrocarbon 
receptor (AhR) and have important roles in gut immune homeostasis (325, 338-341). 
ii) Serotonin is generated from tryptophan by specialised host intestinal enterochromaffin 
cells and by gut-resident bacteria. Serotonin plays an important role in modulating gut 
motility, sensation and secretion. Gut serotonin does not ordinarily cross the blood-to-
brain barrier, but rather is metabolised and excreted in the urine as 5-hydroxy-
indoleacetic acid (5-HIAA). Normally ~2% of ingested tryptophan is metabolised to 5-
HIAA, which can increase to as much as 60% in patients with malignant carcinoid 
syndrome (342-345). 
iii) The human gut immune and epithelial cells can metabolise gut tryptophan through the 
kynurenine pathway via enzymatic action of indoleamine 2,3-dioxygenase (IDO) (346). 
 
In circulating blood, ~90% of total plasma tryptophan is albumin-bound, with the 
remainder as a free, unbound form. The two states exist in equilibrium, and concentrations 
together alter with light-dark cycle circadian rhythms (347-349). Tryptophan is not biologically 
inert, and suppresses gluconeogenesis by the inhibition of phosphoenolpyruvate 
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carboxykinase, so tryptophan depletion tends to increase plasma glucose levels (350). 
Nitrogen-balanced healthy adults use less than 1% of dietary tryptophan for anabolic protein 
synthesis, because the amount of protein degradation and synthesis is well matched (351) 
(302). Where tryptophan is utilised in the biosynthesis of proteins, the action of tryptophanyl 
tRNA synthetase is necessary to catalyse the addition of tryptophan. The plasma concentration 
of tryptophan is ~40-80 µM in humans and slightly higher in mice (~60-100 µM) (352), and 
levels negatively correlates with increased biological age (353). 
Tryptophan can only be transported across the blood-to-brain barrier in its free form by 
neutral amino acid transporters (354). A major determinant of the ratio of free tryptophan to 
albumin-bound tryptophan is the plasma concentration of non-esterified fatty acids (NEFAs), 
which also bind to albumin and by doing so displace tryptophan from its binding site (355), 
resulting in an elevation of plasma free tryptophan (356, 357). In pregnancy, free plasma 
tryptophan levels are elevated by a combination of albumin depletion and NEFA elevation, 
however the total tryptophan levels are actually reduced (351). Clinical studies have shown 
that tryptophan restriction increases rates of psychiatric disturbance in those with pre-existing 
psychiatric disease (358). 
 
1.2.2.5. Tryptophan deficiency 
Tryptophan levels are monitored by at least two distinct signal transduction pathways 
in mammalian species; sufficiency is monitored by mTOR (mammalian target of rapamycin) 
and deficiency by GCN2 (general control nonderepressible 2) (307, 359, 360). GCN2 is an 
amino acid sensor that binds uncharged tRNAs that accumulate when intracellular amino acids 
are depleted. Tryptophan deficiency results in GCN2-dependent phosphorylation and 
activation of the eukaryotic initiation factor 2 alpha (eIF2a), a GTP binding protein which plays 
a central role in initiating protein synthesis and cell growth (361). T lymphocytes are very 
sensitive to tryptophan shortage, which causes their arrest in the G1 phase of the cell cycle 
(362). Furthermore, tryptophan deficiency stress via GCN2 synergizes with proinflammatory 
cytokine production to increase innate immune responsiveness (363).  
Severe dietary tryptophan restriction in laboratory animals has metabolic and 
immunological effects in the form of weight loss and B cell development arrest (364), as well 
as tendency towards cataract formation (365). Prolonged severe deficiency in tryptophan or 
niacin in humans causes pellagra, which is characterized by the “four D’s”: Dermatitis, 
diarrhoea, dementia and death (366, 367). Some disease states are known to correlate with 
altered tryptophan levels. For example, elevated tryptophan levels have been observed in 
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allergic diseases (368) and acute sleep deprivation (348, 349). Low tryptophan levels are seen 
in HIV/AIDS (369, 370), cardiovascular disease, major trauma, sepsis, and multiple organ 
failure, as well as severe AP (371-375). By way of contrast, excess circulating levels of 
tryptophan may cause systemic toxicity, which can more easily affect non-human mammals 
on account of a different form of TDO when they are administered a diet with high tryptophan 
content (376). 
 
1.2.2.6. Tryptophan metabolism 
Tryptophan is the precursor of many physiological important metabolites produced 
during the course of its degradation along 4 pathways; 3 of which are of quantitatively minor 
significance, whilst the kynurenine pathway accounts for ~95% of overall tryptophan 
degradation (377). The three quantitatively minor pathways (and their important products) 
involve: (1) hydroxylation (serotonin as neurotransmitter and gastrointestinal hormone, and 
melatonin in the pineal gland); (2) decarboxylation (trace amine called tryptamine); and (3) 
transamination (indole 3-pyruvate). 
Approximately 1-2% of ingested tryptophan is metabolised by the serotonin pathway 
(337). The neurohormone melatonin is almost exclusively synthesised within the pineal gland 
and varies dramatically in a circadian fashion and plays an important neuroendocrine signalling 
role, conveying circadian and seasonal information to multiple organ systems. The rate-limiting 
step is in the synthesis of melatonin from serotonin is catalysed by the cytoplasmic enzyme 
arylamine N-acetyltransferase (AANAT; EC 2.3.1.5), an enzyme that displays circadian rhythm 
activity, with higher activity during the dark phase, as opposed to the light-phase (347). 
Melatonin is catabolised to kynuramines which are thought to have a role in promoting sexual 
behaviour (350). Trace amines including tryptamine are found at levels approximately 100-fold 
lower than traditional monoamines such as serotonin (378). Tryptamine is thought to play a 
neuromodulatory role, possibly as a neurotransmitter, and has some weak excitatory effects 
in small animals (378, 379). Transamination of tryptophan gives indole-3-pyruvate, which is a 
ligand of the aryl hydrocarbon receptor (AhR) with anti-inflammatory effects and, in clinical 
studies, reduces anxiety and promotes sleep (350, 380, 381), and is a precursor for kynurenic 
acid (382). 
The major catabolic route of tryptophan in both the brain and the periphery, consists of 
metabolism along the kynurenine pathway which generates an array of biologically active 
indole-derived metabolites, collectively termed ‘kynurenines’, which have bioactive properties 
involved in excitatory neurotransmission (383), immune responses and inflammation (308, 
350, 377, 384).  
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1.2.3. The kynurenine pathway 
1.2.3.1. Discovery of the kynurenines  
Half a century before the discovery of tryptophan, German chemist Justus Freiherr von 
Liebig in 1853 isolated a colourless acidic substance from dog urine, which he named 
‘kynurenic acid’ (derived from ‘kynos’ – ‘ouron’ acid) meaning ‘dog’ (‘κῠ́ων’ or ‘kynos’) and 
‘urine’ (‘οὖρον’ or ‘ouron’) in the original Ancient Greek. This is generally considered to be the 
first of the kynurenine pathway metabolites to be identified (although anthranilic acid was 
discovered 12 years prior), which are collectively termed the ‘kynurenines’; a pathway that is 
conserved in insects, rodents and humans (385). By feeding dogs a protein-rich meat diet, 
Liebig later found he could increase urinary quantities of kynurenic acid sufficient to allow 
chemical analysis. The precursor of kynurenic acid, ‘kynurenine’, was discovered in 1925 by 
Japanese investigators Matsuoka and Yoshimatsu (386). Beadle and colleagues later 
determined kynurenine to be an intermediate between tryptophan and nicotinic acid in 1947 
(387). Over the last century, particularly between 1930 to 1980 (Figure 10), many discoveries 
have been made in regard to the identity of metabolites and kynurenine pathway enzymes. 
 
 
Figure 10. Discovery timeline for the kynurenine pathway 
The publication dates of papers reporting the kynurenine pathway metabolites (top) and pathway enzymes 
(bottom) are shown with increasing time (x-axis) from left to right as shown by arrow. Abbreviations: HAAO: 3-
Hydroxyanthranilate 3,4-dioxygenase; IDO: Indoleamine 2,3-dioxygenase; KAT: Kynurenine aminotransferase; 
KMO: Kynurenine 3-monooxygenase; QPRT: Quinolinic acid phosphoribosyltransferase; TDO: Tryptophan 2,3-
dioxygenase. Copyright © 2020 AJ Hayes 
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The metabolites have importance throughout the various biological domains of life, and 
some can be seen in nature as biological pigments (Figure 11). The enzymes are of great 
importance as pathway catalysts. 
 
  
Figure 11. Kynurenines as biological pigments  
Left: The well camouflaged Misumena 
vatia crab spider seen here attacking 
a wasp, is famous for its colour change 
from white to yellow - the spider’s 
yellow pigments are kynurenine and 
3-hydroxykynurenine (388). 
Right: The red pigment in Trametes 
cinnabarina (Jacq.) fungus was 
isolated and named cinnabarinic acid; 
the metabolite derives its name from 





1.2.3.2. The kynurenine pathway of tryptophan oxidation  
A summary illustration of the current understanding of the metabolism of tryptophan is 
shown in Figure 12, with a focus upon the oxidative kynurenine pathway, detailing the main 
features. Before the 1980s, the ‘kynurenines’ were viewed as relatively innocuous precursors 
to nicotinamide adenine dinucleotide (NAD+), and the focus of research in relation to the 
kynurenine pathway was on its role in the biosynthesis of nicotinamide and the CNS indoles, 
serotonin and melatonin. In 1981, it was discovered that quinolinic acid could excite neurons 
(NMDA-receptor agonist), and the following year kynurenic acid was found to block CNS 
glutamate receptors (350, 390, 391). Since that time, the kynurenine metabolites have 
increasingly been found to have physiological and pathological roles, particularly in the CNS. 
Kynurenines have been linked to several neurological and psychiatric disorders such as 
depression, schizophrenia, Huntington’s disease (392). The majority of mammalian 
kynurenine pathway metabolism takes place in hepatocytes, which contain all the enzymes 
necessary for NAD+ biosynthesis from tryptophan, and is responsible for ~90% overall 
tryptophan metabolism under physiological conditions (302, 377, 393). Because tryptophan 
and some of the kynurenines are able to cross the plasma membrane through specific 
transporters, they are able to exert metabolic modifications to the extracellular environment 
(394). 
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Figure 12. Tryptophan metabolism through the oxidative kynurenine pathway 
Metabolites in black with black arrows denotes the main pathway. Compounds in italics are co-factors and by-
products. Dotted arrow ‘---’ denotes multi-step molecular transformation, whereas a solid arrow denotes direct 
transformation. A double ended arrow head denotes a bi-directional transformation. A double-tailed arrow 
denotes dimerization. Hydroxylation to serotonin and melatonin. Transamination to indole-3-pyruvate. 
Decarboxylation to tryptamine. Abbreviations: AA: Anthranilic acid; ACMS: 2-amino-3-carboxymuconic acid-6-
semialdehyde (also known as 2-acroleyl-3-aminofumarate); AMK: N-acetyl-5-methoxykynuramine; AMS: 2-
aminomuconic-6-semialdehyde; ATP: adenine triphosphate; B3: vitamin B3, nicotinic acid; B6: vitamin B6, 
pyridoxal; CBA: cinnabarinic acid; CO2: carbon dioxide; FAD(*B2): flavin-adenine dinucleotide (active form of 
riboflavin, B2 vitamer); 3HAA: 3-hydroxyanthranilic acid; 3HAAO: 3-hydroxyanthranilic acid oxidase; IDO: 
indolamine 2,3-dioxygenase; KAT: kyurenine aminotransferase; KMO: kynurenine 3-monooxygenase; MAO: 
monoamine oxidase; NaMN: nicotinic acid mononucleotide; NAD+: nicotinamide adenine dinucleotide (oxidized); 
O2: oxygen; •O2−: superoxide anion; PLP(*B6): pyridoxal 5’-phosphate (B6 vitamer); PPi: inorganic 
pyrophosphate; PRPP: 5-phosphoribosyl-diphosphate; QA: quinolinic acid; QPRT: quinolinic acid 
phosphoribosyl transferase; TDO: tryptophan 2,3-dioxygenase.  
Copyright © 2020 AJ Hayes 
 
 
1.2.3.3. Peripheral kynurenine metabolism and drug discovery  
Outside of the liver and the brain, the kynurenine pathway metabolites and enzymes 
are widely distributed in many tissues. Tryptophan degradation in non-hepatic tissues is 
normally small (5-10%), but becomes considerably greater under conditions of immune 
activation, including pregnancy (377, 382). The extrahepatic kynurenine pathway does not 
include all the pathway enzymes, and the local expression of pathway enzymes determines 
which intermediates are produced in each site (377). The concentration of enzymes of the 
kynurenine pathway in peripheral tissues tend to be much higher than in the brain (308). 
Between males and females, both in humans and mice, there are baseline differences in KP 
metabolite concentrations (395). Excreted in the urine, investigators have sought to study the 
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association of KP metabolites and bladder tumours, finding a weak carcinogenic association 
with most metabolites (396). 
Due to the close relationship between kynurenine metabolism and inflammatory 
responses, kynurenines are emerging as recognized players in a variety of common diseases 
outside of the nervous system, such as atherosclerosis (397), diabetes (398), cancer (399), 
obesity (400), as well as critical illness (401) and multiple organ dysfunction in acute 
pancreatitis (375). Where kynurenines have pathobiological roles this is anticipated to be a 
fruitful area for drug discovery (350). 
 
1.2.4. Tryptophan oxidation 
The initial and rate-limiting metabolizing step in the kynurenine pathway is the insertion 
of two oxygen atoms from atmospheric oxygen (O2) into the indole ring of tryptophan, which 
opens the ring and thereby forms a substance called N-formyl-kynurenine (see Figures 11 and 
12). This reaction is catalysed by only two classes of heme-dependent dioxygenases in 
human: namely, tryptophan 2,3-dioxygenase (TDO) and two forms of indoleamine 2,3-
dioxygenase (IDO) (402, 403). In humans, TDO and IDOs are apoenzymes, and thus require 
binding by a cofactor to allow enzymatic activation (376, 404). Heme, or iron protoporphyrin, 
which is produced in cytosol and mitochondria, is the necessary cofactor for TDO and IDOs. 
A holoenzyme is a biochemically active compound formed by the combination of an 
apoenzyme (e.g. TDO) with the necessary coenzyme. In humans at healthy steady state, 
~90% of absorbed tryptophan is metabolised within the liver through the hepatic kynurenine 
pathway (405). TDO is thought to contribute to ~70% of tryptophan oxidation, and thus IDO2 
and other enzymes may contribute to a small proportion of hepatic oxidation of tryptophan 
(405). 
 
1.2.4.1. Tryptophan 2,3-dioxygenase (TDO) 
Discovered by Kotake and Masayama in 1936, TDO was originally assigned the 
ambiguous term ‘tryptophan pyrrole’ (EC 1.13.1.12) (406), but as it was shown to incorporate 
two oxygen atoms into tryptophan to form N-formyl-kynurenine, it was renamed as a 
dioxygenase ~20 years later (EC 1.13.11.11) (407). The Tdo gene is widely distributed across 
species from eukaryotes to bacteria and a few species possess two genes, but it is absent 
within the fungi kingdom (404). Most mammalian species constitutively express TDO in the 
liver, and its activity regulates plasma tryptophan concentrations, and thereby the supply of 
tryptophan to the brain under healthy basal conditions. There are, however, some mammals 
which lack TDO, namely gerbil and rabbit, which instead possess a compensatory higher IDO 
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activity (376, 377). The dominant role of TDO in tryptophan metabolism is apparent from the 
resulting biochemical phenotype of murine Tdo gene knockout, which elevates plasma 
tryptophan concentrations nearly 10-fold (347, 408). TDO is a 167 kDa tetrameric heme-
containing cytosolic protein which has a very restricted substrate specificity, thought to be 
limited to the L-tryptophan enantiomer alone. TDO is predominantly expressed in the liver, 
whilst expression in the brain (347, 409, 410) and other tissues is relatively negligible (394). 
TDO has a short half-life of approximately 2 hours, and its gene expression and apoenzyme 
activity is readily and rapidly modifiable (377). A decrease in TDO activity could be caused by: 
(i) inhibition of apoenzyme synthesis; (ii) inactivation of the apoenzyme, by prevention of TDO 
conjugation with heme or allosteric inhibition; (iii): inhibition of the holoenzyme (apoenzyme 
and cofactor together) activity. In humans, but not all mammalian species, TDO can exist as 
an inactive heme-free apoenzyme, as well as a heme-containing holoenzyme (382). Review 
of the literature reveals several factors which have been demonstrated to regulate the 
production and activity of the TDO-heme holoenzyme: 
i) (+) Substrate (tryptophan) activation - TDO mRNA induction (411)  
ii) (+) TDO mRNA induction by glucocorticoid (377, 412-414) 
iii) (+) Increase TDO enzyme activity by histamine, tyrosine & phenylalanine (414) 
iv) (~) Altered TDO activity by various hormones (e.g. adrenaline, glucagon, insulin, 
thyroxine, progesterone, oestrogen) (377, 382, 415, 416) 
v) (-) Feedback inhibition by NADPH (417) and hydroxykynurenines (3HK, 3HAA) (418, 
419) 
vi) (-) TDO activity limited by inadequate cofactor supply (heme or hypoxia) (420) 
 
1.2.4.2. Indoleamine 2,3-dioxygenases (IDOs) 
1.2.4.2.1. Discovery of IDO1 
Aware that TDO was not able catabolize the D-isoform of tryptophan, Kotake and Ito 
in 1937 reported an intriguing finding of D-kynurenine excretion in the urine of rabbits that 
had been fed the D-tryptophan enantiomer; a result which inferred the existence of an 
unknown TDO-like enzyme (406). This mystery was solved in 1967 when Osamu Hayaishi 
and colleagues in Japan discovered another tryptophan oxidising enzyme in the intestine of 
rabbits (406, 421). In contrast to TDO, this new enzyme had a broader substrate specificity for 
compounds containing indole rings, including both L- and D-tryptophan enantiomers, L- and 
D-5-hydroxytryptophan (serotonin) and several indolamines (377, 422). Thus, it was named 
‘indoleamine’ dioxygenase, to reflect this broad substrate tolerance. Just as with TDO, IDO 
also uses oxygen (O2) to in the oxidation of substrates, and not necessarily the superoxide 
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(•O2−) reactive oxygen species, as was the prevailing theory until 2007 (423). IDO is a 41 kDa 
intracellular heme-containing cytosolic monomeric haemoprotein and, unlike TDO, is found in 
fungi too (404). Amongst mammals, IDO is expressed in various organs, with the liver (where 
TDO is abundantly found) being the notable exception, at least for the original enzyme (i.e. for 
IDO1). In humans, IDO is mostly found in the placenta, lung and alimentary canal (424, 425). 
It appears that mice have very high levels of IDO in epididymis (426), which has not been found 
in humans (425). 
 
1.2.4.2.2. Function of IDO1 
From a cellular perspective, IDO is found largely in macrophages in the periphery, but 
is also expressed in the CNS by astrocytes, microglia, infiltrating macrophages and DCs (347). 
There are many differences between properties of IDO and TDO which have been thoroughly 
compared in a recent review by Professor Badawy (351). In contrast with the liver TDO, the 
extrahepatic IDO is fully heme-saturated (382). Another important difference is the affinity each 
enzyme has for L-tryptophan. Specifically, TDO has a far higher capacity for binding 
tryptophan, but a lower binding affinity (KM 190 μM for purified humane enzyme) for the 
kynurenine than IDO (KM <50 μM) (351). 
In the non-inflammatory healthy state, the contribution of IDO to tryptophan oxidation 
is minimal, but can be dramatically increased upon immune activation, transforming IDO into 
the main controller of tryptophan availability in immune-regulated pathological conditions (377). 
Small molecule inhibitors of IDO1 are emerging for novel cancer therapy adjuncts to help blunt 
tumour neovascularisation and restore immune-surveillance (427, 428). 
 
1.2.4.2.3. Discovery of IDO2 
For the remainder of the 20th centaury, only one form of IDO (EC 1.13.11.17) was 
known, which is often now referred to as IDO1 to distinguish it from a recently identified 
similar enzyme. Forty years after Hayaishi et al. discovered the first IDO, an adjacent gene on 
the mammalian chromosome homologous to IDO1 was reported in 2007 (429). This newly 
discovered gene was shown by three separate groups to encode a new enzyme able to oxidize 
tryptophan isoforms, and other indoleamine derivatives, and was therefore named indoleamine 
2,3-dioxygenase-like protein, or IDO2, on account of its enzymatic activity and structural 
similarity to IDO1 (404, 430-433). The important differences between these apoenzymes, is 
that IDO1 has a far greater affinity for tryptophan than IDO2, and IDO2 is expressed in liver. 
Structurally, IDO1 and IDO2 share significant sequence homology at the amino acid level (43% 
identity for human IDOs) and a similar structure, with IDO2 having a slightly greater molecular 
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weight (47 kDa) (433-435). The biological importance of IDO2 in human health and disease 
is likely to be much less than that of IDO1 due to its lower affinity, and indeed up to 50% of 
individuals of European or Asian descent, and 25% of individual of African descent, are thought 
to lack functional IDO2 alleles on account of single nucleotide polymorphisms (SNPs) which 
abolish IDO2 enzyme activity (431). 
 
1.2.4.2.4. Role of IDO in inflammation 
Under normal physiological conditions hepatic TDO will metabolize the majority of 
available tryptophan, but upon certain immune stimuli IDO expression is upregulated, which 
shifts tryptophan catabolism towards the kynurenine pathway in extrahepatic tissues with 
locoregional tryptophan consumption. Although IDO is also a hemoprotein, it exists in the 
active holoenzyme form (not as an apoenzyme), that cannot be further activated by heme. And 
unlike TDO, IDO activity can be inhibited by high tryptophan substrate concentrations (377).		
Interestingly IDO is not induced by glucocorticoid hormones which are known to induce Tdo 
gene expression in liver (347, 426). However, a number of other immunomodulatory mediators 
are known to induce Ido1 transcription, such as lipopolysaccharide (LPS) and interferon type I 
and type II (436-438). Dexamethasone can further enhance the induction of IDO by interferon 
(439). IDO1 activity in the mouse lung can be increased more than 100-fold over basal levels 
by viral infection caused by influenza (440). By contrast, nitric oxide (NO) is known to inhibit 
IDO activity by a variety of mechanisms (352). Activation of IDO1 has many knock-on effects 
which include locoregional tryptophan depletion which blocks protein synthesis via GCN2 
activation (360, 361, 363), inhibits the immunoregulatory kinases mTOR (360) and 
immunosuppressive effects of increased production of kynurenines by regulatory T cells (441) 
and dendritic cells (DCs) which significantly contribute to immune privilege and maternal 
tolerance towards the allogenic fetus (307, 361), and which foster a microenvironment that is 
defective in recognizing and eradicating cancer cells. 
	
1.2.5. Kynurenine transamination and hydrolysis 
After tryptophan is oxidized to form N-formyl-kynurenine (NF-Kyn), this product is 
hydrolysed by arylformamidase (also called kynurenine formamidase and known by 
abbreviations Afmid, FAM, FKF, KFase) (EC 3.5.1.9) to produce kynurenine with the release 
of formate (formic acid) (442, 443). The Afmid gene is predominantly expressed in the liver 
and kidney, but also by a wide range of tissues (377, 444, 445). As yet unidentified 
formamidase enzyme(s) may contribute to a small proportion of the hydrolysis of NF-Kyn, 
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accounting for <15% of total, although some experts are of the view that much of the hydrolysis 
happens spontaneously, especially under acidic conditions (442, 446). 
 
1.2.5.1. Kynurenine 
Kynurenine is the initial and most abundant of the kynurenines (405), providing 
pathway substrate for the downstream KP enzymes. Once formed, kynurenine may be further 
metabolised at the site of local production (e.g. in the liver as is the case of TDO / Afmid 
metabolism), or else enter the circulation where it is available for endothelial and peripheral 
blood cells, or diffusion into other tissues, or urinary excretion. 
 
1.2.5.1.1. Kynurenine in the periphery 
Within the circulation and tissues, kynurenine is transported across cell membranes by 
the large amino acid transporter SLC7A5 (LAT1). In the vasculature, kynurenine is involved in 
arterial blood pressure regulation, particularly upon immune challenge with IFNγ in an IDO1-
dependant manner (447). Kynurenine suppresses binding to pyruvate dehydrogenase kinase 
(PDK1) or aryl hydrocarbon receptor (AhR) in T cells, DCs and other immune cells which serve 
modulate T cell responses (438). Dendritic cells (DCs) are converted into tolerogenic APCs 
that suppress effector T cells (Teff) responses and promote development of Foxp3-lineage T 
cells; namely, regulatory T cells (Tregs), thereby promoting immune tolerance (438). In the 
absence of inflammation, the brain receives ~60-80% of kynurenine from the periphery by 
competitive transport across the blood-to-brain barrier (via LAT1 transporters), with the 
remainder produced locally in the CNS (448, 449). In the event of a systemic immune stimulus 
however, such as a high dose of LPS, >98% of brain kynurenine comes from the periphery 
where tryptophan is catabolized by IDO to kynurenine (449).  
 
1.2.5.1.2. Kynurenine in the mammalian brain 
Within the brain, kynurenine is not known to have any direct electrophysiological effects 
on neuronal activity (383), but functions as an endogenous ligand of the aryl hydrocarbon 
receptor (AhR) and as a substrate for downstream metabolites and end-products, of which KA 
and QA have the greatest electrophysiological activity (382). In the periphery, kynurenine has 
been found to have several functions (Table 10), principally through the activation of the AhR. 
Specifically, kynurenine can affect immune tolerance, by increasing regulatory T cells (Tregs) 
differentiation and suppression of stimulatory T cell responses (450, 451). Additionally, 
kynurenine can affect bone remodelling and regulation of arterial blood pressure (397, 447). 
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KP metabolite  Source Electrophysiological / CNS actions Peripheral actions 
Tryptophan (Trp) Diet • No electrophysiological effects but precursor 
of downstream kynurenines 




Trp • No electrophysiological effects but precursor 
of downstream kynurenines 
• Unknown  
• Serum levels increase in aging rodents (453) 
Kynurenine (Kyn) 
(3-anthriloyl-L-alanine) 
NFK • No electrophysiological effects but precursor 
of downstream kynurenines 
• AhR agonist 
• Blood pressure regulation (447) (397) 
• Immune tolerance by DC & T cell differentiation to 
Tregs by mechanisms including AhR (438) (450) 
• Suppression of T cell stimulatory response (451) 
• Tumour promotion by AhR (410) 
• Altered bone remodelling by AhR / RUNX2 (454) 





• NMDA antagonist (455) (456) 
• Kainate receptor antagonist (456) 
• AMPA receptor antagonist (456) 
• Nicotinic a7 receptor antagonist (457) (456) 
• iNKT cell cytokine suppression by Gpr35 (458) 
• Adipose energy homeostasis by Gpr35 (459) 
• Inflammatory tumour progression by AhR (460) 
• ROS scavenging (461) 
• Altered bone remodelling by NMDA & AMPA 
receptors (454, 462) 
• Anti-inflammatory : reduces TNFα levels (463) 
3-Hydroxykynurenine 
(3HK) 
Kyn • Cytotoxicity affecting specific neurones by 
generation of reactive oxygen species (e.g. 
striatal neurones) (464) (465) (466) 
• Antioxidant function in cerebral cortex (467) 
 
• Suppression of T cell responses (451, 468, 469). 
• Lymphocyte cytotoxicity (T, B & NK cells) (451) 
• Protective UV light filter in human lens (470) 
• Generation of reactive oxygen species (470) (471) 
• Pro-apoptotic (HEK293, HAEC) (472) (473) 
Anthranilic acid (AA) 
(anthranilate, 2-
aminobenzoic acid) 
Kyn • None 
• Precursor for 3HAA & QA (383) 
• Antioxidant (474) 
• Synthetic AA-derivative drugs have immuno-
modulatory properties 




3HK • Possible group II metabotropic glutamate 
receptor agonist (475). Possibly not (476). 
• Inhibits BH4 synthesis – importance in 
serotonin synthesis (477) 
• Vesicular glutamate transport inhibitor (476) 
• Analgesia (478) 
• Diabetogenic (insulin binding, beta cell toxicity & 
impaired insulin production) (398) 
• Inhibits BH4 synthesis (477) 
• Antioxidant properties (479) 





• Antioxidant function in cerebral cortex (467) 
• Precursor for QA (383) 
 
• Suppression of T cell stimulatory response (451) 
• Apoptosis of thymocytes & Th1 cells (481) 
• Generation of reactive oxygen species (471) 
• Suppression of iNOS induction (482) 
• Inhibits expansion & activation of all T-cells (483) 
Cinnabarinic acid 
(CBA) (cinnavalininate) 
3HAA x2 • Weak agonist of type 4 group metabotropic 
glutamate (mGluR4) receptor (484) 
• CBA is an AhR ligand that stimulates IL22 
production by CD4+ T cells (485) 
• mGluR4-CBA activation (484) 
Picolinic acid (PA)     
(2-pyridinecarboxylate) 
AMS • Diverts metabolism away from excitotoxic QA • Zinc binding ligand (486) 
Quinolinic acid (QA) 
(quinolinate, pyridine-
2,3-dicarboxylate) 
ACMS • Excitotoxic effect (487) 
• NMDA receptor agonist (487) 
• QA-Iron complexes cause lipid peroxidation 
(488) 
• NAD+ precursor 
• Altered bone remodelling by NMDA (454) 
• QA-Iron complexes are pro-oxidant (489) 





• NAD+ precursor • NAD+ precursor 
Nicotinamide adenine 
dinucleotide (NAD+) 
NaMN • Redox cofactors, cell viability and DNA repair • Redox cofactors, cell viability and DNA repair 
Table 10. Kynurenine pathway products of the oxidation of tryptophan in humans  
Abbreviations: ACMS: 2-amino-3-carboxymucononic-6-semialdehyde (also known as 2-acroleyl-3-aminofumarate); AhR: aryl hydrocarbon 
receptor; AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; AMS: 2-aminomuconic-6-semialdehyde; BH4: tetrahydrobiopterin; DCs: 
dendritic cells; Gpr35: G protein-coupled receptor 35; iNKT: invariant natural killer T cell; iNOS: inducible nitric oxide synthase; mGlu4: type 4 
metabotropic glutamate; NAD+: nicotinamide adenine dinucleotide (oxidized); NMDA: N-methyl-D-aspartate; ROS: reactive oxygen species. 
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1.2.5.1.3. Kynurenine in disease 
In the clinical setting, increased circulating kynurenine with decreased tryptophan 
concentrations suggestive of IDO-mediated tryptophan catabolism has been observed during 
recovery after major trauma (374) in systemic lupus erythematosus (SLE) (490) and in obesity 
(400, 491). Equivalent tryptophan levels but increased kynurenine and kynurenic acid 
concentrations have been observed in human inflammatory bowel disease (492). 
 
1.2.5.2. PLP Coenzyme (B6 vitamer) 
Both the transamination (to kynurenic acid) and hydrolysis (to anthranilic acid) of 
kynurenine require the B6 vitamer coenzyme, pyridoxal 5′-phosphate (PLP). Pyridoxine is 
passively absorbed from the diet (e.g. meat, poultry, fish, vegetables and bananas) by the 
jejunum and ileum (493). The liver converts pyridoxine into the active form of vitamin B6, PLP, 
by a process which is tightly regulated, even after a high dietary intake, and PLP is released 
into the plasma, strongly bound to albumin (494). Plasma PLP is dephosphorylated before 
uptake by tissues, cells or across the blood-to-brain barrier (495). Approximately 80% of total 
PLP body store resides in muscle tissues, bound to glycogen phosphorylase, where it is not 
readily released (496, 497). When intake of vitamin B6 is low, or there is an increase in demand 
for PLP during inflammation, PLP is derived from much smaller liver and plasma stores, leaving 
plasma PLP concentrations susceptible to depletion during an immune response, including 
trauma, major surgery and myocardial infarction (496, 498). PLP is involved in >150 enzymatic 
reactions including metabolism of amino acids, neurotransmitters, nucleic acids, heme and 
lipids (495). Additionally, PLP has other effects, such as purinoceptor 2X (P2X) receptor 
antagonism and an inhibitor of some NADH-dependent enzymes (499-501). Plasma PLP 
levels are inversely associated with tissue-nonspecific alkaline phosphatase (ALP) and C-
reactive protein (CRP), which are commonly measured in routine liver screen biochemistry. 
Physiologically, PLP deficiency is seen in pregnancy. Interested readers may wish to consult 
a comprehensive review of PLP by Ueland et al. (502). 
 
 
1.2.5.3. Kynurenine transamination (to kynurenic acid) 
1.2.5.3.1. Sources of kynurenic acid 
Whilst kynurenic acid (KA) can be found in many commonly consumed components of 
the western diet (e.g. broccoli, honey, potatoes and alcohol-containing beverages (503-505)), 
it cannot easily pass through the blood-to-brain barrier due to its polar nature and apparent 
lack of efficacious transport processes. Therefore, KA found within the brain is mostly derived 
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by local neosynthesis from its brain-penetrable precursors kynurenine and/or tryptophan (506). 
Human and rodent genomes encode four kynurenine aminotransferase enzyme isoforms (KAT 
enzymes; E.C. 2.6.1.7) which irreversibly convert kynurenine to KA (377, 383) (Tables 10 and 
11). KATs are dependent on the B6 vitamer, pyridoxal 5′-phosphate (PLP), and an α-ketoacid 
co-substrate for kynurenine transamination. PLP serves as a coenzyme and is passively 
absorbed from the diet (e.g. meat, poultry, fish, vegetables and bananas) by the jejunum and 
ileum (493). Kynurenine is transiently converted to a ketoacid intermediate, which 
spontaneously cyclizes to form KA (507). Alternatively, KA may be generated by the effect of 
reactive oxygen species upon kynurenine (508, 509). 
 
1.2.5.3.2. Kynurenic acid in the mammalian brain 
In the brain, KAT II (also known as aminoadipate aminotransferase) is the dominant 
enzyme responsible for synthesis of kynurenic acid which is mostly produced by neurons, glial 
cells (e.g. astrocytes) and macrophages (510, 511). KA protects against neuronal excitotoxicity 
and has neuroprotective anti-epileptic and anxiolytic properties (512). Mechanistically, KA 
exerts an inhibitory effect on acetylcholine-regulated pathways via the neuronal cholinergic α7 
nicotine receptors, exerting anti-glutaminergic properties, and also serves as a broad-spectrum 
endogenous glutamate receptor antagonist, which acts through three known targets (456, 457, 
513, 514): 
i) N-methyl-D-aspartate (NMDA) receptor antagonist by acting on a specific glycine-
binding receptor site (455, 456, 515, 516) 
ii) Kainate receptor antagonist (456) 
iii) AMPA receptor antagonist (456). 
Wirthgen and co-authors recently published a comprehensive review of the current 
understanding of the immunomodulatory effects of KA and its relation to pathological 
conditions, in the brain and peripherally (509). KA has often been found to be present at 
abnormally low levels in the serum of patients with disorders of the nervous system (e.g. 
affective psychosis, migraine and cluster headache) as compared to controls, but can be 
increased in other neurological conditions (509). 
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Reaction type Product  
(by-product) 










O2 / •O2−  
 






LPS(+), PAF(+),  
NO(-), IL4(-), Trp(-), 
Dexamethasone(+) 
(368, 377, 439, 
487, 518). 
Heme DL-Trp, various 
indolamines,  
O2 / •O2−  
 
Oxidation NF-Kyn Extra-hepatic (placenta, 
lung, lymph node, 







Heme DL-Trp, various 
indolamines,  
O2 / •O2− 
Oxidation NF-Kyn Liver, intestine, 
placenta, brain, lung, 





Unknown (414). No 
cofactor 
































I: Liver, brain, many 
others 
II: Brain, liver, many 
others 
III: Widely expressed 
IV: Heart, liver, brain, 
many others (517) 
KAT I – IV 
(2.6.1.7) 
As above As above 
 
As above 3HK, 
Broad 
specificity for 
amino acid and 
α-ketoacid 
(507) 













Kyn, H2O Hydrolysis AA  
(L-alanine) 
Liver, kidney, spleen, 










KMO   
(8564) 
LPS(+) (518, 522), 
IFNg(+) (518, 523), 






Kyn, H+, O2  Hydroxylation 3HK  
(H2O, 
NADP+) 
Liver, kidney, placenta, 




HAAO   
(23498) 
Isoniazid (but not 
other hydrazine 
drugs) (519) 
Fe2+ 3HAA, O2 Oxidation ACMS Liver, kidney, intestine, 





IFNg(-) (524) Zn2+ ACMS, H+ Decarboxylation AMS  
(CO2) 
Kidney, liver (517) 
QPRT 
(2.4.2.19) 
QPRT   
(23475) 





Kidney, liver, many 
others (517) 
Table 11. Enzymes of the kynurenine pathway of tryptophan metabolism and NAD+ synthesis in humans 
Abbreviations: AADAT: aminoadipate aminotransferase; ACMS: 2-amino-3-carboxymuconic acid-6-semialdehyde (acroleyl aminofumarate); 
ACMSD: amino-carboxymuconate-semialdehyde decarboxylase; AMSD: 2-aminomuconate-semialdehyde dehydrogenase; EC: enzyme 
commission; FAD: flavin adenine dinucleotide; FAM: NF-Kyn formamidase; HAAO: 3-hydroyanthranilate 3,4-dioxygenase; 5HT: 5-
hydroxytryptamine (also known as serotonin); IDO: Indoleamine 2,3-dioxygenase; KAT: kynurenine aminotransferase; KYNU: Kynureninase; 
KMO: Kynurenine 3-monooxygenase; NaMN: nicotinic acid mononucleotide; NF-Kyn: N-formyl-L-kynurenine; 2OG: 2-oxoglutarate; P5P: 
Pyridoxal 5’-phosphate; PPi: inorganic pyrophosphate; PRPP: 5-phosphoribosyl-diphosphate; QA: quinolinic acid; QPRT: quinolinic acid 
phosphoribosyl transferase; TDO: Tryptophan 2,3-dioxygenase; TNF: tumour necrosis factor. General literature with particular 
acknowledgement of the work of AAB Badawy (377) [Table 1]. www.brenda-enzymes.org [ref]; UniProtKB uniport.org. Entrez gene. 
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1.2.5.3.3. Kynurenic acid in peripheral tissues 
In the periphery, KA can be sourced from the diet, or produced from kynurenine by the 
action of reactive oxygen species, or by the enzymatic activity of KAT I-IV by many tissues 
including liver, kidney, skeletal muscle (525), endothelium (526) and heart (527). Indeed, 
exercised skeletal muscle increases conversion of kynurenine to kynurenic acid resulting in 
accumulation of circulating kynurenic acid levels (459, 525). KA has specific functions outside 
of the nervous system, and is a selective agonist for the G protein-coupled receptor 35 (Gpr35) 
and the aryl hydrocarbon receptor (AhR). Gpr35 is predominantly expressed by leukocytes, 
particularly peripheral monocytes, and in alimentary tract crypts which are rich in proliferating 
gastrointestinal stem cells (528, 529). Expression of Gpr35 is thought to be involved in the 
pathogenesis of gastric adenocarcinoma (530) and of non-small-cell lung cancer (531). Of all 
the kynurenine pathway metabolites, only anthranilic acid in humans (but not mice or rats) has 
been shown to activate Gpr35, none of the other metabolites are Gpr35 ligands (463). The 
function of Gpr35 in leukocytes has been the focus of investigation for some authors. Kynurenic 
acid may be involved in the early stages of neutrophil and monocyte adhesion to surfaces 
coated with fibrinogen (529). KA reduces TNFα secretion by peripheral blood monocytes (463). 
Via Gpr35, KA deactivates the NLRP3 inflammasome in macrophages, thereby reducing 
production of IL1β (532). Inflammasome activation is protective in colitis, however, and thus 
KA-induced NLRP3 suppression appears to increases susceptibility to inflammatory bowel 
disease (532). Amongst IBD patients, elevated KA levels have been observed, further 
supporting the role of kynurenic acid as a contributory driver of the colitis disease process 
(458, 533). Elevated KA levels have also been positively correlated with systemic diseases 
such as chronic kidney disease and type 2 DM, with variable findings amongst different cancer 
groups (509). The contribution of Merle Mason from the University of Michigan Ann Arbor in 
isolating KATII as well as a multitude of tryptophan, kynurenine and KAT papers between 
1950-1980 is noteworthy (534). 
 
1.2.5.4. Kynurenine hydrolysis (to anthranilic acid) 
As with KATs, kynureninase (EC 3.7.1.3) is also a PLP-dependent enzyme, which is 
required to perform hydrolysis of kynurenine, and its activity is severely impaired by deficiency 
in the B6 vitamer (535). See Table 11 (above) for details regarding kynureninase (KYNU). 
Kynureninase in humans has two main substrates: kynurenine to make anthranilic acid (AA), 
and 3-hydroxykynurenine (3HK) to make 3-hydroxyanthranilic acid (3HAA). Alanine (L-Ala) is 
an additional product of this hydrolysis chemical reaction. In humans, kynureninase has a ~15-
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20-fold higher affinity for 3HK than for kynurenine, favouring the generation of 3HAA over 
anthranilic acid (Figure 12, above) (536). 
 
1.2.5.4.1. Discovery of anthranilic acid 
The discovery of Anthranilic acid (AA) was made in 1841 by German chemist Carl 
Julius Fritzsche (1808-1871). He named the substance related to indigo, the natural plant dye 
compound, as ‘Anthranilsäure’ – meaning coal (anthrax, Greek), indigo (añil, Spanish) and 
acid (säure, German) (537). AA is a white or yellow substance in solid form, but can have a 
bluish fluorescence in solution (537).  
 
1.2.5.4.2. Known pathophysiological functions of anthranilic acid 
It is able to cross the blood-to-brain barrier, apparently by passive diffusion, rather than 
via a transporter (506). With regards to diseases of the CNS, patients with Schizophrenia (538) 
and Parkinson’s disease (539) have been found to have increased circulating AA plasma 
concentrations. As for systemic diseases, diabetes mellitus and rheumatoid arthritis have been 
found to be positively associated with AA levels. Circulating AA levels from serum of fasting 
diabetics have been found to be increased by an average 2.3-fold in type 1 diabetes mellitus 
(T1DM) compared to non-diabetic controls (540). Gestational diabetics have also been found 
to have elevated fasting serum AA levels as compared to normal glucose tolerance matched 
controls (541). In the synovial joint fluid, anthranilic acid levels were higher in rheumatoid 
arthritis than osteoarthritis patients (542). 
 
 
1.2.6. Kynurenine hydroxylation (KMO / vitamin B2 / 3HK) 
1.2.6.1. Kynurenine 3-monooxygenase 
Kynurenine 3-monooxygenase (KMO, EC 1.14.13.9), is a member of the 
monooxygenase superfamily, and a nicotinamide adenine dinucleotide phosphate (NADPH)-
dependent flavin hydroxylase found in many tissues, that catalyses hydroxylation of 
kynurenine. Hydroxylation is the chemical process that results in the incorporation of a hydroxyl 
group (-OH) into a compound. 
 
1.2.6.1.1. Discovery of KMO 
Originally referred to as ‘kynurenine-3-hydroxylase’, KMO was discovered in RR 
Brown’s laboratory in Wisconsin, USA in 1956 (543). The following year, the enzyme was 
determined to be dependent upon NADPH (authors used the term ‘TPNH’, meaning 
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triphosphopyridine nucleotide; an obsolete synonymous term for NADPH) (544). Ten years 
later, Hayaishi’s laboratory in Japan discovered that KMO was a mitochondrial outer 
membrane protein (545), and the B2 vitamer ‘flavin adenine dinucleotide’ (FAD) was found to 
be a necessary co-enzyme for KMO to function (546). Much more recently was it discovered 
that the C-terminal domain of KMO contains a membrane-targeting sequence that allows the 
enzyme to anchor into the mitochondrial outer membrane (547). The majority of the enzyme is 
located inside the mitochondrial membrane, and part of it sits outside, which is likely to be the 
site for substrate interaction (548). The expression of KMO is much higher in peripheral tissues 
(e.g. liver and kidney) than the brain (549). 
 
1.2.6.1.2. Chemical activities of KMO 
The chemical reaction catalysed by KMO is the incorporation of one atom of oxygen 
into kynurenine in the presence of NADPH as an electron donor (499). KMO is classified as a 
‘flavoenzyme’ (‘flavus’, meaning yellow in Latin), referring to the necessary contribution of the 
yellow-coloured vitamin B2 co-enzyme, FAD, with the ‘flavin’ functional group that facilitates 
electron transfer. The reaction catalysed by KMO and FAD is remarkably complex and has 
recently been studied in fantastic detail, by quantum mechanical calculations, showing that 
there are four successive transformations during the reaction process (550). Many KMO 
inhibitors have been engineered and can be found in the literature (551-553). 
The production of 3-hydroxykynurenine (3HK) by KMO is the dominant route of 
kynurenine metabolism, and hydroxylation of kynurenine proceeds at a rate at least three fold 
that of transamination (to KA) at steady state (302, 554) (see Figure 10, above). Despite its 
key importance in the kynurenine-NAD+ pathway, the activity of KMO, at least in mice, is not 
essential for life as Kmo deleted mice are overtly healthy (555). That said, there are differences 
in tissue expression and activity of KMO amongst different species evidenced by the finding 
that KMO inhibitors produce different biochemical effects in different species (551). 
The KMO gene is located on human chromosome 1q42. Functionally relevant KMO 
single nucleotide polymorphisms have been identified which likely affect substrate binding 
(SNPs) and impair KMO activity (548). The B6 vitamer, PLP, has been shown to inhibit KMO 
activity, most likely by blocking a phosphate binding site, as detailed above (in section 1.2.6.2.) 
(499). KMO is inducible by innate stimuli such as TLR4 agonist LPS (518, 522), and 
proinflammatory cytokines (e.g. IFNγ and TNFα) (518, 523). Under particular circumstances, 
KMO activity can be anti-inflammatory, such as the amelioration of experimental autoimmune 
gastritis, which is a Th17-driven disease model. Pro-inflammatory Th17 helper lymphocytes 
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express KMO, whose activity can be upregulated to catabolise kynurenine, an AhR agonist, 
and thus minimise elevated production of the IL-17 cytokine by Th17 cells (556). 
KMO gene expression has been found to be increased in adipose tissues in obesity on 
account of the fat resident macrophages (400). In end stage renal failure (ESRF) 3HK plasma 
concentrations were ~3 fold higher than controls (557). 
 
1.2.6.2. B2 vitamer: Flavin adenine dinucleotide 
The term ‘vitamin B2’ encompasses three vitamers: riboflavin (7,8-dimethyl-10-
ribitylisoalloxazine), flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). 
Riboflavin is the precursor for the other two, and is enzymatically converted to FMN by 
riboflavin kinase, which by the action of FAD synthase catalysed to produce FAD (558). Dietary 
components rich in riboflavin include meat, poultry, fish, eggs, dairy and green vegetables 
(559). FAD is a redox-active coenzyme associated with various proteins. Deficiency of vitamin 
B2 tends not to occur in isolation in humans, and so there is uncertainty with respect to the 
clinical manifestations of this deficiency (559). Mason helped to define the importance of 
vitamin B2 in tryptophan metabolism (560). Riboflavin and the B2 vitamers are relied upon by 
flavin-dependent proteins, of which there are 90 in humans, with the majority of such enzymes 
catalyse redox processes in primary metabolic pathways such as the Krebs cycle, oxidation 
and degradation of amino acids (561). 
 
1.2.6.3. 3-Hydroxykynurenine 
Originally isolated from pupae of the blowfly (Calliphora erythrocephala) in yellow 
crystalline form, 3-hydroxykynurenine (3HK) was first identified in mammalian biological 
systems in the mid-20th centaury (562). Along with kynurenine, 3HK is known as a yellow 
biological pigment in spiders and other insects (Figure 11, above). In humans, 3HK along with 
kynurenine and other KP metabolites can be found in the lens of the eye where it functions as 
one of many UV light filtering compounds (563). Another known physiological role for 3HK is 
its suppressive effect upon T-cell stimulatory responses (451, 468, 469).  
Circulating 3HK shares the large neutral amino acid transporters used by kynurenine, 
to penetrate the blood-to-brain barrier (506) and thereafter enter into brain cells (564). This is 
not surprising since 3HK and kynurenine are both neutral alpha-amino acids (506). The 
biochemical effects of 3HK have been most closely studied in the brain, where both damaging 
(464-466) and protective effects have been reported (467). The hydroxykynurenines, 3HK and 
3HAA, which share an o-aminophenol structure, are redox modulators which can enact strong 
anti-oxidant and pro-oxidant effects under certain conditions, which is likely due to the ease of 
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electron or H-atom abstraction (565). Prime examples, of this paradoxical redox effect is 
observed in the oxidation and reduction of haemoglobin by hydroxykynurenines (566), and in 
physiological and pathological roles in the human lens (471, 563, 567). Both 
hydroxykynurenines have been shown to function as antioxidant scavenging radicals, mostly 
likely due to their phenolic moiety – a term which refers to the presence of a hydroxyl group (-
OH) bound to an aromatic hydrocarbon ring (Figure 13) (467, 479, 563). 
 
 
Figure 13. Chemical structures of tryptophan and the kynurenine metabolites  
Dotted arrow ‘---’ denotes multi-step molecular transformation, whereas a solid arrow denotes direct 
transformation. Abbreviations: CHO2: formate; 3HAA: 3-hydroxyanthranilic acid; NAD+: nicotinamide adenine 
dinucleotide (oxidized); O2: molecular oxygen; •O2−: superoxide anion; PPi: inorganic pyrophosphate; PRPP: 5-
phosphoribosyl-diphosphate; QA: quinolinic acid.  
Copyright © 2020 AJ Hayes 
 
 
1.2.6.3.1 Autoxidation of 3HK and release of ROS during spontaneous transformation 
In the presence of molecular oxygen, and under physiological conditions (i.e. pH and 
temperature), 3HK is readily autoxidized (shown under in vitro conditions) (465). Oxidation 
takes place when a molecule, atom or an ion lose an electron, which simultaneously causes 
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reduction (meaning gain of electrons) of oxygen-containing chemical species. Redox-active 
transition metals (e.g. Cu2+ and Fe3+) strongly catalyse the oxidation of 3HK (471), and this 
oxidized 3HK can spontaneously form several compounds (464, 465, 471, 568-573). These 
compounds comprise xanthommatin (Xan) and hydroxy-xanthommatin (OHXan), and 
dihydroxy-quinolinequinone-carboxylic acid (DHQCA), as well as small quantities of other 
unidentified compounds (572, 574) (Figure 14). OHXan and Xan are products of self-
dimerizing oxidised 3HK - requiring two molecules of 3HK to make a single molecule of Xan. 
During 3HK oxidation, molecular oxygen (O2) gains electrons, making reactive oxygen species, 




Figure 14. Cellular toxicity from 3-hydroxykynurenine-induced reactive oxygen species.  
Three mechanisms known to cause redox stress (A-C): A: Autooxidation of 3-hydroxykynurenine (3HK) has 
been described by authors with H+ abstraction postulated from the -OH group, -COOH group, or the -NH2 group, 
in the presence of transition metals (Fe3+ or Cu2+) giving rise to generation of superoxide (O2•-), which 
subsequently produce hydrogen peroxide (H2O2) and hydroxyl radicals (•OH). B: Autooxidation can result in 
spontaneous production of metabolites besides oxidized 3HK, including DHQCA, and 3HK self-dimerization 
products xanthommatin (Xan) or hydroxy-xanthommatin (OHXan) which results in the production of various 
reactive oxygen species (ROS) when two molecules of 3HK combine. C: 3HK has also been shown to modify 
cytosolic NAD(P)H oxidase subunits, which promotes translocation to the plasma membrane for assembly to 
NAD(P)H oxidase which makes O2•-. The observed effects of unchecked ROS caused by 3HK are listed in (D) 
and the specific targets of ROS are proximal in location to the site of ROS generation. Effects include 
mitochondrial membrane damage and cytosolic release of cytochrome c, high intracellular calcium 
concentrations by endoplasmic reticulum release, apoptosis, NF-κB activator, and DNA damage.  
Copyright © 2020 AJ Hayes 
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-wise would only react very slowly with biomolecules such as DNA, proteins and membranes 
(575, 576). Additionally, 3HK can react with, and chemically modify, cytosolic NAD(P)H 
oxidase subunits, which promotes translocation of subunits to the plasma membrane for 
construction of NAD(P)H oxidase which produces superoxide (•O2−) in the process of 
generating NADP+ from NADPH (473). As well as producing other reactive oxygen species 
(ROS), superoxide (•O2−) can react with nitric oxide (e.g. in the vasculature) to form 
peroxynitrite, a reactive nitrogen species (RNS). Superoxide (•O2−) is rapidly converted to 
hydrogen peroxide (H2O2) by the enzymatic activity of superoxide dismutase enzymes 1 and 
2. Unlike superoxide, H2O2 is not a free radical and has a much greater diffusion radius, and 
can readily diffuse across biological membranes. H2O2 can activate NF-κB by stimulating the 
phosphorylation of the IκB kinase complex, which is degraded, releasing NF-κB p50/p65 dimer 
to bind DNA (577). H2O2 reacts with metal cations (Fe2+ or Cu+) to generate the highly reactive 
hydroxyl radical (OH•), termed the ‘Fenton reaction’ (575). Hydrogen peroxide can cause 
neuronal apoptotic death, by mechanisms which include increase of intracellular free Ca2+ 
(578, 579). Oxidized 3HK can exert many damaging effects (573). These include the ability for 
oxidized 3HK to directly bind protein amino groups, 3HK-generated ROS can modify proteins, 
oxidise lipids, break DNA strand and modify nucleic acids, modify gene expression by 
activation of redox-sensitive transcription factors, induce cytochrome c release into the cytosol 
and induce apoptosis (473, 573). 3HK-induced cytotoxicity can be rescued by the use of free 
radical scavengers, caspase inhibitors and pharmacological closure of the mitochondrial 
permeability transition pore (580). Lastly, some of the damaging properties attributed to 3HK 
may be caused by its onward metabolites, for example, 3HAA which can also undergo 
autooxidation with the formation of ROS (350). Also, 3HK may potentiate the effects of other 
metabolites, such as quinolinic acid, and together can synergistically cause toxicity in the brain 
and aggravate excitotoxic nerve cell loss (581). 
 
1.2.6.3.2  3HK in diseases 
With regard to neurological disease, elevated levels of 3HK have been found in different 
parts of the brain in post-mortem brains of patients with Huntington’s disease (582-584), 
Parkinson’s disease (585), pneumococcal meningitis (586), and in AIDS-related dementia 
(587). Different types of neurons have different threshold levels for neurotoxicity to increased 
3HK concentrations. Further specifics regarding 3HK in neurodegenerative diseases can be 
read in a thorough review of the topic by Colín-González et al. (573). 
In relation to systemic human disease, elevated plasma 3HK concentrations have been 
found to confer an increased risk of acute coronary events over a 10-year period (588), and is 
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associated with incidence of obesity and diabetes mellitus (588, 589), and chronic renal failure 
(557) and severe acute pancreatitis (375). In an animal model of viral pneumonia, 3HK levels 
were elevated in lung homogenate (479). Additionally, along with 3HAA, 3HK appears to be 
an endogenous carcinogen, particularly with respect to bladder cancer by causing DNA 
damage through generation of H2O2 (570, 590).  
A state of oxidative stress only exists, however, where there is an excessive production 
of ROS (such as by the aforementioned mechanisms – Figure 14) which saturate the cell’s 
defence redox antioxidant systems. Furthermore, ROS are not always deleterious, and the 
literature supports a broader role for ROS, which include intracellular signalling mediators to 
regulate numerous physiological and biological responses. Examples include growth factor 
regulation, intracellular signalling, hypoxic signal transduction, autophagy, immune response 
and stem cell proliferation and differentiation (591, 592). 3HK can be eliminated by onward 
metabolism or transported out of a compartment using the large neutral amino acid transporter 
(564, 568, 573). Similar to kynurenine, 3HK in humans serves as a substrate for competing 
enzymes: kynureninase and KATs (Table 11). Humans do not make phenoxazinone synthases 
which catalyse the conversion of 3HK to XA in many forms of life (e.g. fungi, plants, bacteria 
and insects), rather humans rely on KATs to convert 3HK to XA. The majority of 3HK is 
metabolised by kynureninase to give 3-hydroxyanthranilate (3HAA) and amino acid L-alanine, 
by hydrolytic cleavage of the Cβ-Cγ bond (565). Indeed, mammalian kynureninase 
preferentially utilises 3HK over kynurenine as a substrate, which in the human liver has been 
reported to have an activity ratio of ~15-20:1 (593, 594). Kynureninase is heavily dependent 
upon coenzyme vitamin B6 (PLP) (see 1.2.6.2.), and is exquisitely sensitive to lack of this 
vitamin; resulting in accumulation of 3HK when the supply of PLP is insufficient (535, 595, 
596). And on replacement of PLP, plasma 3HK levels reduce (597). 
 
1.2.7. 3HK transamination (to xanthurenic acid) 
3HK has two primary metabolic fates (see Figure 15, below): either it is hydrolysed to 
3HAA, or converted into the more chemically stable compound xanthurenic acid (XA) (598). 
On account of its yellow colour (‘xantho’ meaning ‘yellow’) and isolation from urine, 4,8-
dihydroxyquinoline-2-carboxylic acid was named ‘xanthurenic acid’, and was first described by 
L Musajo in 1935 (599).  
In humans, XA is formed by transamination of 3HK by KAT enzymes I-IV (E.C. 2.6.1.7), 
in the same way as KATs convert kynurenine into kynurenic acid with coenzyme PLP (see 
1.2.5.2.). Intriguingly, mosquitoes have poorly functioning KAT enzymes with respect to 3HK 
transamination and do not possess kynureninase which is the major enzyme for 3HK 
Metabolic regulators of inflammation in acute pancreatitis                                                         S0897427 
Alastair J Hayes 
  - 75 -  
 
catabolism in most species (600). To prevent cytotoxic accumulation of 3HK, mosquitoes use 
two alanine glyoxalate aminotransferase enzymes (AGTs) to catalyse 3HK transamination to 
XA (601), which may give the additional benefit of antioxidant protection of the mosquito gut 
during ingestion of a blood meal (602). 
The main biological functions of XA are listed in Table 10 (above). XA can penetrate 
the blood-to-brain barrier and has a particular neurophysiological role with regard to glutamate 
neurophysiology. Some have reported XA as an agonist for group II metabotropic glutamate 
receptors (mGluR2 and mGluR3) (475), but these conclusions have been brought into question, 
and XA may instead modulate synaptic transmission by vesicular glutamate transport (VGLUT) 
inhibition (476). VGLUTs transport glutamate, an excitatory neurotransmitter, from the 
cytoplasm and into synaptic vesicles. As well as having apparent analgesic effects (478), XA 
may also limit serotonin biosynthesis by inhibiting production of the tryptophan hydroxylase 
cofactor tetrahydrobiopterin (BH4) (477). In the periphery, XA has diabetogenic effects (insulin 
binding, beta cell toxicity with impaired insulin production) (398), pro-apoptotic effects (480), 
and also antioxidant properties (479, 602). 
 
Figure 15. 3-Hydroxykynurenine catabolism and NAD+ biosynthesis  
Metabolites in black with black arrows denotes the main pathway. Compounds in italics are co-factors and by-
products. Dotted arrow ‘---’ denotes multi-step molecular transformation, whereas a solid arrow denotes direct 
transformation. A double ended arrow head denotes a bi-directional transformation. A double-tailed arrow 
denotes dimerization. Abbreviations: ACMS: 2-amino-3-carboxymuconic acid-6-semialdehyde (also known as 2-
acroleyl-3-aminofumarate); AMK: N-acetyl-5-methoxykynuramine; AMS: 2-aminomuconic-6-semialdehyde; ATP: 
adenine triphosphate; B3: vitamin B3, nicotinic acid; B6: vitamin B6, pyridoxal; CBA: cinnabarinic acid; CO2: 
carbon dioxide; 3HAA: 3-hydroxyanthranilic acid; 3HAAO: 3-hydroxyanthranilic acid oxidase; KAT: kynurenine 
aminotransferase; MAO: monoamine oxidase; NaMN: nicotinic acid mononucleotide; NAD+: nicotinamide 
adenine dinucleotide (oxidized); PLP(*B6): pyridoxal 5’-phosphate (B6 vitamer); PPi: inorganic pyrophosphate; 
PRPP: 5-phosphoribosyl-diphosphate; QA: quinolinic acid; QPRT: quinolinic acid phosphoribosyl transferase.  
Copyright © 2020 AJ Hayes 
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1.2.8. 3-Hydroxyanthranilic acid formation and onward metabolism (CA, ACMS, QA, 
PA) 
3HK is converted by kynureninase and PLP into 3HAA (Figure 15). PLP deficiency 
causes increased 3HK due to impaired 3HK hydrolysis activity (595). 3HAA is structurally 
similar to 3HK (Figure 13, above) and shares many biochemical properties. 3HAA also has 
anti-oxidant (467, 479, 603), and pro-oxidant properties (471).  
Two molecules of 3HAA are converted into one molecule of cinnabarinic acid by 
oxidative dimerization, which may occur by non-enzymatic and enzymatic processes (e.g. 
cinnabarinate synthase, ceruloplasmin, superoxide dismutase, catalase) (485, 604, 605). This 
red coloured compound ‘2-amino-3-oxo-3h-phenoxazine-1,9-dicarboxylic acid’, was originally 
extracted from the red coloured fungus Trametes cinnabarina (Jacq.), and its name, 
‘cinnabarinic acid’ is a reference to this fungi (Figure 11, above) (389). Cinnabarinic acid is an 
endogenous ligand of the aryl hydrocarbon receptor which can drive IL-22 production (485), 
and is a weak agonist of type 4 group metabotropic glutamate receptors (mGluR4) (606). 
Alternatively, 3HAA may be converted into 2-amino-3-carboxymuconic acid-6-
semialdehyde (ACMS), also known as 2-acroleyl-3-aminofumarate, by 3-hydroxyanthraniliate 
3,4-dioxygenase (HAAO; E.C. 1.13.11.6). This unstable compound sits at a junction in the 
kynurenine pathway (Figure 15) (377); ACMS can either proceed towards NAD+ formation via 
quinolinic acid (QA) or form 2-aminomuconic-6-semialdehyde (AMS), the common precursor 
for picolinic acid and acetyl-CoA. Basal metabolic function favours the non-enzymatic 
cyclization of ACMS to QA (towards NAD+ production), over the production of AMS (377). 
Quinolinic acid (QA) (pyridine-2,3-dicarboxylic acid), was first identified as an 
tryptophan intermediate by LM Henderson (607). 3HAA-3,4-dioxygenase (HAAO; E.C. 
1.13.11.6) (Table 11, above) is reportedly the most active kynurenine pathway enzyme and 
rapidly converts 3HAA into the unstable 2-amino-3-carboxymuconate semialdehyde (ACMS), 
which undergoes nonenzymic cyclization to form quinolinic acid (Figure 15) (377, 608, 609). 
The name quinolinic acid (QA) derives from quinoline, from which it can be produced through 
an oxidation reaction. And the term quinoline is derived from quinine, a medical alkaloid first 
isolated from the bark of a cinchona tree species. Unlike other KP metabolites, QA is a 
colourless solid substance, but has multiple physiological roles in the brain and the periphery 
(see Table 10, above). Because of its polar nature and lack of efficacious transport processes, 
similar to KA, QA cannot easily cross the blood-to-brain barrier, and accordingly all QA found 
in the brain is generated from oxidised 3HAA (506, 554, 610). In addition to providing substrate 
for NAD+ production, QA has many excitotoxic effects in the brain (487): It is a powerful 
glutamate agonist and exerts an excitatory effect at the NMDA receptor located on primary 
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astrocytes (487, 554); QA-Iron complexes can cause lipid peroxidation (488); QA potentiates 
cytotoxic damage when present with 3HK (581); and QA may be pathologically important in an 
array of common and debilitating neurological and psychiatric diseases (554, 611). In the 
periphery, QA functions as an NAD+ precursor but has other effects, such as altered bone 
remodelling by NMDA (454), pro-oxidant effects as QA-Iron complexes (489), and apoptosis 
of thymocytes and Th1 cells (481). QA metabolism proceeds towards NaMN and then NAD+ 
biosynthesis. 
Formation of picolinic acid (PA), also known as pyridine-2-carboxylic acid, diverts 
metabolism away from QA production (Figure 15). PA is a bidentate chelating ligand (meaning 
it binds with two sites) and facilitates zinc absorption from the intestine (377, 382, 486). 
Picolinic acid is formed by non-enzymatic cyclization of AMS. However, PA formation depends 
on the degree of the substrate saturation of the enzyme (ACMSD; E.C. 4.1.1.45) competing 
with this cyclization. Only when ACMSD is maximally saturated with ACMS is there sufficient 
quantity of AMS substrate to allow PA production to proceed faster than QA formation (377). 
AMS that is not converted into PA is available for 2-aminomuconic-6-semialdehyde 
dehydrogenase (AMSD) production of 2-aminomuconic acid, which is further metabolised to 
yield acetyl coenzyme A (Co-A) (377). Acetyl CoA is oxidised through the Krebs cycle (named 
after physician and biochemist Sir Hans A Krebs, 1900-1981, Nobel prize winner 1953). 
 
1.2.9. Nicotinamide adenine dinucleotide (NAD+) 
Quinolinic acid is metabolised by quinolinic acid phosphoribosyl transferase (QPRT; 
EC 2.4.2.19) with 5-phosporibosyl-diphosphate (PRPP), by a phosphoribosyl transfer reaction 
followed by decarboxylation, to form nicotinic acid mononucleotide (NaMN); the substrate for 
nicotinic acid adenine dinucleotide (NAAD), which is converted into NAD+ (367, 612, 613) 
(Figure 15, above). Nicotinic acid (also known as niacin), a form of vitamin B3, can also be 
converted to NaMN and to NAD+ by the Preiss-Handler pathway. Vitamin B3 consists of three 
vitamers: nicotinamide, niacin (nicotinic acid) and nicotinamide riboside (see Figure 7 for 
chemical structure of nicotinic acid). Dietary nicotinamide can be used to produce NAD+ by the 
salvage pathway (Figure 15). However, dietary tryptophan is more effective than dietary 
nicotinamide or nicotinic acid in elevating liver nicotinamide dinucleotides and urinary levels of 
N-methylnicotinamide (377). NAD+ is an essential pyridine nucleotide that serves as an 
electron carrier in cellular metabolism. Beyond its role as a co-enzyme in redox reactions, 
NAD+ is an important co-substrate for three classes of enzymes: Sirtuins (SIRTs), adenosine 
diphosphate (ADP)-ribose transferases (ARTs) and poly(ADP-ribose) polymerases (PARPs), 
the cyclic ADP-ribose (cADPR) synthases (367, 382). NAD+ is consumed by these enzymes 
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and continuously degraded. To maintain stable cellular concentrations of NAD+, organisms 
primarily use a NAD+ salvage pathway but also rely on biosynthetic pathways. Without enough 
NAD+, pellagra occurs, and this is why vitamin B3 is referred to as the pellagra-preventing factor 
(367, 382). 60 mg of dietary tryptophan is considered to be roughly equivalent to 1mg of niacin 
(614), but there are wide individual variations on this approximate ratio (302). Daily niacin 
requirements of adults are ~15 mg. In the absence of niacin, a daily intake of ~1 g of tryptophan 
can meet this requirement. However, this necessitates an intake of ~100 g of protein, as the 
tryptophan content of most proteins is ~1% (419). For interested readers, review publications 
by A Badawy make for a thorough introduction on the topic of the kynurenine pathway of 
Tryptophan-NAD+ metabolism (377). 
 
1.3. Kynurenine pathway flux in acute inflammation 
The acute phase response refers to an array of rapid host responses which involves 
dramatic leukocyte, humoral immunity, neuroendocrine and metabolic changes after a 
stressful physical stimulus. Collectively, these responses are generally protective and infer 
host survival advantage, when they are modest and short-lived. The acute phase components 
work in concert and biochemically interact in this multi-system organ response. The least well 
defined component of the acute phase response is arguably the metabolic changes which 
orchestrate nutrient/energy flux (615). 
First described in 1942 by Sir David Cuthbertson (1900-1989, University of Glasgow), 
the ‘ebb’ and ‘flow’ phases of the acute stress response to injury and trauma are concepts 
which have been taught over the generations and still found in postgraduate textbooks more 
than 70-years later (e.g. Sabiston Textbook of Surgery, 20th Edition) (615-617). Broadly, the 
‘ebb period’ denotes the early period of depressed metabolism and reduced energy 
expenditure after major injury, whilst the ‘flow period’ refers to a hypercatabolic phase (616). 
Contemporary scientific understanding of the metabolic response to injury includes altered 
metabolic rate, preference of certain macronutrients for energy substrate, stress 
hyperglycaemia, muscle wasting, changes in body composition and behaviour (615). 
Metabolism of macronutrients during critical illness is altered at several stages: digestive 
absorption, intracellular intermediate metabolism and substrate oxidation (615). Recently 
investigators have shown how transcriptional reprogramming in critical illness helps protect 
against the prooxidative effects of the inflammation by maintaining redox homeostasis (618). 
In critical illness, particularly in the ‘flow’ phase, there is a robust phenotype of negative 
nitrogen balance which is under the influence of hormones and inflammatory mediators. 
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Proteins are dismantled by cellular proteasomes and the resulting peptides and amino acids 
are used in the synthesis of inflammatory mediators, gluconeogenesis (mainly alanine and 
glutamine) or oxidised and excreted as nitrogenous wastes (e.g. urea and ammonia) (615). 
Amino acid metabolism in critical illness, specifically tryptophan oxidation, in the so-called ‘ebb’ 
phase, is of particular interest and how this contributes to the acute phase response. 
 
1.3.1. Flavin Adenine Dinucleotide (B2) and Pyridoxal 5-Phosphate (B6) in inflammation  
Several of the kynurenine pathway enzymes are dependent upon B2 (see section 
1.2.6.2.) and B6 (section 1.2.5.2) vitamers, as co-enzymes. Such reliance has been well 
demonstrated from B2 (560) and B6 (619) deficiency and supplementation studies with 
tryptophan loading. B2 vitamer, flavin adenine dinucleotide (FAD), is required by KMO, whist 
B6 vitamer, pyridoxal 5’-phosphate (PLP), is required by kynureninase and KATs (I-IV). In 
systemic inflammation and critical illness, several studies have consistently found that whilst 
red cell concentrations of FAD and PLP are preserved, plasma levels significantly drop (494, 
620-627). Some investigators have sought to understand why and how plasma levels drop 
(e.g. redistribution of vitamers, including mobilisation to and consumption at sites of 
inflammation, or vitamer catabolism), and how erythrocytes maintain vitamer concentrations 
(495, 496, 625, 628, 629).  
Riboflavin, which is a co-enzyme for 90 human proteins, has been found to have 
protective effects against sterile injury (630). PLP also has multiple inflammatory and 
immunomodulatory effects, and Ueland et al. have helpfully reviewed the vitamin B6-
dependent inflammatory pathways; namely, the kynurenine pathway, the trans-sulfuration 
pathway (homocysteine metabolism), serine and glycine metabolism (300). Interestingly, 
vitamin B6 supplementation has been shown to have cytoprotective effects by preventing 
oxygen radical generation and lipid peroxidation during hydrogen peroxide challenge (631). 
Sustained PLP deficiency in critically ill patients is associated with hyperglycaemia, a feature 
of the so-called ‘ebb period’ of the acute phase response (627).  
 
1.3.2. Tryptophan, kynurenines and NAD+ in inflammation  
Systemic inflammation, and in particular AP, has been shown to cause disturbances of 
the serum amino acid profile in humans (632). Of the 23 amino acids studied, most were found 
to have statistically significant changes in serum concentrations between samples taken on 
hospital admission (day 0), day 5, or 6-weeks later (632).  
Flux in the kynurenine pathway metabolites has been observed in the mesenteric 
lymph of rats with AP, and peripheral blood from humans with AP-associated multiple organ 
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dysfunction, with depletion of tryptophan and increases in 3HK (375, 633). The previous 
sections detail some of the modulatory effects of kynurenines on the immune system. Diverting 
kynurenine pathway metabolism can have protective effects, for example KMO inhibition was 
found to ameliorate multi-organ dysfunction in the early phase of experimental AP, suggesting 
a mechanistic role for 3HK in multiple organ dysfunction seen in critical illness (634). A whole 
raft of inflammatory mediators is known to modulate activity of KP enzymes: Glucocorticoid, 
platelet activating factor, nitric oxide, IL-1β, IL-4, IL-10, TNFα, IFNg (Table 11, above). KMO 
inactivation is of particular interest given the cytotoxic effects of endogenous 3HK and 3HAA 
on peripheral tissues (473). Elevated 3HK levels are inversely related to decreased PLP levels 
in inflammation/injury (597). Figure 16 provides an overview of the known effects of 




Figure 16. Kynurenine pathway flux in systemic inflammation 
Enzymes depicted by red boxes (IDO, KMO, KATs, KYNU), Cytokines in green boxes (IFNg, TNFα, PAF, LPS, 
IL-1β), metabolites in blue boxes (Kyn, 3HK, XA, 3HAA), vitamer co-enzymes in orange boxes (FAD, PLP). 
Abbreviations: 3HAA: 3-hydroxyanthranilic acid; 3HK: 3-hydroxykynurenine; FAD: Flavin adenine dinucleotide; 
IDO: Indoleamine 2,3-dioxygenase; IFN: Interferon; IL-1β: Interleukin 1β; KAT: Kynurenine aminotransferase; 
KMO: Kynurenine 3-monooxygenase; Kyn: Kynurenine; KYNU: Kynureninase; LPS: Lipopolysaccharide; PAF: 
Platelet activating factor; PLP: Pyridoxal 5’-phosphate; TNF: Tumor necrosis factor; XA: Xanthurenic acid 
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1.4. Research aims 
 
In light of the data that human AP severity correlates with increased plasma 3HK levels 
(375), and that using a severe, non-recovery model of experimental AP in mice with KMO 
deletion reduced multiple organ injury at 24-hrs (634), my hypothesis was formed to investigate 
the role of 3HK recovery phase of AP. 
 
 
1.4.1. Overall hypothesis 
Elevated levels of KMO product, 3-hydroxykynurenine, impairs survival in experimental 
AP, and suppression of 3HK improves recovery in experimental AP. 
 
 
1.4.2. Research hypotheses 
1) Inactivation of KMO activity, by Kmo genetic deletion, and thus abolition of 3HK levels, 
improves recovery in experimental AP [Experiment 1] 
2) Conversely, elevated 3HK concentrations by genetic alteration, would impair AP 
recovery [Experiments 2 + 3] 
3) Altered kynurenine levels by genetic alteration, would alter the systemic inflammatory 
response in AP in terms of the innate immune cellular response (blood and infiltrative 
leukocytes), non-cellular mediators (e.g. proinflammatory cytokines) and biochemical 
markers of end organ injury [Experiment 4] 
4) Use of KMO inhibitor therapy for those mice with elevated 3HK levels, would provide 
protection against critical illness [Experiment 5] 
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2. MATERIALS AND METHODS 
2.1. Genetically altered mice 
Throughout the project, male mice were investigated. All experiments using animals 
are conducted in accordance with the Animals (Scientific Procedures) Act, 1986 governed by 
the UK Government Home Office, and after review from the University of Edinburgh research 
ethics committee and veterinary services (PPL: 60/4433). Genetically-altered mouse strains 
with a C57BL/6J background have been generated by our group for the study of kynurenine-
3-monooxygenase (KMO). Specifically, we have developed a global KMO knockout mouse 
strain (referred to as KMOnull) engineered with FRT restriction sites flanking a transcription stop 
signal in exon 3 of Kmo and with integral loxP sites flanking key gene regions to give 
conditional (tissue-specific) knockout capability as needed; a wild-type control strain, created 
by crossing (and backcrossing) KMOnull mice with a FLP-deleter strain to excise the FRT-
flanked stop signal to restore Kmo transcription (KMOFRT-deleted, hereafter referred to as KMOwt); 
and a hepatocyte-specific KMO knockout line where FLP-deleted KMO mice homozygous for 
loxP-flanked Kmo have been crossed with a Cre-recombinase expressing strain in which Cre 
expression (and therefore KMO inactivation) is driven by the albumin promoter and thus only 
occurs in liver tissue (hereafter referred to as KMOalb-cre mice). The latter have a KMO knockout 
biochemical phenotype in the blood plasma, but wild-type KMO expression in non-hepatic 
tissues. Genotyping is conducted by PCR of earmark clippings and only homozygous 
genotypes are used. Of these, only adult male mice, aged between 18 to 25 weeks old, and 
weighing ≥ 20 grams, are used. To compare outcomes between strains, mice from different 
lines are age-matched (≤ 14 days). 
 
2.1.1. Genotyping 
KMOnull (KMO knock out) and KMOFRT-deleted (FLPKMO, wild type) mice were generated 
in our laboratory (634). To create hepatocyte-restricted KMO knock out mice, KMOFRT-
deleted mice were crossed with the Albumin-Cre B6.Cg-Tg (Alb-cre) 21Mgn/J mice. These mice 
were backcrossed for at least 6 generations to generate homozygous KMOFRT-deleted and 
Albumin cre positive mice. All mouse genotypes were confirmed by standard PCR-based 
genotyping of genomic DNA isolated from ear clips by Dr Xiaozheng Zhong (Senior Research 
Assistant, Mole Group). The following primer sequences were used for PCR genotyping: 5’-
GCGGTCTGGCAGTAAAAACTATC-3’ and 5’-GTGAAACAGCATTGCTGTCACTT-3’ to yield 
a single PCR product of 100 base pairs representing albumin cre positive. 
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2.2. Analgesia 
Pain is a major factor in clinical AP, and I had no reason to think that animals do not 
experience pain in experimental AP. Therefore, considerable efforts were taken to provide 
analgesia for experimental subjects throughout the disease course. The total dosing of animals 
in longitudinal studies was variable as it depended on cage-side pain scores and was protocol 
driven. Animal dosing in longitudinal studies is detailed in the appropriate results sections.  
 
2.2.1.  Parenteral analgesia 
All operated mice were given pre-emptive analgesia whilst under general anaesthesia 
immediately before laparotomy with subcutaneous buprenorphine (0.05 mg/kg body weight, in 
5% dextrose-DPBS wt/vol), and a further two doses (6-8 hrs and 20-24 hrs post-operatively). 
Additional doses of subcutaneous buprenorphine were given in accordance with prospectively 
defined criteria outlined in the cage-side clinical observation score sheet (Appendix 3). 
 
2.2.2.  Enteral analgesia 
In anticipation of pain throughout the 7-day study period, animals were provided each 
morning (between 09:00 – 10:00 hrs) with oral Buprenorphine (0.01 mg) in a 0.5 mL dot of 
jelly, and consumption was monitored to allow consumption calculations. Jelly was not given 
on the day of cull to avoid post-prandial fluctuations in plasma glucose. Prior to 
experimentation, mice are supplied vehicle jelly dots (i.e. without Buprenorphine) to become 
accustomed to the jelly. 
 
Protocol 
1) Cut a half cube of concentrated stock jelly (Strawberry jelly, Hartley®) into small pieces 
and transfer into a stack of 60 ml medicine cups (preferably n = 4 cup stack to insulate 
users’ hand). 
2) Add 6 ml of hot water (just off boiling). 
3) Stir until all jelly stock dissolved. 
4) Cool to room temperature. To expedite this step, remove medicine cup from its stack 
and briefly place in freezer to allow rapid cooling. 
5) Add 0.8 ml 0.3 mg/ml Buprenorphine (Vetergesic, Ceva Animal Health) and stir to mix. 
When making vehicle jelly, instead add 0.8 ml water at this step. 
6) Aliquot 0.5 ml volumes into wells of a suitable plastic blister pack mold.  
7) Use dental spatula (Medentra, #859-m9) to transfer 0.5 ml medicated jelly to petri dish 
for animal consumption.  
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2.3. Acute pancreatitis model 
Transduodenal retrograde infusion of a bile acid salt solution to the pancreatic duct is 
a well-recognised model of AP, and is frequently reported to show evidence of injury at extra-
pancreatic sites (eg. lung, kidney). Sodium taurocholic acid (Na-TCA), has been used for 
intraductal infusion by several research groups to successfully induce AP. Elevated plasma 
amylase levels and pancreatic histopathological changes are used to confirm presence of AP 
for 24-hr timepoint experiments. The control group consisted of a sham operation wherein the 
duodenal loop was handled and the pancreatic head and duodenal papilla were identified. The 
abdomen was left open for an equal length of time as the AP group. The protocol described is 
the final version (Protocol 9) resulting from preliminary work detailed in Results 3.1. 
  
2.3.1. Materials – Retrograde biliopancreatic duct infusion 
The materials used for surgical procedures, including induction of experimental AP, 
telemeter implantation, minipump implantation and in vivo tracer studies is listed in Table 12. 
 
2.3.2. Protocol for induction of experimental acute pancreatitis 
1) Prepare 2% sodium taurocholate (NaTCA) (wt/vol) in phosphate buffered saline 
(PBS) (37 mM) in 20 mL syringe. 
2) Prepare analgesia for subcutaneous dosing (5% Dextrose, PBS, Buprenorphine). 
3) Prepare clean surgical instruments using Enzystel instrument cleaner and Medistel 
instrument disinfectant. 
4) Prepare 70% ethanol (in water) for disinfectant spray. 
5) Set up equipment, including infusion pump. 
6) Induce anaesthesia using vaporised Isofluorane (5%) in oxygen in the induction 
chamber of the anaesthetic rig. 
7) Record the animal’s weight (include details of any in-situ surgical devices such as 
skin clips or implants to allow body weight calculation). 
8) Shave hair from the animal’s operative site(s) and transfer the mouse to operating 
field on top of a pre-warmed heat mat. 
9) Administer weight-adjusted dose of subcutaneous analgesia for pre-emptive post-
operative analgesia (0.05 mg/kg body weight, in 5% dextrose-PBS wt/vol). 
10) Apply a dot of protective Lacri-lube ointment to each eye. 
11) Turn down the anaesthesia dose for maintenance at surgical depth (ie. 2-3%). 
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Equipment Details 
Infusion pump – PHD Ultra Harvard Apparatus 
5-0 Mersilk suture (round bodied, single ended) Ethicon (W595) 
5-0 steel suture B Braun 
7-0 Prolene suture (round bodied, double ended) Ethicon (W8702) 
Lacri-lube eye ointment Allergan Ltd. (PL00426/0041) 
Lacrimal cannula (26G x 1/18 in)  BD Visitec (Medguard Healthcare Ltd.) 581276 
Polyethylene tubing, for infusion General supplier 
Colibri retractor (for laparotomy) Fine Science Tools (17000-02) 
Tissue scissors Fine Science Tools (14095-11) 
Skin scissors Fine Science Tools (14072-10) 
Guthrie retractor (liver retractor) Fine Science Tools (17023-13) 
Stainless steel micro serrefine microclamp (curved 
90 degrees) 
Fine Science Tools (18055-06) 
Forceps style clip applicator Fine Science Tools (18057-14) 
Tissue forceps Fine Science Tools (11052-10 and 11152-10) 
Autoclip wound clip system  Harvard Apparatus Ltd. (34-0557) 
Isofluorane IsoFlo Zoetis (Vm42058/4195) 
Taurocholic acid sodium salt hydrate Sigma-Aldrich (T4009-5G) 
Glucose (Dextrose) Sigma-Aldrich (G-8270) 
Medistel Tristel, MD311 
Enzystel Tristel, MD315 
Phosphate Buffered Saline Dulbecco’s PBS, Gibco 
Operating Microscope Zeiss 
Buprenorphine Vetergesic, Ceva Animal Health 
Table 12. Surgical materials 
 
12) Prepare the skin with disinfectant (ie. 70% ethanol or Betadine) and arrange surgical 
drapes around the operative field 
13) Arrange surgical microscope and don the sterile surgical gloves.  
14) Using surgical scissors and forceps, open the abdomen and maintain wound edge 
retraction with a Colibri retractor. 
15) Place a piece of gauze under liver edge and gently retract liver using Guthrie retractor 
to allow clear visualisation of the duodenal loop and bile duct. 
16) Rotate the duodenal loop medially and identify the duodenal ampulla before placing a 
7-0 Prolene stay suture through the duodenum proximal to the ampulla. 
17) Puncture the duodenum with a 23G hypodermic needle just distal to the ampulla on 
the antimesenteric border. 
18) Using a lacrimal cannula, cannulate the biliopancreatic duct. 
19) Temporary occlude the proximal hepatic duct with a serrefine microclamp using 
forceps style clip applicator.  
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20) Infuse 50 μl sodium-taurocholic acid at a constant rate over 5 mins into the duct with 
an infusion pump.  
21) Use a ‘z’ stich to close the duodenotomy with 7-0 Prolene. 
22) Where appropriate, implant telemetry device (see methods 2.3.1.). 
23) Give 0.5 ml intraperitoneal bolus of PBS.  
24) Mass abdominal wall closure (all layers except skin) with 5-0 Mersilk. 
25) Close skin with Autoclip skin clips. 
26) Transfer to warm box (set 30oC) for recovery from anaesthesia for half an hour. 
 
Sham laparotomy 
Sham laparotomy consists of an equivalent surgical wound incision length as AP 
subjects, handling of small bowel with visualisation of the pancreas, with time delay of 
abdominal wall closure (bearing in mind the length of time required for the AP group to 
cannulate the duct, complete 5 min infusion and suture close the duodenal puncture site). As 
with the AP, a 0.5 ml intraperitoneal bolus of PBS was given before mass closure with Mersilk 
and skin closure with autoclips. 
 
2.4. Telemetry 
2.4.1. Implantation of cardiometabolic telemeter (G2 HR E-mitter) 
Large telemetry implants in small animals have been shown to delay recovery, and 
therefore small devices are preferable (635). Battery-free telemetry devices are smaller and 
lighter than those that containing batteries, these are instead powered by a plate positioned 
beneath the cage. The G2 HR E-mitter radio-telemetry device (Starr Life Sciences) is at 
present unique on the commercial market as the only battery-free telemeter that records heart 
rate. Additionally, this device also measures core body temperature (CBT) and locomotor 
activity (Figure 17). 
1) At laparotomy, the G2 HR E-mitter telemetry device was implanted into the abdominal 
cavity and the two chest leads exteriorised through the abdominal wall using large bore 
needle and forceps.  
2) The E-mitter leads were then tunnelled under the skin to the appropriate sites on the chest 
wall. Metal ferules are attached and crimped flat to act as receiver pads. Both leads are 
anchored to chest wall muscle with 5-0 steel suture. 
3) Skin wounds are closed with wound Autoclip skin slips. 
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Figure 17: Surgically implantable telemetry devices – G2 HR Emitter 
A: G2 HR E-Mitter device (referred to as ‘cardiometabolic telemeter’ in thesis to distinguish 
it from the other telemeter. B-E: Images reproduced from manufacturer’s instruction 
manual. B: Picture depicts orientation of cardiac lead placement. C: Picture shows insertion 
of device within abdominal cavity. D: Lead is tunnelled subcutaneously to reach pectoral 
muscle. E: A separate pectoral incision is made to allow lead suture to pectoral muscle. 
 
 
The original telemeter used, seen in Figure 17, involved a longer operation to implant 
chest leads. Later, a smaller telemeter device (Figure 18) was used as this was smaller and 
required invasive surgery to implant. Indeed, it required no more surgery than just a securing 
suture to the anterior abdominal wall than the AP or sham laparotomy and with hindsight was 
ideal for AP studies and preferable to the cardiometabolic device. 
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Figure 18: Surgically implantable telemetry devices – G2 E-mitter 
A: G2 E-Mitter device (referred to as ‘pill’ or ‘mini’ telemeter to distinguish 
it from the other telemeter). B and C: Images reproduced from 
manufacturer’s instruction manual. B: Picture depicts laparotomy incision 
(same size as that needed for pancreatic ductal infusion). C: Picture 
shows insertion of device within abdominal cavity and is secured to the 
anterior abdominal wall with a single suture. 
 
 
2.4.2. Experimental design 
Mice were singly housed and supplied vehicle jelly the day before surgery, in order to 
build their nest and become accustomed to the jelly. The next day, during the early light phase, 
two mice went either AP model or sham operation, and insertion of an E-mitter telemetry device 
(. After 30-mins in the warming box (300C air temperature), mice are housed on top of a 
telemetry receiver / energizer pad in a dedicated circadian room. Telemetry recording starts at 
the midpoint of the light phase on the day of surgery – termed zeitgeber time (ZT) 0-hr. 
Mice are culled at set timepoints following ZT 0-hr, and this allows for a full telemetry 
dataset. For example, a 7-d experiment would be culled immediately following 168-hrs after 
ZT0 (Figure 19). Schedule 1 cull is performed by under terminal anaesthesia. An open cardiac 
puncture performed to acquire blood plasma. Fresh samples of lung, liver, kidney and body/tail 
of pancreas are frozen and stored along with plasma at -800C. Samples of lung, liver, kidney 
and head of pancreas are also fixed in 10% formalin. The total body weight at the start and 
end of the experiment is measured (to 2 d.p.), correcting for the mass of the E-mitter and 
remaining skin clips, to calculate change in body weight. 
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Figure 19. Experimental plan for 7-day recovery AP studies  
The schematic demonstrates the time schedule for surgery (acute pancreatitis, AP; or sham operation), start of 
telemetry recording (at ZT 0-hr). Light and dark phase cycles are indicated along the timeline, with each 24-hr 
period consisting of a 6-hr light phase, 12-hr dark phase and 6-hr light phase. 
 
 
2.4.3. Telemetry system installation and troubleshooting 
Data acquisition was performed using the E-mitter system. PC with Windows operating 
system. Telemetry hardware with Vital View software. ER4000 receiver pads (Starr Life 
Sciences) (Figure 20). Telemetry data were recorded by a computer (Hewlett-Packard 
desktop computer, Windows 7 Enterprise) using VitalView animal monitoring software (version 
5.0, STARR Life Sciences). The telemetry system was initially installed by the UK supplier 
company (Linton Instrumentation) using current software (v5.1) but failed to work as the 
application failed to detect the hardware. After testing a variety of new cables and computers 
to no avail, the software was replaced with an older version (v5.0); and the communication 
between the software and hardware was successfully established. 
 
 
Figure 20. ER-4000 telemetry hardware  
The caged telemetered mouse is housed on top of ER-4000. 
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2.4.4. Remote desktop 
Install ‘Microsoft Remote Desktop’ for Mac OS X, version 8.0.38. This allows monitoring 
of mice remotely informing the investigator of extremes physiological data (e.g. hypothermia), 
which may warrant an unscheduled cage side clinical check. 
 
2.4.5. Telemetry software setup 
Calibration settings which accompany with each telemeter device issued by the 
manufacturer are entered into the VitalView software prior to each telemetry experiment. 
Settings for the smaller (‘pill’ or ‘mini’) telemeters are reproduced in Table 13. See Appendix 
6.1. for the VitalView software setup. 
 
 Low High 
Telemeter ID Temp. Freq. Temp. Freq. 
EM21 37.0 843.5 41.0 1005.0 
EM22 37.0 853.4 41.0 1017.5 
EM23 37.0 850.3 41.0 1019.5 
EM24 37.0 842.0 41.0 1001.7 
EM25 37.0 823.5 41.0 983.9 
EM26 37.0 859.6 41.0 1027.4 
EM27 37.0 847.4 41.0 1013.6 
EM28 37.0 847.1 41.0 1016.7 
Table 13. Two-point calibration frequencies for mini-telemeters 
 
2.4.6. Processing ASCII files for downstream processing 
Creation of ASCII files were converted to Comma-Separated-Value files. VitalView 
software (version 5.0) was used. Version 5.1 was originally tried but hardware installation 
problems arose which were eventually overcome by using version 5.0 of the software. 
 
2.4.7. Telemetry data analysis 
The original intention was to use the VitalView software to analyse the telemetry data. 
However, the analysis functions in the software were very limited and the data visualisations 
were of very poor quality. However, the data could easily be exported to be analysed elsewhere 
with a variety of options. Having discussed this problem with scientists from other disciplines 
who were familiar with time series data, it quickly became apparent that scientific Python 
computing modules offered a very attractive solution because its capabilities exceeded my 
requirements, it was open source with no financial costs, it was a very intuitive computer 
language with enormous online troubleshooting support (e.g. <www.stackoverflow.com>), and 
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it allowed complete transparency of my data analysis which would be easily reproduced and 
the code could be shared with other investigators.  
 
2.4.8. Telemetry data visualisation and export in VitalView 
Python scripts for visualising CSV file data outputs from VitalView are shown in 
Appendix 6.2. Python is a flexible computer language which can be used for any programming 
tasks and is a very popular language for data science due to the excellent and expanding 
scientific libraries. The installation of the SciPy stack was performed using the Anaconda 
Python distribution from Continuum Analytics (http://continuum.io/downloads.html). The 
Jupyter notebook interface was used (which has subsequently been superseded by 
JupyterLab). Data wrangling was performed with the Pandas library, calculations were 
performed using Numpy, and plotting was performed with Seaborn. 
 
2.4.9. In-house check and re-calibration of G2 HR telemeters 
One of the ‘cardiometabolic’ G2 HR telemeters (EM09) gave consistently lower 
temperature readings than the other devices, whilst giving equivalent heart rate and locomotor 
activity readings. This device had been a recently purchased from the company so did not qualify 
for recalibration which they offer at 1-year. To ascertain the calibration quality of all telemeters, 
an in-house quality control calibration was performed for every device individually using a 
single scientific thermometer for all readings (Fisher Scientific UK Ltd, Cat. #11735853): 
1) Vitalview software was calibrated to the E-mitter with 2-point frequencies (Table 13) 
2) A large waterbath was placed on top of the ER-4000 receiver containing warm water 
(>40oC). 
3) The telemeter was placed within a submerged open inner glass jar (to prevent water 
currents around the E-mitter) 
4) Water was allowed to slowly cool and E-mitter temperature readings taken at each 
temperature integer (e.g. 39.0oC, 38.0oC, 37oC) between 30 to 40oC. 
5) Step 4 was repeated 3 times for each device, recorded and a mean average calculated. 
The smaller, mini-telemeters (G2 E-mitters) had temperature readings <1oC from the waterbath 
themermometer and therefore in-house calibration was not applied as the differences were small 
and within limits of accuracy. However, the suspected mis-calibrated EM09 device was confirmed 
to be an outlier with respect to temperature readings (by 3.08oC), and therefore a correction was 
applied to all temperature data from the G2 HR telemeters. Additionally, the difference (~3oC) was 
consistant across the temperature range (30-40oC). Appendix 3 (section 6.3.) documents the 
mean calibration differences at 37oC which was used to correct the data. 
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2.4.10. COSINOR analysis of telemetry data  
To determine circadian variations in telemetry parameter data, the open access 
circadian rhythm analysis software package, ChronosFit (Version 1.06), was used to fit a 
Cosinor curve with a 24-hr rhythm. The purpose of the Cosinor analysis was to fit a circadian 
trend curve to the physiological telemetry data points, a technique which has been used by 
other investigators studying the effects upon physiological data from systemic disease (636). 
The components of the Cosinor analysis are illustrated in Figure 25D: mesor (mean of the 
oscillation; called the midline estimating statistic of rhythm), amplitude (half the difference 
between the highest and lowest values), and acrophase (timing of the cosine maximum given 
the degrees, where 3600 corresponds to a 24-hr cycle). The Cosinor curve is represented by 
the following function: C(t) = MESOR + amplitude cos(2 pi (t- acrophase)/ 24-h], where MESOR 
(mean of the oscillation), amplitude (half the difference between the highest and lowest 
values), and acrophase (timing of the cosine maximum given in degrees, where 360 degrees 
corresponded to a 24-h cycle). 
 
2.4.11. Periodogram rhythm analysis 
Chronos-Fit version 1.06 data analysis software program (Zuther et al. 2009) was used 
to analyse data. This program fits a cosinor curve to the measured data points and calculated 
the midline estimating statistic of rhythm (mesor; a rhythm-adjusted 24-h mean), amplitude 
(half of peak-to-trough of rhythmic change) and the acrophase (peak time of the rhythm).  
 
 
2.5. Animal housing and welfare 
2.5.1. Animal housing 
Mice were housed in University of Edinburgh facilities with a 12:12-hr light-dark (LD) 
cycle. During experimentation, mice have access to both dry and wet diet (RM1; Rat and 
Mouse No.1 Maintenance, Special Diets Services) and water ad libitum. The RM1 standard 
feed used contains a variety of amino acids, including tryptophan (0.18%). Mice are individually 
housed, and environmental enrichment is standardised (nesting material, single tube). 
Because the circadian system is well known to drive daily rhythms in mammalian physiology 
and behaviour, we synchronise the timing of our experiments to the LD cycle. Telemetry 
recording starts at the midpoint of the light phase on the day of surgery (denoted Zeitgeber 
Time zero; ‘ZT0’). In our institution, with a 07:00:00 – 19:00:00 light phase, ZT0 is therefore 
13:00:00. The air temperature in the telemetry room is maintained at a mean 26.50C (range 
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24.0 – 29.2oC) and monitored at hourly intervals with a scientific thermometer data logger 
(SL52USB, Signatrol).  
In an effort to maintain optimal animal welfare, I designed a specific clinical observation 
score sheet for this project in consultation with University of Edinburgh Veterinary colleagues 
(Appendix 6.4.). This clinical sheet lists defined humane-endpoints beyond which animals are 
culled, and is used for routine cage-side checks. Additionally, longitudinal telemetry readings 
(e.g. core body temperature) are also informative in relation to welfare (e.g. sustained profound 
hypothermia during the experiment is an indication to humanely cull an animal). 
 
 
2.6. Animal cull and plasma processing 
2.6.1.  Humane cull procedure 
Blood samples were taken by cardiac blood sampling under terminal anaesthesia, 
transferred to EDTA tubes (Microvette®,CB 300 K2E, Sarstedt) and centrifuged at 5,000 rpm 
for 3 mins, and plasma stored at -80oC. Histologically examined tissues (i.e. head and body of 
pancreas, half kidney, liver segment, lung) were fixed in 4% neutral- buffered formalin 
overnight before transfer into 70% aqueous ethanol prior to paraffin-embedding. 
 
2.6.2.  Blood plasma clinical chemistry  
Plasma a-amylase, urea, creatinine, ALT, albumin and glucose concentrations were 
analysed using commercial kits from Alpha Laboratories Ltd. (Eastleigh, UK) adapted for use 
on the Cobas Fara centrifugal analyser (Roche Diagnostics Ltd., Welwyn Gareden City, UK). 
These were by senior biochemist Dr. Forbes Howie PhD, of the Shared University Reaserch 
Facilities (SuRF) at the Queen’s Medical Research Institute, University of Edinburgh who was 
blinded to the treatments and mouse lines by the use of anonymising sample codes. 
 
2.6.3.  Plasma cytokine assay  
Plasma cytokine levels were analysed using the Meso Scale Discovery (Rockville) V-
PLEX Proinflammatory Panel1 mouse kit in accordance with MSD’s instructions which are 
summarise in this protocol. An MSD calibration curve is shown in Appendix 10 (section 6.10). 
Samples were run in duplicate.  
 
Protocol 
1) Prepare wash buffer (PBS 0.05 % Tween-20). 
2) Prepare calibration curve. 
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3) Prepare samples (1:1 dilution of plasma with Dilutent 41). 
4) Wash MSD plate 3 x 150 μl per well wash buffer. 
5) Add 50 μl per well of diluted plasma. 
6) Incubate at room temperature, shaking gently for 2-hrs. 
7) Meanwhile, prepare antibodies in Dilutent 45. 
8) After 2-hrs, shake off wells. 
9) Wash MSD plate 3 x 150 μl per well wash buffer. 
10) Add antibodies mix to each well. 
11) Incubate at room temperature, shaking gently for 2 hours. 
12) Add 150 μl 2X Read Buffer T to each well. 
13) Read on MSD plate reader. 
 
2.7. Kmo gene expression 
Isolation of total RNA and quantitative reverse transcription polymerase chain reaction 
(RT-PCR). Total RNA was isolated with RNeasy Mini Kit (Qiagen, 74106). The first-strand 
cDNA was synthesised from 0.5 μg of total RNA using kit (QuantiTect Reverse Transcription 
Kit, Qiagen) with G-Storm thermal cycler machine. RT-PCR was performed using cDNA and 
TaqMan probes. 
 
Protocol – Preparation for RNA extraction 
1) Prepare clean beads and dry prior to use, using protocols. 
2) Label 2 ml eppendorf tubes (e.g. ‘1’ – ‘9’). 
3) Prepare 1:100 dilution h β-mercaptoethanol (β-ME) in RLT buffer from RNeasy mini 
kit. 
4) Prepare 70% ethanol in dH20. 
5) Prepare fume hood and clean centrifuge. 
6) Finally, transfer pre-prepared <20 mg tissue sections from -80oC storage to laboratory. 
 
Protocol – RNA extraction 
1) In hood, add 2 clean metal balls to each tube containing cut tissue [note: avoid tissue 
‘jumping’ out tube by holding it at an angle]. 
2) Add 400 μl RLT (with β-ME) buffer and transfer to shaker (Qiagen TissueLyser). 
3) Homogenise by 3 min shake (at 25 Hz) on shaker. 
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4) Centrifuge spin 3 mins at full speed (13,000 rpm = 16060 RCF, Biofuge fresco 
Hareaeus). 
5) Aspirate lysate & transfer into new labelled eppendorf (labelled ‘1 to 9’). Keep balls for 
reuse. 
6) Spin lysate 3 mins at full speed (16060 RCF) 
7) Transfer 350 μl lysate into new labelled eppendorf, avoiding pellet aspiration. 
8) Add 350 μl of 70% ethanol to lysate. 
9) Invert all Eppendorf tubes together (x10) to mix immediately. Do not vortex. 
10) Label the pink top of each RNeasy spin column. 
11) Transfer 700 μl sample to corresponding RNeasy spin column (with collecting tube). 
12) Spin 15 secs at 16060 RCF. Discard flow through. 
13) In hood, wash 1: Add 700 μl RW1 buffer to RNeasy spin column. 
14) Spin 16060 RCF for 15 secs. Discard flow through. 
15) Continue at lab bench. Wash 2: Add 500 μl RPE buffer to RNeasy spin column. 
16) Spin 16060 RCF for 15 secs. Discard flow through. 
17) Wash 3: Add 500 μl RPE buffer to RNeasy spin column. 
18) Spin for 2 mins at 16060 RCF. 
19) Place column onto new 2 ml collection tube (supplied) & spin 16060 RCF for 60s. 
20) Place RNeasy spin column in a new 1.5 ml collection tube (supplied). 
21) Add 40 μl RNase free water (supplied) directly onto spin column membrane. 
22) Arrange in centrifuge to prevent lids spinning, then spin 16060 RCF 60s to elute the 
RNA. 
23) Use 1.3 μl from each on NanoDrop 1000 Spectrophotometer (ThermoScientific) to 
quantify RNA concentration of each sample. 
24) Store RNA samples at -80oC. 
 
Protocol – Preparation for reverse transcription 
1) Calculate volume of RNA needed (= X μl), referring to NanoDrop results from previous 
and calculate volume of RNase-free water needed for each sample (12 μl – X μl). 
 
Protocol – Reverse transcription 
1) Defrost RNase-free water on bench and thaw gDNA Wipeout buffer (from QuantiTect 
Reverse Transcription Kit, Qiagen) on ice. 
2) Transfer RNA samples from -80oC storage to laboratory on dry ice, and allow to thaw. 
3) Add volume of RNase-free water into corresponding well of PCR plate.  
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4) Add volume of RNA solution from each sample to corresponding well of PCR plate, 
thus making up to 12 μl. 
5) Add 2 μl gDNA Wipeout buffer to each well of PCR plate, thus making 14 μl per well. 
6) Attach PCR flat cap lids (in separately cut column strips). 
7) Mix PCR plate by vortex. 
8) Spin down sample (briefly spin up to 1000 rpm on Rotina centrifuge 420R, and stop) 
9) G-Storm PCR Machine: Template RNA generation: Incubate at 42 oC for 5 mins [use 
WIPE protocol: in Xiao folder]. Secure machine lid upon closing. 
10) Prepare Mastermix using ratio in Table 14, making and extra ~10% to avoid running 







11) Add 6 μl of mastermix to 14 μl of tRNA to each plate well. 
12) Mix PCR plate by vortex. 
13) Spin down sample (briefly spin down). 
14) G-Storm PCR Machine: Incubate 42oC for 25 mins, and then at 95oC for 3 mins, before 
cool to 4oC at end of run [use CDNA protocol: in Xiao folder]. Secure lid upon closing. 
 
Dilute all samples of cDNA 
1) Briefly centrifuge plate to spin down contents. 
2) Add 80 μl molecular water (RNase free) to make 100 μl stock of cDNA (from 500 ng 
total RNA). 
3) Store dilute cDNA samples at -20oC until ready for real-time PCR. 
 
 
Protocol – Preparation for Real Time Polymerase Chain Reaction (RT-PCR) 
1) Create PCR plate plan: Duplicates of 20 μl and x2 NTC (‘no template control’). 
 
Protocol – RT-PCR 
1) Make up enough 18S + Probe Mixture for each plate well, with ratio of: 
Mastermix component Volume 
Quantiscript Reverse Transcriptase 1 μl 
Quantiscript RT Buffer 4 μl 
RT Primer Mix 1 μl 
Table 14. Ratio of mastermix components 
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a. 6 ul molecular H2O / RNase-free water 
b. 10 μl TaqMan Fast Universal PCR Master Mix (2X), No AmpErase 
c. 1 μl 18S VIC/MGB probe 20x (ThermoFisher Scientific, 4319413E) 
d. 1 μl target probe 20x. 
2) Add 2.2 x 18 μl of 18S/Target Mixture to tube for each sample (= 39.6 μl). 
3) Add 2.2 x 18 μl of 18S/Target Mixture to tube for each sample (= 39.6 μl). 
4) Add 2.2 x 2 μl cDNA to tube or molecular water for NTC (= 4.4 μl). 
5) Add 20 μl sample to corresponding 2 wells in PCR plate. 




I used high performance liquid chromatography – mass spec / mass spec (LC-MS/MS) 
to quantify concentrations of circulatory endogenous kynurenine metabolites, injected tracer 
compounds, and drug concentrations in the plasma, urine and tissue homogenates. The 
following describes the method I employed. Deuterated-5-Tryptophan was the default single 
internal standard used, and others were used only where specified in the results section. 0 ng 




Oasis Hydrophilic Lipophilic Balanced (HLB) 96-well 
plate (10 mg Sorbent, 30 μm particle size) 
Waters (#186000128) 
Bovine Serum Albumin Sigma 
Collection plate Masterblock® 
Sciex 6500 Sciex 
Borosilicate glass tube (13x100mm) Fisherbrand (14-961-27) 
Dri-Block DB-3 sample concentrator Jencons (Scientific) Ltd. 
SPE Dry tm 96 Dual Argonaut 
Centrifuge Heraeus Fresco 21 Thermo Scientific 
Water (HPLC grade) Fisher Scientific (W/0106/17) 
L-tryptophan-(indole-d5) (D5-TRP) Sigma-Aldrich 
[13C6]-L-Kynurenine (13C6-KYN) Sigma-Aldrich 
[U-Ring-13C6]-3-Hydroxykynureine (13C6-3HK) Sigma-Aldrich 
Kynurenic acid-3,5,6,7,8,-d5 (D5-KA) Sigma-Aldrich 
Acetonitrile (HPLC grade) VWR Chemicals BDH (UN1648) 
Methanol (HPLC grade) Fisher Scientific (M/4000/17) 
Phosphoric acid BDH Anala R (10173BC) 
Dulbecco’s PBS Gibco 
Cryotube vials ThermoScientific 
Table 15. Equipment for LC-MS/MS 
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2.8.1.1.  Preparation of calibration curve standard 
The following 12 calibration standards were used routinely: 100 ng, 50 ng, 20 ng, 10 
ng, 5 ng, 2 ng, 1 ng, 0.5 ng, 0.2 ng, 0.1 ng, 0 ng, Double Blank. The following compounds were 
used: L-Tryptophan, L-Kynurenine, Kynurenic acid, Anthranilic acid, 3-Hydroxy-DL-
kynurenine, Xanthurenic acid, 2-hydroxykynurenic acid, Quinolinic acid. All compounds were 
sourced in powder form from Sigma Aldrich. 
 
2.8.1.2.  Preparation of plasma samples for extraction 
1) Remove frozen plasma samples from -80oC storage, and thaw at room temperature. 
2) Label one borosilicate glass tube for every sample and calibration standard. 
3) Add 10 μl of the internal standard* (e.g. 5 μg/mL D5-Trp) to all tubes except Double 
Blank.  
4) Add 100 μl of standard analyte mix to the calibration curve tubes. 
5) Transfer glass tubes to Dri-block heater at 40oC, and evaporate to dryness. 
6) Return all glass tubes to lab bench. 
7) Add 100 μl of 4% phosphoric acid to all sample and calibration tubes, including 
Double Blank, and briefly vortex to mix. 
8) Add 100 μl of mouse plasma to the corresponding glass tube and briefly vortex. 
9) Add 100 μl of 1% Bovine Serum Albumin in PBS to each calibration standard tube 
and briefly vortex. 
   
2.8.1.3.  Preparation of extraction plate 
1) Use a printed 96-well plate map to record with a unique identifier each well to be used 
for every sample and calibration standard. 
2) Assemble the vacuum manifold and place an Oasis HLB 96-well plate on top. Do not 
place collection plate underneath at this stage. 
3) Add 500 μl of Methanol to each well to be used, and vacuum to dryness. 
4) Add 500 μl of high performance liquid chromatography (HPLC) water to each well to 
be used, and vacuum to dryness. 
 
2.8.1.4.  Sample extraction 
1) Add all prepared sample to corresponding cartridge (i.e 100 μl plasma). 
2) Subject manifold to vacuum (0.35 Bar) to dryness. 
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3) Add 500 μl of HPLC water, to wash each well, and subject manifold to vacuum to 
dryness. 
4) Place Masterblock® 96-well collection plate inside vacuum manifold, underneath the 
plate. 
5) Ensure the lid of the manifold is sealed. 
6) Add 200 μl 80% methanol to elute the extract into the collection plate, and vacuum to 
dryness. 
7) Transfer the collection plate to the SPE Dry Dual Sample Concentrator System. 
8) Insert needles into collection plate (above elute) and set oxygen free nitrogen flow at 
30 l/min at 60oC to dry down elute. 
9) If not proceeding directly LC-MS/MS, secure cover film to collection plate and store at 
-20oC until processing.  
 
2.8.1.5.  Analyte resuspension 
1) Add 70 μl of HPLC water and shake for 5 mins on KS 260 Basic Shaker (at 200 rpm). 
2) Add 30 μl of methanol and shake for 5 mins on shaker (at 200 rpm). 
3) Secure cover film to collection plate and placed into the LC-MS/MS autosampler. 
 
Injection Volume 10 μl 
Column ACE Excel UHPLC C18 PFP 1.7 μm (2.1 x 100 mm) 
Mobile Phase A H2O / 0.1% CH2O2 
Mobile Phase B CH3OH / 0.1% CH2O2 
Flow Rate 400 μl/min 
Temperature Oven 400C 
Table 16. Liquid chromatography settings - Shimadzu / QTRAP 6500+ 
 
CAD -2 
Ionspray voltage 4500 / -4500 
Temperature 600  
GS1 60 
GS1 40 
Spray voltage 5500 
Turbospray / APCI Turbospray 
Entrance potential 10 / -10 
Table 17. Mass spectrometry settings - Shimadzu / QTRAP 6500+ 
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2.8.2. Tracer studies 
Given the surprising finding of elevated concentrations of 3HK in Kmoalb-cre mice, I 
wanted to investigate the metabolism of 3HK. I performed pilot studies to determine a suitable 
concentration of tracer to allow detection by LC-MS/MS at 20 mins. 
 
2.8.2.1.  Protocol – preparation of intravenous tracer mix     
1) Prepare 100 μg/mL L-tryptophan-(indole-d5) in PBS (A) 
2) Prepare 100 μg/mL [U-Ring-13C6]-3-Hydroxykynureine in PBS (B) 
3) Mix 1:1 volume of (A) and (B) to give: 50 μg/ml D5-TRP and 50 μg/ml 13C6-3HK in PBS. 
 
2.8.2.2.  Protocol – tracer mix injection and sample collection     
1) A 0.3 ml syringe with the tracer mixture was prepared (50 μg/mL D5-TRP and 50 
μg/mL 13C6-3HK in PBS). 
2) General anaesthesia induction was induced with 5% isoflurane gas in oxygen, which 
was reduced to ~2% isofluorane for maintenance. 
3) A warming mat was used throughout and temperature of the mat checked at regular 
intervals. 
4) Respiration was continuously monitored by the operator to ensure a regular rate and 
that anaesthesia not excessively deep or light, requiring adjustment of isofluorane.   
5) Record the animal’s weight and calculate the mixture volume for weight-adjusted 
injection. 
6) Perform IV injection by tail vein (or penile vein where attempts to use tail vein fail). 
7) Maintain animal under anaesthesia for 20 mins measured from tracer injection time 
point. 
8) At 20 mins, open chest and perform cardiac puncture. 
9) Transfer whole blood into EDTA tubes. 
10) Aspirate urine and store at -80oC. 
11) Harvest lung, liver, kidney and spleen tissues, and transfer tissues into individual 
Cryotube vials and snap freeze in liquid nitrogen. 
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2.8.2.3. LC-MS/MS Instrumentation method 
Samples were then injected onto the LC-MS/MS system (10 μl). Shimadzu Nexera MP 
UHPLC with an AB SCIEX QTRAP 6500+ triple quadrupole system mass spectrometer, 
operated by Analyst® software (SCIEX, Cheshire, UK). The column used for analysis was an 
ACE Excel UHPLC silica column comprised of a C18 bonded to pentafluorophenyl (PFP) 
phase (C18-PFP) (1.7 μm, 2.1 x 100 mm, Advanced Chromatography Technologies Ltd., 
Aberdeen, Scotland). The sample was injected (10 μl); the column oven temperature was 
400C. Two mobile phases were used 0.1% formic acid (Phase A) in water and 0.1% formic acid 
in methanol (Phase B) at a flow rate of 0.4 mL/min. Data processing was performed using 
MultiQuant™ Software, Version 3.0.2 (SCIEX, Cheshire, UK). All peaks analysed were 
individually assessed. 
 
2.9. Flow cytometry 
Dissociation of murine lung and liver samples was performed using the ‘Lung 
Dissociation Kit, mouse’ and ‘Liver Dissociation Kit, mouse’ kits by Miltenyi Biotec Ltd. Ex-vivo 
lung perfusion was performed using Phosphate buffered saline (PBS) via the right cardiac 
ventricle, with the aim of flushing out pulmonary erythrocytes. Liver perfusion was performed 
in situ by cannulation of the portal vein and PBS perfusion. Lung and liver organs were 
homogenized using the gentleMACS Dissociator (Miltenyi Biotec Ltd.) with organ-specific 
programs. I designed a single protocol for simultaneous lung and liver dissociation for flow 
cytometry applications. The modifications made to the original separate Miltenyi protocols were 
to maximise cellular yield, lyse erythrocytes, and optimize work-flow efficiency. 
 
2.9.1. Preparation 
Sodium citrate 3.8% (aqueous) was prepared in sterile water (wt/vol). 
 
2.9.2. Blood preparation for flow cytometry 
For analysis of the circulating blood innate immune cells population, blood was 
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Equipment Manufacturer 
FACS DIVA software BD 
FACS tubes BD 
FlowJo software (Version 10.1r5) TreeStar 
gentleMACSTM Dissociator Miltenyi Biotec 
LSRFortessaTM cell analyser BD 
Nucleocounter Chemometec 
Rotina centrifuge 420R Hettich 
 
Reagents Manufacturer 
autoMACS® rinsing solution Miltenyi Biotec (130-091-222) 
Bovine Serum Albumin solution Miltenyi Biotec 
CD115-APC (clone CSF-1R) BioLegend UK Ltd (135510) 
CD3-PE (clone 17A2) BioLegend UK Ltd (100205) 
CD11b-BV421 (clone M1/70) BioLengend UK Ltd (101236) 
CD11c-PE/Cy7 (clone N418) BioLegend UK Ltd (117318) 
CD19-PE (clone 6D5) BioLegend UK Ltd (115508) 
CD45-AF700 (clone 30-F11) BioLegend UK Ltd (103128) 
CD64-APC (clone FcyRI) BioLegend UK Ltd (139306) 
Dulbecco’s Modified Eagle Medium (DMEM) Gibco 
F4/80-APC (rat anti mouse APC Clone CI:A3-1) AbD Serotec (MCA497APCT) 
Fc-Block anti-CD16/CD32 (purified rat anti-mouse) BD Biosciences (553142) 
Fixable Viability Dye eFluor455UV eBioscience (65-0868-14) 
Fix/Lyse eBioscience 
Ly6C-FITC (clone HK1.4) BioLegend UK Ltd (128006) 
Ly6G-PerCP/Cy5.5 (clone 1A8) BioLegend UK Ltd (127616) 
MHCII-APC/Fire 750 (clone I-A/I-E) BioLegend UK Ltd (107652) 
Liver Dissociation Kit, mouse Miltenyi Biotect (130-105-807) 
Lung Dissociation Kit, mouse Miltenyi Biotect (130-095-927) 
NK1.1-PE (clone PK136) BioLegend UK Ltd (108708) 
Red cell lysing buffer Hybrid-Max  Sigma Aldrich (R7757-100ML) 
SiglecF-PE-CF594 (clone E50-2440) BD Bioscience (562757) 
UltraComp eBeads eBioscience (01-2222-41) 




Blood and organ harvest 
1) Label the 6-well plates, and decant Dulbecco’s Modified Eagle Medium (DMEM) 
medium into each well to be used. 
2) Open chest and perform cardiac puncture to retrieve blood and decant into 1.5 mL 
Eppendorf tube. 
3) Mix 50 μl whole blood with 50 μl sodium citrate (3.8% aqueous) and keep on ice. 
4) Perfuse lungs with syringe with 2 ml PBS via right ventricle. 
5) Surgically remove lungs and perform a second perfusion with another 2 ml PBS.  
Metabolic regulators of inflammation in acute pancreatitis                                                         S0897427 
Alastair J Hayes 
  - 103 -  
 
6) The lungs were transferred into a single well containing DMEM, in 6-well tissue culture 
plate, labelled “lung plate”. 
7) Cannulate the portal vein and perform a 4ml PBS perfusion of liver in situ. 
8) Excised and transfer the liver to a sterile petri dish and remove obvious non-hepatic 
tissue (i.e. connective tissue or gallbladder). 
9) The left lobe of the liver was transferred into one well of a 6-well tissue culture plate 
containing Roswell park memorial institute (RPMI) media, labelled “liver plate”. 
10) Kidney – place in labelled cryotube tube and snap freeze in liquid nitrogen. 
11) Pancreas – place in labelled cryotube tube and snap freeze in liquid nitrogen. 
 
Tissue Digestion 
1) Warm Liver dissociation mix to 37oC (from Liver Dissociation Kit, Miltenyi Biotec) 
2) Tissue weights were recorded 
3) For each liver sample, transfer tissue into an individual C Tube (Miltenyi Biotech) 
containing prewarmed dissociation mix. 
4) For each lung sample, transfer tissue into an individual C Tube (Miltenyi Biotech) 
5) Add enzyme mix into tube from kit (Lung Dissociation Kit mouse; Miltenyi Biotec). 
6) Using a syringe and needle, repeatedly aspirate enzyme mix into tissue. 
7) Cut tissue into small pieces with dissecting scissors, close tube and label appropriately 
(ie. Liv M1). 
   
Blood processing 
1) In lab, take 100 μl blood/ sodium citrate samples off ice 
2) Add 50 μl anti-CD16/CD32 Fc-block (to give 1:500 final concentration Fc-block) and 
incubate for 10 mins 4oC for 30 mins dark [making 150 μl] 
3) Add 50 μl antibody stain mix (see below) at 4oC for 30 mins dark [making 200 μl] 
4) Add 500 μl Fix/Lyse solution (eBioscience) for 30 mins dark at room temperature 
5) Store 4oC for 30 mins dark until Flow cytometry 
 
gentleMACSTM  
1) Attach C Tubes containing Lung in pairs to the gentleMACSTM Dissociator. Run 
program m_lung_01.01 (8s). 
2) Attach C Tubes containing Liver in pairs to the gentleMACSTM Dissociator. Run 
program m_liver_03.01 (37s). 
3) Incubate all samples at 37°C under continuous rotations for 30 mins. 
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4) Re-attach C Tubes containing Lung in pairs to the Dissociator and run program 
m_lung_02.01 (38s). 
5) Re-attach C Tubes containing Liver in pairs to the Dissociator and run program 
m_liver_04.01 (37s). 




1) Label 15 ml Falcon to match each C Tube and place in large rack in line with 
corresponding C Tube. 
2) Place a 70 μm SmartStrainer (Miltenyi Biotec) on top of 15 ml Falcon and decant 
’clean PBS’ through the SmartStrainer. 
3) Discard the PBS used to pre-wet the strainer membrane, and replace strainer back 
onto of the same Falcon. 
4) Re-suspend sample (flick) and pour cell suspension through SmartStrainer, collecting 
sample in the Falcon. 
5) Wash each C Tube with 2.5 ml 1x Buffer S (close lid, invert x2), and decant this 
through corresponding strainer. 
6) Using a separate rubber plunger (from 2 ml syringe) for each sample in turn, 
repeatedly press strainer membrane to encourage remaining cells on membrane 
through the strainer. Discard each plunger after use. 
7) Wash C Tube with 2.5 ml ‘clean PBS’ (close lid, invert x2), and decant this through 
corresponding strainer. 




1) Label 15 ml Falcon to match each C Tube and place in large rack in line with 
corresponding C Tube. 
2) Place a 100 μm SmartStrainer (Miltenyi Biotec) on top of 15 ml Falcon and decant 
’clean DMEM’ through the SmartStrainer. 
3) Discard the DMEM used to pre-wet the strainer membrane, and replace strainer back 
onto of the same Falcon. 
4) Re-suspend sample and pour cell suspension through SmartStrainer, collecting 
sample in the Falcon. 
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5) Wash each C Tube with 2.5 ml DMEM (close lid, invert x2), and decant this through 
corresponding strainer. 
6) Using a separate rubber plunger (from a 2 ml syringe) for each sample in turn, 
repeatedly press strainer membrane to encourage remaining cells on membrane 
through the strainer. Discard each plunger after use. 
7) Wash C Tube with 2.5 ml DMEM (close lid, invert x2), and decant this through the 
corresponding strainer. 
8) Screw close lid of Falcon. Last check that Falcon tube is labelled appropriately. 
Discard SmartStrainers. 
 
Red cell lysis (organs) 
1) Centrifuge all (liver, lung) samples together (300 x g for 10 mins). Meanwhile, label 
96-well plate and place on ice to chill. 
2) Aspirate supernatant without disturbing pellet. 
3) Re-suspend pellet in residual by vortex. 
4) Add 1 ml of red cell lysis buffer from stock. Keep at room temperature. 
5) Remove any remaining large particles (connective debris) from the suspension using 
pipette tip, and gently mix for 5 mins. 
6) Add 10 ml ‘cold sterile PBS’ (from fridge) to each, and centrifuge all samples together 
(300 x g for 5 mins). 




1) Label eppendorf tubes (x1 for each sample). 
2) Decant required volume PEB buffer from stock (in fridge) into a 15 ml Falcon. Label 
Falcon tube: ‘PEB’. 
3) For Lung, add 600 μl PEB buffer to each sample and mix. Keep these stock samples 
on ice. 
4) For Liver, add 700 μl PEB buffer to each sample and mix. Keep these stock samples 
on ice. 
5) For Kidney, add 1100 μl PEB buffer to each sample and mix. Keep these stock 
samples on ice. 
6) Transfer 40 μl of PEB buffer to an eppendorf tube. Do one for each sample. 
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7) Transfer 10 μl of cell suspension from stock to eppendorf tube. Label eppendorf tube. 
Do this for each sample. 
8) In the cell counting room (Flow suite), add 50 μl Reagent A to each eppendorf tube, 
and mix. 
9) Add 50 μl Reagent B, to each eppendorf tube, and mix. 
10) In turn, aspirate the sample mix with a NucleoCassette and count cells with the NC-
100 system. 
11) Document the cell concentration for each sample from computer, and discard each 
NucleoCassette after use. 
12) Complete a cell count for each sample in turn. 
13) Use 2 million cells for each staining sample and 1 million for unstained compensation. 
 
Cell staining 
The following stain panel mixes were used for blood, lung and liver after considerable 
consultation with peers experienced in flow cytometry and my own preliminary 
experimentation. 
Fluorophore BV421 FITC PE PE PE PE-Cf594 APC AF700 PE-Cy7 PerCP-Cy5.5 PEB buffer 
Antibody CD11b Ly6C CD3 CD19 NK1.1 SiglecF CD115 CD45 CD11c Ly6G - 
Vol. (μl) for 50 ul 1.0 0.7 1.0 1.0 1.0 1.0 1.0 1.0 0.7 1.0 40.6 
Final conc. 1:200 1:285 1:200 1:200 1:200 1:200 1:200 1:200 1:285 1:200 - 
Table 19: Blood (200 μl total volume [blood 50, citrate 50, Fc block 50, stain 50]) 
 
Fluorophore BV421 FITC PE PE PE PE-Cf594 APC AF700 PE-Cy7 PerCP-Cy5.5 APC-Fire Buffer 
Antibody CD11b Ly6C CD3 CD19 NK1.1 SiglecF CD64 CD45 CD11c Ly6G MHCII - 
Vol. (μl) for 25 ul 0.25 0.33 0.33 0.33 0.33 0.25 0.5 0.5 0.25 0.5 0.33 21.1 
Final conc. 1:400 1:300 1:300 1:300 1:300 1:400 1:200 1:200 1:400 1:200 1:300 - 
Table 20: Lung (100 μl total volume [cells 50, Fc block 25, stain 25]) 
 
Fluorophore BV421 FITC PE PE PE PE-Cf594 APC AF700 PE-Cy7 PerCP-Cy5.5 APC-Fire Buffer 
Antibody CD11b Ly6C CD3 CD19 NK1.1 SiglecF F4/80 CD45 CD11c Ly6G MHCII - 
Vol. (μl) for 25 ul 0.25 0.33 0.33 0.33 0.33 0.33 0.5 0.5 0.25 0.33 0.5 21.0 
Final conc. 1:400 1:300 1:300 1:300 1:300 1:300 1:200 1:200 1:400 1:300 1:200 - 




Single cell suspensions are analysed by flow cytometry using BD LSRFortessa™ 
instrument with BD FACSDiva™ software. Use of unstained cells, fluorescence minus one 
(FMO) controls, and stained beads (with +ve and -ve beads) were used with Flow cytometry 
staff to set up compensations with the lasers.  
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2.10. In-vivo drug studies 
2.10.1. Drinking-water drug study protocol 
Sonicator : Homogenisers Status US 70, MS 72. Philip Harris Scientific. 
75 ml mini drinking bottle (Classic Pet Products: 0190) 
 
2.10.2. Parenteral mini pump drug study protocol 
Preparation of the drug solution (250 mg/mL) 
1) Weigh required mass of GSK898 into an eppendorf tube. 
2) Add volume required to make 500 mg/mL in Dimethyl sulphoxide (Sigma-Aldrich) 
3) Add equal volume of sterile filtered PEG 400, thereby making 250 mg/mL solution. 
4) Vortex mix. 
 
Filling micro-osmotic pumps 
1) Record the weight of an empty micro-osmotic Alzet Model 1002 [100 μl reservoir, 
0.25 μl/hr, 14 days] pump (Charles River Ltd. 0004317) together with its flow 
moderator in a tissue culture hood, taking sterile precautions.  
2) Fill the pump with drug solution using a 27G needle (GSK898, 250 mg/mL in DMSO : 
PEG) or vehicle solution (1 : 1, DMSO : PEG, no drug). 
3) Fully insert flow moderator into body of pump. 
4) Record the weight of the filled pump. 
5) Place pumps in sterile 0.9% saline overnight at 37oC before implantation (to ensure 
pumps start immediately on implantation. In accordance with manufacturer’s 
instructions). 
 
Implantation of micro-osmotic pump 
1) Induce general anaesthesia. 
2) Administer weight-adjusted subcutaneous pre-emptive analgesia bolus away from 
surgical site. 
3) Clipper hair to upper back. 
4) Transfer animal to operative field. 
5) Prepare skin with disinfectant (70% ethanol in water or Betadine) 
6) Incise skin and dissect free a subcutaneous tissue pocket. 
7) Insert pump into pocket. 
8) Close with autoclip skin clips. 
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9) Allow recovery in warm box. 
 
2.11. In-vitro studies 
2.11.1.  HMVEC-L Cell Passage 
Materials 
Reagents Manufacturer Cat number 
EBM-2 MV BulletKit (CC-3156 & CC-4147) Lonza CC-3202 
Trypsin-EDTA 0.05% (1x) Gibco 25300-054 




1) Make up Endothelial cell growth basal medium 2 (EBM-2) using EBM-2 BulletKit in 
accordance with manufactures’ instructions. 
2) Retrieve flask from incubator. 
3) Aspirate off medium from flask and discard. 
4) Wash cells with pre-warmed (37oC) PBS (10 mL) and discard. Repeat & discard 
wash. 
5) Add 5 ml pre-warmed Trypsin/EDTA to old flask. 
6) Incubate at 37oC for 3 mins and agitate flask to suspend cells. 
7) Add 5 ml EBM-2 medium to flask (making 10 ml). 
8) Transfer 10 ml cell suspension to falcon. 
9) Spin 300g for 5 min. 
10) Pour off supernatant from cell pellet. 
11) Flick resuspend cells. 
12) Add 1 ml EBM-2 medium and repeat resuspend cells. 
13) Cell count (number of cells in 25 squares is X x10^4 per ml concentration). 
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2.11.2.  Cell treatments 
Equipment Manufacturer Cat Number 
96-well flat bottom white plate (no lid) Costar 3912 
96-well flat bottom transparent plate + low evaporation lid Costar 3595 
Tecan Infinite M1000 plate reader Tecan  
  
Reagents  Manufacturer Cat Number 
Caspase-Glo® 3/7 Assay Promega Corporation  G8091 
Human IL-1β (1 μg) Miltenyi Biotec 130-093-895 
Human IL-6 (25 μg) Miltenyi Biotec 130-093-929 
Human IL-10 (25 μg) Miltenyi Biotec 130-093-948 
Human TNF-alpha Miltenyi Biotec 130-094-017 
Staurosporine from Streptomyces sp. Sigma-Aldrich S5921-.1MG 
DiOC6 (3) dye 100 mg Thermo Fisher Scientific D273 
Dimethyl sulphoxide (DMSO) Sigma-Aldrich D8418-250ML 
L-Tryptophan  Sigma-Aldrich T0254-1G 
L-Kynurenine Sigma-Aldrich K8625-25MG 
IL-1 Receptor antagonist human Sigma-Aldrich SRP3327 
Kynurenic acid Sigma-Aldrich K3375-1G 
3-hydroxy-DL-kynurenine Sigma-Aldrich H1771-25MG 
Xanthurenic acid Sigma-Aldrich D120804-1G 
3-hydroxyanthranilic acid Sigma-Aldrich 148776-250MG 
Table 23. Cell treatments 
 
2.11.3.  Caspase 3/7 activity assay 
Protocol 
1) Seed HMVEC-L cells at 5 x 10^4 per well in a white flat-bottom 96-well plate. 
2) Incubate 24 hrs at 37oC, 5% CO2. 
3) Aspirate and discard 20 μl supernatant from each well. 
4) Add 20 μl of treatment mixture to designated well (DMSO 0.5% final concentration). 
5) Gently mix contents of wells using plate shaker (at 150 rpm for 30 secs). 
6) Incubate for 4 hours at 37oC, 5% CO2. 
7) Meanwhile, prepare the Caspase-Glo® reagent by adding Caspase-Glo® buffer to 
Caspase-Glo® substrate to make Caspase-Glo® reagent. 
8) Remove 100 μl of supernatant from each well (store at -20 or -80 oC, as required) 
9) Add 100 μl of Caspase-Glo® reagent to each well. 
10) Gently mix contents of wells using plate shaker (at 150 rpm for 30 secs). 
11) Incubate for 90 mins at 37oC, 5% CO2. 
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12) Ensure plate reader (Tecan Infinite M1000) is switched on for >10 mins before use. 
13) Transfer plate(s) to plate reader. 
14) Read luminescence for each sample with the following settings: Attenuation OD1; 
Integration time 1000 ms. 
 
 
2.12. Statistical analysis 
2.12.1.  Assessment of data variation 
Conformity of data to the normal distribution was assessed by one-sample 
Kolmogorov-Smirnov with Lilliefors Significance Correction and Shapiro-Wilk tests. The 
Levene statistic was used to test homogeneity of variance between groups. 
 
2.12.2.  Statistical tests between groups 
Two group data that were normally distributed were compared by unpaired t-test 
without assumption of equal variance (Welch), and non-parametric two-group data were 
compared by the Mann-Whitney U test. Multiple groups testing two categorical variables and 
a continuous variable were tested by two-way ANOVA. Multiple groups of normally distributed 
data were compared by ordinary one-way analysis of variance (ANOVA). Where significant, 
pairwise post hoc comparisons were performed by post hoc Tukey’s multiple comparison tests 
if the data met the homogeneity of variance assumption, or by Games-Howell test where the 
data had unequal variances. Multiple groups of normally data that did not conform to the normal 
distribution were compared by Kruskal-Wallis one-way ANOVA test with post hoc pairwise 
comparisons made using the Dunn’s approach. Comparison of survival curves was conducted 
with Log-rank (Mantel-Cox) test. All statistical tests were based on a two-sided α-value of 0.05, 
and P values ≤ 0.05 were considered statistically significant. 
 
2.12.3.  Power analyses 
Power calculations were performed using G*Power (v3.1.9.4) software. A priori 
analysis was performed where suitable data were available, otherwise post hoc 
power calculations were performed. The following input parameters were routinely used: 2-
tailed, a-error probability of 0.05, and power (1-b error probability) ³ 0.9. Cohen’s measures 
for the effect size d were determined with group means and standard deviations. Specific 
mention is given to power calculations in appropriate sections. 
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2.12.3.  Statistical software packages 
Data were analysed using IBM SPSS Statistics version 23.0 (IBM Corp., Armonk, NY, 
USA) and GraphPad Prism v7.0. 
 
2.12.3.  Statistical advice and resources 
Statistical advice was taken from colleagues in the MRC Centre for Inflammation 
Research, University of Edinburgh, most helpfully my primary PhD supervisor. My main 
textbook was ‘Statistics Explained: Introductory Guide for Life Scientists, 2nd Edition by Steve 
McKillop, Cambridge University Press [2012]. Online resources were also informative, in 
particular the helpful website authored by chartered statistician and retired biomedical 
academic, Dr MFW Festing <www.3rs-reduction.co.uk>. 
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3. RESULTS 
3.1. Model optimization – Phase I – Telemetered AP recovery studies 
3.1.1. Introduction 
A rat model of biliary AP was first reported in 1980, describing the retrograde infusion 
of a bile acid, sodium taurocholate, into the distal biliopancreatic duct (12). More recently, this 
was modified as a mouse model (13) and has been adopted by other groups (14), including 
our own (106, 634). In this model, increasing concentrations of sodium taurocholate are 
associated with severity and multi-organ injury (134, 637). The reported infusion time 
employed by different groups is variable, and the preference of our lab was a 60-second 
infusion for severe injury studies, which others have used to good effect (134). Male mice alone 
were used. Although a limitation of this preliminary work, a mixture of Kmowt and Kmonull mice 
were used (Table 21) as the preferred Kmowt litter stocks alone were insufficient. However, 
from previous work the Kmonull mice were anticipated to be more resistant to lethality than 
Kmowt mice (634). 
 
3.1.1.1. Initial choice of disease model protocol 
The study of the resolution phase of an experimental severe inflammatory disease 
process, requires negotiating a fine balance between excessive lethality and too mild a disease 
model. The literature had reported a 95% survival rate at 7-days with 2% (wt/vol) sodium 
taurocholic acid (Na-TCA) (13), but at this concentration lung injury has been reported an being 
absent (638). Therefore, at the outset a dose higher than 2% was selected, whilst aiming to 
avoid the reported 60% lethality reported by one group using 5% sodium taurocholic acid 
(NaTCA) infusion (637). Additionally, we had chosen to use implantable radiotelemetry devices 
to study the physiological and sickness behaviour over the 7-day recovery interval, for scientific 
and welfare purposes, as agreed with veterinary colleagues. The extent to which a surgically 
implanted telemetry device (extended anaesthesia time and tissue injury) would contribute to 
sickness behaviour was unknown. We chose to use the cardiometabolic G2 HR telemeters 
(Starr Life Sciences) at the outset, as these measured core body temperature, locomotor 
activity and heart rate; all physiological parameters which alter with systemic inflammation.  
The cardiometabolic telemeter implantation had to be implanted at the same time as 
the intraductal infusion because it would not be technically feasible to access the pancreas at 
subsequent laparotomy due to the size of the device, the chest leads which reduce mobility, 
and risk of bowel injury at re-laparotomy. The starting point for studying the early resolution 
phase of AP-associated multi-organ injury was therefore 100 μl 3% Na-TCA infused over 60-
seconds, in conjunction with telemeter implantation. 
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3.1.1.2. Requirement to amend protocol 
The high lethality encountered at the outset forced a revision to the protocol after 
consultation with veterinary colleagues due to Home Office restriction and ethical 
considerations. A stepwise logical approach was employed, testing key modifiable variables. 
 
3.1.2. Aim 
To determine a suitable protocol for studying the recovery of experimental AP for use 
with telemetry monitoring. 
 
3.1.3. Results  
With the use of Protocol 1 [3% NaTCA, 100 μl, over 60s], 7 of 9 mice died (see Figure 
21), leaving only two mice to survive the 7-day experimental period. This was a far higher 
lethality than anticipated, and after discussions with veterinary colleagues, the lethality of the 
model was investigated by trying to separate the surgery from the bile acid, by omitting the 
latter. Thus, Protocol 2 consisted of the same volume and flow rate of infusate as in Protocol 
1 (100 μl, over 60s), but using only PBS alone. There was no modification besides the omission 
of NaTCA. All six available mice survived 7 days (Figure 21). Therefore, it was concluded that 
it was not the surgical insult (i.e. tissue injury, anaesthesia and telemeter implantation) per se 
which was the cause of the lethality observed in Protocol 1, and that the lethality could be 
reduced by altering the infusate.  
There were seemingly 3 modifiable components to the model with which may be 
responsible for severity: i) concentration of the chosen bile acid; ii) volume of infusate; iii) flow 
rate. The reason to consider more than just the bile concentration was that other research 
groups used far slower flow rates, and no other group reported faster infusion rates. I chose to 
modify the concentration as an initial variable, as the literature supports correlation of lethality 
with concentration. For Protocol 3, it was agreed with veterinary colleagues to use 1% NaTCA 
initially, using a concentration of bile acid that was lower than used in the literature to induce 
AP (2% is minimum), but keeping the infusate volume and flow rate consistent (100 μl, 60s). 
The first two mice tested with Protocol 3 died by ~30-hrs. It was concluded that the lethality 
might be modified by lessening the infusate volume or flow rate. As available animals and 
research time were increasingly limited, both the infusate volume and the flow rate were 
reduced, as other investigators had suggested that the ductal infusate dynamics may cause 
severe damage and rupture of the pancreatic ductal system which is of considerable 
importance in disease recovery studies. Specifically, Perides et al. state: “We avoid flow rate 
higher than 10µl/min to avoid artifacts and injury due to rapid increase in intrapancreatic 
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pressure” [Perides et al., Retrograde infusion of bile acids into the pancreatic duct to induce 
pancreatitis in rats and mice. Pancreapedia: Exocrine Pancreas Knowledge Base, DOI: 
10.3998/panc.2011.8]. Furthermore, since lethality observed in Protocols 1-3 occurred £72-
hrs, the next protocol was limited to 72-hr duration for expediency. 
For Protocol 4, the same bile acid concentration as in Protocol 3 (1% TCA) was used 
but the infusate volume was halved, to 50 μl [used by other groups (13)], and the flow rate 
reduced by a factor of ten (over 5 mins = 300s; rate 0.167 μl/s). As both subjects survived, it 
was concluded that infusate volume and rate were preferable. However, as 1% NaTCA is not 
a concentration used by other groups to induce AP, a returned was made to the highest 
concentration used previously (3% NaTCA), but with the reduced infusion volume and flow 
rate. With Protocol 5 (3% NaTCA, 50 μl, 300s) only 1 of 6 mice survived the 7-days. As with 
Protocol 1, this was an unworkable for recovery studies and therefore the concentration of 
NaTCA was reduced in Protocol 6 (2% NaTCA, 50 μl, 300s) where the first two mice survived. 
As others had reported minimal lung injury with 2% model, I next tested the dose of 2.5%. With 
hindsight, lung injury with Protocol 6 could perhaps have been tested at this juncture, but as 
there was no consensus on how best to measure lung injury and efforts were focused on 
reaching a final infusion protocol as soon as possible, the lung assay option was overlooked. 
With Protocol 7 (2.5% NaTCA, 50 μl, 300s) both subjects reached humane endpoints.  
One supervisor suggested that sterile filtering the infusate may be give more consistent 
results by increasing the homogeneity of the infusate solution. Thus, Protocol 8 (2.5% NaTCA, 
filtered, 50 μl, 300s) was tested, but still resulted in >50% 7-day lethality (n = 4 of 6 failed to 
survive 7-day). At this juncture, a pragmatic decision was taken to select the final choice of 
2.0% NaTCA (37 mM), with sterile filtered, 50 μl infusion over 300s, (Protocol 9) for all of the 
AP studies. Survival results from the first experiment using Protocol 9 are included in Table 
24. Further detail is Appendix 5, Table 66 (section 6.5). Survival curves of all protocol 
permutations are illustrated in Figure 21. 
 












P1 G2 HR 3.0 % (56 mM) 100 μl 100 μl/ min 9 (WT n=2, KMO n=7) No 7 of 9 (168h) 
P2 G2 HR 0%      (0 mM) 100 μl 100 μl/ min 6 (WT n=3, KMO n=3) No 0 of 6 (168h) 
P3 G2 HR 1.0 % (19mM) 100 μl 100 μl/ min 2 (WT n=1, KMO n=1) No 2 of 2 (168h) 
P4 G2 HR 1.0 % (19mM) 50 μl 10 μl/ min 2 (WT n=2) No 0 of 2 (72h) 
P5 G2 HR 3.0 % (56 mM) 50 μl 10 μl/ min 6 (WT n=5, KMO n=1) No 5 of 6 (168h) 
P6 G2 HR 2.0 % (37mM) 50 μl 10 μl/ min 2 (WT n=2) No 0 of 2 (168h) 
P7 G2 HR 2.5 % (47mM) 50 μl 10 μl/ min 2 (WT n=2) No 2 of 2 (168h) 
P8 G2 HR 2.5 % (47mM) 50 μl 10 μl/ min 6 (WT n=5, KMO n=1) Yes 4 of 6 (168h) 
P9 - Final G2 HR  2.0 % (37mM) 50 μl 10 μl/ min 6 (WT n=6) Yes 5 of 6 (168h) 
Table 24. Model optimization for telemetered AP 7-day recovery studies 
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Figure 21.  Infusion protocols towards optimization of telemetered AP 
model for recovery 
P1: 3%TCA/PBS (56 mM) 100 μl over 60s, 7d;  
P2: 0%TCA/PBS (0 mM) 100 μl, 60s, 7d;   
P3: 1%TCA/PBS (19 mM) 100 μl, 60s, 7d;  
P4: 1%TCA/PBS (19 mM) 50 μl, 300s, 3d;   
P5: 3%TCA/PBS (56 mM) 50 μl, 300s, 7d;  
P6: 2%TCA/PBS (37 mM), 50 μl, 300s, 7d;  
P7: 2.5%TCA/PBS (47 mM), 50 μl over 300s, 7d;  
P8: 2.5%TCA/PBS (47 mM), Filtered, 50 μl, 300s, 7d;  
P9: 2.0% TCA/PBS (37 mM), Filtered, 50 μl, 300s, 7d: The final protocol taken 




A final retrograde infusion of Na-TCA protocol was reached for use with telemetry, to 
study experimental AP and recovery over 7-days. The pancreatic injury and markers of the 
systemic inflammatory response at 24-hrs from this protocol are examined in section 3.6. 
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3.2. Experiment 1 – KMO deletion improves AP recovery 
3.2.1. Animal welfare considerations  
I defined critical illness humane endpoints in consultation with University of Edinburgh 
Named Veterinary Surgeons (NVS), as recognised by the UK Home Office. The humane 
endpoints indicating imminent death were: Unresponsiveness, severe laboured breathing and 
sustained profound hypothermia. All mice were given weight-adjusted pre-emptive analgesia 
under anaesthesia with buprenorphine subcutaneously, as well as two ealy post-operative 
doses (6-8 hrs and 20-24 hrs post-operatively). Daily oral post-operatively buprenorphine in 
jelly cubes was provided and consumption recorded. 
Additional subcutaneous analgesia was administered if there were cage-side clinical 
signs that would trigger analgesia as recorded on the clinical score sheet Appendix 4 (section 
6.4). In the absence of a humane endpoint being reached, any of the following signs observed 
during daily cage-side checks triggered a subcutaneous weight-adjusted dose of analgesia: 
‘Hunched posture’, ‘not inquisitive or alert’, ‘not eating or drinking’, ‘abdominal writhing’. See 
methods section (2.2.) for further detail.  
 
3.2.2. Hypothesis 
Absent 3HK, by KMO deletion (Kmonull), is protective against multi-organ injury in a 7-
day recovery AP model (with cardiometabolic telemeter) compared to wildtype. 
 
3.2.3. Methods considerations 
To measure the critical illness response to AP in mice and to monitor the recovery from 
systemic inflammation, we compared heart rate, temperature and locomotor activity between 
Kmonull mice with AP and Kmowt mice with AP. Additional sham-operated control Kmowt mice 
underwent laparotomy and telemeter implantation, but without AP induction. Block 
randomisation was performed to ensure equal utilisation of specific telemeters between the 
three experimental groups to control for any variation in telemeter performance efficiency. This 
was done by random number generation in a spreadsheet (Excel by Microsoft) and sorting 




The mean age, weight and length of anaesthesia did not differ significantly between the 
three groups: Kmowt sham, Kmowt AP and Kmonull AP (Table 25). The mean duration of the  
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Group No. / Sex Rx Mean age ± SEM (d)  Mean weight ± SEM (g) Mean anaesthetic time ± SEM 
(min) 
KMOwt 6 / Male Sham 143 ± 3.48 30.46 ± 0.70 46.2 ± 1.6 
KMOwt 6 / Male AP 143 ± 0.73 28.86 ± 0.29 45.5 ± 2.0 
KMOnull 6 / Male AP 143 ± 2.03 30.46 ± 1.08 46.0 ± 1.1 
1-way ANOVA p = 1.0, ns p = 0.26, ns p = 0.95, ns 
Table 25. Study subjects for experiment 1 
SEM = Standard error of mean. ns = not significant. 
 
experiment was significantly shorter (p = 0.01, KW 1-W ANOVA) in Kmowt AP group (69.4-hrs) 
compared to Kmowt Sham (168-hrs) and Kmonull AP (147.5-hrs), since 5 of 6 Kmowt AP mice 
reached humane endpoints during the experiment.  
 
3.2.3.2. Analgesia consumption 
Whilst the mean subcutaneous buprenorphine dosing was equivalent between 
experimental groups (p = 0.179, KW 1-W ANOVA), the time-adjusted dosing was significantly 
higher (p = 0.008, KW 1-W ANOVA) in the Kmowt AP mice (0.111 µg/hr) due to the shortened 
experimental period and the peri-operative dosing given at the start of the experiment (Table 
26). The mean oral buprenorphine dose consumed was significantly higher (p = 0.006, KW 1-
W ANOVA) in the Kmowt Sham group (70 µg), which can be explained by an improved 
voluntary oral intake compared to AP mice, as well as longer survival (with daily oral analgesia 
supply). Therefore, because overall AP mice had reduced experimental times, there was no 




Line Treatment Number 
Exp duration – 
mean (SD) 
S/C Bup. Dose – 
mean (SD) 
S/C Bup. Dose : Time 
adjusted – mean (SD) 
Oral Bup. Dose – 
mean (SD) 
Oral Bup. Dose : 
Time adjusted – 
mean (SD) 
Kmowt  AP N = 6 69.4 (50.9) hrs 5.500 (1.225) µg 0.111 (0.055) µg/hr 26.333 µg (23.51) 0.330 (0.181) µg/hr 
Kmowt Sham N = 6 168.0 (0) hrs 4.500 (0.000) µg 0.027 (0.000) µg/hr 70.000 µg (00.00) 0.417 (0.000) µg/hr 
Kmonull AP N = 6 147.5 (50.2) hrs 4.625 (0.737) µg 0.044 (0.044) µg/hr 45.000 µg (35.07) 0.268 (0.209) µg/hr 
1-way ANOVA between 3 groups **p = 0.010, KW ns p = 0.179, KW **p = 0.008, KW **p = 0.006, KW ns p = 0.345, KW 
Table 26. Analgesia given during AP experiment 1 
Columns: ‘Exp duration – mean (SD)’ denotes the mean number of hrs of experimented mice in the cohort with standard 
deviation (SD), with a maximum of 168-hrs. ‘S/C Bup. Dose / group’ denotes mean total dosing of subcutaneous 
buprenorphine of cohort. ‘S/C Bup. Dose : Time adjusted’ denotes the group’s mean total dose per mouse divided by number 
of experimental hours for each mouse. ‘Oral Bup. Dose – mean’ denotes the group’s mean total oral buprenorphine dose. 
‘Oral Bup. Dose : Time adjusted – mean’ denotes the group’s mean total oral dose per mouse divided by the number of 
experimental hours of each mouse. Oral buprenorphine single dose 0.01 mg. S/C buprenorphine single dose 0.05 mg/kg. 
KW: Kruskal-Wallis. ns = not significant; *p < 0.05; **p < 0.01. 
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3.2.3.3. Telemetry and humane endpoints 
The telemetry data are shown in Figures 22A to 22D. Sham-operated control Kmowt 
mice (n = 6) showed a disturbance in locomotor activity, including post-anaesthesia 
hyperactivity, in the first 24-hr period that reverted to a normal physiological crepuscular 
pattern by day 3 after surgery, with increased activity at the start of the dark phase (Figure 
22B: dark phase depicted by vertical grey panels on timeline). Sham-operated Kmowt mice 
showed a much lesser degree of autonomic dysfunction by maintaining a stable oscillating 
core body temperature without significant hypothermic episodes (Figures 22A).  
Kmowt mice with AP (n = 6) had repression of locomotor activity in the first 24-hrs similar 
to Kmonull mice with AP (Figure 22D), but unlike Kmonull mice, failed to recover over the 
subsequent 6 days due to significant hypothermia and reaching humane endpoints (Figure 
22A). Five of the six Kmowt AP deteriorated with to critical illness and reached predefined 
humane endpoints requiring humane cull within the first 72-hrs. Specific signs in these mice 
were profound hypothermia (n = 5) and one of these additionally had severe labored breathing.  
Critically ill mice heart had abnormal heart rates which were either profoundly 
bradycardic in 4 mice, with a mean heart rate of 217 b.p.m. (SEM 20 b.p.m) at the last data 
reading before cull, or conversely severely tachycardic (757 b.p.m.) in 1 mouse which exhibited 
severe labored breathing (Figure 22C). Telemetered Kmonull mice with AP (n = 6) showed an 
initial reduction in locomotor activity equivalent to that observed in Kmowt mice with AP during 
the first 24-hrs (Figure 22D), which strengthened over the subsequent recovery period (Figure 
22B). Furthermore, survival was significantly better in Kmonull mice, with only 1 of 6 Kmonull 
mice reaching a predefined humane endpoint throughout the 7-day experimental period. 
Specifically, this mouse had profound hypothermia (23.5oC) and minimal response to gentle 
stimulation as humane endpoints. 
 
3.2.3.4. Blood biochemistry & cytokines in humane endpoint mice confirmed multi-organ injury 
In those mice which reached humane endpoints, blood sampling was performed at 
humane cull to confirm multiple organ failure and tissue injury, and results were compared with 
samples from Kmowt sham mice (samples taken at day 7). Specifically, alanine transaminase 
(ALT) indicating hepatocyte injury, lactate dehydrogenase (LDH) indicating diverse cellular 
injury, elevated urea indicating renal dysfunction, and a reduction in plasma albumin levels 
were measured and results were compatible with an acute phase response and vascular 
leakage (Figure 23).  
Four of the 5 Kmowt AP mice which reached humane endpoints had sufficient plasma 
for cytokine assay in addition to biochemical assay. MSD V-Plex mouse assay confirmed elev- 
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Figure 22. Experimental AP in telemetry-monitored mice can cause profound sickness behaviour but is 
ameliorated by Kmo deletion 
Experimental 7-day recovery studies. Kmowt mice were randomized to sham operation (n = 6) or AP (n = 6). Kmonull mice 
(n = 6) underwent AP alone. ‘+’ symbol indicates the time when a mouse reached humane endpoint(s) and were culled 
under terminal anaesthesia. Humane endpoints were persistent hypothermia < 26oC, minimal response or severe labored 
breathing. Plots show 7-day AP survival curve (E), hourly mean core body temperature (A), heart rate (C) and locomotor 
activity (B) over 168-hrs. Vertical dark panels are the 12-hr dark phase intervals, with light phase in between. Telemetry 
recording started half-way through the light phase (Zeitgeber 0-hr) on the day of surgery (< 2hrs after recovery from 
anaesthesia for AP induction or sham laparotomy). Here Kmowt mice with AP had poor recovery, with 5 of 6 mice 
reaching humane endpoint(s). A: Temperature; B: Locomotor activity; C: Heart rate; D: Locomotor activity over 0-24-hrs; 
E: Survival. Profound sustained hypothermia (A), suppressed locomotor activity (B) and bradycardia (C) was more 
frequently observed in Kmowt as compared to Kmonull mice with AP. Critical illness was most frequently observed on days 
2 and 3 after AP induction in this telemetered model. Statistical tests were 1way-ANOVA post-hoc Tukey’s (D) and log 
rank (E). ns = not significant (p > 0.05), *p < 0.05. 
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-ated concentrations of the pro-inflammatory cytokines interleukin 1β (IL-1β), interleukin 6 (IL-








Figure 24. Plasma cytokines - experiment 1 
A: Interleukin 1β (IL-1β); B: Interleukin 6 (IL-6); C: tumour necrosis factor a (TNFa). 
Statistical tests are depicted by p-values for t-tests. Primary data are recorded in Table 70, 
Appendix 6.6.  
 
3.2.3.5. Limitations 
An alternative method when comparing blood results from critically ill mice with sham 
controls is to cull the paired mice that were randomised to sham and the disease model at the 
same timepoint (639). Whilst there are merits in such an approach by giving equal sampling 
timepoints, the main disadvantage in a telemetered study such as this is the lost opportunity 
to collect telemetry data-stream from controls. 
 
3.2.4. Conclusions 
Together, these data extend the concept that global Kmo gene blockade protects 
against AP-MODS, by demonstrating an impact on sickness behaviours as well as end organ 
dysfunction and demonstrating that the protection against AP-MODS in Kmonull mice with AP 









Figure 23. Biochemical analysis – experiment 1 
A: alanine aminotransferase (ALT); B: Lactate dehydrogenase (LDH); C: Urea; D: Albumin. Statistical tests are depicted 
by p-values for t-tests. Primary data are recorded in Table 69, Appendix 6.6. 
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3.3. Experiment 2 – Hepatocyte-restricted Kmo knockout increases plasma 3HK 
3.3.1. Background 
Prior to joining the Mole lab in 2014, a novel mouse line was created by Dr. Xiaozhong 
Zheng (Senior Technical Assistant, Mole Group, University of Edinburgh) in 2013, in which 
Kmo gene deletion was conditional upon Cre recombinase, which restricted to cells with the 
serum albumin (alb) gene promotor (using cre-loxP technology), which is robustly hepatocyte-
specific and highly efficient by adulthood (640, 641). Specifically, the Kmotm1c(KOMPWtsi/flox(ex5) 
mouse strain which has loxP sites flanking exon 5 of the Kmo gene was crossed with a mouse 
strain that expresses Cre recombinase under the control of the promoter of the Alb gene (which 
encodes the protein serum albumin), B6.Cg-Tg (Alb-Cre) 21Mgn/J, which expresses Cre 
recombinase exclusively in hepatocytes. Offspring were further backcrossed for at least 6 
generations to generate homozygous KmoFRT-deleted/alb-cre mice (hereafter referred to as Kmoalb-
cre mice). I undertook biochemical characterization of this novel mouse line by LC-MS/MS and 
confirmed genetic alteration by RT-qPCR. After conducting initial pancreatitis studies with this 
mouse line, and finding a disease phenotype (section 3.5, experiment 3), I undertook the tracer 
experiment to better understand this intriguing biochemical phenotype. After finishing work in 
the lab, Dr. Zheng extracted RNA from my frozen tissue samples which were sent to a 
commercial biotech RNA sequencing company (Novogene Limited, Hong Kong). The RNA 
sequencing data was generated and analysed by others in the research group, principally Miss 
Lucile Neyton and Professor Mole. 
 
3.3.2. Hypotheses 
1) Kmo gene deletion restricted to hepatocytes (Kmoalb-cre) would show reduced 
expression of Kmo RNA in the liver compared to wildtype (Kmowt), but no difference 
in expression in kidney or spleen compared to Kmowt.  
2) Kmo gene deletion restricted to hepatocytes (Kmoalb-cre) would alter blood kynurenine 
biochemistry in a pattern similar with global Kmo deletion. 
3) No difference between clearance of tracer 3HK (13C6-3HK) between mouse lines. 
4) In light of the finding of elevated 3HK in Kmoalb-cre mice, this biochemical phenotype 
was anticipated to alter inflammatory gene regulation. 
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3.3.3. Kmo gene tissue expression – Hypothesis 1 
I confirmed tissue specific loss in Kmo gene expression in Kmoalb-cre mice based on 
mRNA levels in liver, kidney and spleen. Data are tabulated in Tables 71 to 75 (Appendix 7) 
and displayed in Figure 25 with 1-way ANOVA with post-hoc Tukey’s tests.  
Sample size and power calculations were assessed post-hoc from mean values and 
standard deviations using liver Kmo gene expression values [Log10(2^-ddCT)] between 
Kmonull (mean = 2e-10 expression fold, SD = 0.776) and Kmoalb-cre (mean = 1.332 expression 
fold; SD = 0.157), giving an effect size d = 2.38 and power 0.96. 
 
Figure 25. Gene expression of a novel 
hepatocyte-restricted Kmo knockout mouse 
line (Kmoalb-cre) 
RT-PCR tissue expression of Kmo gene in liver, 
kidney and spleen of wildtype (Kmowt), Kmo 
deleted (Kmonull) and hepatocyte-restricted Kmo 
knockout (Kmoalb-cre) mice (n = 5 per group). 
Kmoalb-cre mice have reduced Kmo in expression 
in whole liver tissue as compared to wildtype. 
Bars are mean ± s.e.m. Statistical tests shown 
are 1-way ANOVA with post-hoc Tukey’s tests. 
Data are tabulated in Appendix 7.  
 
 
3.3.4. Kynurenine metabolites in three mouse lines – Hypothesis 2 
Next, I compared steady-state kynurenine pathway metabolites of Kmowt, Kmonull and 
Kmoalb-cre healthy mice (n = 6 male mice per group) by measuring upstream and downstream 
metabolite levels in plasma by liquid chromatography-tandem mass spectrometry using six 
adult male mice (Figure 26).  
Effect and sample size were used to calculate power post-hoc from mean values and 
standard deviations using concentrations of kynurenine, the substrate of KMO enzyme, 
between Kmonull (mean = 61.4 μM, SD = 20.3 μM) and Kmoalb-cre (mean = 24.8 μM; SD = 6.6 
μM), giving an effect size d = 2.42 and the power 0.96. 
Kmowt, Kmonull, and Kmoalb-cre mice had equivalent (p = 0.075, one-way ANOVA) plasma 
[tryptophan] concentrations ~100 μM (Figure 26A). Kmonull mice had a 21-fold (median 60.9 
μM vs 2.8 μM, p = 0.002, Mann Whitney test) and Kmoalb-cre an 8-fold (median 23.4 μM vs 2.8 
μM p = 0.002, Mann Whitney test) increase in plasma kynurenine at steady-state compared to 
Kmowt (Figure 26B). Kmonull mice had an 18-fold (median 3.7 μM vs 0.2 μM, p = 0.001, t-test) 
increase in plasma anthranilic acid compared to Kmowt, and Kmoalb-cre had a 14-fold (median 
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2.7 μM vs 0.2 μM, p < 0.001, t-test) increase (Figure 26C). Plasma kynurenic acid was 
extremely elevated in Kmonull mice had a 119-fold excess (median 13.9 μM vs 0.1 μM, p = 
0.002, Mann Whitney test) and Kmoalb-cre a 51-fold increase (5.9 μM vs 0.1 μM, p = 0.002, 














Figure 26: Biochemical characterization of the hepatocyte-restricted Kmo knockout mouse line (Kmoalb-cre) 
Steadystate plasma concentrations of kynurenine pathway metabolites measured by LC-MS/MS for Kmowt, Kmonull 
and Kmoalb-cre mouse lines (n = 6 per group). A: Tryptophan; B: Kynurenine; C: Anthranilic acid; D: Kynurenic acid; 
E: 3-Hydroxykynurenine, with all samples in Kmowt and Kmonull below limit of quantification (BLQ; --- 0.089 μM); F: 
Xanthurenic acid, with 3 of 6 samples in Kmonull group BLQ (--- 0.049 μM). Plots show individual data and horizontal 
lines are median with interquartile range. Statistical tests are depicted by p-values: Group analysis by 1-way ANOVA 
(A) and pairwise tests shown are Welch’s t-tests (C and F) or Mann Whitney U tests (B, D and E), depending on 
data conformity to normal or parametric distributions, as determined by normality tests. 
 
Levels of the KMO product, 3-hydroxykynurenine, were below limit of detection (0.089 μM) at 
steady-state in Kmowt and Kmonull mice. Unexpectedly, Kmoalb-cre mice had high levels of 3-
hydroxykynurenine, greater than 8-fold higher (median 0.769 μM vs 0.089 μM, p = 0.002, Mann 
Whitney test) than Kmowt levels (Figure 26E). 3-Hydroxykynurenine can also be metabolised 
by KAT enzymes (I-IV) to form xanthurenic acid. Kmoalb-cre mice have a 11-fold increase 
(median 1.060 μM vs 0.100 μM, p < 0.001, t-test) and Kmowt a 3-fold increase (0.35 μM vs 
0.10 μM, p = 0.003, t-test) in xanthurenic acid compared to Kmonull mice (Figure 26F). 
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3.3.5. Kynurenine tracer study 
To determine whether elevated [3HK] was in proportion to the elevated kynurenine (due 
to extrahepatic KMO activity) or whether there were any additional alterations in 3-
hydroxykynurenine metabolism in Kmoalb-cre mice, a tracer study was performed (Figure 27). 
I conducted preliminary work (not shown) to determine workable concentrations of 
tracer compounds for use at 20 min timepoint. Following which, I intravenously injected a 
premixed weight-adjusted (50 μg/g body weight) bolus of deuterated tryptophan-indole-d5 and 
13C6-3-hydroxykynurenine, and sampled cardiac blood 20 mins after injection and measured 
native and deuterated metabolites in plasma. Equivalent concentrations of d5-tryptophan 
indicated that tail vein injections were technically efficient (Figure 27A). D4-kynurenine tracer 
levels (metabolised from injected d5-tryptophan) (Figure 27C) were highest with complete Kmo 
deletion (Kmonull) and lowest in wildtype (Kmowt), and followed a similar profile to steady state 
endogenous kynurenine (Figure 27B). However, and unexpectedly, I detected higher 13C6-3-
hydroxykynurenine tracer levels in Kmoalb-cre mice compared to Kmonull (4-fold lower) and Kmowt 
(10-fold lower) mice (Figure 27B). The tracer metabolite 13C6-xanthurenic acid was highest in 










Figure 27: Kynurenine pathway metabolite tracer study  
Plasma concentrations of tracer compounds and metabolites are shown 20 mins after weight-adjusted (50 μg/g) IV bolus 
containing deuterated tryptophan-indole-d5 (D5-TRP) and 13C6-3-hydroxykynurenine (13C6-3HK). A: Comparable 
concentrations of D5-TRP indicates equivalent injection efficiency. B: 13C6-3HK tracer levels were higher in Kmoalb-cre 
mice compared to Kmonull (3.8-fold) and Kmowt (6.3-fold), reflecting reduced 3HK clearance in this line. For 13C6-3HK, 
limit of detection was 0.0432 μM. C: In stark contrast to the low endogenous levels of pathway side-product Xanthurenic 
acid in Kmonull mice, and high levels in Kmoalb-cre mice, the tracer metabolite 13C6-Xanthurenic acid was highest in Kmonull 
mice and relatively reduced in Kmoalb-cre mice. D: Tracer D5-Tryptophan was metabolised to D4-Kynurenine with highest 
levels in Kmonull line. D4-Kynurenine levels were significantly lower in Kmowt (p < 0.0001, t-test) and in Kmoalb-cre (p = 
0.002, t-test) when compared to Kmonull. Individual data are shown and lines represent median values with interquartile 
range. Mice were adult males (n = 6 per group). Statistical tests are depicted by p-values: Group analysis by 1-way 
ANOVA (A) and pairwise tests shown are Welch’s t-tests (B, C and D). 
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3.3.6. Kmoalb-cre versus Kmonull transcriptomics 
Given the intriguing biochemical phenotype of the three mouse strains with regards to 
circulating kynurenine metabolites, I was interested to know what effect altered chronic 
alterations in kynurenine pathway metabolism may have on peripheral tissues. The 
comparison between Kmonull mice (with elevated kynurenine/KA but negligible 3HK) versus 
Kmoalb-cre (partial elevation of kynurenine/KA and very high 3HK levels) offers a particular tool 
to assess the biological effects of elevated 3HK concentrations. Computational RNA 
sequencing analysis revealed an array of significant (p < 0.05) transcriptional differences in 
liver tissue between Kmoalb-cre and Kmonull mice at steady state (Figure 28). There was 
upregulation of TLR cascades, MyD88 cascade, NFkB induction, MAP kinase activation, 
TRAF6, cytokine signalling, interleukin signalling, cellular responses to stress, cellular 
responses to external stimuli, biological oxidations, RIP kinase. Transcriptomal upregulation 
of proinflammatory genes in Kmoalb-cre mice, which have elevated 3HK levels, suggest that 
these mice have a chronic proinflammatory state which may limit their capacity to adapt to 
insults (e.g. DAMPs/PAMPs) such as in AP. 
 
 
Figure 28. Barplot showing significant transcriptomic differences in liver tissue between Kmoalb-cre 
versus Kmonull 
Paired pathway analysis of differentially expressed genes in liver using a q-value threshold of 0.1 in Reactome 
software comparing Kmoalb-cre to Kmonull (baseline). 
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3.3.7. Conclusions 
I confirmed that Kmoalb-cre mice, with Kmo gene deletion restricted to hepatocytes using 
cre-loxP technology, had equivalent Kmo expression in spleen and kidney as Kmowt mice, but 
reduced expression in homogenised liver tissue. Kmo expression in livers from Kmonull mice 
was lower than that in Kmoalb-cre mice, which was not surprising given the presence of non-
hepatocyte cells within liver tissue which is the most likely explanation. Additionally, another 
plausible explanation is that the cre-loxP technology may lack 100% efficiency. However, this 
process is age-dependent with studies showing efficiency to be only 60% by 1 week, but it 
appears to be complete by 6 weeks (641), and all mice used in this work were adult. Analysis 
on a purified hepatocyte population was not performed since the equipment and protocols 
established for liver flow cytometry were designed to extract leukocytes from liver tissue.    
Using LC-MS/MS, I detected an unanticipated elevation in plasma 3HK and XA levels. 
As this mouse line has elevated kynurenine and kynurenic acid concentrations (relative to 
Kmowt), which are potentially cytoprotective (as endogenous ligands of the AhR etc), this 
mouse line provides a useful tool alongside Kmonull mice (which have very high levels of 
kynurenine and kynurenic acid), due to the stark contrast in circulating 3HK levels, whilst both 
having elevated kynurenine and kynureninc acid levels (relative to Kmowt).  Lastly, Kmoalb-cre 
mice surprisingly had delayed clearance of trace 3HK (13C6-3HK), likely due to competition with 
amino acid transporter and metabolizing enzymes (KATs and kynureninase). Increased 13C6-
XA levels in Kmonull likely represents uncompetitive metabolism by KATs due to the absence 
of endogenous 3HK in Kmonull. These results suggest that Kmoalb-cre mice have such high 
circulating concentrations of endogenous 3HK that onward transport and metabolism are 
saturated. This suggests that further production of 3HK by pathway flux would quickly 
accumulate due to congested processes to eliminate 3HK, such as by onward catabolism or 
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3.4. Model optimization – Phase II – Telemetered recovery studies 
3.4.1. Background 
The high lethality of Kmowt mice with the 2% Na-TCA (experiment 1) was a particular 
concern for both researchers and veterinary staff, for experimental and ethical reasons. The 
intention had been to experimentally compare mice at 7-days after AP using cardiometabolic 
telemeters in all recovery studies. However, repeated loss of study subjects during the 
experimental time interval would have a dramatic effect on the results, as those reaching 
humane endpoints would be the sickest. Furthermore, Kmoalb-cre mice with high circulating 
[3HK], would not be expected to have improved survival. Since the disease model could not 
be altered, and there was an option for a smaller telemeter device that could still record the 
two most reliable physiological parameters (core body temperature and locomotor activity), I 
proposed to switch the mini telemeter and therefore to provide some evidence supporting the 
hypothesis of a lesser systemic insult with a smaller implantable telemetry device. 
   
3.4.2. Hypothesis 
A smaller implantable device requiring less invasive surgery would cause a lesser 




Data shown are from Kmowt mice randomly allocated to sham laparotomy (with telemeter 
implantation), with n = 6 mini telemeters compared to n = 6 cardiotelemeter. Data listing the 
study subjects, weight loss and telemetry can be found in Appendix 8. Figure 29 (below) shows 
earlier return to baseline physiological circadian profiles, with greater locomotor activity (29B) 
throughout the 7-day study period, and earlier return of circadian core body temperature 
profiling (29C). COSINOR analysis can be used to measure circadian oscillating rhythms by 
mathematically fitting a Cosine curve to the raw data (29D). The flatter core body profile 
observed in larger cardiometabolic telemeter (29C) was assessed by measuring daily 
COSINOR amplitude in all subjects. All amplitude measurements were significantly lower (60% 
reduction, p < 0.001, MWU) with the larger telemeters as compared to the mini pill telemeters 
(29D). The suppressed circadian body temperature was more marked initially, with associated 
impaired locomotor activity (Figures 29A and 29B), and return towards baseline physiological 
oscillations by days 3-4, with a significant (p = 0.027 post hoc Dunn’s) reduction in temperature 
amplitude during days 1-2 with the larger cardiometabolic telemeter (29F). 
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Figure 29. Physiological insult is reduced after non-cardiac telemeter 
implantation in Kmowt mice  
Recovery from the less invasive non-cardiac telemeter (depicted by blue) is quicker 
than the larger G2 HR E-mitter cardiometabolic telemeter (depicted by green) in sham 
operated Kmowt mice. A: Rolling hourly mean locomotor activity (bold line) with 95% CI 
(shaded line) shows earlier plateau of normal circadian light-dark corpuscular locomotor 
activity of non-cardiac telemetered mice after 48-hrs (green) which is delayed in mice 
with larger cardiometabolic device (blue). B: Total daily activity levels are significantly 
higher in non-cardiac telemeter (green) as compared to mice with the larger device. 
Pairwise statistical analysis was performed by t-test, with significant differences marked 
in bold. C: Hourly mean core body temperatures are shown (bold line) with 95%CI 
(shaded line) showing higher mean core temperatures of more active mice with smaller 
F  
 
non-cardiac telemeters, and reduced circadian light-dark oscillation of body temperature of mice in the first 48 
hours after implantation of larger cardiometabolic telemeter. Cosinor analysis of circadian physiological behaviour 
comparing less invasive non-cardiac telemeter to cardiometabolic telemeter. D: Diagrammatic representation of 
cosinor analysis, with circadian parameters illustrated, including amplitude. E: Cosinor analysis revealed at 60% 
reduction in amplitude (p < 0.001, Mann Whitney U test) in circadian body temperature changes in cardiometabolic 
telemetered mice (median 0.484) compared to non-cardiac telemetered subjects throughout 7-days (median 
0.815). F: The flattening of the body temperature amplitude which was significantly reduced in the first 2 days (p = 
0.0267 post hoc Dunn’s Kruskal Wallis test) resolved with time. Individual data are shown and horizontal lines are 




The data confirm and help quantify the greater systemic insult to the mice with the 
larger telemeter device, supporting the decision to switch to the less invasive telemeter for 7-
day AP recovery studies with the Kmoalb-cre line which, with elevated 3HK levels at baseline 
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3.5. Experiment 3 – Hepatocyte-restricted Kmo knockout out impairs recovery 
in AP 
3.5.1. Background 
Experiment 2 demonstrated elevated circulating concentration of 3HK in the novel 
Kmoalb-cre mouse line, and impaired onward clearance from the circulation of an intravenous 
3HK tracer indicating 3HK elimination saturation. As this metabolite is considered to be 
contributory to multiple organ dysfunction in AP, as supported by elevated serum [3HK] in 
human severe AP which correlates with elevated C-reactive protein (CRP) levels (375) and 
protection against severe AP in rodent models (297, 634), my hypothesis was that mice with 
elevated [3HK] levels would have impaired recovery during a telemetered 7-day study period. 
Given that the Kmowt mice had poor 7-day recovery (Experiment 1) with AP using the 
cardiometabolic telemeter, and that confirmatory data (section 3.4) supported the notation that 
the larger cardiometabolic tracer had measurably impaired recovery after implantation, I chose 
to switch to the smaller telemeter device when comparing sickness behaviour and recovery 
over 7-days between the three related mouse lines (Kmowt, Kmoalb-cre and Kmonull). Age-
matched male mice from each colony were randomly assigned (by random number generation, 
between 0.00 to 1.00, with the lower number assigned to sham in Microsoft Excel) to sham or 
AP, where there were odd littermate numbers, a ratio of 2 AP: 1 sham was used, or 1:1 where 
even number of mice were available, until there was n=7 sham for each group. 
 
3.5.2. Hypotheses 
The Kmoalb-cre mice, with higher circulating [3HK], would display increased sickness 
behaviour and biochemical changes consistent with multiple organ injury. 
 
3.5.3 Results 
Details of study participants are fully listed in Appendix 9. Group sizes consisted of 
Kmowt (7 sham: 9 AP), Kmonull (7 sham: 9 AP) and Kmoalb-cre (7 sham: 10 AP). Core body 
temperature and locomotor activity telemetry profiles shown in Figure 30. The key finding was 
of the high proportion of Kmoalb-cre AP mice reaching humane cull endpoints during this 
recovery study. With regards to Kmowt mice, in light of the Experiment 1 findings, it was 
unexpected that all mice would survive and not meet humane endpoints, however, this less 
invasive telemetry device might have made this model more akin to moderate AP, as opposed 
to severe AP, when extrapolated to the human situation. 
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Figure 30: Kmoalb-cre mice were sicker and had worse survival to predefined humane endpoints 
in experimental AP compared to Kmowt and Kmoalb-cre mice.  
Hourly mean core body temperatures (A) and locomotor activity (B) are shown for individual mice. 
A+B: Left side panels are sham surgery controls; Right side panels are AP. Top paired panels are 
Kmowt (n = 7 sham, n = 9 AP), middle panels are Kmonull (n = 7 sham, n = 9 AP), and lowest paired 
panels are Kmoalb-cre (n = 7 sham, n = 10 AP). 
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Figure 31: Biochemical evidence of multiple organ injury with AP in Kmoalb-cre 
Using the less invasive non-cardiac mini telemeters in AP Kmoalb-cre mice, those which reached humane 
endpoints are compared to matched mini telemetered Kmoalb-cre mice randomised to sham culled at 168-hrs.  
A: ALT was significantly elevated in humane endpoint mice (p = 0.003, Mann Whitney test). B: Urea was 
significantly elevated in humane endpoint mice (p = 0.007, t-test). C: LDH was increased in 3 of 4 mice 
reaching humane endpoint but because of unequal intergroup data variance (Levene’s test p = 0.009) t-test 
found no significant difference (p = 0.061, independent t-test without assumption of equal variance. Individual 
data are shown and horizontal lines are median with interquartile range. 
 
Figure 31 shows biochemical evidence of multi-organ injury in Kmoalb-cre mice reaching 
humane endpoints, as compared to recovered sham Kmoalb-cre. Figure 32 depicts the survival 
curves of the mouse lines and with statistical testing, showing a significantly impaired survival 
of Kmoalb-cre. Table 27 details the analgesia administered to the mice during the study, in line 
with the protocol. 
 
Line Treatment Number Exp duration – mean (SD) 
S/C Bup. Dose – 
mean (SD) 
S/C Bup. Dose : Time 
adjusted – mean (SD) 
Oral Bup. Dose – 
mean (SD) 
Oral Bup. Dose : 
Time adjusted – 
mean (SD) 
Kmowt  Sham N = 7 168.0 (0) hrs 4.393 (0.283) µg 0.026 (0.002) µg/hr 65.71 µg (11.34) 0.391 (0.062) µg/hr 
Kmowt AP N = 9 168.0 (0) hrs 5.000 (0.750) µg 0.030 (0.004) µg/hr 61.11 µg (23.15) 0.364 (0.138) µg/hr 
Kmonull Sham N = 7 168.0 (0) hrs 4.500 (0.000) µg 0.027 (0.000) µg/hr 61.43 µg (22.68) 0.366 (0.135) µg/hr 
Kmonull AP N = 9 143.6 (51.4) hrs 4.667 (0.500) µg 0.049 (0.055) µg/hr 40.00 µg (33.54) 0.243 (0.195) µg/hr 
Kmoalb-cre Sham N = 7 168.0 (0) hrs 4.500 (0.000) µg 0.027 (0.000) µg/hr 68.57 µg (3.78) 0.408 (0.022) µg/hr 
Kmoalb-cre AP N = 10 91.9 (66.1) hrs 5.250 (0.791) µg 0.110 (0.078) µg/hr 28.30 µg (34.58) 0.183 (0.202) µg/hr 
1-way ANOVA between 6 groups **p = 0.002, KW *p = 0.019, KW **p = 0.006, KW *p = 0.020, KW *p = 0.022, KW 
Table 27. Analgesia given in AP experiment 3 
Oral Buprenorphine single dose 0.01 mg. S/C Buprenorphine single dose 0.05 mg/kg.  
KW: Kruskal-Wallis. *p < 0.05, **p < 0.01. 
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Figure 32. Impaired survival to humane endpoints in AP for Kmoalb-cre line in 
mini telemeter study.  
Over 7-days, the 3 mouse lines with AP had statistically significant differences in 
survival to humane endpoint(s) (p = 0.011, 3-way log-rank (Mantel-Cox) test). 
Kmoalb-cre mice with AP had a reduced survival (median of 48-hrs), and 40% 7-day 
recovery. The lower 7-day survival of Kmonull compared to Kmowt did not 
significantly differ (p = 0.145). ns = not significant (p > 0.05). 
One Kmonull subject which reached humane endpoint at 23-hrs was found to have 




These results demonstrated a significant impairment in survival in Kmoalb-cre mice after 
insult by experimental AP, with a tendency toward critical illness at early time points (<72 
hours). 
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3.6. Experiment 4 – A comparison of early injury metrics at 24-hrs in recovery 
AP between differentially expressed KMO mouse lines 
3.6.1. Introduction 
Pairs of age-matched male mice from three groups were randomly assigned to AP or 
sham laparotomy treatment. The three mouse lines were wildtype Kmowt [genotype: FLP 
(HOM) or Acre(-)], Kmoalb-cre [geneotype: Acre(+)] and Kmonull [geneotype: KMO (HOM)]. 
Randomisation was performed by computer generation (paired random number generation 
[between 0.00 to 1.00]: mouse with highest number was assigned to AP). AP treatment 
consisted of a retrograde biliopancreatic duct infusion with 50 μl 2% sodium taurocholic acid 
(Na-TCA) (in PBS) over 5 mins, for further detail see methods (section 2.3). These 24-hr 
experiments did not involve implantation of telemeters for both practical (limited numbers of 
telemetry systems) and experimental reasons (these were not 7-day recovery studies, but 24-
hr timepoint chosen to minimise risk of death before end timepoint). Principally, subjects were 
used for either histology or flow cytometry experiments. Details of experimental subjects can 
be found in Appendix 10. Results of plasma biochemistry and cytokines, pancreas injury 
histology and flow cytometry of blood, lung digest and liver digest comparing sham to AP at 
24-hrs post-surgery in Kmowt, Kmoalb-cre and Kmonull are reported below. 
 
3.6.2. Hypothesis 
The null hypothesis was that there would be no statistically significant differences 
between mouse lines in any parameter measured. Samples sizes and power calculations detail 
in the corresponding sections. 
 
 
3.6.3. Results – Biochemistry at 24-hr 
Experimental subjects for biochemistry were all those mice used for 24-hr multi-organ 
histological experiments and flow cytometry experiments. Appendix 10, Table 88 lists all of the 
primary biochemical data. Post-hoc power analysis revealed sufficiently sized cohorts to power 
the experiment satisfactorily, with a power 0.95. Amylase was measured in all 90 mice at 24-
hr, whilst the full biochemistry panel was measured in all but two of these (i.e. n = 88). 
Initially, a two-way ANOVA was used to statistically test for clinical biochemistry 
differences with treatment (AP versus sham) across all 3 mouse lines, with null hypotheses of 
‘no treatment effect’ and ‘no mouse line effect’ (Table 28). Next, an analysis was performed 
between AP groups of the 3 mouse lines to test the primary null hypothesis (section 3.6.2.). 
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These results are tablulated (Tables 28 to 34) and displayed (Figure 33) with statistical 
analysis between AP groups shown. 
 
3.6.3.1. 2-way ANOVA on biochemistry 
AP treatment effects on clinical biochemistry across mouse lines are shown in Table 
28, revealing a statistically significant increase in amylase (log10 amylase) (p < 0.001), LDH 
(p = 0.002), and urea (p = 0.008). A statistically significant decrease in glucose (p < 0.001) and 
albumin (p = 0.002) with AP were also detected. Mean ALT concentrations were higher in AP 
than sham, but this was not significantly significant (p = 0.214). 
Biochemistry Number  
(Sham, AP) 
Mean Sham  
(St. Dev) 
Mean AP  
(St. Dev) 
Mean square  F-statistic P-value 
Log10 amylase (U/L) 45, 45 3.373 (0.095) 4.059 (0.398) 10.7 128.79 <0.001 
LDH (U/L) 44, 44 211.4 (88.8) 403.5 (386.0) 818228.9 10.76 0.002 
Glucose (mmol/L) 44, 44 16.7 (3.2) 12.5 (4.8) 386.2 22.38 <0.001 
Albumin (g/L) 44, 44 26.3 (2.3) 24.8 (2.6) 51.5 9.91 0.002 
Urea (mmol/L) 44, 44 6.1 (1.4) 8.8 (6.5) 155.6 7.46 0.008 
ALT (U/L) 44, 44 77.4 (79.7) 94.8 (59.7) 7057.6 1.57 n/s 0.214 
Table 28. Treatment effect (AP versus sham) across 3 mouse lines on biochemistry, 2-way ANOVA 
  
  
3.6.3.2.  Amylase 
Amylase results were converted from linear scale to log10 scale to allow data to be 
plotted meaningfully. There was no significant difference in log10 plasma amylase levels 
comparing AP groups across the 3 mouse lines (Table 29). There were significant increases 
in amylase with AP compared to sham across all three mouse lines: Kmowt (p < 0.001, GH), 
Kmoalb-cre (p < 0.001, GH) and Kmonull (p < 0.001, GH). 
Biochemistry 
Group size 






Post Hoc Mean 
difference 
Amylase 
n = 16 
n = 15 
n = 14  
AP Log10 amylase 
Kmowt       3.927 g/l  (0.384) 
Kmoalb-cre  4.181 g/l  (0.399) 
Kmonull      3.859 g/l  (0.407) 
Passed 1-way 
ANOVA 
p = 0.316  
Tukey post-hoc multiple testing 
Kmowt AP vs Kmonull AP, p = 0.965 
Kmowt AP vs Kmoalb-cre AP, p = 0.451 






n = 16 
n = 15 
n = 14 
Sham Log10 amylase 
Kmowt        3.355 g/l  (0.060) 
Kmoalb-cre   3.355 g/l  (0.080) 
Kmonull       3.333 g/l  (0.115) 
Passed  1-way 
ANOVA 
p = 0.883 
n/a n/a 
 
Table 29. Amylase AP, 1-way ANOVA 
 
  
3.6.3.3.  Albumin and ALT 
There was no significant difference in plasma albumin levels comparing AP groups 
across the 3 mouse lines (Table 30). Sham groups had a statistically significant difference in 
albumin levels, with a reduced albumin in Kmoalb-cre mice compared to Kmowt. Whilst biologica- 
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Post Hoc Mean 
difference 
Albumin 
n = 16 
n = 14 
n = 14 
AP  
Kmowt        25.4 g/l  (1.8) 
Kmoalb-cre   23.8 g/l  (3.3) 
Kmonull      25.3 g/l   (2.0) 
Passed 1-way 
ANOVA 
p = 0.056  
Tukey post-hoc multiple testing 
Kmowt AP vs Kmonull AP, p = 0.992 
Kmowt AP vs Kmoalb-cre AP, p = 0.094 






n = 16 
n = 14 
n = 14 
Sham  
Kmowt       26.8 g/l  (2.8) 
Kmoalb-cre   25.1 g/l  (1.2) 
Kmonull      26.3 g/l (1.8) 
Passed  1-way 
ANOVA 
p = 0.020  
Tukey post-hoc multiple testing 
Kmowt Sham vs Kmonull Sham, p = 0.333 
Kmowt Sham vs Kmoalb-cre Sham, p = 0.015 





Table 30. Albumin AP, 1-way ANOVA 
 
-ally interesting, given the alb-cre genetic background of these mice, the difference was 
quantitatively small (<2 g/l) and therefore of no particular biological relevance in this context. 
There was a significant difference in plasma ALT levels comparing AP groups across 
the 3 mouse lines with AP and sham (Table 31). Data was compared by Kruskal-Wallis test 
and post-hoc Dunn’s tests due to non-parametric distributions. ALT was lowest in AP Kmonull 
group (median 46.5 U/L, SD 34.0 U/L) which was lower (p = 0.001, Dunn’s) than Kmowt (median 
99.0 U/L, SD 55.1 U/L) and lower (p = 0.026, Dunn’s) than Kmoalb-cre (median 86.0 U/L, SD 
69.9 U/L). Similarly, after sham laparotomy, Kmonull had lower ALT levels than Kmowt, but levels 
did not differ between the two genetically altered mouse lines (i.e. Kmonull and Kmoalb-cre). 
Biochemistry 
Group size 






Post Hoc Mean 
difference 
ALT 
n = 16 
n = 14 
n = 14 
AP  
Kmowt       99.0 U/l (55.1) 
Kmoalb-cre  86.0 U/l (69.9) 
Kmonull      46.5 U/l (34.0) 
Failed Kruskal-
Wallis  
p = 0.001 
Dunn’s post-hoc multiple testing  
Kmowt AP vs Kmonull AP, p = 0.001 
Kmowt AP vs Kmoalb-cre AP, p = 1.000 






n = 16 
n = 14 
n = 14 
Sham  
Kmowt       91.0 U/l  (70.5) 
Kmoalb-cre   49.0 U/l  (22.7) 
Kmonull      30.0 U/l (112.2) 
Failed Kruskal-
Wallis  
p < 0.001  
Dunn’s post-hoc multiple testing  
Kmowt Sham vs Kmonull Sham, p < 0.001 
Kmowt Sham vs Kmoalb-cre Sham, p = 0.181 





Table 31. ALT AP, 1-way ANOVA 
 
3.6.3.4.  LDH, Glucose and urea 
There were no significant differences in plasma LDH (Table 32), glucose (Table 33) or 
urea (Table 34) levels between AP groups across the 3 mouse lines. 
Biochemistry 
Group size 






Post Hoc Mean 
difference 
LDH 
n = 16 
n = 14 
n = 14 
AP  
Kmowt       254 U/l   (440) 
Kmoalb-cre   312 U/l  (472) 
Kmonull      235 U/l  (109) 
Failed Kruskal-
Wallis  
p = 0.432  
Dunn’s post-hoc multiple testing 
Kmowt AP vs Kmonull AP, p = 0.866 
Kmowt AP vs Kmoalb-cre AP, p = 1.000 






n = 16 
n = 14 
n = 14 
Sham  
Kmowt        267 U/l  (117) 
Kmoalb-cre   163 U/l  (68.8) 
Kmonull      169 U/l  (36.2) 
Failed Kruskal-
Wallis  
p = 0.066  
n/a n/a 
 
Table 32. LDH AP, 1-way ANOVA 
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Post Hoc Mean 
difference 
Glucose 
n = 16 
n = 14 
n = 14 
AP  
Kmowt    13.3 mmol/l  (3.1) 
Kmoalb-cre 10.7 mmol/l (6.3) 
Kmonull    14.2 mmol/l (5.0) 
Passed 1-way 
ANOVA 
p = 0.739 
Tukey post-hoc multiple testing 
Kmowt AP vs Kmonull AP, p = 0.999 
Kmowt AP vs Kmoalb-cre AP, p = 0.759 






n = 16 
n = 14 
n = 14 
Sham  
Kmowt    17.3 mmol/l  (3.4) 
Kmoalb-cre 16.6 mmol/l (2.9) 
Kmonull    18.8 mmol/l (3.3) 
Passed  1-way 
ANOVA 
p = 0.386 
n/a n/a 
 










Post Hoc Mean 
difference 
Urea 
n = 16 
n = 14 
n = 14 
AP  
Kmowt      6.65 mmol/l  (3.8) 
Kmoalb-cre 6.15 mmol/l (10.2) 
Kmonull    6.25 mmol/l (2.2) 
Failed Kruskal-
Wallis  
p = 0.451  
Dunn’s post-hoc multiple testing 
Kmowt AP vs Kmonull AP, p = 0.832 
Kmowt AP vs Kmoalb-cre AP, p = 1.000 






n = 16 
n = 14 
n = 14 
Sham  
Kmowt      5.95 mmol/l (1.4) 
Kmoalb-cre 6.00 mmol/l (1.1) 
Kmonull    5.50 mmol/l (1.8) 
Failed Kruskal-
Wallis  
p = 0.930  
n/a n/a 
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Figure 33. Plasma biochemistry 24h post sham laparotomy or AP in Kmowt, Kmoalb-cre and Kmonull.  
EDTA plasma at 24-hr post AP or Sham. Subjects: Kmowt n = 32 [16 sham: 16 AP]) and Kmoalb-cre n = 28 (14 
sham: 14 AP); in all analyses except amylase, (i.e. B-F), Kmonull n = 28 (14 sham: 14 AP), whilst in amylase 
analysis (A) there was an additional pair of Kmonull that did not have all biochemical full testing [Kmonull (15 sham: 
15 AP)]. Male, age-matched Kmowt, Kmoalb-cre, and Kmonull mice were electronically randomised to AP or sham. 
Statistical annotations depict those ANOVAs with post-hoc testing between AP groups as calculated in Tables 26 
to 31. A: Amylase results displayed on log10 scale for practical reasons due to wide variability in results amongst 
AP subjects. B: Albumin. C: Alanine aminotransferase (ALT). D: Lactate dehydrogenase (LDH). E: Glucose. F: 
Urea. Individual data are shown and horizontal lines are median with interquartile range. ns = not significant (p > 
0.05); *p < 0.05, **p < 0.01. 
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3.6.4. Results – Cytokines at 24-hr 
The cytokine data is detailed in Appendix 10, with the limits of detection for each 
cytokine for both V-PLEX plates (A and B) documented. In line with 3Rs principles, all efforts 
to maximise yield samples was made from the outset. As there were separate groups of mice 
used for multi-organ histological storage and other groups used for multi-organ flow cytometry, 
thus there were greater numbers of subjects with stored plasma available for measurement of 
circulating cytokine concentrations than for histology alone. Specifically, there was up to n = 
11 for all groups. Post-hoc power calculations using n = 11 Kmowt data (sham and AP; using 
IL-1β), gave d = 1.672 and a satisfactory power (0.96). 
Initially, a two-way ANOVA was used to statistically test for cytokine differences with 
treatment (AP versus sham) across all 3 mouse lines, with null hypotheses of ‘no treatment 
effect’ and ‘no mouse line effect’ (Table 32). Next, an analysis was performed between AP 
groups of the 3 mouse lines to test the primary null hypothesis (section 3.6.2.). These results 
are tablulated (Tables 33 to 42) and displayed (Figure 34) with statistical analysis between AP 
groups shown. 
 
3.6.4.1. 2-way ANOVA on cytokines 
AP treatment effects on cytokine plasma levels across mouse lines are shown in Table 
35, revealing a statistically significant increase in IL-1β (p < 0.001), IL-2 (p = 0.013), IL-6 
(log10) (p < 0.001), TNFα (log10) (p = 0.016), and KC/GRO (p = 0.045) with AP. There was 
no significant treatment effect upon IL-4 (p = 0.50), IL-5 (p = 0.28), IL-10 (p = 0.08), IL-12p70 





Mean Sham (pg/ml)  
(St. Dev) 
Mean AP (pg/ml)  
(St. Dev) 
Mean square  F-statistic P-value 
IL-1β 36, 35 1.572 (0.42) 5.064 (5.22) 210.150 16.515 <0.001 
IL-2 36, 35 2.331 (1.41) 3.991 (3.69) 46.829 6.491 0.013 
IL-4  36, 35 0.495 (0.61) 0.417 (0.39) 0.114 0.456 n/s 0.502 
IL-5 36, 35 52.709 (40.60) 43.537 (25.99) 1448.941 1.181 n/s 0.281 
IL-6 log10 36, 35 1.912 (0.211) 2.554 (0.754) 7.177 25.579 <0.001 
IL-10 36, 35 18.030 (4.241) 79.536 (201.028) 63698.020 3.252 n/s 0.076 
IL-12p70 36, 35 52.127 (36.488) 69.967 (77.673) 5397.865 1.572 n/s 0.214 
IFNγ 36, 35 0.7318 (0.573) 0.685 (0.581) 0.034 0.097 n/s 0.757 
TNFα Log10 36, 35 1.002 (0.116) 1.176 (0.400) 0.530 6.139 0.016 
KC/GRO 36, 35 36.870 (16.771) 364.109 (964.841) 1835719.19 4.180 0.045 
Table 35. Treatment effect (AP versus sham) across mouse lines on cytokines, 2-way ANOVA 
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3.6.4.2.  IL-1β, IL-5, IL-6, IL-10, IFNγ, TNFα, KC/GRO 
There was no significant difference in IL-1β (Table 36), IL-5 (Table 37), IL-6 (Table 
38), IL-10 (Table 39), IFNγ (Table 40), TNFα (Table 41) or KC/GRO (Table 42) levels between 
AP groups across the 3 mouse lines. 
Cytokine 
Group size 






Post Hoc Mean 
difference 
IL-1β  
n = 11 
n = 11 
n = 11 
AP  
Kmowt      2.91 pg/ml  (1.4) 
Kmoalb-cre  4.01 pg/ml (8.0) 
Kmonull     2.86 pg/ml (3.4) 
Failed Kruskal-
Wallis  
p = 0.186  
Dunn’s post-hoc multiple testing 
Kmowt AP vs Kmoalb-cre AP, p = 0.515 
Kmowt AP vs Kmonull AP, p = 1.0 






n = 11 
n = 11 
n = 11 
Sham  
Kmowt      1.47 pg/ml (0.5) 
Kmoalb-cre 1.43 pg/ml (0.2) 
Kmonull    1.63 pg/ml (0.5) 
Failed Kruskal-
Wallis  
p = 0.471  
n/a n/a 
 










Post Hoc Mean 
difference 
IL-5 
n = 11 
n = 11 
n = 11 
AP  
Kmowt      49.5 pg/ml  (23.6) 
Kmoalb-cre  30.7 pg/ml (22.3) 
Kmonull     26.7 pg/ml (33.4) 
Failed Kruskal-
Wallis  
p = 0.556  
Dunn’s post-hoc multiple testing 
Kmowt AP vs Kmoalb-cre AP, p = 1.000 
Kmowt AP vs Kmonull AP, p = 0.931 






n = 11 
n = 11 
n = 11 
Sham  
Kmowt      36.3 pg/ml (28.7) 
Kmoalb-cre  47.3 pg/ml (18.6) 
Kmonull     34.8 pg/ml (57.7) 
Failed Kruskal-
Wallis  
p = 0.531  
n/a n/a 
 










Post Hoc Mean 
difference 
IL-6 
n = 11 
n = 11 
n = 11 
AP  
Kmowt       2.10 pg/ml (0.66) 
Kmoalb-cre  2.72 pg/ml  (0.92) 
Kmonull      2.19 pg/ml  (0.50) 
Failed Kruskal-
Wallis  
p = 0.066  
Dunn’s post-hoc multiple testing 
Kmowt AP vs Kmoalb-cre AP, p = 0.121 
Kmowt AP vs Kmonull AP, p = 1.000 






n = 11 
n = 11 
n = 11 
Sham  
Kmowt      2.05 pg/ml (0.26) 
Kmoalb-cre  2.01 pg/ml (0.17) 
Kmonull     1.82 pg/ml (0.20) 
Passed 1-way 
ANOVA 
p = 0.244  
n/a n/a 
 










Post Hoc Mean 
difference 
IL-10 
n = 11 
n = 11 
n = 11 
AP  
Kmowt       18.4 pg/ml (16.1) 
Kmoalb-cre  19.8 pg/ml  (322.9) 
Kmonull      17.0 pg/ml  (7.8) 
Failed Kruskal-
Wallis  
p = 0.201  
Dunn’s post-hoc multiple testing 
Kmowt AP vs Kmoalb-cre AP, p = 0.627 
Kmowt AP vs Kmonull AP, p = 1.000 






n = 11 
n = 11 
n = 11 
Sham  
Kmowt      15.6 pg/ml (5.8) 
Kmoalb-cre  16.4 pg/ml (3.9) 
Kmonull     18.6 pg/ml (2.8) 
Failed Kruskal-
Wallis  
p = 0.075  
n/a n/a 
 
Table 39. IL-10 AP, 1-way ANOVA 
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Post Hoc Mean 
difference 
IFNγ  
n = 11 
n = 11 
n = 11 
AP  
Kmowt       0.38 pg/ml (0.78) 
Kmoalb-cre  0.39 pg/ml  (0.51) 
Kmonull      0.45 pg/ml  (0.51) 
Failed Kruskal-
Wallis  
p = 0.929  
Dunn’s post-hoc multiple testing 
Kmowt AP vs Kmoalb-cre AP, p = 1.0 
Kmowt AP vs Kmonull AP, p = 1.0 






n = 11 
n = 11 
n = 11 
Sham  
Kmowt      0.33 pg/ml (0.83) 
Kmoalb-cre  0.61 pg/ml (0.51) 
Kmonull     0.48 pg/ml (0.41) 
Failed Kruskal-
Wallis  
p = 0.716  
n/a n/a 
 










Post Hoc Mean 
difference 
TNFα 
n = 11 
n = 11 
n = 11 
AP TNF log10 
Kmowt       0.980 pg/ml (0.516) 
Kmoalb-cre  1.097 pg/ml (0.442) 
Kmonull     1.012 pg/ml (0.134) 
Failed Kruskal-
Wallis  
p = 0.197  
Dunn’s post-hoc multiple testing 
Kmowt AP vs Kmoalb-cre AP, p = 0.308 
Kmowt AP vs Kmonull AP, p = 1.0 






n = 11 
n = 11 
n = 11 
Sham TNF log10 
Kmowt       0.920 pg/ml (0.152) 
Kmoalb-cre  1.051 pg/ml (0.085) 
Kmonull     1.004 pg/ml (0.114) 
Failed Kruskal-
Wallis  
p = 0.545  
n/a n/a 
 










Post Hoc Mean 
difference 
KC/GRO  
n = xx 
n = xx 
n = xx 
AP  
Kmowt        63.8 pg/ml  (298.3) 
Kmoalb-cre  211.9 pg/ml  (1633.0) 
Kmonull      57.9 pg/ml   147.9) 
Failed Kruskal-
Wallis  
p = 0.430  
Dunn’s post-hoc multiple testing 
Kmowt AP vs Kmoalb-cre AP, p = 1.0 
Kmowt AP vs Kmonull AP, p = 1.0 






n = xx 
n = xx 
n = xx 
Sham  
Kmowt       48.0 pg/ml (19.1) 
Kmoalb-cre  33.0 pg/ml (10.8) 
Kmonull     34.7 pg/ml (15.7) 
Passed 1-way 
ANOVA  
p = 0.102  
n/a n/a 
 
Table 42. KC/GRO AP, 1-way ANOVA 
 
3.6.4.3.  IL-2 
There were significantly elevated levels of IL-2 in Kmoalb-cre line compare with the Kmowt 
line in AP (mean rank difference -10.6, p = 0.03) on Dunn’s post-hoc testing (Table 43). 
Cytokine 
Group size 






Post Hoc Mean 
difference 
IL-2  
n = 11 
n = 11 
n = 11 
AP  
Kmowt      1.74 pg/ml  (3.0) 
Kmoalb-cre  5.19 pg/ml (5.1) 
Kmonull     3.02 pg/ml (2.0) 
Failed Kruskal-
Wallis  
p = 0.036  
Dunn’s post-hoc multiple testing 
Kmowt AP vs Kmoalb-cre AP, p = 0.030 
Kmowt AP vs Kmonull AP, p = 0.626 






n = 11 
n = 11 
n = 11 
Sham  
Kmowt      0.72 pg/ml (1.8) 
Kmoalb-cre 3.07 pg/ml (1.3) 
Kmonull    2.26 pg/ml (1.1) 
Failed Kruskal-
Wallis  
p = 0.097  
n/a n/a 
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3.6.4.4.  IL-4 
Kruskal-Wallis testing revealed a significantly elevated levels of IL-4 in Kmoalb-cre line 
compare with the Kmonull line in AP (mean rank difference 10.5, p = 0.03) on Dunn’s post-hoc 
testing (Table 44). 
Cytokine 
Group size 






Post Hoc Mean 
difference 
IL-4 
n = 11 
n = 11 
n = 11 
AP  
Kmowt      0.238 pg/ml  (0.221) 
Kmoalb-cre  0.305 pg/ml (0.486) 
Kmonull     0.127 pg/ml (0.448) 
Failed Kruskal-
Wallis  
p = 0.035  
Dunn’s post-hoc multiple testing 
Kmowt AP vs Kmoalb-cre AP, p = 0.309 
Kmowt AP vs Kmonull AP, p = 1.000 






n = 11 
n = 11 
n = 11 
Sham  
Kmowt       0.344 pg/ml (0.962) 
Kmoalb-cre  0.349 pg/ml (0.362) 
Kmonull      0.170 pg/ml (0.175) 
Failed Kruskal-
Wallis  
p = 0.077  
n/a n/a 
 
Table 44. IL-4 AP, 1-way ANOVA 
 
 
3.6.4.5.  IL-12p70 
There were significantly elevated levels of IL-12p70 in Kmoalb-cre line compared to both 
the Kmowt line and the Kmonull line on Dunn’s post-hoc testing both in AP and sham (Table 45). 
Cytokine 
Group size 






Post Hoc Mean 
difference 
IL-12p70  
n = 11 
n = 11 
n = 11 
AP  
Kmowt       22.7 pg/ml (83.9) 
Kmoalb-cre  81.0 pg/ml (96.9) 
Kmonull     22.7 pg/ml (37.2) 
Failed Kruskal-
Wallis  
p = 0.005  
Dunn’s post-hoc multiple testing 
Kmowt AP vs Kmoalb-cre AP, p = 0.010 
Kmowt AP vs Kmonull AP, p = 1.000 






n = 11 
n = 11 
n = 11 
Sham  
Kmowt      31.4 pg/ml (55.6) 
Kmoalb-cre  55.8 pg/ml (24.1) 
Kmonull     22.7 pg/ml (14.7) 
Failed Kruskal-
Wallis  
p = 0.002  
Dunn’s post-hoc multiple testing 
Kmowt Sham vs Kmoalb-cre Sham, p = 0.030 
Kmowt Sham vs Kmonull Sham, p = 1.000 
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C – IL-4 
 
D – IL-5 
 
E – IL-6 
 
F – IL-10 
 
G – IL-12p70 
 
H – IFNγ 
 
I – KC/GRO 
 
Figure 34. Plasma cytokines 24h post sham laparotomy or AP in Kmowt, 
Kmoalb-cre and Kmonull 
EDTA plasma plasma cytokines levels were assessed in mice at 24-hrs after AP 
or sham in Kmowt n = 23 [12 sham: 11 AP]), Kmoalb-cre n = 24 (12 sham: 12 AP) 
and Kmonull n = 24 (12 sham: 12 AP). One Kmowt AP mouse had insufficient 
blood for testing. IL-6 (E) and TNFα (J) results displayed on log10 scale for 
practical reasons due to wide linear variability in the results. Individual data are 
shown and horizontal lines are median with interquartile range. ns = not 
significant (p > 0.05); *p < 0.05. Stattisitical tests are those in Tables 33 to 42. 
J – TNFα 
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3.6.5. Results – Pancreas histology at 24-hr 
An independent mouse histologist (Dr. J. Baily, formerly of the Centre for 
Cardiovascular Science, QMRI) experienced in scoring experimental AP, and blinded to the 
treatment groups, conducted the pancreas injury scoring. Post-hoc analysis on data from 











   
 Kmowt Kmoalb-cre Kmonull 
Figure 35. Histological pancreas injury scores  
Composite histological pancreas injury scores (0 - 9) of 
mice at 24-hr: Kmowt (n=8 sham, n=8 AP), Kmoalb-cre (n=7 
sham, n=7 AP) and Kmonull (n=8 sham, n=8 AP). Example 
pancreatic head haematoxylin & eosin stain shows normal 
tissue morphology in sham control and features of acute 
inflammation in AP; PMN cell infiltrate, oedema and acinar 
necrosis. Subject ID: Kmowt sham (FK463), AP (FK496); 
Kmoalb-cre sham (Acre157), AP (Acre149); Kmonull sham 
(K1151), Kmonull AP (K1142). Unit distance on histological 
H&E images shown are 100 μm. Graph shows Individual 
data points and horizontal lines are median with 
interquartile range. Statistical analysis by Kruskal-Wallis 
ANOVA with post hoc Dunn’s paired comparisons (failed 
normal data distribution testing). ns = not significant (p > 
0.05); *p < 0.05, **p < 0.01.  
 
Appendix 10, Table 86 lists the scores for each subject, alongside plasma amylase 
results. Two-way ANOVA was used to statistically test for pancreas histological injury score 
differences with treatment (AP versus sham) across the 3 mouse lines. There were 46 mice 
electronically randomized to AP or sham: Kmowt (7 AP, 7 sham); Kmoalb-cre (8 AP, 8 sham); 
Kmonull (8 AP, 8 sham). The AP treatment (2% NaTCA biliopancreatic duct infusion) produced 
a significant (F-statistic = 76.0, mean square 264.3, p < 0.001, 2-way ANOVA) increase in 
injury score from a sham laparotomy mean 0.57 units (Std dev. 0.99) to AP mean 5.35 units 
(Std dev. 2.39) on the 0 to 9 scoring scale.  There was no significant difference across mouse 
line groups (F-statistic 0.829, mean square 2.88, p = 0.444, 2-way ANOVA). Kruskal-Wallis 
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one-way ANOVA (K-W statistic = 30.56, p < 0.001) was used to compare differences in 
pancreas injury score between groups comprised of data which failed normality testing. Post 
hoc Dunn’s testing found no significant difference in pancreas injury scores between 
genetically altered mouse line groups in AP (Figure 35, above).  
 
3.6.6. Results – Flow cytometry blood at 24-hr 
Flow cytometry was performed on cardiac blood aspirated under anaesthesia, 24-hr 
following AP or sham in mice from the three mouse lines. Gating strategy for blood flow 
cytometry and the proportions of myeloid blood populations are shown in Figure 36. Firstly, a 
two-way ANOVA was used to statistically test blood flow cytometry population differences with 
treatment (AP versus sham) across the mouse lines, with null hypotheses of ‘no treatment 
effect’ and ‘no mouse line effect’ (Table 43). Appendix 10, Table 93 lists all of the blood flow 
cytometery data. 
 
3.6.6.1. 2-way ANOVA on blood flow cytometry myeloid populations 
AP treatment effects on blood leukocyte populations across mouse lines are shown in 
Table 46, revealing a statistically significant increase in proportion of circulating neutrophils 
(%CD45+) (F-statistic 23.99, p < 0.001, 2-way ANOVA), with a mean increase from 18.5% in 
sham laparotomy to 45.8%, across the mouse lines with AP. There was a significant decrease 
in eosinophil proportion of leukocytes after AP (F-statistic 6.38, p = 0.017, 2-way ANOVA), with 
a mean decrease from 2.4% in shams to 1.3% in AP. There was no significant treatment effect 
upon monocyte proportions (%CD45+) or Ly6Chi monocyte (%monocytes). 




Mean Sham  
(St. Dev) 
Mean AP  
(St. Dev) 
Mean square  F-statistic P-value 
Eosinophil  
(count, %CD45+) 
18, 18 2.389 (1.042) 1.346 (1.308) 9.691 6.38 0.017 
Neutrophil 
(count, %CD45+) 
18, 18 18.511 (4.498) 45.75 (22.456) 6558.921 23.99 <0.001 
Monocyte 
(count, %CD45+) 
18, 18 4.889 (1.453) 5.020 (1.700) 0.151 0.59 n/s 0.810 
L6C hi monocyte 
(count, %monocytes) 
18, 18 40.606 (9.609) 45.667 (21.211) 230.512 0.77 n/s 0.389 
Table 46. Treatment effect across mouse lines on blood flow cytometry myeloid, 2-way ANOVA 
 
 
3.6.6.2.  Blood eosinophils and neutrophils 
There were no significant differences in eosinophil (Table 47) or neutrophil (Table 48) 
proprtions of blood leukocytes in AP between Kmowt, Kmoalb-cre or Kmonull. 
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Flow - blood 
Group size 






Post Hoc Mean 
difference 
Eosinophil  
n = 6 
n = 6 
n = 6 
AP %CD45+ 
Kmowt       1.72 (1.44) 
Kmoalb-cre   1.40 (1.59) 
Kmonull      0.58 (0.92) 
Passed 1-way 
ANOVA  
p = 0.599  
Tukey post-hoc multiple testing 
Kmowt AP vs Kmoalb-cre AP, p = 0.995 
Kmowt AP vs Kmonull AP, p = 0.626 






n = 5 
n = 7 
n = 6 
Sham %CD45+ 
Kmowt      2.13  (0.91) 
Kmoalb-cre  2.43 (0.75) 
Kmonull     2.36 (1.53) 
Passed 1-way 
ANOVA  
p = 0.984  
n/a n/a 
 
Table 47. Blood Eosinophil AP, 1-way ANOVA 
 
Flow - blood 
Group size 






Post Hoc Mean 
difference 
Neutrophil  
n = 6 
n = 6 
n = 6 
AP %CD45+ 
Kmowt       54.9 (25.5) 
Kmoalb-cre  27.9 (25.2) 
Kmonull      43.9 (17.1) 
Passed 1-way 
ANOVA  
p = 0.528  
Tukey post-hoc multiple testing 
Kmowt AP vs Kmoalb-cre AP, p = 0.520 
Kmowt AP vs Kmonull AP, p = 0.699 






n = 5 
n = 7 
n = 6 
Sham %CD45+ 
Kmowt      18.0  (6.4) 
Kmoalb-cre  17.6 (3.9) 
Kmonull     18.6 (3.8) 
Failed Kruskal-
Wallis  
p = 0.840  
n/a n/a 
 
Table 48. Blood Neutrophil AP, 1-way ANOVA 
 
3.6.6.3.  Blood monocytes 
There was no significant difference in blood monocyte proportions of leucocytes (Table 
49), or the proportion of monocytes with Ly6Chi cell surface expression (Table 50) with AP 
across the mouse lines. 
Flow - blood 
Group size 






Post Hoc Mean 
difference 
Monocyte 
n = 6 
n = 6 
n = 6 
AP %CD45+ 
Kmowt       4.62 (1.73) 
Kmoalb-cre  4.38 (1.20) 
Kmonull     5.23 (2.27) 
Passed 1-way 
ANOVA  
p = 0.852  
Tukey post-hoc multiple testing 
Kmowt AP vs Kmoalb-cre AP, p = 0.958 
Kmowt AP vs Kmonull AP, p = 0.948 






n = 5 
n = 7 
n = 6 
Sham %CD45+ 
Kmowt      4.87 (1.62) 
Kmoalb-cre  5.18 (1.34) 
Kmonull     3.56 (1.25) 
Passed 1-way 
ANOVA  
p = 0.205  
n/a n/a 
 
Table 49. Blood Monocyte AP, 1-way ANOVA 
 
Flow - blood 
Group size 






Post Hoc Mean 
difference 
Ly6C hi 
n = 6 
n = 6 
n = 6 
AP %Monocytes 
Kmowt       44.7  (21.51) 
Kmoalb-cre  43.5  (21.53) 
Kmonull     29.9  (23.81) 
Failed Kruskal-
Wallis  
p = 0.728  
Dunn’s post-hoc multiple testing 
Kmowt AP vs Kmoalb-cre AP, p = 1.0 
Kmowt AP vs Kmonull AP, p = 1.0 






n = 5 
n = 7 
n = 6 
Sham %Monocytes 
Kmowt       38.0   (6.5) 
Kmoalb-cre  42.6  (12.0) 
Kmonull     42.5  (10.3) 
Passed 1-way 
ANOVA  
p = 0.997  
n/a n/a 
 
Table 50. Blood Ly6hi Monocytes AP, 1-way ANOVA 
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A Gating strategy for blood – flow cytometry 
 
B - Eosinophils (ii) %CD45+ C - Neutrophils (iii) %CD45+ 
  
D - Monocytes (iv) %CD45+ E - Ly6C hi monocytes (v) %monocytes 
  
Figure 36. Flow cytometry used to quantify myeloid populations in blood 
AP or sham at 24-hrs in Kmowt and Kmoalb-cre Kmonull mice. A: Flow cytometry gating strategy for blood is shown. First, singlets 
are gated with side scatter to identify cell populations: CD45+ cells (leukocytes); Sink channel used to remove B cells (CD19+), T 
cells (CD3+) and NK cells (NK1.1+) from the analysis, leaving myeloid cell population (i); blood eosinophils (ii) are separated 
from the myeloid population using Siglec F; neutrophils are isolated as Ly6G+ (iii); blood monocyte population (iv) identified as 
CD115+; Ly6Chi blood monocyte population (v). Results of blood cell populations are plotted, and statitistical analysis performed 
using post-hoc subgroup analysis where statistically significant 1-way ANOVA testing was determined. Immunophenotyping: B: 
Eosinophils (CD45+, CD11B+, CD3/CD19/NK1.1 neg, SiglecF hi) as %CD45+ cells; C: Neutrophils (CD45+, CD11B+, 
CD3/CD19/NK1.1 neg, Siglec F lo, Ly6G hi) as %CD45+ cells; D: Monocytes (CD45+, CD11B hi, CD3/CD19/NK1.1 neg, Siglec 
F lo, Ly6G neg, CD115 hi) as %CD45+ cells; E: Ly6Chi monocytes as %monocytes. Individual data are shown and horizontal 
lines are median with interquartile range. 
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3.6.7. Results – Flow cytometry lung at 24-hr 
Flow cytometry was performed on fresh lung digest at 24-hrs following AP or sham in 
mice from the three genetic lines. Lungs were homogenised into single cell suspensions by 
mechanical dissociation and enzymatic digestion using a commercial kit designed for lung 
leukocyte isolation. The gating strategy for flow cytometry of PBS-perfused lung digests and 
the proportions of myeloid populations are shown in Figure 37. Appendix 10, Table 95 lists all 
of the lung flow cytometery data. Two-way ANOVA was used to statistically test lung flow 
cytometry populations differences with treatment (Table 51). 
 
3.6.7.1. 2-way ANOVA on lung flow cytometry myeloid populations 
AP treatment effects on lung myeloid populations across mouse lines are shown in 
Table 51, revealing a statistically significant increase in the proportion of circulating neutrophils 
(%CD45+) (F-statistic 15.8, p < 0.001, 2-way ANOVA), with a mean increase from 7.7% with 
sham laparotomy to 25.5% in AP. There was a significant decrease in eosinophil proportion of 
leukocytes with AP (%CD45+) (F-statistic 11.0, p = 0.002, 2-way ANOVA), with a mean 
decrease from 3.9% in shams to 2.0% in AP. After gating out neutrophils, alveolar 
macrophages and eosinophils, the was a significant increase in infiltrative monocytes in the 
lung digests of AP mice, from a mean of 9.5% in shams to 12.1% of CD45+ cells in AP (F-
statistic 4.8, p = 0.035, 2-way ANOVA). There was no significant treatment effect upon Ly6Chi 
monocyte proportions (%monocytes). 




Mean Sham  
(St. Dev) 
Mean AP  
(St. Dev) 
Mean square  F-statistic P-value 
Neutrophil 
(count, %CD45+) 
19, 19 7.745 (2.417) 25.457 (18.19) 2953.426 15.763 <0.001 
Eosinophil 
(count, %CD45+) 
19, 19 3.946 (1.433) 2.041 (1.954) 33.980 11.002 0.002 
Monocyte 
(count, %CD45+) 
19, 19 9.456 (2.158) 12.096 (4.434) 65.527 4.833 0.035 
Ly6C hi monocyte 
(count, %monocytes) 
19, 19 25.74 (7.785) 31.06 (14.080) 259.619 1.827 n/s 0.186 
Table 51. Treatment effect (AP versus sham) across mouse lines on lung flow cytometry, 2-way ANOVA 
 
 
3.6.7.2.  Lung neutrophils and eosinophils  
There were no significant differences in neutrophil (Table 52) or eosinophil (Table 53) 
proprtions of PBS-perfused lung digest leukocytes in AP between Kmowt, Kmoalb-cre or Kmonull 
mouse lines. 
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Flow - lung 
Group size 






Post Hoc Mean 
difference 
Neutrophil  
n = 6 
n = 7 
n = 6 
AP %CD45+ 
Kmowt       24.52 (19.43) 
Kmoalb-cre  20.26 (23.10) 
Kmonull     23.15 (12.92) 
Passed 1-way 
ANOVA  
p = 0.074  
Tukey post-hoc multiple testing 
Kmowt AP vs Kmoalb-cre AP, p = 0.965 
Kmowt AP vs Kmonull AP, p = 0.924 






n = 6 
n = 7 
n = 6 
Sham %CD45+ 
Kmowt      7.65 (3.26) 
Kmoalb-cre  6.67 (2.01) 
Kmonull     8.63 (1.83) 
Passed 1-way 
ANOVA  
p = 0.410  
n/a n/a 
 
Table 52. Lung Neutrophil AP, 1-way ANOVA 
 
Flow - lung 
Group size 






Post Hoc Mean 
difference 
Eosinophil  
n = 6 
n = 7 
n = 6 
AP %CD45+ 
Kmowt       3.54 (1.96) 
Kmoalb-cre  0.29 (2.37) 
Kmonull     1.28 (1.57) 
Failed Kruskal-
Wallis  
p = 0.780  
Dunn’s post-hoc multiple testing 
Kmowt AP vs Kmoalb-cre AP, p = 1.0 
Kmowt AP vs Kmonull AP, p = 1.0 






n = 6 
n = 7 
n = 6 
Sham %CD45+ 
Kmowt      3.48 (0.91) 
Kmoalb-cre  4.34 (0.90) 
Kmonull     4.50 (2.22) 
Passed 1-way 
ANOVA  
p = 0.469  
n/a n/a 
 
Table 53. Lung Eosinophil AP, 1-way ANOVA 
 
 
3.6.7.3.  Lung monocytes 
Similarly, there was no significant difference in infiltrative (non-alveolar) monocytes 
proportions of CD45+ cells between AP groups across the 3 mouse lines (Table 54), nor was 
there any significant difference in Ly6C cell surface expression of monocytes (Table 55). 
Flow - lung 
Group size 






Post Hoc Mean 
difference 
Monocyte 
n = 6 
n = 7 
n = 6 
AP %CD45+ 
Kmowt       11.43 (3.83) 
Kmoalb-cre  11.40 (4.20) 
Kmonull       9.33 (5.85) 
Passed 1-way 
ANOVA  
p = 0.086  
Tukey post-hoc multiple testing 
Kmowt AP vs Kmoalb-cre AP, p = 0.997 
Kmowt AP vs Kmonull AP, p = 0.922 






n = 6 
n = 7 
n = 6 
Sham %CD45+ 
Kmowt       8.80 (2.09) 
Kmoalb-cre  8.41 (2.36) 
Kmonull     9.69 (2.39) 
Passed 1-way 
ANOVA  
p = 0.989  
n/a n/a 
 
Table 54. Lung Monocyte AP, 1-way ANOVA 
 
Flow - lung 
Group size 






Post Hoc Mean 
difference 
Ly6C hi 
n = 6 
n = 7 
n = 6 
AP %Monocytes 
Kmowt       28.65 (8.64) 
Kmoalb-cre  31.76 (17.32) 
Kmonull     24.18 (16.19) 
Failed Kruskal-
Wallis  
p = 0.701  
Dunn’s post-hoc multiple testing 
Kmowt AP vs Kmoalb-cre AP, p = 1.0 
Kmowt AP vs Kmonull AP, p = 1.0 






n = 6 
n = 7 
n = 6 
Sham %Monocytes 
Kmowt      23.49 (9.96) 
Kmoalb-cre  24.07 (8.79) 
Kmonull     25.15 (4.63) 
Passed 1-way 
ANOVA  
p = 0.830  
n/a n/a 
 
Table 55. Lung Ly6hi Monocytes AP, 1-way ANOVA 
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A Gating strategy for lung digest – flow cytometry 
 
B - Neutrophils (iv) %CD45+ C - Eosinophils (vi) %CD45+ 
  
D - Monocytes (vii) non-alvMf, non-DC %CD45+ E - Ly6C hi monocytes (ix) %non-alvMf, non-DC %CD45+ 
  
Figure 37. Flow cytometry used to quantify myeloid populations in lung digest 
AP or sham at 24-hrs in Kmowt and Kmoalb-cre Kmonull mice. A: Flow cytometry gating strategy for lung digest is shown. First, singlets are 
gated with side scatter to identify cell populations: Dead marker used to gate live cells (i); CD45+ cells (leukocytes) identified (ii); Sink 
channel used to remove B cells (CD19+), T cells (CD3+) and NK cells (NK1.1+) from the analysis, leaving myeloid cell population (iii); 
neutrophil population are isolated as Ly6G+ (iv); alveolar macrophages (v); eosinophils (vi); infiltrative monocytes (non-alveolar 
macrophages/ non-dendritic cells)(vii); lung dendritic cells (viii), Ly6C hi monocyte subpopulation (ix). Immunophenotyping: B: 
Neutrophils (non-dead, CD45+, CD3/CD19/NK1.1 neg, CD11B hi, Ly6G hi), C: Eosinophils (non-dead, CD45+, CD3/CD19/NK1.1 neg, 
Ly6G neg, CD64 lo, CD11C neg, Siglec-F hi). D: Infiltrative monocytes (non-dead, CD45+, CD3/CD19/NK1.1 neg, Ly6G neg, CD64 lo, 
non-CD11C/MHCII double pos); E: Ly6Chi monocytes. Individual data are shown and horizontal lines are median with interquartile range. 
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3.6.8. Results – Flow cytometry liver at 24-hr 
As with the lungs, flow cytometry was performed on fresh liver digests at 24-hrs 
following AP or sham in mice from the three genetic lines. Livers were homogenised into single 
cell suspensions by mechanical dissociation and enzymatic digestion using a commercial kit 
designed for liver leukocyte isolation. The gating strategy for flow cytometry of PBS-perfused 
liver digests and the proportions of myeloid populations are shown in Figure 38. Appendix 10, 
Table 97 lists all of the liver flow cytometery data.  
 
3.6.8.1. 2-way ANOVA on liver flow cytometry myeloid populations 
AP treatment effects on liver leukocyte populations across mouse lines are shown in 
Table 56, revealing a statistically significant increase in the proportion of circulating neutrophils 
(%CD45+) (F-statistic 20.3, p < 0.001, 2-way ANOVA), with a mean increase from 7.8% with 
sham laparotomy to 15.3% in AP, across the mouse lines with AP. There was a significant 
decrease in eosinophil proportion of leukocytes with AP (%CD45+) (F-statistic 29.0, p < 0.001, 
2-way ANOVA), with a mean decrease from 4.9% in shams to 2.0% in AP. There was no 
significant treatment effect upon non-Kupffer/non-DC monocytes (%CD45+) or Ly6Chi 
monocyte proportions (%monocytes). 




Mean Sham  
(St. Dev) 
Mean AP  
(St. Dev) 
Mean square  F-statistic P-value 
Neutrophil 
(count, %CD45+) 
19, 18 7.86 (1.932) 15.32 (6.976) 515.212 20.308 <0.001 
Eosinophil 
(count, %CD45+) 
19, 18 4.86 (1.802) 2.05 (1.317) 70.344 29.008 <0.001 
Non-Kupffer/ non-DC monocytes 
(count, %CD45+) 
19, 18 12.18 (4.45) 10.05 (2.41) 40.53 2.891 n/s 0.099 
Ly6Chi infiltrative monocytes 
(count, %monocytes) 
19, 18 37.20 (7.23) 38.74 (10.19) 21.239 0.293 n/s 0.592 
Table 56. Treatment effect (AP versus sham) across mouse lines on liver flow cytometry, 2-way ANOVA 
 
 
3.6.8.2.  Liver neutrophils and eosinophils 
There was no significant difference in neutrophils (Table 57) or eosinophils (Table 58) 
proprtions of PBS-perfused liver digest leukocytes comparing AP groups across the 3 mouse 
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Flow - liver 
Group size 






Post Hoc Mean 
difference 
Neutrophil  
n = 6 
n = 6 
n = 6 
AP %CD45+ 
Kmowt       18.17 (8.90) 
Kmoalb-cre  11.96 (4.41) 
Kmonull     13.07 (6.73) 
Passed 1-way 
ANOVA   
p = 0.354  
Tukey post-hoc multiple testing 
Kmowt AP vs Kmoalb-cre AP, p = 0.323 
Kmowt AP vs Kmonull AP, p = 0.702 






n = 6 
n = 7 
n = 6 
Sham %CD45+ 
Kmowt       7.43 (1.50) 
Kmoalb-cre  7.20 (2.67) 
Kmonull     8.17 (1.57) 
Passed 1-way 
ANOVA   
p = 0.891  
n/a n/a 
 
Table 57. Liver Neutrophil AP, 1-way ANOVA 
 
Flow - liver 
Group size 






Post Hoc Mean 
difference 
Eosinophil  
n = 6 
n = 6 
n = 6 
AP %CD45+ 
Kmowt       2.24 (1.09) 
Kmoalb-cre  2.07 (1.60) 
Kmonull     1.17 (1.27) 
Passed 1-way 
ANOVA   
p = 0.494  
Tukey post-hoc multiple testing 
Kmowt AP vs Kmoalb-cre AP, p = 0.945 
Kmowt AP vs Kmonull AP, p = 0.485 






n = 6 
n = 7 
n = 6 
Sham %CD45+ 
Kmowt      4.88 (1.28) 
Kmoalb-cre  6.38 (2.16) 
Kmonull     4.67 (1.57) 
Passed 1-way 
ANOVA   
p = 0.219  
n/a n/a 
 
Table 58. Liver Eosinophil AP, 1-way ANOVA 
 
 
3.6.8.3.  Liver monocytes (non-Kupffer/ non-DC) and Ly6Chi monocytes 
Similarly, there was no significant difference in infiltrative (non-Kupffer/non-DC) 
monocytes proportions of CD45+ cells in PBS-perfused liver digests between AP groups 
across the 3 mouse lines (Table 59). Nor was there any significant difference in Ly6C cell 
surface expression of these infiltrative monocytes (Table 60). 
Flow - liver 
Group size 






Post Hoc Mean 
difference 
Monocyte 
n = 6 
n = 6 
n = 6 
AP %CD45+ 
Kmowt       11.84 (4.58) 
Kmoalb-cre  11.23  (5.70) 
Kmonull     12.89  (3.63) 
Passed 1-way 
ANOVA    
p = 0.906  
Tukey post-hoc multiple testing 
Kmowt AP vs Kmoalb-cre AP, p = 0.918 
Kmowt AP vs Kmonull AP, p = 0.999 






n = 6 
n = 7 
n = 6 
Sham %CD45+ 
Kmowt      10.11 (3.16) 
Kmoalb-cre   8.52 (1.84) 
Kmonull     10.96 (2.51) 
Passed 1-way 
ANOVA   
p = 0.818  
n/a n/a 
 
Table 59. Liver Monocyte AP, 1-way ANOVA 
 
 
Flow - liver 
Group size 






Post Hoc Mean 
difference 
Ly6C hi 
n = 6 
n = 6 
n = 6 
AP %Monocytes 
Kmowt       34.70  (7.93) 
Kmoalb-cre  38.67 (10.65) 
Kmonull     46.82  (9.31) 
Passed 1-way 
ANOVA    
p = 0.110  
Tukey post-hoc multiple testing 
Kmowt AP vs Kmoalb-cre AP, p = 0.857 
Kmowt AP vs Kmonull AP, p = 0.109 






n = 6 
n = 7 
n = 6 
Sham %Monocytes 
Kmowt      42.73  (9.76) 
Kmoalb-cre  35.96  (5.74) 
Kmonull     34.96  (7.22) 
Passed 1-way 
ANOVA    
p = 0.948  
n/a n/a 
 
Table 60. Liver Ly6hi Monocytes AP, 1-way ANOVA 
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A Gating strategy for liver digest – flow cytometry 
 
B - Neutrophils (iv) %CD45+ C - Eosinophils (v) %CD45+ 
  
D - Infiltrative monocytes (viii) %CD45+ E - Ly6Chi infiltrative monocytes (x) 
  
Figure 38. Flow cytometry used to quantify myeloid populations in liver digest 
AP or sham at 24-hrs in Kmowt and Kmoalb-cre Kmonull mice. A: Flow cytometry gating strategy for liver digest is shown. First, 
singlets are gated with side scatter to identify cell populations: Dead marker used to gate live cells (i); CD45+ cells (leukocytes) 
identified (ii); Sink channel used to remove B cells (CD19+), T cells (CD3+) and NK cells (NK1.1+) from the analysis, leaving 
myeloid cell population (iii); neutrophil population are isolated as Ly6G hi/ CD11B hi (iv); Eosinophils identified as Siglec F hi 
(v); Kupffer cell monocytes by F4/80 hi (vi); Infiltrative monocytes (non-Kupffer/ non-dendritic cells) (vii); liver dendritic cells 
(ix), Ly6C hi monocyte/ macrophage subpopulation (x). Immunophenotyping: B: Neutrophils (non-dead, CD45+, 
CD3/CD19/NK1.1 neg, CD11B hi, Ly6G hi); C: Eosinophils (non-dead, CD45+, CD3/CD19/NK1.1 neg, Ly6G neg, CD11B hi, 
Siglec-F hi); D: Infiltrative monocytes (non-dead, CD45+, CD3/CD19/NK1.1 neg, Ly6G neg, CD11B hi, non-CD11C/MHCII 
double pos); E: Ly6Chi infiltrative monocytes. Individual data are shown and horizontal lines are median with interquartile range. 
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3.6.9. Results – Kynurenine metabolites at 24-hr 
Two-way ANOVA was used to statistically test for changes in blood plasma kynurenine 
metabolites concentrations with treatment (AP versus sham) across the mouse lines on and is 
shown in Table 61. The only metabolite found to differ significantly was an associated increase 
in 3-hydroxykynrenine (F-statistic 4.8, p = 0.034, 2-way ANOVA) with AP treatment. 
Kynurenine metabolites Number  
(Sham, AP) 
Mean Sham 
(μM) (St. Dev) 
Mean AP  
(μM) (St. Dev) 
Mean square  F-statistic P-value 
Tryptophan 23, 23 20950 (3634) 19611 (5153) 25690848 1.436 n/s 0.238 
Kynurenine  23, 23 2371 (2654) 2945 (2411) 4065952.7 1.588 n/s 0.215 
Kynurenic acid 23, 23 288.8 (489.3) 493.2 (561.2) 494660.2 3.294 n/s 0.077 
Anthranilic acid 23, 23 66.6 (70.4) 75.2 (64.0) 887.6 0.421 n/s 0.520 
3-Hydroxykyurenine 23, 23 16.4 (29.3) 101.6 (243.8) 99892.9 4.801 0.034 
3-Hydroxy-anthranilic acid 23, 23 2.86 (3.99) 2.48 (2.01) 1.493 0.702 n/s 0.702 
Xanthurenic acid 23, 23 101.6 (250.6) 162.9 (490.4) 53430. 0.417 n/s 0.522 
Picolinic acid 23, 23 11.81 (3.78) 29.93 (53.64) 4574.9 4.076 n/s 0.050 
Table 61. Treatment effect across mouse line groups on kynurenine metabolites, 2-way ANOVA 
 
 
3.6.10. Conclusions - Experiment 4 
The purpose of experiment 4 studies was to investigate for mechanistic insights which 
might explain the dramatic results seen in the previous experiment (#3); specifically, to 
investigate why Kmoalb-cre mice appeared more susceptible to severe sickness in experimental 
AP over 7-days using a recovery disease model. Specifically, these studies were designed to 
detect differences in the primary pancreatic injury (histology and amylase), activation of the 
cellular component of the innate immune response (blood flow cytometry), the humoral innate 
response (plasma cytokines), innate cellular organ infiltration (lung and liver flow cytometry) 
and end-organ dysfunction (LDH, ALT, albumin, urea, glucose), as well as to assess for flux in 
the kynurenine pathway. Unlike the results in experiment 3, however, which had shown a 
distinct difference in the response to AP by way of increased sickness behaviour by Kmoalb-cre 
mice, at 24-hrs in this recovery AP model, few significant differences were found between 
Kmowt, Kmoalb-cre and Kmonull mouse lines. However, the following conclusions in relation to the 
effect of AP, and effect of mouse lines can be drawn from the data: 
 
Effects of AP, compared to sham (24-hr in 2% NaTCA model) 
1) Elevated plasma amylase, LDH, and urea concentrations  
2) Reduction in plasma glucose and albumin concentrations 
3) Elevated pancreas injury histology score 
4) Elevated plasma levels of IL-1β, IL-2, IL-6, TNFα, and KC/GRO 
5) No difference in IL-4, IL-5, IL-10, IL-12p70 and IFNγ levels 
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6) Increased neutrophil proportions in blood, and lung and liver digests 
7) Increased proportion of infiltrative monocytes in lung (but not liver), but no increase in 
Ly6C expression 
8) Decreased proportion of eosinophils in blood, lung and liver. Likely secondary to 
neutrophilia 
9) Increase in plasma 3HK concentrations, but not other kynurenine metabolites 
 
Effects of mouse line (other than kynurenine metabolite changes) 
1) No difference in amylase or pancreatic injury scores between mouse lines 
2) Kmonull mice had lower ALT levels that other mouse lines after surgery (regardless of 
sham or AP treatment) 
3) Kmoalb-cre mice had elevated IL-2 and IL-4 levels in AP compared to other mouse lines, 
and had elevated IL-12p70 concentrations in both sham and AP 
4) No differences in myeloid innate immune cell proportions due to mouse line 
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3.7. Experiment 5 – KMO inhibition prevents early critical illness in recovery AP 
3.7.1. Background 
The KMO inhibitor (KMOi) drug compound used in these studies, referred to as 
‘GSK898’, was a kind gift from collaborators at GSK. This compound was found to have good 
oral bioavailability, having undergone PKPD (pharmacokinetic/pharmacodynamic) testing by 
the pharmaceutical laboratory. The particular data regarding the biochemical and PKPD 
properties of GSK898 were reviewed during in a joint drug discovery partnership with 
academia (DPAc) meeting between the Mole Group and GSK, but were not made available 
for publication in this thesis as they were the intellectual property of GlaxoSmithKline.  
The compound became available during experiment number 3, when 7-day 
comparisons between Kmowt, Kmonull and Kmoalb-cre mouse lines found impaired survival of the 
latter group with AP. Around this same time, I had conducted plasma kynurenine metabolite 
analysis and discovered that Kmoalb-cre mice had elevated circulating plasma 3HK levels (see 
experiment #2). After discussions with GSK collaborators, I decided to add-in a ‘KMO inhibitor 
Kmoalb-cre AP’ group, to test the efficacy of the drug in reducing sickness behaviour and survival. 
This was not unreasonable because when conducting telemetered experiements, staggering 
of groups is unavoidable, as there is a finite number of hardward units (i.e. no more than 8 
mice). Further groups of AP mice were randomly assigned to either ‘KMOi drinking water’ or 
‘vehicle/normal drinking water’ (using a random number generator function in Excel, Microsoft), 
making this add-in group scientifically justifiable. By way of explanation with regards to 
unavoidable group staggering, repeated use of the same telemeters in different groups is best 
practice, rather than using different telemeters for different groups which could bias telemeter 
data if one group of telemeters does not function well. Also, induction of pancreatitis and 
telemeter implantation is time consuming and only up to n = 4 mice can added on a single day, 
allowing adequate time for surgery and recovery from anaesthesia to start telemetry recording 
at 13:00hrs, which was half way through the 12-hr light phase. Accordingly, I used additional 
Kmoalb-cre mice of appropriate age from the breeding colony, randomising available Kmoalb-cre 
littermates in a 2:1 or 3:1 (Drug: Vehicle) ratio. The drug delivery was by drinking water, 
maintaining vehicle equivalence with previous groups in which all mice had ad libitum access 
to drinking water. 
A pilot study was performed to ensure suitable drinking water GSK898 dosing (3HK 
concentrations by LC/MS-MS) for Kmoalb-cre mice. In this pilot study, male adult mice were 
randomised to 3-days drinking water with GSK898 at 0.25mg/ml or vehicle (drinking water 
without drug. This dose of GSK838 gave a mean 6.5-fold reduction in [3HK] (vehicle mean 
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0.441 μM, standard error of mean (SEM) 0.110 μM, range 0.180 to 0.715 μM; 0.25mg/ml 
GSK898 mean 0.068 μM, SEM 0.010 μM, range 0.046 to 0.085 μM) (p = 0.042, t-test Welch), 
or can be understood as an 85% reduction of vehicle [3HK] concentrations. These data are 
documented in Appendix 11 Table 99. As there was opportunity for further reduction in 3HK 
levels the concentration of the drug was therefore doubled. Therefore, the drug concentration 
for the oral KMO inhibitor study was 0.5 mg/ml GSK898 (in filtered water). A sonicade 
device was used to aid dissolution of the compound in water. Higher concentrations might have 
been achievable with the use of solvents such as DMSO or PEG but adding such substances 
to the drug group would necessitate adding these to the vehicle group, and would have made 
void the drinking water group without such additives and was therefore not performed for the 
drinking water drug study. DMSO and PEG solvents are not biologically inert and are known 
to have effects on the immune system and thus their use (i.e. in minipump study and cytokine 
experiments described later) is minimised and with the use of solvent-added controls. Aqueous 
KMOi solution was protected from light to remove the possibility of photochemical degredation.  
 
3.7.2. Hypotheses 
Treatment with KMOi in AP, compared to vehicle, improves sickness behaviour and 
survival (to humane endpoints). 
 
3.7.3. Results – Oral KMOi study 
Details of the study participants are listed in  Appendix 11 and all mice used in the 
KMOi studies were Kmoalb-cre, the line with elevated steady-state 3HK levels. Briefly, the 
experiment consisted of n = 7 sham Kmoalb-cre mice (vehicle drinking water), n = 13 AP Kmoalb-
cre mice (vehicle water), and n = 8 AP Kmoalb-cre mice (GSK898 drinking water 0.5 mg/ml).  
 
3.7.3.1. Analgesia consumption 
The mean subcutaneous buprenorphine dosing was significantly greater in the KMOi 
drinking water AP group which received the greatest mean dose (6.47 µg) (Table 62). 
However, the time-adjusted dosing was equivalent between groups (p = 0.096, 1-W ANOVA). 
This can be explained by longer survival of AP mice in the KMOi group compared to AP vehicle. 
The mean oral buprenorphine dose consumed was significantly higher (p = 0.044, 1-
W ANOVA) in the Sham group compared to the AP groups, which can be explained by an 
improved voluntary oral intake compared to AP mice, as well as longer survival (with daily oral 
analgesia supply). Therefore, because overall AP mice had reduced survival times, there were  
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Line Treatment Number Exp duration – mean (SD) 
S/C Bup. Dose – 
mean (SD) 
S/C Bup. Dose : Time 
adjusted – mean (SD) 
Oral Bup. Dose – 
mean (SD) 
Oral Bup. Dose : 
Time adjusted – 
mean (SD) 
Kmoalb-cre Sham + VDW N = 7 168.0 (0) hrs 4.500 (0.000) µg 0.027 (0.000) µg/hr 68.57 (03.78) µg 0.408 (0.021) µg/hr 
Kmoalb-cre AP + VDW N = 13 98.1 (68.0) hrs 4.904 (0.998) µg 0.092 (0.069) µg/hr 32.54 (35.13) µg 0.205 (0.205) µg/hr 
Kmoalb-cre AP + KMOiDW N = 8 124.7 (46.3) hrs 6.469 (2.081) µg 0.067 (0.053) µg/hr 47.00 (21.92) µg 0.365 (0.072) µg/hr 
1-way ANOVA between 3 groups *p = 0.043, KW *p = 0.046, KW ns p = 0.096, KW *p = 0.044, KW ns p = 0.065, KW 
Table 62. Analgesia given in AP oral KMOi 
VDW: Vehicle drinking water (filtered water); KMOiDW: KMO inhibitor drinking water. Oral Buprenorphine single dose 0.01 mg. S/C 
Buprenorphine single dose 0.05 mg/kg. KW: Kruskal-Wallis. *p < 0.05. 
 
no significant differences (p = 0.065, 1-W ANOVA) with time-adjusted oral buprenorphine 
consumption. 
 
3.7.3.2. Telemetry and humane endpoints 
Sham-operated control Kmoalb-cre mice (n = 7) showed a higher activities levels 
throughout compared to AP, with a repeated normal physiological crepuscular pattern from 48-
hrs onwards (Figure 40A, next page). Additionally, sham-operated mice established baseline 
oscillating core body temperature profiles after 48-hrs, and without significant hypothermic 
episodes seen with critically ill AP mice (Figure 40B, next page). 
Unlike sham mice, the main finding with AP-treated mice was the tendency to develop 
of profound persistent hypothermia, which occurred earlier in vehicle mice (all occurred ~24 to 
48-hrs), but mostly later in KMOi AP mice (Figure 40A). By the end of the 7-day experimental 
period, however, a similar proportion of mice in each AP group had deteriorated to predefined 
humane endpoints requiring humane cull (Figure 39A): Specifically, 5 of 8 with KMOi, and 9 







Figure 39. Survival in oral KMOi drug study 
Oral drug 0.5mg/ml GSK898. A: Median survival of AP Vehicle = 52.9-hr. Median survival AP KMOi 112.6-hr. Log-rank 
(Mantel-Cox) between AP vehicle and AP drug p=0.810, chi square 0.05. Comparison of AP Vehicle to sham vehicle, p = 
0.024, chi square 5.071; AP drug to sham vehicle 0.0143, chi square 6.00. B: Comparison of survival time to humane 
endpoint between AP vehicle and AP drug in non-survivors. T-test with Welch’s correction for heterogenous data distribution 
p = 0.022. Individual data are shown and horizontal lines are median with interquartile range. ns = not significant (p > 0.05); *p 
< 0.05. 
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Figure 40. Telemetry in AP - vehicle drinking water versus GSK898 oral 
drug study. A: Core body temperature. B: Locomotor activity. ‘+’ symbol 
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curves at 7-days, it was notable that the vehicle mice died significantly earlier (median 53-hrs) 
than the KMOi group (median 113-hrs) (Figure 39B, above). 
Oral KMOi consumption was monitored daily by recording drinking bottle weights.  
Figure 41 shows daily mean KMOi drinking water fluid consumption (with standard error of the 
mean error bars) starting from 3-days prior to AP when the KMOi drinking water was 
introduced. It is noted that after AP, oral consumption of drinking water reduced compared to 
the pre-AP levels, for at least 5 days after AP. After 5-days mice tend to be drinking more or 
else have died. Since drug delivery was through the oral route, one explanation for the late 
deaths in the KMOi group could be that the plasma drug concentrations dropped below the 
threshold required for 3HK suppression, and thereby loosing a mechanism of protection 
against critical illness.  
 
 
Figure 41. Oral KMO inhibitor drug consumption 
Consumption of drugged drinking water at concentration of 0.5 mg/ml 
GSK898). Symbols are mean, error bars are standard error of the mean 
(SEM). Volume (y-axis) is volume of drugged water consumed per day. 
  
 
3.7.4. Results – Mini pump KMOi study 
Following the oral KMOi experiment, a parenteral study was designed to better 
evaluate whether inhibition of KMO provides protection against AP-MODS in the Kmoalb-cre 
mice, using a mini pump continuous drug administration technique. These animals underwent 
induction of AP and non-cardiac mini telemeter implantation 3 days after implantation of the 
Alzet 1002 osmotic pump [100 μl reservoir, 0.25 μl/hr, duration 14 days]. The pump contained 
KMO inhibitor drug (GSK898, 250 mg/ml, in 50:50 DMSO:PEG 400) or vehicle (50:50 
DMSO:PEG 400). Manufacteurer documentation with the osmotic pumps listed 50:50 
DMSO:PEG 400 as a compatible solvent mixture for the Alzet pumps. Given that the mini pump 
concentration was 500-fold greater than that used the oral drug study, a dual-solvent vehicle 
with both DMSO and PEG was employed. 
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3.7.4.1. Analgesia consumption 
There were no significant differences in subcutaneous buprenorphine administration or 
oral buprenorphine dose consumption between AP groups treated with mini pump vehicle or 
KMOi (Table 63). 
Line Treatment Number Exp duration – mean (SD) 
S/C Bup. Dose – 
mean (SD) 
S/C Bup. Dose : Time 
adjusted – mean (SD) 
Oral Bup. Dose – 
mean (SD) 
Oral Bup. Dose : 
Time adjusted – 
mean (SD) 
Kmoalb-cre AP + PumpV N = 10 139.6 (59.8) hrs 4.175 (0.635) µg 0.050 (0.054) µg/hr 34.00 (35.14) µg 0.203 (0.209) µg/hr 
Kmoalb-cre AP + PumpKi N = 07 167.8 (0.45) hrs 4.286 (0.466) µg 0.026 (0.003) µg/hr 47.14 (32.51) µg 0.281 (0.194) µg/hr 
MWU test between 2 groups ns p = 0.691 ns p = 0.842 ns p = 0.695 ns p = 0.678 ns p = 0.556 
Table 63. Analgesia given in AP mini pump 
PumpV: Vehicle solution (DMSO/PEG); PKi: KMO inhibitor 250 mg/ml in DMSO/PEG. Oral Buprenorphine single dose 0.01 mg. S/C 
Buprenorphine single dose 0.05 mg/kg. MWU: Mann Whitney U test. ns: not significant. 
 
 3.7.4.2. Telemetry and humane endpoints 
 Two Kmoalb-cre mice with AP treated with vehicle reached the humane endpoint <30-
hrs after AP and were humanely culled, whilst KMOi-treated mice all survived into the 7th day, 
albeit with one mouse reaching a humane endpoint at 166-hrs (see telemetry data overleaf in 
Figure 42). Plasma GKS898 drug levels (Figure 43A) and [3HK] levels (Figure 43B) were 
measured in all subjects at the time of euthanasia (at humane endpoint or after the standard 
168-hr experiment endpoint), and a significant reduction in plasma [3HK] was confirmed in 
KMOi treated group (p < 0.001, Mann Whitney test). The two Kmoalb-cre mice in the vehicle 
group which reached the humane endpoints had elevated plasma [3HK] levels (Figure 43B), 
more than double that of surviving Kmoalb-cre mice, further supporting the concept of increased 
circulating [3HK] in critical illness. As there was no significant difference in survival between 
the two groups at the end of the 
experiment, nor was there a 
significant difference in injected 
analgesia volumes, a comparison in 
total body weight was made between 
those suriving mice treated with 
GSK898 versus vehicle. The KMOi-
treated mice had less weight loss than 
vehicle-treated controls, suggesting 
improved recovery, particularly with 
regard to oral intake over the 
experimental period (Figure 44, 
below).  
Figure 43. Plasma 3HK and drug 
levels with mini pump  
Plasma [3HK] from blood sampled at 
time of cull (168-hrs or earlier if 
reached humane endpoint).  
A: Log10 concentration of GSK898 
drug in plasma. The outlier in GSK898 
group represents, A436, the subject 
which reached humane endpoint at 
166.8-hr. 
B: Plasma 3HK concentrations. The 
two outliers in vehicle group represent 
A415 (endpoint 23.5-hr) and A450 
(28.9-hr) showing an elevated 3HK 
levels in critical illness. Data 
nonparametric. Mann-Whitney U test p 
= 0.001. Individual data are shown and 
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Figure 42. Telemetry in AP. Minipump study - vehicle versus GSK898  
A: Core body temperature. B: Locomotor activity. + represents timepoint of removal 
from study due to reaching humane cull endpoint. 
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Figure 44. Minipump KMO 
inhibitor associated with 
reduced weight loss in 7-
day AP in Kmoalb-cre 
Percentage of weight loss 
from baseline amongst 168-
hr survivors in GSK898 
minipump study. Vehicle 
survivors had mean 12.34% 
weight loss (SEM 1.94), 
compared to 4.44% (SEM 
1.82) in drug treatment 
group, which was significant 
(p = 0.012, t-test). 
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3.8. Experiment 6 – 3HK synergies with IL1β to activate apoptosis in vitro 
3.8.1.  Background 
As there appeared to be no significant differences in the cellular myeloid innate 
response (e.g. equivalent neutrophil counts in the blood and lungs) in the Kmoalb-cre as 
compared to Kmowt and Kmonull lines (experiment #4), I wanted to investigated the potential 
mechanisms responsible for the apparent increased susceptibility to tissue injury of the Kmoalb-
cre observed in AP recovery experiments, by exploring possible cytotoxic synergy between 
inflammatory cytokines and kynurenine pathway metabolites. The surprise finding of elevated 
circulating 3HK and XA in Kmoalb-cre mice at steady state, which appeared healthy, suggested 
that the toxic effects of 3HK (and potentially XA) are ‘uncovered’ by an acute inflammatory 
stressor. Since 3HAA has similar chemistry and redox activity as 3HK, I wanted to compare 
effects of this metabolite. 
Because respiratory failure is the most common organ system for extra-pancreatic 
organ dysfunction in AP-MODS, and since the vascular endothelium is directly exposed to 
plasma kynurenines and cytokines, I used human lung vascular endothelial cells, HMVEC-L 
(Lonza). Cells were seeded (at 5,000 or 6,000 cells per well) and plated 24-hrs prior to 
treatment. Cells were treated for 4-hrs with the assigned treatment. This duration of agonist 
contact was determined from information from Sundquist et al. from Promega showing ‘time 
dependence of caspase activities’ from 1 to 7-hrs, and from my own preliminary work using 
this assay on HMVEC-L cells (not shown). 
<www.promega.co.uk/resources/pubhub/cellnotes/timing-your-apoptosis-assays>.  
Each data point represents a separate well. Control wells, including 0 ng/ml ‘zero 
cytokines’ wells, were performed in duplicate on each plate, giving twice the number as 
treatment wells. The treatment well results were performed in triplicate (i.e. three separate 
plates). Activation of apoptotic cell death pathways was measured using a caspase 3 and 7 
luminometric assay (Promega). Cytokines IL-1β, IL-6 and IL-10 were co-cultured with HMVEC-
L cells at titrated concentrations. I chose these cytokines because IL-1β (F-statistic 16.5, p < 
0.001, 2-way ANOVA, Table 24, section 3.6) and IL-6 (F = 25.6, p < 0.001, 2-way ANOVA, 
Table 24) were robustly elevated in circulating plasma in my experimental AP model, and 
frequently reported in human AP studies, and IL-10 was chosen to compare any differences 
observed with proinflammatory cytokines with this anti-inflammatory mediator. All primary and 
control-converted data are available in Appendix 12. 
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3.8.2.  Hypothesis 
Potentially toxic hydroxykynurenines, 3HK and 3HAA, would induce endothelial cell 
caspase activation, and increasingly in the presence of pro-inflammatory cytokines (IL-1β, IL-
6) but not anti-inflammatory cytokine IL-10. 
 
3.8.3.  Results 
IL-6 or IL-10, alone or in combination with tryptophan, kynurenine, kynurenic acid, 3-
hydroxykynurenine, anthranilic acid, or 3-hydroxyanthranilic acid, did not induce significant 
levels of caspase activity (Table 64). However, IL-1β at concentrations greater than or equal 
to 10 pg/ml co-administered with 3HK at 500 μM synergistically induced endothelial cell death 
(Figure 45). Comparative data between the 3 cytokines are displayed in Figure 46, having 
converted the luminescence values into a percentage proportion of positive (caspase activator, 
Staurosporin) and negative controls (cells, no caspase reagent). 
 
3.8.4. Conclusions 
These results suggest that the synergistic effects of IL-1β in the presence of elevated 
3HK is particularly cytotoxic and is a strong activator of apoptotic cell death. Interestingly the 
other cytokines tested, whether proinflammatory (IL-6) or anti-inflammatory (IL-10), did not 
induce caspase activation. Additionally, other kynurenine metabolites, specifically XA (which 
found at elevated plasma concentrations in Kmoalb-cre mice, the mouse line more susceptible 
to critical illness in experimental AP) and 3HAA (which is chemically similar to 3HK) did not 
induce caspase. Together these data demonstrate that elevated circulating levels of IL-1β in 
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 Caspase 3/7 activity / Luminescence % relative to controls 
Cytokine Metabolite 
[Metabolite] IL-1β IL-6 IL-10 Trp Kyn KA 3HK 3HAA XA 
100 μM 
0 0 0 
21.195 23.698 30.519 25.683 19.632 26.332 
17.913 20.237 21.793 21.082 14.066 18.538 
17.788 17.918 19.723 20.499 13.912 17.100 
23.509 27.571 35.354 21.139 16.120 21.701 
30.643 26.655 28.883 23.811 18.289 33.711 
29.112 25.591 25.391 20.421 24.785 28.119 
         
IL-1β 
10 pg/ml 0 0 
35.514 27.535 23.005 23.988 14.333 20.267 
32.328 33.183 32.915 30.645 20.734 30.849 
35.695 29.312 33.500 26.841 21.261 31.533 
         
IL-1β 
100 pg/ml 0 0 
38.882 37.724 35.996 30.133 26.455 25.362 
39.330 50.969 43.490 40.358 30.267 40.794 
50.050 42.474 49.365 41.057 35.489 42.847 
         
0 IL-6 100 ng/ml 0 
20.256 19.644 28.781 26.495 18.218 26.574 
18.016 19.058 19.212 18.553 13.572 19.210 
16.952 19.973 17.214 19.926 13.432 16.238 
         
0 0 IL-10 100 ng/ml 
24.268 23.482 29.424 26.816 21.625 26.135 
19.844 18.875 19.177 18.798 18.105 16.097 
18.250 19.458 17.775 20.604 12.872 17.989 
          
 500 μM 
0 0 0 
29.939 22.807 21.838 48.233 21.684 25.684 
19.705 20.760 16.065 31.577 15.121 16.789 
19.503 21.050 20.745 32.118 23.370 15.289 
29.864 25.148 28.087 9.685 9.774 20.694 
29.747 25.008 30.968 8.135 14.239 32.756 
29.542 27.644 32.593 12.004 9.729 26.700 
         
IL-1β 
10 pg/ml 0 0 
41.351 27.019 31.866 98.588 17.169 23.586 
25.410 51.645 37.911 135.570 23.938 35.941 
36.576 31.996 31.870 111.520 18.709 34.251 
         
IL-1β 
100 pg/ml 0 0 
43.597 34.865 63.397 138.641 35.302 30.029 
51.204 46.212 55.878 131.479 53.679 45.986 
52.846 41.243 54.120 122.378 33.948 44.596 
         
0 IL-6 100 ng/ml 0 
22.634 30.844 25.480 26.629 27.511 22.302 
19.454 16.466 18.343 24.217 15.002 17.593 
20.750 21.566 19.095 27.196 23.385 15.410 
         
0 0 IL-10 100 ng/ml 
22.687 22.276 23.150 27.573 26.204 25.170 
20.875 20.068 24.422 26.638 14.471 16.597 
20.973 22.513 23.944 24.434 17.515 15.753 
Table 64. Comparison of relative endothelial caspase 3/7 activity with kynurenines and cytokines 
Staurosporin 10 μM was used for positive control for caspase 3/7 activation. Negative control to gauge absence of luminescence took 
the form of a ‘no caspase reagent’ reading of wells containing cells, medium and DMSO to allow for cellular autofluorence. 
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Figure 45: 3-Hydoxykynurenine in co-culture with IL1β synergistically induces 
endothelial apoptosis. Increasing concentrations of tryptophan catabolites were 
tested for endothelial cell (HMVEC-L in EBM2 medium) caspase activation in 
presence or absence of increasing IL1β doses. C: 3HK alone (at 500 µM) 
potentiated caspase 3/7 activity with IL-1β (≥10 pg/mL). Groups (n = 3 or 6, as 
shown) were compared by 1-way ANOVA with Dunnett’s post-hoc test or Kruskal-
Wallis with Dunn’s test, as appropriate. Post-hoc tests were made against medium 





Metabolic regulators of inflammation in acute pancreatitis                                                         S0897427 
Alastair J Hayes 








Figure 46: Comparison of cytokines IL-1β, IL-6, and IL-10 with kynurenine 
metabolites to potentiate endothelial cell apoptosis.  
A comparison of caspase 3 and 7 activity in endothelial cells (HMVEC-L in EBM2 
medium) comparing co-culture with kynurenine metabolites and cytokines IL-1β (low 
and high dose), IL-6 and IL-10 showing luminescence relative to controls for 
metabolites at 100 μM (A) and 500 μM (B). Staurosporin 10 μM was used for positive 
control for caspase 3/7 activation. Negative control to gauge absence of luminescence 
was a ‘no caspase reagent’ reading of wells containing cells, medium and DMSO. 
Whilst IL-1β had a pro-apoptotic effect with 3HK (as statistically confirmed in Figure 45), 
here no synergistic effect by IL-6 or IL-10 are observed, despite the use of high 
concentrations (100 ng/m). 
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4. DISCUSSION AND CONCLUSIONS 
 
Acute pancreatitis is a sterile activator of the immune system. After pancreatic insult, 
there is release of DAMPS, cytokines, initiation of inflammatory signalling cascades, along with 
leukocyte and platelet activation and a neuro-endocrine stress response. This often gives rise 
to alterations in human physiology, which may arise far earlier than changes in the routine 
blood tests, which typically measure end-organ damage (e.g. creatinine, ALT), or radiological 
changes. Such altered physiological changes are characterized by the SIRS; whereby there 
are changes in bodily temperature, tachycardia, and an increased respiratory rate. Telemetry 
is an automated communications technology where measurements (’metron’) are made 
remotely (‘tele’) and data are typically transferred through a wireless connection (e.g. radio 
waves). In biomedical research, telemetry is used to continuously record physiological 
parameters in unrestrained animals over prolonged time intervals, which is a different 
approach to the standard practice where large groups of animals are sacrificed at several 
timepoints. The literature contains many examples of interesting studies where telemetry has 
played a central role in sickness behaviour (636, 642). For scientific translational purposes, as 
well as welfare and standardising humane endpoint decision making (e.g. hypothermia <26oC 
was our humane cull threshold), from the outset of the project we had planned to use telemetry 
monitoring animal physiological behaviour. Radiotelemetry devices have not been previously 
used in experimental AP, but would intuitively offer a useful adjunct in investigating the 
recovery phase. The design of studies involving telemetry requires an appreciation of the 
normal murine circadian physiological changes, how these may be perturbed by the 
experimental design, and how to minimise and control for such effects (e.g. timing of surgery) 
(643-645). Furthermore, circadian cycles are known to be important in health of critically ill 
patients (646, 647). Limited information exists regarding the physiological response after 
telemetry implantation, but it has been suggested that mice should be given ‘sufficient time to 
adapt to bearing the transmitter before starting experiments’ (648). Given that our Na-TCA AP 
model involves opening the abdomen, it seemed logical to implant the intraperitoneal device 
at the same operation. 
 
4.1. Model optimization – Phase I and II – for telemetered AP recovery studies 
Large telemetry implants in small animals with batteries to monitor rodent physiology 
are problematic in that they are known to delay recover and require change of batteries (635). 
With the new battery-free telemeter technology used in this project, using a receiver pad 
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beneath the cage to provide electromagnetic current, I managed for the first time to capture 
the physiological changes of mice with AP.  
With hindsight, lung injury with Protocol 6 could perhaps have been tested earlier, but 
as there was no consensus on how best to measure lung injury and efforts were focused on 
reaching a final infusion protocol as soon as possible, the lung assay option was overlooked 
with preference to test a higher dose of NaTCA as detailed in Protocol 7. 
The impact of the telemeter device, in particular the larger cardiometabolic G2 HR 
device, is not without complication and from the data presented in sections 3.1, 3.3, and 3.5, 
there is compelling evidence that the added insult of the larger device which increased the 
systemic insult on these mice, increasing the tendency towards critical illness. This was not 
unforeseen, but was quantitatively unknown with respect to the degree to which critical illness 
would be poteniated in experimental AP. The added systemic insult from the larger 
cardiometabolic G2 HR telemeter likely made defining the protocol for recovery AP 
problematic. With the benefit of hindsight, I would rather have used the mini telemeter from the 
outset, and then perhaps 3% NaTCA infusate would have then worked satisfactorily, however, 
I suspect the high flow rate (100 μl over 60s), I may still have required adjustment. 
 
4.2. Experiment 1 – KMO deletion improves AP recovery 
Use of the radiotelemetry system, however, brought considerable advantages, allowing 
the investigator to remotely monitor mice. During the pilot model optimization phase I, I decided 
early on to adopt a protocol whereby should mice drop below 30oC on a single occasion, but 
failed to meet humane endpoint criteria (see clinical score sheet - Appendix 3, section 6.3) 
they would be transferred to a warming chamber for ~30 mins, and receive a weight-adjusted 
subcutaneous bolus of warm saline, 5% dextrose and buprenorphine analgesia. Thereafter, 
where mice became hypothermic for a second time, they were not allowed to be re-warmed 
and would be culled if they reached a humane endpoint criterion, including hypothermia <26oC, 
(as determined by telemetry). Using this system, I was better able to identify critically ill mice 
prior to their death, which allowed for tissue sampling under terminal anaesthesia, allowing 
confirmation of multi-organ dysfunction by biochemistry (Figure 23) and proinflammatory 
cytokine release (Figure 24). 
The main finding of Experiment 1 was an improved survival difference with Kmonull, as 
compared to Kmowt, with regards to protection against critical illness over a 7-day recovery 
study interval. This experiment conceptually extended the findings by my supervisor and 
collaborators (634) whereby the protective effects of KMO blockade now appeared to extend 
beyond the early 24-hour timepoint. The breeding colony of Kmonull mice was very small at the 
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time of this experiment, and there were no age-matched Kmonull mice available for a sham 
laparotomy group. However, a Kmonull sham group would not have added to the findings of the 
experiment because the necessary sham group was that of the poorly surviving mouse line, 
which was the Kmowt mice. 
 
4.3. Experiment 2 – Hepatocyte-restricted Kmo knockout increases plasma 3HK 
The plasma kynurenine pathway metabolite profile in the Kmoalb-cre line, in particular the 
elevated [3HK] levels, had not been anticipated. Indeed, it may a first appear counter-intuitive 
that a partial KMO knockout (in terms of total bodily Kmo expression) would have elevated 
[3HK], as opposed to concentrations somewhere between that of wildtype (Kmowt) and full 
knockout (Kmonull) mice. However, when considering the multi-compartment nature of 
mammalian metabolism, the results can be rationalised. Specifically, it is likely that a large 
proportion of bodily kynurenine is normally converted into 3HK within the (wildtype) 
hepatocytes, where it is intracellularly metabolised onwards (towards NAD+ biosynthesis or 
else Acetyl CoA generation for the Krebs cycle). When hepatocyte kynurenine hydroxylation 
is blocked, as in Kmoalb-cre mice, kynurenine, which can more readily can cross membranes 
compartments, can pass into the circulation giving an abundant substrate for extra-hepatic 
KMO activity, and thus generating high quantities of plasma [3HK]. From the tracer study we 
can conclude that onward elimination of 3HK (e.g. metabolism or transportation) from the 
intravascular compartment is near saturation, as this would explain why 13C6-3HK levels are 
higher in Kmoalb-cre than in Kmowt and Kmonull.  
One curious observation of these mice with high [3HK], is that they survive into 
adulthood and appear relatively healthy. However, RNA sequencing data (generated by my 
colleagues after I left the lab), indicate altered expression of pro-inflammatory genes in adult 
Kmoalb-cre mice at steadystate. 
 
4.4. Experiment 3 – Hepatocyte-restricted Kmo knockout impairs AP recovery 
Having established that the Kmoalb-cre line has a particular biochemical phenotype, with 
respect to the kynurenine pathway, and in particular high plasma [3HK], it was important to 
test this in the setting of AP, since elevated serum [3HK] in human AP patients is associated 
with increased disease severity with organ failure (375). The mini telemeter was used to 
monitor mice in these AP recovery studies, comparing sickness behaviour in Kmoalb-cre against 
Kmowt, and using Kmonull as a 3HK negative control group.  
From the data, a null hypothesis of ‘no difference in critical illness and survival between 
these lines’ was rejected, due to the significant tendency towards critical illness and humane 
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endpoints in the Kmoalb-cre line. One observation which was not expected was the complete 
survival of the Kmowt mouse line, following the poor survival of Kmowt mice with AP and the 
more invasive cardiometabolic telemeter system in Experiment 1. However, given that the 
overall insult was reduced by switching to a less invasive telemeter, this telemetered AP model 
was a less severe disease model in terms of systemic injury, and in the case of Kmowt and 
Kmonull, was generally under the threshold for critical illness as there was no significant 
difference in survival in AP between these two lines. The difference between cardiometabolic 
telemetered AP and mini telemetered AP, could conceptually be considered as moving from 
severe AP (using cardiometabolic telemeter) to moderate AP, when considered in terms of 
clinical terminology. That said, the finding of two deaths in Kmonull mouse line during the study 
could be used against such a statement. In reality, researchers must be honest about the 
limitations in our disease models and the inherent disease severity variability which does exist 
despite our best efforts. One of these Kmonull AP mice, culled ~24-hrs (K1217), was a surgical 
failure with a bile leak from the duodenotomy ‘closure’ site found at post mortem. Whilst it likely 
developed critical illness due to peritonitis secondary to leakage of enteric/bilious fluid content, 
it was not excluded for transparency reasons and the principal of ‘intention-to-treat’. There was 
another notable Kmonull mouse which developed severe hypothermia with associated reduction 
in locomotor activity overnight, having appeared clinically well on cage side checks the evening 
before and the morning after. It is difficult to understand why that might have occurred and how 
it was able to spontaneously recover, but the telemetry trace is convincing with a simultaneous 
decline, and then recovery, in both locomotor and core temperature data readouts. This event 
highlights the benefits of telemetry recording, as without monitoring this transient episode 
would have passed unnoticed. Kmoalb-cre mice which reached humane endpoints were 
confirmed to have multiple organ injury by biochemical markers and cytokines, where there 
was sufficient blood sample for analysis (critically ill mice can yield very little blood due to 
cardiovascular changes). 
 
4.5. Experiment 4 – Altered kynurenines did not alter early injury in recovery AP 
There were little differences between mouse lines at 24-hrs but some discussion is 
required to give some wider context, technical detail and limitations. One particular strength of 
the 24-hr experiment was the controlled timepoint reached by all subjects, which was not 
feasible with the 7-day recover experiemnts due to the inherent disease variability and severity 
with subjects reaching humane endpoints before 168-hrs. 
The data presented do raise some need for comment about the limitations of 
histological scoring by nature of examining a slice of the pancreas, however, often a large 
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cross-section of the pancreas is captured. Artefact changes in the pancreas may occur by 
suboptimal tissue fixation, which can be minimized by care to submerge the tissue in adequate 
volumes of fixative by the researcher. Interested readers can inspect histological injury score 
alongside plasma amylase concentrations in appendix 9, Table 53 and refer to cytokine levels 
(Table 56) to gauge systemic inflammatory insult. A noticeable outlier for histological 
assessment of pancreas injury was FK487 (wildtype, Kmowt, AP) which had a normal looking 
pancreas (in the section analysed) and low circulating cytokine levels (Table 56) comparable 
to that of sham laparotomy controls. These data would be expected in the sham group, 
however this mouse (FK487) did have an elevated amylase (7632 U/l) ~3-fold higher than 
shams and equivalent to another subject with clear histological changes (FK501, amylase 
7740 U/l, maximal histology score 9/9). With regards to amylase, which usually is elevated in 
experimental AP, as can be seen in ‘normal-amylase AP’ in humans, occasionally a low 
amylase result is encountered despite having pancreatic inflammation. For example, FK486 
(wildtype, AP) mouse with low amylase (1940 U/l) had a maximal histology injury score, and 
elevated IL-1β (3.7 pg/ml) and IL-6 (334.2 pg/ml). Creatinine was found to to have poor 
sensitivity (data not shown) for renal dysfunction as it was often undetected in mice which had 
reached humane endpoints, despite having high urea levels, and other markers of organ 
dysfunction (i.e. high ALT and LDH) and therefore creatinine was soon removed from the 
biochemical panel. 
With respect to cytokines specifically, the sham laparotomy group were used as the 
control as opposed to steadystate healthy controls. The reason for omitting steady state 
controls on the assay was prinicipally for economic reasons and the MSD assay was not 
inexpensive and would have added very little scientific benefit. 
Noteably, Kmoalb-cre mice were found to have elevated IL-12p70 in both sham and AP 
compared to other mouse linese. IL12 is a heterodimer cytokine produced by myeloid (i.e. 
monocytes, macrophages, neutrophils, DCs) and B cells. It is produced in response to 
microbial stimul and drives Th1 differentiation and IFN production (649). However, no 
differences in IFN were observed (Table 32 and 37). Additionally, Kmoalb-cre mice had elevated 
IL-2 and IL-4 in AP. The relevance of IL-4 here is questionable since overall, IL-4 levels did not 
appear to differ across mouse lines with AP (Table 32). However, IL-2 levels did appear to 
increase with AP (Table 32), and were more elevated in Kmoalb-cre mice compared to other 
mouse lines (Table 40). IL-2 is known for its role in lymphocyte proliferation, however elevated 
[3HK] levels are known to suppress T-cells (451). Most interestingly from Experiment 4 (section 
3.6), we see that similar to humans with AP that have elevated blood [3HK], experimental AP 
is also associated with increased 3HK concentrations (Table 33). 
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4.6. Experiment 5 – KMO inhibition prevents early critical illness in recovery AP 
Given the high concentrations of 3HK in Kmoalb-cre mice, in association with early 
lethality of these mice with AP, I performed KMO inhibitor (KMOi) studies. In answer a specific 
question raised by peers; ‘why perform a KMOi study in the Kmoalb-cre AP mice with the mini 
telemeter rather than the use the drug in Kmowt mice with the cardiometabolic telemeter (after 
all humans are ‘wildtype’!)’ the answer is 3-fold:  
i) Firstly, this was a mechanistic question, as opposed to a mock clinical trial. The test 
was to determine whether the KMOi would reduce the early lethality phenotype 
observed in the Kmoalb-cre mouse line with AP, with reduced plasma [3HK]. Because the 
Kmowt mice had levels around the limit of detection, we would not have been able to 
demonstrate a reduction in plasma [3HK] levels, therefore the obvious first choice was 
the Kmoalb-cre line. 
ii) Secondly, I did not have consistent data showing that Kmowt mice had elevated 3HK 
with 2% NaTCA, likely because substantial elevations of 3HK in Kmowt mice only 
appeared to occur with the onset of substantial multi-organ injury/ impending lethality, 
requiring a more severe injury challenge such as the addition of the invasive 
cardiometabolic telemeter or increased NaTCA concentrations (e.g. 5% NaTCA). 
iii) By this point in the research, our Veterinary colleagues and I (working under Home 
Office licencing restrictions, 3Rs principles and ethical principles) were content with the 
lethality of the AP model using the mini telemeter which appeared to add very little, if 
any, further insult and severity to the model, as opposed to the cardiometabolic device 
which substantially synergised the severity of the AP model. If time and resources had 
allowed for an experiment using Kmowt mice and the severe model (i.e. AP with the 
cardiometabolic telemeter), it would have been carefully discussed and considered with 
Veterinary colleagues. 
 
The drug is orally bioavailable and thus suitable to add to drinking water. Figure 36 shows 
similar 7-day survival, however the deaths in the drugged subjects were generally much later, 
indeed there was a significant delay in time to humane endpoint (Figure 36B). I had carefully 
recovered daily consumption of drugged water, and with a decrease in consumption of water 
in AP (Figure 37), arguably they dosing effect might have bear wearing off with time, meaning 
that the initial protection wore off. 
To take things forwards, and circumvent the problem of impaired voluntary oral drinking 
water consumption in AP, I performed a parenteral, mini pump drug study. Again, this was 
performed in Kmoalb-cre mice. Interestingly in the minipump study (section 3.7, Figure 42B), we 
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see that the two vehicle-treated minipump mice that developed critical illness have elevated 
3HK levels and were outliers with regards 3HK concentration data. There were not as many 
deaths in the Kmoalb-cre vehicle mini pump group as anticipated by the results from Experiment 
3. There was one non-survivor amongst the mini pump KMO inhibitor treatment group, which 
was humanely culled at 166-hrs. Again, those reaching humane endpoint in the vehicle group 
did so at a much earlier time point than the KMOi drug-treated group. Comparing survivors 
between the drug and vehicle groups, there was a significant weight loss in the vehicle group. 
 
4.7. Experiment 6 – Casepase 3/7 assay 3HK synergies with IL1β to activate apoptosis 
in vitro 
3HK is known to have many deleteriorus cytotoxic effects (see section 1.2.6.3.), but 
Kmoalb-cre mice, with high circulating levels of [3HK], survive into adulthood and appear healthy. 
Therefore, I was lead to consider that elevated [3HK] levels may be more cytotoxic during 
inflammation as opposed to steadystate. I wanted to test the hypothesis that certain kynurenine 
metabolites may be more cytotoxic in co-culture with certain cytokines. I tested all available 
kynureine compounds, along with pro- (IL-1, IL-6) and anti-inflammatory cytokines (IL-10). 
Whilst did not specifically test activity of these cytokines, they were all freshly sourced from the 
supplier which undertakes in-house testing (Miltenyi Biotec). Compounds were dissolved with 
the use of DMSO, which required to be dissoclved in DMSO (0.5% final concentration) with 
controls. It was surprising that 3HK alone did not have significantly elevated caspase 3/7 
actiivty after 4-hrs treatment, however, one explanation could be that the EBM-2 medium 




The academic and pharmaceutical interest in the kynurenine pathway outside of the 
central nervous system is growing as increasingly researchers are finding the mechanistic 
relevance of the kynurenines in an increasing number of peripheral inflammatory and 
metabolic and diseases and the concept of metabolic support in critical illness is gaining 
traction (650). In my research, I found that KMO blockade in genetically-altered mice protects 
against critical illness and improves recovery in an experimental model of severe AP. I 
discovered a hepatocyte-specific role for KMO, where mice generated to lack Kmo solely in 
hepatocytes (Kmoalb-cre) showed elevated plasma [3HK], reduced 13C6-3-hydroxykynurenine 
tracer clearance, and transcriptomic alterations in key innate immunity pathways in liver tissue, 
Metabolic regulators of inflammation in acute pancreatitis                                                         S0897427 
Alastair J Hayes 
  - 175 -  
 
specifically modulating expression of canonical toll-like receptor pathway signalling genes, 
including MyD88, RIP kinase, MAP kinases and NF-κB. Although Kmoalb-cre mice with elevated 
3HK mice did not significantly differ in pancreas injury metrics, multiple-organ neutrophilia 
infiltrate or routine biochemistry at an early timepoint (24-hr) using a less severe recovery 
model of AP, these mice succumbed fatally earlier and more readily to experimental AP over 
7-days, thus indicating an impaired recovery and increased susceptibility for critical illness. 
Therapeutically reducing 3HK to undetectable levels through systemic blockade using a highly-
specific KMO inhibitor rescues the phenotype, protecting against critical illness and early 
mortality in 7-day recovery experimental AP. In vitro, 3HK was the only kynurenine metabolite 
to induce cytotoxic insult, by way of caspase 3/7 activation, which required pro-inflammatiory 
cytokine, interleukin-1β, to potentiate this effect. These findings support the notion of a 
potential deleterious cytotoxic interaction between 3HK with innate immune mediators. The 
other kynurenine metabolites did not induce caspase activation. 
Together, these findings establish the KMO product 3HK as a modulator of innate 
immunity that exhibits a complex interaction with inflammatory cytokines during critical illness 
to promote excess morbidity and death from multiple organ failure that may be rescued by 
systemic KMO blockade. 
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6. APPENDIX 
6.1. Appendix 1 – Telemetry software setup 
The following instructions should allow a new user to set up a new telemetry experiment. 
1) Open VitalView icon in programs to open software application. 
2) An error will appear (‘Initialization error number 1’), click ‘OK’ to continue. 
3) On the left side four options will appear: ‘System Setup’, ‘Animal & Groups Setup’; ‘Data 
Collection Monitor’, and ‘Data Load & Analysis’.  
4) Select ‘System Setup’: 
a. Clipping limit default: Change lower limit temperature clipping from default 30oC 
to 20.0oC. No changes to Activity and Heart Rate. 
b.  DP-24 DataPort Configuration: No changes. 
c. ER-4000 Configuration: ‘# of ER-4000’s’ change to 8 (alter to the number 
connected). No change to ‘HR Oversample Buffer Size’ or ‘Temp. Oversample 
Buffer Size’. No change to ‘COM Port’ (keep at default ‘COM1’). No change to 
‘Filter’ (keep at default 4). 
d. Sample Timing Defaults: Keep at default interval 0hh, 1mm, 0ss. 
e. Data file defaults: Max File Size = 5.0M. 
5) Select ‘Animal & Group Setup’: 
a. Temperature Calibration 
i. Select ‘Temperature Calibration’ (in bottom right corner) 
ii. Make a note of the serial number for each device (eg. EM015379) and 
assign it a code (eg. EM33). 
iii. Ensure ‘Series 4000’ is selected. 
iv. For each telemeter, enter the designated user friendly code name along 
with the factory supplied calibration frequency points for the high and 
low temperatures – these details are found on the individual packaging 
for each device. To illustrate, the frequencies of non-cardiac telemeters 
used in this work are listed in Table X. 
v. After all telemeters have been entered, save this information by 
selecting ‘File’ drop down menu (top left) and then select ‘Exit’ (bottom 
right) to return to ‘Animal & Group Setup’ screen. 
b. Add Animals to experiment 
i. First, click ‘Group’ drop down menu and select ‘New’ to create an 
experimental group and assign a suitable name (eg. ‘2017jul07_Pump’). 
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ii. Next, click ‘Animal’ drop down menu and select ‘New’ to enter an animal 
into the experiment. A new window will appear (‘VitalView Animal 
Configuration’). 
iii. In ‘Animal ID’ (top left) enter name of experimental subject. It simplifies 
matters to name this by the device code name and ER-4000 receiver 
plate number (ie. EM21/ER1). 
iv. In ‘Group ID’ select the name of the group (from above – 5.b.i). 
v. Next select from ‘Parameter’ the telemeter device and channel of 
interest from drop down menu (ie. ‘ER-4000 Temperature’) to replace 
default ‘TR-3000 Temperature’. 
vi. From immediately below this, select the telemeter (ie. EM21) 
vii. Select ‘Enable’ to highlight box. 
viii. Under ‘Con’ select the corresponding ER-4000 plate for use with this 
selected telemeter (ie. ‘1’). 
ix. Under ‘Chn’ select ‘1’ for temperature, ‘2’ for activity, ‘3’ for heart rate. 
Check clipping limits are acceptable (ie. 20.00 to 42.00 Deg for 
temperature). 
x. To add activity counts, chose ‘ER-4000 Activity’ under drop down 
‘parameter’ options. Select ‘Enable’. Select ‘1’ under ‘Con’ for ER-4000 
#1, and chose channel ‘2’. 
xi. Finally, an image icon can be selected (top left) at users’ preference. 
xii. Click ‘OK’ (bottom left) to save changes. 
c. Save ‘Animal & Group Setup’ changes by selecting ‘File’ drop down (top left) 
and choose ‘Save Configuration to File’. And exit to main menu by selecting 
‘Exit’ from ‘File’ drop down menu in ‘Animal & Group setup’. 
6) Start data recording 
a. In main menu, select ‘File’ drop down (top left) and choose ‘Start Data 
Collection’. 
b. The user will be given the choice of ‘Standard’ or ‘Test’. Select ‘Test’ initially to 
run checks. 
c. The software will check connection with each ER-4000 plate; ensure these are 
connected in series as per manual. Click ‘list is OK’ and select start time of test 
to run immediately. 
d. Save logfile as test, to allow identification (ie. ‘logfile_test2017jul07_Pump’) 
e. In the main menu, select ‘Data Collection Monitor’ to visualise live datastream. 
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f. In the main menu, select ‘File’ drop down (top left) and choose ‘Stop Data 
Collection’ to terminate test. 
For the experiment (including delayed start), select ‘Start Data Collection’ from ‘File’ drop down 
in main menu, and choose ‘Standard’. Click ‘list is OK’ when prompted and select date time to 
start telemetry recording. 
 
 
The following steps allow brief data inspection and export: 
1) In main menu, select ‘Data Load & Analysis’, and select from ‘File’ drop down (top left) 
the option ‘Load from VitalView Data File’. 
2) Choose experiment of interest (ie. ‘ .log’ file) and click ‘OK’ to load. 
3) A new window will appear (‘Data Available From Selected Experiment’). Select one 
subject of interest (ie. EM21/ER1) and corresponding channels (i.e. temperature and 
activity). 
4) Select ‘Special Span ?’ (bottom middle) and adjust date and time from the start and 
end of the experiment. 
5) An alert will appear regarding the number of data points, select ‘Continue Load’ and 
the data will appear visually. 
6) To export data, select from ‘File’ drop down in ‘Data Load & Analysis’ the option ‘Save 
To ASCII File’. 
7) An alert will appear, relating to file format: Select ‘Old Format’ and save the file in the 
appropriate window. 
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6.2. Appendix 2 – Python code 
 
In[1]: # Python packages 
import numpy as np; import pandas as pd; from __future__ import division  
import matplotlib as mpl; import matplotlib.pyplot as plt; %matplotlib inline; import seaborn as sns 
In[2]: dfA415 = pd.read_csv('/Users/alastairhayes/Documents/Telemetry/Data/A415/A415.csv') 
df1A415 = dfA415.drop(['time', 'ddmmyyyy'], axis=1) 
# Change datetime stamps from object dtype to datetime64 dtype 
df1A415.datetime = pd.to_datetime(df1A415.datetime, dayfirst=True) 
df1A415.ZT0 = pd.to_datetime(df1A415.ZT0, dayfirst=True) 
# Create column with accumulative activity 
ActSum_A415 = df1A415['act'].expanding(min_periods=1).sum() 
ActSum_A415.name = 'sumAct' 
# Create column with ZT 
tXA415 = df1A415.datetime; tYA415 = df1A415.ZT0 
deltaZTA415 = tXA415 - tYA415 
ZTA415 = deltaZTA415 / np.timedelta64(1, 'h') 
ZTA415.name = 'ZT' 
# Append ZT and sumAct series to df1 and drop useless column 
df2A415 = pd.concat([df1A415, ActSum_A415, ZTA415], axis=1) 
df3A415 = df2A415.drop(['ZT0'], axis=1) 
df4A415 = df3A415.set_index('ZT') 
# Set datetime as index and then separate telemetry parameters 
DTindexdfA415 = df3A415.set_index('datetime') 
df_tempA415 = DTindexdfA415['temp'] 
df_actA415 = DTindexdfA415['act'] 
df_ActSum_A415 = DTindexdfA415['sumAct'] 
df_ZTA415 = DTindexdfA415['ZT'] 
# Resample data at 60 min intervals (using mean for Temp and sum for Activity) 
s1A415 = df_tempA415.resample('60min').mean() 
s2A415 = df_actA415.resample('60min').sum() 
s3A415 = df_ActSum_A415.resample('60min').last() 
s4A415 = df_ZTA415.resample('60min').first() 
df5A415 = pd.concat([s1A415, s2A415, s3A415, s4A415], axis=1); df5A415.insert(3, 'Exp', 'Vehicle'); 
df5A415.insert(4, 'ID', 'A415') 
df5A415.head(1) 
Figure 47. Python code for data wrangling 
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 from matplotlib import gridspec                           #special function 
sns.set_context("notebook"); sns.set_style("ticks"); 
fig = plt.figure(figsize=(10, 6))                             #Figure size 
gs = gridspec.GridSpec(2, 1, height_ratios=[0.5,0.5]) #Ratio of upper and lower subplots 
ax0 = plt.subplot(gs[0]);  
#Data - KMO albcre, AP, Vehicle (n=10) 
plt.plot(df5A415['ZT'][0:10080], df5A415['temp'][0:10080], linewidth=1.0, color='navy') 
plt.plot(df5A416['ZT'][0:10080], df5A416['temp'][0:10080], linewidth=1.0, color='navy') 
plt.plot(df5A421['ZT'][0:10080], df5A421['temp'][0:10080], linewidth=1.0, color='navy') 
plt.plot(df5A422['ZT'][0:10080], df5A422['temp'][0:10080], linewidth=1.0, color='navy') 
plt.plot(df5A432['ZT'][0:10080], df5A432['temp'][0:10080], linewidth=1.0, color='navy') 
plt.plot(df5A439['ZT'][0:10080], df5A439['temp'][0:10080], linewidth=1.0, color='navy') 
plt.plot(df5A440['ZT'][0:10080], df5A440['temp'][0:10080], linewidth=1.0, color='navy') 
plt.plot(df5A449['ZT'][0:10080], df5A449['temp'][0:10080], linewidth=1.0, color='navy') 
plt.plot(df5A450['ZT'][0:10080], df5A450['temp'][0:10080], linewidth=1.0, color='navy') 
plt.plot(df5A451['ZT'][0:10080], df5A451['temp'][0:10080], linewidth=1.0, color='navy') 
ax0.tick_params(labelsize=13) 
plt.plot([24, 24], [20, 50], 'k--', lw=1); plt.plot([48, 48], [20, 50], 'k--', lw=1); plt.plot([72, 72], [20, 50], 'k--', lw=1); plt.plot([96, 
96], [20, 50], 'k--', lw=1); plt.plot([120, 120], [20, 50], 'k--', lw=1); plt.plot([144, 144], [20, 50], 'k--', lw=1); 
plt.ylabel('Temperature ($^\circ$C)', fontsize=14) 
ax1 = plt.subplot(gs[1]);  
#Data - KMO albcre, AP, GSK898 (n=7) 
plt.plot(df5A411['ZT'][0:10080], df5A411['temp'][0:10080], linewidth=1.0, color='navy') 
plt.plot(df5A420['ZT'][0:10080], df5A420['temp'][0:10080], linewidth=1.0, color='navy') 
plt.plot(df5A430['ZT'][0:10080], df5A430['temp'][0:10080], linewidth=1.0, color='navy') 
plt.plot(df5A431['ZT'][0:10080], df5A431['temp'][0:10080], linewidth=1.0, color='navy') 
plt.plot(df5A436['ZT'][0:10080], df5A436['temp'][0:10080], linewidth=1.0, color='navy') 
plt.plot(df5A438['ZT'][0:10080], df5A438['temp'][0:10080], linewidth=1.0, color='navy') 
plt.plot(df5A452['ZT'][0:10080], df5A452['temp'][0:10080], linewidth=1.0, color='navy') 
ax1.tick_params(labelsize=13) 
plt.plot([24, 24], [20, 50], 'k--', lw=1); plt.plot([48, 48], [20, 50], 'k--', lw=1); plt.plot([72, 72], [20, 50], 'k--', lw=1); plt.plot([96, 
96], [20, 50], 'k--', lw=1); plt.plot([120, 120], [20, 50], 'k--', lw=1); plt.plot([144, 144], [20, 50], 'k--', lw=1); 
plt.ylabel('Temperature ($^\circ$C)', fontsize=14); plt.xlabel('Zeitgeber Time (hours)', fontsize=14) 
#Titles 
ax0.set_title('KMO alb-cre - AP - Vehicle n=10', fontsize=14) 
ax1.set_title('KMO alb-cre - AP - GSK898 n=7', fontsize=14) 
#Dark phase panels in upper left subplot 
ax0.set_xticks([0, 24, 48, 72, 96, 120, 144, 168]) 
ax0.axvspan(6,18,color='k',alpha=0.2);ax0.axvspan(30,42,color='k',alpha=0.2);ax0.axvspan(54,66,color='k',alpha=0.2);ax




#Set upper subplot limits 
ax0.set_ylim(25.0,40.0); ax0.set_xlim(0,168) 
#Dark phase panels in upper middle subplot 
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#Set upper subplot limits 
ax1.set_ylim(25.0,40.0); ax1.set_xlim(0,168) 
sns.despine(top=False, right=False); plt.tight_layout() 
plt.savefig('Test001.png', dpi=600) 




6.3. Appendix 3 – G2 HR E-mitter in-house calibration 
E-mitter Waterbath temp. (oC) Mean E-mitter temp. (oC) [of 3] Difference (oC) 
EM03s 37.0 36.75 0.25 
EM04s 37.0 36.92 0.08  
EM06s 37.0 33.93 3.08 
EM09s 37.0 36.88 0.12 
Table 65. In-house calibration of Recalibration of G2 HR E-mitters 
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6.4. Appendix 4 – Clinical score sheet 
 
Figure 49. Clinical score sheet 
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6.5. Appendix 5 – Supplementary data of Model Optimization – Phase I 
  
Line ID Cohort Treatment Survival 




Other - WT ITGAX135 WT 3% TCA, 100 ul, 60s, U/F, G2HR Survived 168.00 P1 1 
Other - WT ITGAX136 WT 3% TCA, 100 ul, 60s, U/F, G2HR Lethal 22.53 P1 2 
Kmonull K1044 Kmonull 3% TCA, 100 ul, 60s, U/F, G2HR Lethal 50.92 P1 3 
Kmonull K1045 Kmonull 3% TCA, 100 ul, 60s, U/F, G2HR Lethal 21.50 P1 4 
Kmonull K1046 Kmonull 3% TCA, 100 ul, 60s, U/F, G2HR Survived 168.00 P1 5 
Kmonull K1047 Kmonull 3% TCA, 100 ul, 60s, U/F, G2HR Lethal 23.00 P1 6 
Kmowt K1052 Kmonull 3% TCA, 100 ul, 60s, U/F, G2HR Lethal 19.75 P1 7 
Kmowt K1053 Kmonull 3% TCA, 100 ul, 60s, U/F, G2HR Lethal 19.00 P1 8 
Kmowt K1050 Kmonull 3% TCA, 100 ul, 60s, U/F, G2HR Lethal 28.67 P1 9 
        Kmowt FK372 WT 0% TCA, 100 ul, 60s, U/F, G2HR Survived 168.00 P2 1 
Kmonull K1056 Kmonull 0% TCA, 100 ul, 60s, U/F, G2HR Survived 168.00 P2 2 
Kmonull K1059 Kmonull 0% TCA, 100 ul, 60s, U/F, G2HR Survived 168.00 P2 3 
Kmowt FK382 WT 0% TCA, 100 ul, 60s, U/F, G2HR Survived 168.00 P2 4 
Kmonull K1057 Kmonull 0% TCA, 100 ul, 60s, U/F, G2HR Survived 168.00 P2 5 
Kmowt FK374 WT 0% TCA, 100 ul, 60s, U/F, G2HR Survived 168.00 P2 6 
        Kmowt FK385 WT 1% TCA, 100 ul, 60s, U/F, G2HR Survived 168.00 P3 1 
Kmonull K1062 Kmonull 1% TCA, 100 ul, 60s, U/F, G2HR Survived 168.00 P3 2 
        Kmowt FK391 WT 1% TCA, 50 ul, 300s, U/F, G2HR Survived 72.00 P4 1 
Kmowt FK392 WT 1% TCA, 50 ul, 300s, U/F, G2HR Survived 72.00 P4 2 
        Kmowt FK393 WT 3% TCA, 50 ul, 300s, U/F, G2HR Survived 168.00 P5 1 
Kmowt FK394 WT 3% TCA, 50 ul, 300s, U/F, G2HR Lethal 48.73 P5 2 
Kmowt FK399 WT 3% TCA, 50 ul, 300s, U/F, G2HR Lethal 30.88 P5 3 
Kmowt FK402 WT 3% TCA, 50 ul, 300s, U/F, G2HR Lethal 94.43 P5 4 
Kmonull K1106 Kmonull 3% TCA, 50 ul, 300s, U/F, G2HR Lethal 35.58 P5 5 
Kmowt FK429 WT 3% TCA, 50 ul, 300s, U/F, G2HR Lethal 45.73 P5 6 
        Kmowt FK420 WT 2% TCA, 50 ul, 300s, U/F, G2HR Survived 168.00 P6 1 
Kmowt FK421 WT 2% TCA, 50 ul, 300s, U/F, G2HR Survived 168.00 P6 2 
        Kmowt FK434 WT 2.5% TCA, 50 ul, 300s, U/F, G2HR Lethal 23.18 P7 1 
Kmowt FK435 WT 2.5% TCA, 50 ul, 300s, U/F, G2HR Lethal 23.18 P7 2 
        Kmowt FK436 WT 2.5% TCA, 50 ul, 300s, Filt., G2HR Survived 168.00 P8 1 
Kmowt FK437 WT 2.5% TCA, 50 ul, 300s, Filt., G2HR Survived 168.00 P8 2 
Kmonull K1114 Kmonull 2.5% TCA, 50 ul, 300s, Filt., G2HR Lethal 26.70 P8 3 
Kmonull FK449 WT 2.5% TCA, 50 ul, 300s, Filt., G2HR Lethal 26.30 P8 4 
Kmoalb-cre [-/-] FKA126 WT 2.5% TCA, 50 ul, 300s, Filt., G2HR Lethal 47.00 P8 5 
Kmoalb-cre [-/-] FKA127 WT 2.5% TCA, 50 ul, 300s, Filt., G2HR Lethal 47.10 P8 6 
        Kmowt FK459 WT 2.0% TCA, 50 ul, 300s, Filt., G2HR Lethal 55.50 P9 1 
Kmowt FK460 WT 2.0% TCA, 50 ul, 300s, Filt., G2HR Lethal 21.62 P9 2 
Kmowt FK468 WT 2.0% TCA, 50 ul, 300s, Filt., G2HR Lethal 47.43 P9 3 
Kmowt FK473 WT 2.0% TCA, 50 ul, 300s, Filt., G2HR Lethal 70.08 P9 4 
Kmowt FK506 WT 2.0% TCA, 50 ul, 300s, Filt., G2HR Lethal 53.70 P9 5 
Kmowt FK507 WT 2.0% TCA, 50 ul, 300s, Filt., G2HR Survived 168.00 P9 6 
Table 66. Model optimization I. 
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6.6. Appendix 6 – Supplementary data of experiment 1 (cardiotelemeter study) 
 
Line ID Gene Sex DOB Date Age (d) Rx Telemeter Weight (g) Group Anaesthetic (min) 
Kmowt FK459 FK (HOM) M 23/06/15 11/11/15 141 AP EM-03s 28.63 WT/ AP 47 
Kmowt FK460 FK (HOM) M 23/06/15 11/11/15 141 AP EM-04s 29.35 WT / AP 44 
Kmowt FK468 FK (HOM) M 15/07/15 07/12/15 145 AP EM-03s 29.60 WT / AP 49 
Kmowt FK473 FK (HOM) M 15/07/15 07/12/15 145 AP EM-04s 27.84 WT / AP 43 
Kmowt FK506 FK (HOM) M 20/09/15 10/02/16 143 AP EM-09s 29.45 WT / AP 52 
Kmowt FK507 FK (HOM) M 20/09/15 10/02/16 143 AP EM-06s 28.28 WT / AP 38 
 
Kmowt FK508 FK (HOM) M 20/09/15 11/02/16 144 Sham EM-03s 27.90 WT / Sham 46 
Kmowt FK509 FK (HOM) M 20/09/15 11/02/16 144 Sham EM-04s 32.43 WT / Sham 47 
Kmowt FK520 FK (HOM) M 02/11/15 14/03/16 133 Sham EM-03s 31.65 WT / Sham 41 
Kmowt FK521 FK (HOM) M 02/11/15 14/03/16 133 Sham EM-04s 31.60 WT / Sham 43 
Kmoalb-cre FKA123 Cre(-) M 22/05/15 21/10/15 152 Sham EM-09s 29.56 WT / Sham 52 
Kmoalb-cre FKA128 Cre(-) M 22/05/15 21/10/15 152 Sham EM-06s 29.62 WT / Sham 48 
 
Kmonull K1140 HOM M 29/06/15 24/11/15 148 AP EM-09s 32.60 Null / AP 50 
Kmonull K1141 HOM M 29/06/15 24/11/15 148 AP EM-06s 31.75 Null / AP 46 
Kmonull K1166 HOM M 12/09/15 03/02/16 144 AP EM-03s 32.93 Null / AP 47 
Kmonull K1168 HOM M 12/09/15 03/02/16 144 AP EM-04s 29.57 Null / AP 42 
Kmonull K1191 HOM M 15/10/15 29/02/16 137 AP EM-03s 25.81 Null / AP 46 
Kmonull K1192 HOM M 15/10/15 29/02/16 137 AP EM-04s 30.11 Null / AP 45 
Table 67. Study subjects – experiment 1 
 
 
Line ID Group Exp. Length (h) Start Weight (g) End body weight (g) Weight loss (% start) 
Kmowt FK459 WT/ AP 55.5 28.63 25.02 12.609 
Kmowt FK460 WT / AP 21.6 29.35 28.90 1.533 
Kmowt FK468 WT / AP 47.4 29.60 25.19 14.899 
Kmowt FK473 WT / AP 70.1 27.84 24.67 11.386 
Kmowt FK506 WT / AP 53.7 29.45 26.53 9.915 
Kmowt FK507 WT / AP 168 28.28 25.91 8.380 
 
Kmowt FK508 WT / Sham 168 27.90 26.26 5.878 
Kmowt FK509 WT / Sham 168 32.43 29.03 10.484 
Kmowt FK520 WT / Sham 168 31.65 28.01 11.501 
Kmowt FK521 WT / Sham 168 31.60 29.30 7.278 
Kmoalb-cre FKA123 WT / Sham 168 29.56 29.46 0.338 
Kmoalb-cre FKA128 WT / Sham 168 29.62 27.97 5.571 
 
Kmonull K1140 Null / AP 168 32.60 31.55 3.221 
Kmonull K1141 Null / AP 45.12 31.75 28.27 10.961 
Kmonull K1166 Null / AP 168 32.93 27.84 15.457 
Kmonull K1168 Null / AP 168 29.57 26.22 11.329 
Kmonull K1191 Null / AP 168 25.81 22.87 11.391 
Kmonull K1192 Null / AP 168 30.11 24.79 17.669 
Table 68. Outcomes of study subjects 
Experiment length is 168 hours or less, where specified, due to mice reaching humane endpoint(s). The same scales 
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6.6. Appendix 6 – Supplementary data of experiment 1 (cardiotelemeter study). Cont. 
 














Kmowt FK459 WT/ AP 18.8 348 6960 <10 1.8 1420 12.0 
Kmowt FK460 WT / AP 20.2 694 18860 38 6.2 2760 24.2 
Kmowt FK468 WT / AP 18.4 508 3700 <10 0.6 5940 16.8 
Kmowt FK473 WT / AP 21.0 560 645 <10 4.0 3150 31.5 
Kmowt FK506 WT / AP 21.2 234 26140 <10 2.0 828 14.8 
Kmowt FK507 WT / AP 20.4 22 350 <10 10.6 120 6.8 
 
Kmowt FK508 WT / Sham 21.4 16 572 <10 9.2 128 7.4 
Kmowt FK509 WT / Sham 23.2 34 518 <10 14.2 198 6.2 
Kmowt FK520 WT / Sham 22.2 20 416 <10 12.0 120 6.2 
Kmowt FK521 WT / Sham 22.0 16 446 <10 13.2 120 7.8 
Kmoalb-cre FKA123 WT / Sham 23.0 32 584 <10 12.6 174 6.0 
Kmoalb-cre FKA128 WT / Sham 24.8 18 614 <10 10.8 136 7.4 
 
Kmonull K1140 Null / AP 25.0 16 618 <10 16.6 166 10.4 
Kmonull K1141 Null / AP 22.4 156 1184 14 0.8 1136 21.8 
Kmonull K1166 Null / AP 23.8 16 426 <10 13.0 180 5.2 
Kmonull K1168 Null / AP 22.0 14 414 <10 9.4 92 6.2 
Kmonull K1191 Null / AP 22.8 72 1194 <10 11.6 194 6.8 
Kmonull K1192 Null / AP 21.4 398 566 <10 6.2 456 6.4 
Table 69. Biochemistry from experiment 1 subjects 
 
 



















LOD =   0.350 
IL12p70 (pg/ml) 
LOD = 22.682 
KCGRO 
(pg/ml) 
LOD = 0.320 
TNFα (pg/ml) 
LOD = 0.147 
Kmowt FK459 WT/ AP 1.7568 10.7794 6.7511 0.4434 1.2149 5048.9452 535.4282 69.8694 333.3103 119.8801 
Kmowt FK460 WT / AP 2.2794 126.3120 24.9114 5.9961 25.7080 26810.9542 797.8872 865.2830 6515.7199 212.7989 
Kmowt FK468 WT / AP I/S I/S I/S I/S I/S I/S I/S I/S I/S I/S 
Kmowt FK473 WT / AP I/S I/S I/S I/S I/S I/S I/S I/S I/S I/S 
Kmowt FK506 WT / AP 6.0403 3.0918 1.9556 0.3182 0.8505 5779.2782 72.3329 28.1512 1056.4771 34.8871 
Kmowt FK507 WT / AP 1.2129 4.9766 1.7986 0.9273 9.9952 203.1203 29.1542 <22.682 49.3533 17.8667 
 
Kmowt FK508 WT / Sham 0.9293 1.7043 2.4496 0.1917 10.2532 43.8162 29.4185 42.9806 23.8182 12.9753 
Kmowt FK509 WT / Sham 0.9590 2.0161 3.1719 1.8408 11.1699 46.1513 23.0893 55.3155 33.5665 12.2347 
Kmowt FK520 WT / Sham 1.0280 2.3307 0.8824 0.3085 2.9311 120.6068 28.6132 <22.682 56.2881 12.5529 
Kmowt FK521 WT / Sham 0.7547 2.0833 1.5192 BLQ 11.1215 129.3931 28.2643 <22.682 37.9779 14.4455 
Kmoalb-cre FKA123 WT / Sham 0.6674 2.6588 1.6632 0.1029 3.1869 53.7508 28.1198 <22.682 32.5653 13.7827 
Kmoalb-cre FKA128 WT / Sham 0.5116 2.1682 1.0876 0.1819 6.0296 104.0456 20.1513 <22.682 45.2230 12.3750 
 
Kmonull K1140 Null / AP 0.8245 2.4331 1.8136 1.1120 6.4532 136.1978 22.1892 94.3316 45.2665 18.1821 
Kmonull K1141 Null / AP 6.1805 314.6119 43.2671 10.8707 21.4628 27107.5944 9169.6493 1213.8133 6521.2530 2611.0276 
Kmonull K1166 Null / AP 0.9279 2.9406 2.6171 0.7764 30.4867 84.4920 28.8176 <22.682 60.2789 23.5861 
Kmonull K1168 Null / AP 5.4861 1.0027 2.7404 <0.0558 10.3892 99.8789 29.2142 <22.682 17.7348 16.1200 
Kmonull K1191 Null / AP 0.1814 1.1456 0.3817 <0.0558 69.6805 89.5571 27.1922 <22.682 12.1530 12.7360 
Kmonull K1192 Null / AP 142.0417 1.6475 5.6905 <0.0558 5.2332 1321.7306 83.5197 <22.682 59.3600 105.4563 
Table 70. Cytokine panel from experiment 1 subjects 
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6.6. Appendix 6 – Supplementary data of experiment 1 (cardiotelemeter). Cont. 
 
Line ID Group IL1β 
(mmol/L) 
Log10 IL1β IL6 
(mmol/L) 
Log10 IL6 TNFα 
(mmol/L) 
Log10 TNFα 
Kmowt FK459 WT/ AP 10.7794 1.0325951 5048.9452 3.7032007 119.8801 2.078747 
Kmowt FK460 WT / AP 126.3120 2.1014446 26810.9541 4.4283123 212.7989 2.327969 
Kmowt FK468 WT / AP N/S N/S N/S N/S N/S N/S 
Kmowt FK473 WT / AP N/S N/S N/S N/S N/S N/S 
Kmowt FK506 WT / AP 3.0918 0.4902157 5779.2782 3.7618736 34.8871 1.542665 
Kmowt FK507 WT / AP 4.9766 0.6969334 203.1203 2.3077533 17.8667 1.252045 
 
Kmowt FK508 WT / Sham 1.7043 0.2315338 43.8162 1.6416351 12.9753 1.113119 
Kmowt FK509 WT / Sham 2.0161 0.3045085 46.1513 1.6641843 12.2347 1.087593 
Kmowt FK520 WT / Sham 2.3307 0.3674899 120.6068 2.0813719 12.5529 1.098743 
Kmowt FK521 WT / Sham 2.0833 0.3187541 129.3931 2.1119111 14.4455 1.159732 
Kmoalb-cre FKA123 WT / Sham 2.6588 0.4246881 53.7508 1.7303852 13.7827 1.139334 
Kmoalb-cre FKA128 WT / Sham 2.1682 0.3360961 104.0456 2.0172238 12.3750 1.092544 
 
Kmonull K1140 Null / AP 2.4331 0.3861596 136.1978 2.1341701 18.1821 1.259643 
Kmonull K1141 Null / AP 314.6119 2.4977751 27107.5944 4.4330909 2611.0280 3.416812 
Kmonull K1166 Null / AP 2.9406 0.4684302 84.4920 1.9268156 23.5862 1.372657 
Kmonull K1168 Null / AP 1.0027 0.0011697 99.8789 1.9994738 16.1200 1.207364 
Kmonull K1191 Null / AP 1.1456 0.0590417 89.5571 1.9520999 12.7360 1.105032 
Kmonull K1192 Null / AP 1.6475 0.2168167 1321.7306 3.1211431 105.4536 2.023073 
Table 71. Cytokines – Log10 from experiment 1 subjects 
Plasma proinflammatory cytokines. BLQ: below level of quantification; I/S: insufficient sample. 
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6.7. Appendix 7 – Supplementary data of experiment 2 (kynurenines at steady 
state) 
 
ID Group Sample 
ID 
KMO ct values Mean KMO ct 
(mKMO ct) 
S18 Ct values Mean S18 Ct 
value (mS18 ct) 
dCt (mKMO ct-
mS18 ct) 
dCt[NULL] ddCt (dCt – 
dCt[NULL]) 






17.1179715 8.955758 22.5210942 -13.5653362 12121.9670 4.08357310 





18.0070135 7.6467315 22.5210942 -14.8743627 30035.1178 4.47762934 





17.1941625 7.971991 22.5210942 -14.5491032 23972.6737 4.37971647 





17.0126565 8.1802045 22.5210942 -14.3408897 20750.9491 4.31703796 





18.0744515 6.6150675 22.5210942 -15.9060267 61403.2203 4.78819115 






17.652882 20.785214 22.5210942 -1.7358802 3.33082648 0.52255201 
L3B 38.11175 17.716984 
K1396 Null 




17.8583165 20.2096275 22.5210942 -2.3114667 4.96387470 0.69582081 





16.8018895 26.6517585 22.5210942 4.1306643 0.05708817 -1.2434539 










17.008682 23.2344325 22.5210942 0.7133383 0.60990722 -0.2147362 






18.0377530 17.3686710 22.5210942 -5.1524232 35.5659107 1.55103393 





19.4750715 17.9977525 22.5210942 -4.5233417 22.9964889 1.36166153 





17.0602005 18.1520485 22.5210942 -4.3690457 20.6639722 1.31521381 





17.4540815 18.8364135 22.5210942 -3.6846807 12.8587696 1.10919942 





17.6437880 18.1213935 22.5210942 -4.3997007 21.1077471 1.32444188 
L15B 36.385080 17.367723 
Table 72. Kmo gene expression by RT-PCR: Liver raw data. Corrected to Kmonull.  




Metabolic regulators of inflammation in acute pancreatitis                                                         S0897427 
Alastair J Hayes 
  - 226 -  
 
6.7. Appendix 7 – Supplementary data of experiment 2 (kynurenines at steady state). Cont. 
 
 
ID Group Sample 
ID 
KMO ct values Mean KMO ct 
(mKMO ct) 
S18 Ct values Mean S18 Ct 




dCt of NULL 
ddCt (dCt – 
dCt[NULL]) 






17.3015385 9.0823155 23.9648602 -14.8825447 30205.9408 4.48009237 





16.3022535 10.0733610 23.9648602 -13.8914992 15197.0028 4.18175794 





15.1056265 10.9002065 23.9648602 -13.0646537 8567.47107 3.93285265 





18.5983265 7.2723220 23.9648602 -16.6925382 105914.325 5.0249547 





16.3112485 10.3360765 23.9648602 -13.6287837 12666.9687 4.10267270 
K13B 26.513968 16.009422 
 
K1395 Null 
K3A >45 Undet. 
(T/hold = 45) 
19.73155 
18.448718 26.551282 23.9648602 2.5864218 0.16649817 -0.7785905 
K3B >45 17.165886 
K1396 Null 
K6A >45 Undet. 
(T/hold = 45) 
23.664488 
22.937664 22.062336 23.9648602 -1.9025242 3.73866758 0.57271685 
K6B >45 22.21084 
K1399 Null 
K7A >45 Undet. 
(T/hold = 45) 
22.224007 
21.5975945 23.4024055 23.9648602 -0.5624547 1.47677977 0.16931574 





16.4332255 24.4647755 23.9648602 0.4999153 0.70714830 -0.1504895 
K8B 41.210358 16.052177 
K1408 Null 
K14A >45 Undet. 
(T/hold = 45) 
22.660158 
21.656498 23.343502 23.9648602 -0.6213582 1.53832273 0.18704746 






15.1845165 12.4767185 23.9648602 -11.4881417 2872.6006 3.45827525 





15.2441345 11.1334775 23.9648602 -12.8313827 7288.38119 3.86263108 





15.464157 10.3153740 23.9648602 -13.6494862 12850.0486 4.10890477 





19.565133 6.2419105 23.9648602 -17.7229497 216341.318 5.33513947 





16.999927 10.256006 23.9648602 -13.7088542 13389.8688 4.12677632 
K15B 26.502188 15.935304 
Table 73. Kmo gene expression by RT-PCR: Kidney raw data. Corrected to Kmonull 
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6.7. Appendix 7 – Supplementary data of experiment 2 (kynurenines at steady state). Cont. 
 
ID Group Sample 
ID 
KMO ct values Mean KMO ct 
(mKMO ct) 
S18 Ct values Mean S18 Ct 




dCt of WT 
ddCt (dCt – 
dCt[WT]) 






14.818042 16.917557 27.9364357 -11.0188787 2074.97566 3.31701301 





14.9070865 15.044646 27.9364357 -12.8917897 7600.03159 3.88081540 
S4B 29.907873 14.54936 
FK640 WT 




18.5010165 11.6609695 27.9364357 -16.2754662 79323.8016 4.89940352 





18.167251 11.9635625 27.9364357 -15.9728732 64315.2482 4.80831395 





16.886976 12.614528 27.9364357 -15.3219077 40959.4210 4.61235381 
S13B 29.51845 16.739962 
 
K1395 Null 
S3A >45 Undet. 
(T/hold = 45) 
14.212608 
14.2057995 30.7942005 27.9364357 2.8577648 0.13795171 -0.8602729 
S3B >45 14.198991 
K1396 Null 
S6A >45 Undet. 
(T/hold = 45) 
16.199295 
16.3192875 28.6807125 27.9364357 0.7442768 0.59696705 -0.2240496 
S6B >45 16.43928 
K1399 Null 
S7A >45 Undet. 
(T/hold = 45) 
17.473673 
17.3311845 27.6688155 27.9364357 -0.2676202 1.20382042 0.08056171 
S7B >45 17.188696 
K1405 Null 
S8A >45 Undet. 
(T/hold = 45) 
19.552778 
19.912213 25.087787 27.9364357 -2.8486487 7.20325361 0.85752871 
S8B >45 20.271648 
K1408 Null 
S14A >45 Undet. 
(T/hold = 45) 
17.55173 
17.549337 27.450663 27.9364357 -0.4857727 1.40033568 0.14623215 






15.1862795 15.5184975 27.9364357 -12.4179382 5472.325 3.73817188 





15.6481855 12.6172355 27.9364357 -15.3192002 40882.6247 4.61153877 







12.499159 27.9364357 -15.4372767 44369.3777 4.64708334 





16.4892475 12.693294 27.9364357 -15.2431417 38783.1321 4.58864288 





17.7780685 12.670562 27.9364357 -15.2658737 39399.063 4.59548589 
S15B 30.072289 17.183916 
Table 74. Kmo gene expression by RT-PCR: Spleen raw data. Corrected to Kmowt 
Experiment 2 subjects.  
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6.7. Appendix 7 – Supplementary data of experiment 2 (kynurenines at steady state). Cont. 
 
Line ID Gene Sex DOB Cull Age Group Liver Kidney Spleen 
Kmowt FK638 FK (HOM) M 29/10/16 08/02/17 102 WT 4.083573097 4.480092367 3.317013007 
Kmowt FK639 FK (HOM) M 29/10/16 08/02/17 102 WT 4.477629339 3.932852647 3.880815397 
Kmowt FK640 FK (HOM) M 29/10/16 14/02/17 108 WT 4.379716473 5.024954702 4.89940352 
Kmowt FK641 FK (HOM) M 29/10/16 14/02/17 108 WT 4.317037964 4.181757944 4.80831395 
Kmoalb-cre FKA385 Cre(-) M 30/11/16 14/02/17 108 WT 4.788191149 4.102672698 4.612353808 
           
Kmonull K1395 HOM M 28/10/16 08/02/17 103 Null 0.522552009 -0.778590543 -0.860272925 
Kmonull K1396 HOM M 28/10/16 08/02/17 103 Null 0.695820811 0.572716852 -0.224049642 
Kmonull K1399 HOM M 16/11/16 14/02/17 90 Null -1.243453856 0.169315736 0.080561708 
Kmonull K1405 HOM M 16/11/16 14/02/17 90 Null 0.239817262 -0.150489501 0.857528706 
Kmonull K1408 HOM M 16/11/16 14/02/17 90 Null -0.214736225 0.187047456 0.146232154 
           
Kmoalb-cre A355 Cre(+) M 24/10/19 08/02/17 107 Alb-cre 1.551033934 3.458275246 3.738171883 
Kmoalb-cre A356 Cre(+) M 24/10/19 08/02/17 107 Alb-cre 1.361661532 3.862631079 4.61153877 
Kmoalb-cre A363 Cre(+) M 10/11/16 14/02/17 96 Alb-cre 1.315213808 4.108904772 4.647083338 
Kmoalb-cre A364 Cre(+) M 10/11/16 14/02/17 96 Alb-cre 1.109199415 5.335139471 4.58864288 
Kmoalb-cre A365W Cre(+) M 10/11/16 14/02/19 96 Alb-cre 1.324441883 4.126776320 4.595485894 






















Kmowt FK491 FK (HOM) M 20/08/15 11/01/16 144 WT 100.659 7.149 0.067 0.193 BLQ 0.340 
Kmowt FK515 FK (HOM) M 04/10/15 15/02/16 134 WT 130.970 1.931 0.069 0.190 BLQ 0.302 
Kmoalb-cre FKA173 Cre (-) M 12/11/15 24/03/16 133 WT 138.466 3.008 0.070 0.235 BLQ 0.296 
Kmoalb-cre FKA174 Cre (-) M 12/11/15 24/03/16 133 WT 108.399 2.855 0.163 0.220 BLQ 0.349 
Kmoalb-cre FKA194 Cre (-) M 27/12/15 18/05/16 143 WT 95.944 2.829 0.174 0.188 BLQ 0.395 
Kmowt FK529 FK (HOM) M 02/01/16 12/07/19 192 WT 108.671 2.199 0.172 0.209 BLQ 0.376 
 
Kmonull K1153 HOM M 17/08/15 11/01/16 147 Null 102.040 32.169 10.624 2.369 BLQ 0.152 
Kmonull K1163 HOM M 27/08/15 11/01/16 137 Null 101.735 66.043 22.276 5.020 BLQ 0.109 
Kmonull K1184 HOM M 13/10/15 07/03/16 146 Null 124.350 79.267 9.747 4.309 BLQ 0.119 
Kmonull K1195 HOM M 15/10/15 07/03/16 144 Null 80.512 86.973 16.821 4.952 BLQ 0.084 
Kmonull K1196 HOM M 15/10/15 07/03/16 144 Null 81.072 48.035 10.878 2.304 BLQ 0.074 
Kmonull K1226 HOM M 27/01/16 30/06/16 155 Null 91.553 55.752 17.849 2.998 BLQ 0.082 
  
Kmoalb-cre A166 Cre (+) M 05/09/15 15/04/16 233 Alb-cre 91.063 31.912 7.047 3.032 1.173 1.283 
Kmoalb-cre A172 Cre (+) M 12/11/15 24/03/16 133 Alb-cre 100.025 23.559 4.828 2.465 0.923 1.711 
Kmoalb-cre A193 Cre (+) M 27/12/15 18/04/16 113 Alb-cre 97.126 33.379 7.928 3.090 1.643 1.676 
Kmoalb-cre A210 Cre (+) M 09/02/16 30/06/16 142 Alb-cre 104.897 20.056 3.028 2.970 0.230 0.678 
Kmoalb-cre A224 Cre (+) M 28/02/16 27/07/16 150 Alb-cre 76.022 23.296 9.736 2.066 0.614 0.837 
Kmoalb-cre A225 Cre (+) M 28/02/16 27/07/16 150 Alb-cre 96.036 16.775 2.952 1.604 0.531 0.739 
Table 76. Steady state concentrations of kynurenine metabolites 
Columns indicate which mouse line mice were derived from, arbitrary ID, genotype, sex, body weight, age at cull, experimental group, 
and plasma concentration of analyte according to LC-MS/MS analysis. Abbreviations: 3HK: 3-hydroxykynurenine; AA: anthranilic acid; 
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6.7. Appendix 7 – Supplementary data of experiment 2 (kynurenines at steady state). Cont. 
 
Line ID Group D5-TRP (μM) D4-KYN (PAU) 13C6-3HK (μM) 13C6-XA (PAU) 
Kmowt FK491 WT 0.702045302 14369 0.116826693 368300 
Kmowt FK515 WT 0.72675141 32786 BLQ 321869 
Kmoalb-cre FKA173 WT 0.578992641 21110 BLQ 197558 
Kmoalb-cre FKA174 WT 1.033833509 56875 0.426988747 421688 
Kmoalb-cre FKA194 WT 1.925881678 29603 0.141156536 305167 
KMOwt FK529 WT 0.591035076 40869 0.078898206 382113 
 
Kmonull K1153 Null 0.548886553 1032544 0.085154451 501032 
Kmonull K1163 Null 0.560021026 1525039 0.258070122 657516 
Kmonull K1184 Null 0.791264456 2150600 0.553938393 901618 
Kmonull K1195 Null 0.873411068 2018067 0.235434679 997133 
Kmonull K1196 Null 0.474816018 1874645 BLQ 940961 
Kmonull K1226 Null 1.025279557 1888389 0.249511231 739837 
 
Kmoalb-cre A166 Alb-cre 0.801060881 757101 1.044141287 522774 
Kmoalb-cre A172 Alb-cre 1.283857402 1177993 1.230742495 368609 
Kmoalb-cre A193 Alb-cre 0.924448055 946110 0.981144372 595663 
Kmoalb-cre A210 Alb-cre 0.504253082 671717 0.52183169 366370 
Kmoalb-cre A224 Alb-cre 0.64063844 679186 0.606855802 553134 
Kmoalb-cre A225 Alb-cre 1.268469846 1101418 0.976408741 361585 
Table 77. Tracer metabolites in tracer study 
Columns indicate which mouse line mice were derived from, arbitrary ID, experimental group, and plasma concentration of 
analyte or peak area units (PAU) according to LC-MS/MS analysis. Abbreviations: 13C6-3HK: 13C6-3-hydroxykynurenine; 
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6.8. Appendix 8 – Supplementary data of Model Optimization – Phase II 
 
Line ID Gene Sex DOB Date Age (d) Rx Telemeter Weight Group Anaesthetic 
(min) 
Kmowt FK502 FK (HOM) M 20/09/15 09/02/16 142 Sham EM-22 28.84 Pill 37 
Kmoalb-cre FKA180 Cre(-) M 19/12/15 20/04/16 123 Sham EM-22 28.40 Pill 31 
Kmowt FK534 FK (HOM) M 03/01/16 31/05/16 149 Sham EM-23 27.12 Pill 37 
Kmowt FK535 FK (HOM) M 03/01/16 31/05/16 149 Sham EM-21 29.58 Pill 27 
Kmoalb-cre FKA205 Cre(-) M 28/01/16 16/06/16 140 Sham EM-24 27.04 Pill 36 
Kmowt FK545 FK (HOM) M 12/02/16 23/06/16 132 Sham EM-25 27.85 Pill 34 
 
Kmoalb-cre FKA123 Cre(-) M 22/05/15 21/10/15 152 Sham EM-09s 29.56 HR 52 
Kmoalb-cre FKA128 Cre(-) M 22/05/15 21/10/15 152 Sham EM-06s 29.62 HR 48 
Kmowt FK508 FK (HOM) M 20/09/15 11/02/16 144 Sham EM-03s 27.90 HR 46 
Kmowt FK509 FK (HOM) M 20/09/15 11/02/16 144 Sham EM-04s 32.43 HR 47 
Kmowt FK520 FK (HOM) M 02/11/15 14/03/16 133 Sham EM-03s 31.65 HR 41 
Kmowt FK521 FK (HOM) M 02/11/15 14/03/16 133 Sham EM-04s 31.60 HR 43 
Table 78. Model optimization II - Study subjects 
Pilot work testing recovery telemetry profiles in cardiometabolic telemetered versus mini-pill telemetered mice. 
 
Line ID Group Exp. Length (h) Weight (g) End body weight (g) Weight loss (% start) 
Kmowt FK502 Pill 180 28.84 29.54 2.427 
Kmoalb-cre FKA180 Pill 180 28.40 26.94 5.141 
Kmowt FK534 Pill 180 27.12 25.18 7.153 
Kmowt FK535 Pill 180 29.58 26.86 9.195 
Kmoalb-cre FKA205 Pill 180 27.04 25.70 4.956 
Kmowt FK545 Pill 180 27.85 25.23 9.408 
 
Kmoalb-cre FKA123 HR 180 29.56 29.46 0.338 
Kmoalb-cre FKA128 HR 180 29.62 27.97 5.571 
Kmowt FK508 HR 180 27.90 26.26 5.878 
Kmowt FK509 HR 180 32.43 29.03 10.484 
Kmowt FK520 HR 180 31.65 28.01 11.501 
Kmowt FK521 HR 180 31.60 29.30 7.278 
Table 79. Model optimization II - Outcomes of study subjects (survival and weight loss) 
Experiment length is 168 hours or less, where specified, due to mice reaching humane endpoint(s). 
 
Line ID Group Total activity (counts) Telemeter 
Kmowt FK502 Pill 116840 EM-22 
Kmoalb-cre FKA180 Pill 135839 EM-22 
Kmowt FK534 Pill 152427 EM-23 
Kmowt FK535 Pill 142834 EM-21 
Kmoalb-cre FKA205 Pill 138721 EM-24 
Kmowt FK545 Pill 154782 EM-25 
     
Kmoalb-cre FKA123 Cardio-telemeter 83679 EM-09s 
Kmoalb-cre FKA128 Cardio-telemeter 82980 EM-06s 
Kmowt FK508 Cardio-telemeter 83375 EM-03s 
Kmowt FK509 Cardio-telemeter 91527 EM-04s 
Kmowt FK520 Cardio-telemeter 115905 EM-03s 
Kmowt FK521 Cardio-telemeter 114507 EM-04s 
Table 80. Model optimization II – Outcomes of study subjects (telemetry) 
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6.9. Appendix 9 – Supplementary data of experiment 3 (Kmoalb-cre) 
 
Line ID Gene Sex DOB Date Age 
(d) 





Kmowt FK502 FK (HOM) M 20/09/15 09/02/16 142 Sham EM-22 28.84 WT / Sham 37  
Kmowt FK503 FK (HOM) M 20/09/15 09/02/16 142 AP EM-21 29.10 WT/ AP 38  
Kmowt FK504 FK (HOM) M 20/09/15 09/02/16 142 AP EM-23 31.18 WT/ AP 35  
Kmoalb-cre FKA177 Cre(-) M 19/12/15 20/04/16 123 AP EM-24 29.12 WT/ AP 32  
Kmoalb-cre FKA179 Cre(-) M 19/12/15 20/04/16 123 AP EM-23 29.68 WT/ AP 38  
Kmoalb-cre FKA180 Cre(-) M 19/12/15 20/04/16 123 Sham EM-22 28.40 WT/ Sham 31  
Kmowt FK534 FK (HOM) M 03/01/16 31/05/16 149 Sham EM-23 27.12 WT/ Sham 37  
Kmowt FK535 FK (HOM) M 03/01/16 31/05/16 149 Sham EM-21 29.58 WT/ Sham 27  
Kmowt FK536 FK (HOM) M 03/01/16 31/05/16 149 AP EM-24 30.15 WT/ AP 38  
Kmowt FK537 FK (HOM) M 03/01/16 31/05/16 149 AP EM-22 28.70 WT/ AP 30  
Kmoalb-cre FKA202 Cre(-) M 28/01/16 16/06/16 140 AP EM-21 26.77 WT/ AP 36  
Kmoalb-cre FKA205 Cre(-) M 28/01/16 16/06/16 140 Sham EM-24 27.04 WT/ Sham 36  
Kmowt FK544 FK (HOM) M 12/02/16 23/06/16 132 AP EM-26 26.47 WT/ AP 35  
Kmowt FK545 FK (HOM) M 12/02/16 23/06/16 132 Sham EM-25 27.85 WT/ Sham 34  
Kmoalb-cre FKA229 Cre(-) M 28/02/16 01/08/16 155 Sham EM-24 29.04 WT/ Sham 29  
Kmoalb-cre FKA230 Cre(-) M 28/02/16 01/08/16 155 AP 27.86 27.86 WT/ AP 31  
             Kmonull K1179 KMO (HOM) M 13/10/15 03/03/16 142 AP EM-22 33.20 Null/ AP 35  
Kmonull K1180 KMO (HOM) M 13/10/15 03/03/16 142 Sham EM-23 31.58 Null/ Sham 35  
Kmonull K1181 KMO (HOM) M 13/10/15 03/03/16 142 AP EM-21 33.38 Null/ AP 37  
Kmonull K1216 KMO (HOM) M 25/01/16 01/06/16 128 Sham EM-26 29.15 Null/ Sham 34  
Kmonull K1217 KMO (HOM) M 25/01/16 01/06/16 128 AP EM-25 dna Null/ AP 33.    
Kmonull K1222 KMO (HOM) M 27/01/16 01/06/16 126 AP EM-27 30.85 Null/ AP 30  
Kmonull K1223 KMO (HOM) M 27/01/16 01/06/16 126 Sham EM-28 32.18 Null/ Sham 29  
Kmonull K1224 KMO (HOM) M 27/01/16 16/06/16 141 Sham EM-22 32.63 Null/ Sham 33  
Kmonull K1225 KMO (HOM) M 27/01/16 16/06/16 141 AP EM-23 31.93 Null/ AP 31  
Kmonull K1246 KMO (HOM) M 09/03/16 28/07/16 141 AP EM-27 31.41 Null/ AP 35  
Kmonull K1247 KMO (HOM) M 09/03/16 28/07/16 141 Sham EM-26 30.34 Null/ Sham 35  
Kmonull K1248 KMO (HOM) M 09/03/16 28/07/16 141 AP EM-25 31.40 Null/ AP 32  
Kmonull K1261 KMO (HOM) M 17/04/16 08/09/16 144 AP EM-21 32.38 Null/ AP 30  
Kmonull K1262 KMO (HOM) M 17/04/16 08/09/16 144 AP EM-26 32.20 Null/ AP 28  
Kmonull K1263 KMO (HOM) M 17/04/16 08/09/16 144 Sham EM-24 31.47 Null/ Sham 28  
Kmonull K1264 KMO (HOM) M 17/04/16 08/09/16 144 Sham EM-22 33.84 Null/ Sham 30  
             Kmoalb-cre A226 Cre(+) M 28/02/16 01/08/16 155 AP EM-22 26.59 Acre/ AP 32  
Kmoalb-cre A227 Cre(+) M 28/02/16 01/08/16 155 Sham EM-23 27.36 Acre/ Sham 31  
Kmoalb-cre A234 Cre(+) M 21/03/16 02/08/16 134 Sham EM-28 30.55 Acre/ Sham 31  
Kmoalb-cre A235 Cre(+) M 21/03/16 02/08/16 134 AP EM-25 29.76 Acre/ AP 32  
Kmoalb-cre A238 Cre(+) M 04/04/16 16/08/16 134 AP EM-22 31.41 Acre/ AP 31  
Kmoalb-cre A241 Cre(+) M 06/04/16 16/08/16 132 AP EM-23 29.89 Acre/ AP 31  
Kmoalb-cre A243 Cre(+) M 06/04/16 16/08/16 132 Sham EM-21 27.60 Acre/ Sham 29  
Kmoalb-cre A244 Cre(+) M 06/04/16 17/08/16 133 AP EM-24 28.43 Acre/ AP 32  
Kmoalb-cre A246 Cre(+) M 06/04/16 17/08/16 133 AP EM-26 28.01 Acre/ AP 29  
Kmoalb-cre A252 Cre(+) M 09/04/16 17/08/16 130 Sham EM-25 27.37 Acre/ Sham 30  
Kmoalb-cre A253 Cre(+) M 09/04/16 30/08/16 143 Sham EM-24 28.00 Acre/ Sham 30  
Kmoalb-cre A265 Cre(+) M 16/04/16 30/08/16 136 AP EM-22 27.25 Acre/ AP 34  
Kmoalb-cre A270 Cre(+) M 16/04/16 30/08/16 136 Sham EM-21 27.93 Acre/ Sham 36  
Kmoalb-cre A272 Cre(+) M 16/04/16 30/08/16 136 AP EM-23 28.85 Acre/ AP 35  
Kmoalb-cre A280 Cre(+) M 29/04/16 06/09/16 130 AP EM-23 29.00 Acre/ AP 35  
Kmoalb-cre A281 Cre(+) M 29/04/16 06/09/16 130 AP EM-22 28.72 Acre/ AP 31  
Kmoalb-cre A282 Cre(+) M 29/04/16 06/09/16 130 Sham EM-25 29.54 Acre/ Sham 33  
Table 81. Study subjects – experiment 3 
dna.: data not available. Subject K1217 was excluded as it was found to have a bile leak from the suture line and therefore critical 










Metabolic regulators of inflammation in acute pancreatitis                                                         S0897427 
Alastair J Hayes 
  - 232 -  
 
6.9. Appendix 9 – Supplementary data of experiment 3 (Kmoalb-cre). Cont. 
 
Line ID Group Exp. Length (h) Start Weight (g) End body weight (g) Weight loss (% start) 
Kmowt FK502 WT / Sham 168.0 28.84 29.54 Gain 2.427 
Kmowt FK503 WT/ AP 168.0 29.10 27.57 5.258 
Kmowt FK504 WT/ AP 168.0 31.18 25.65 17.736 
Kmoalb-cre FKA177 WT/ AP 168.0 29.12 25.96 10.852 
Kmoalb-cre FKA179 WT/ AP 168.0 29.68 22.16 25.337 
Kmoalb-cre FKA180 WT/ Sham 168.0 28.40 26.94 5.141 
Kmowt FK534 WT/ Sham 168.0 27.12 25.18 7.153 
Kmowt FK535 WT/ Sham 168.0 29.58 26.86 9.195 
Kmowt FK536 WT/ AP 168.0 30.15 26.82 11.045 
Kmowt FK537 WT/ AP 168.0 28.70 26.81 6.585 
Kmoalb-cre FKA202 WT/ AP 168.0 26.77 24.07 10.086 
Kmoalb-cre FKA205 WT/ Sham 168.0 27.04 25.70 4.956 
Kmowt FK544 WT/ AP 168.0 26.47 20.98 20.740 
Kmowt FK545 WT/ Sham 168.0 27.85 25.23 9.408 
Kmoalb-cre FKA229 WT/ Sham 168.0 29.04 27.76 4.408 
Kmoalb-cre FKA230 WT/ AP 168.0 27.86 23.06 17.229 
 
Kmonull K1179 Null/ AP 168.0 33.20 31.80 4.217 
Kmonull K1180 Null/ Sham 168.0 31.58 29.72 5.890 
Kmonull K1181 Null/ AP 168.0 33.38 31.88 4.494 
Kmonull K1216 Null/ Sham 168.0 29.15 26.82 7.993 
Kmonull K1217 Null/ AP 23.5 29.15 28.82 1.132 
Kmonull K1222 Null/ AP 168.0 30.85 25.48 17.407 
Kmonull K1223 Null/ Sham 168.0 32.18 29.71 7.676 
Kmonull K1224 Null/ Sham 168.0 32.63 32.65 Gain 0.061  
Kmonull K1225 Null/ AP 168.0 31.93 30.90 3.226 
Kmonull K1246 Null/ AP 168.0 31.41 28.70 8.628 
Kmonull K1247 Null/ Sham 168.0 30.34 28.64 5.603 
Kmonull K1248 Null/ AP 93.1 31.40 26.82 14.586 
Kmonull K1261 Null/ AP 168.0 32.38 31.15 3.799 
Kmonull K1262 Null/ AP 168.0 32.20 29.13 9.534 
Kmonull K1263 Null/ Sham 168.0 31.47 30.65 2.606 
Kmonull K1264 Null/ Sham 168.0 33.84 32.17 4.935 
 
Kmoalb-cre A226 Acre/ AP 28.9 26.59 24.67 7.221 
Kmoalb-cre A227 Acre/ Sham 168.0 27.36 26.16 4.386 
Kmoalb-cre A234 Acre/ Sham 168.0 30.55 27.19 10.998 
Kmoalb-cre A235 Acre/ AP 46.5 29.76 27.92 6.183 
Kmoalb-cre A238 Acre/ AP 168.0 31.41 22.98 26.839 
Kmoalb-cre A241 Acre/ AP 168.0 29.89 28.47 4.751 
Kmoalb-cre A243 Acre/ Sham 168.0 27.60 26.66 3.406 
Kmoalb-cre A244 Acre/ AP 168.0 28.43 24.10 15.230 
Kmoalb-cre A246 Acre/ AP 48.0 28.01 25.11 10.353 
Kmoalb-cre A252 Acre/ Sham 168.0 27.37 25.32 7.490 
Kmoalb-cre A253 Acre/ Sham 168.0 28.00 26.75 4.464 
Kmoalb-cre A265 Acre/ AP 22.8 27.25 27.68 Gain 1.578 
Kmoalb-cre A270 Acre/ Sham 168.0 27.93 25.07 10.240 
Kmoalb-cre A272 Acre/ AP 47.9 28.85 25.44 11.820 
Kmoalb-cre A280 Acre/ AP 168.0 29.00 27.22 6.138 
Kmoalb-cre A281 Acre/ AP 29.2 28.72 28.97 Gain 0.870 
Kmoalb-cre A282 Acre/ Sham 168.0 29.54 27.94 5.416 
Table 82. Outcomes of study subjects – experiment 3 (survival and weight loss) 
Experiment length is 168 hours or less, where specified, due to mice reaching humane endpoint(s). The same scales 
instrument was used for every measurement. Subject K1217 was found to have a bile leak from the suture line and 
therefore critical illness attributed to surgical failure and biliary peritonitis – however, it was not excluded in line with 
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6.9. Appendix 9 – Supplementary data of experiment 3 (Kmoalb-cre). Cont. 
 












Kmowt FK502 WT / Sham 168.0 618 18 7.5 168 26.3 12.8 
Kmowt FK503 WT/ AP 168.0 618 38 6.5 133 26.0 13.3 
Kmowt FK504 WT/ AP 168.0 515 105 10.0 235 26.8 11.3 
Kmoalb-cre FKA177 WT/ AP 168.0 998 33 8.5 208 26.8 14.0 
Kmoalb-cre FKA179 WT/ AP 168.0 710 63 19.8 620 24.0 8.0 
Kmoalb-cre FKA180 WT/ Sham 168.0 605 20 7.0 165 28.5 13.8 
Kmowt FK534 WT/ Sham 168.0 598 28 5.8 130 29.0 14.8 
Kmowt FK535 WT/ Sham 168.0 650 13 10.5 140 30.3 13.8 
Kmowt FK536 WT/ AP 168.0 505 13 6.5 165 27.0 16.8 
Kmowt FK537 WT/ AP 168.0 738 15 9.3 173 27.5 12.0 
Kmoalb-cre FKA202 WT/ AP 168.0 983 538 5.3 780 26.5 15.3 
Kmoalb-cre FKA205 WT/ Sham 168.0 583 40 7.0 150 28.3 14.3 
Kmowt FK544 WT/ AP 168.0 85175 1678 6.5 2885 29.0 11.8 
Kmowt FK545 WT/ Sham 168.0 3575 58 6.8 265 29.0 13.5 
Kmoalb-cre FKA229 WT/ Sham 168.0 513 28 6.0 130 27.8 11.5 
Kmoalb-cre FKA230 WT/ AP 168.0 6075 1500 5.8 2250 27.3 7.8 
 
Kmonull K1179 Null/ AP 168.0 613 48 8.5 180 28.0 13.5 
Kmonull K1180 Null/ Sham 168.0 628 33 8.8 153 30.5 15.0 
Kmonull K1181 Null/ AP 168.0 555 30 8.0 263 31.3 15.3 
Kmonull K1216 Null/ Sham 168.0 468 20 5.8 133 28.5 18.5 
Kmonull K1217 Null/ AP 23.5 26525 135 33.5 1463 33.8 5.3 
Kmonull K1222 Null/ AP 168.0 2085 83 7.5 225 26.0 6.3 
Kmonull K1223 Null/ Sham 168.0 475 13 6.5 118 27.8 11.3 
Kmonull K1224 Null/ Sham 168.0 570 23 7.0 148 26.8 11.3 
Kmonull K1225 Null/ AP 168.0 568 15 6.8 150 27.8 16.0 
Kmonull K1246 Null/ AP 168.0 603 15 7.3 140 27.5 13.0 
Kmonull K1247 Null/ Sham 168.0 560 20 9.0 163 30.3 14.8 
Kmonull K1248 Null/ AP 93.1 I/S I/S I/S I/S I/S I/S 
Kmonull K1261 Null/ AP 168.0 663 23 7.8 215 28.0 16.5 
Kmonull K1262 Null/ AP 168.0 3100 350 6.0 625 26.5 19.8 
Kmonull K1263 Null/ Sham 168.0 683 20 7.3 145 29.5 12.0 
Kmonull K1264 Null/ Sham 168.0 485 18 6.0 108 27.0 13.5 
 
Kmoalb-cre A226 Acre/ AP 28.9 7325 603 37.3 2383 25.8 3.0 
Kmoalb-cre A227 Acre/ Sham 168.0 755 40 6.8 235 28.5 15.8 
Kmoalb-cre A234 Acre/ Sham 168.0 623 23 7.3 128 29.8 15.5 
Kmoalb-cre A235 Acre/ AP 46.5 I/S I/S I/S I/S I/S I/S 
Kmoalb-cre A238 Acre/ AP 168.0 5275 248 8.3 508 19.3 4.0 
Kmoalb-cre A241 Acre/ AP 168.0 673 35 6.5 138 26.0 16.5 
Kmoalb-cre A243 Acre/ Sham 168.0 563 23 6.5 315 26.3 17.3 
Kmoalb-cre A244 Acre/ AP 168.0 67325 25 9.0 328 23.0 10.3 
Kmoalb-cre A246 Acre/ AP 48.0 I/S I/S I/S I/S I/S I/S 
Kmoalb-cre A252 Acre/ Sham 168.0 1773 20 5.8 135 26.5 17.3 
Kmoalb-cre A253 Acre/ Sham 168.0 850 20 5.8 185 27.3 15.5 
Kmoalb-cre A265 Acre/ AP 22.8 50050 233 28.5 3045 18.5 15.8 
Kmoalb-cre A270 Acre/ Sham 168.0 1870 30 7.3 258 28.3 13.8 
Kmoalb-cre A272 Acre/ AP 47.9 28025 928 21.8 2233 21.3 15.3 
Kmoalb-cre A280 Acre/ AP 168.0 1293 43 7.3 293 28.0 16.0 
Kmoalb-cre A281 Acre/ AP 29.2 13850 293 37.0 245 35.5 3.0 
Kmoalb-cre A282 Acre/ Sham 168.0 663 23 6.8 193 25.8 7.5 
Table 83. Outcomes of study subjects – experiment 3 (biochemistry at end point) 
Experiment length is 168 hours or less, where specified, due to mice reaching humane endpoint(s). The same scales 
instrument was used for every measurement. Subject K1217 was excluded as it was found to have a bile leak from 
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6.9. Appendix 9 – Supplementary data of experiment 3 (Kmoalb-cre). Cont. 
Group Rx Total group 
time (hrs) 
Total s.c. dose / 
group 
s.c. dose (x105) / 
exp time / group 
Total oral dose 
(0.01 mg) 
Oral dose (x103) / 
exp time / group 
Kmowt Sham 7 * 168 = Total = 1176 
FK502 = 0.0015mg*3 
FKA180 = 0.0015mg*3 
FK534 = 0.0015mg*3 
FK535 = 0.0015mg*3 
FKA205= 0.00125mg*3 
FK545 = 0.0015mg*3 
FKA229 = 0.0015mg*3 
Total = 0.03075 mg 
0.03075 x105 / 1176 = 
= 2.6147959 
1.FK502 = 7eaten 
2.FKA180 = 7eaten 
3.FK534 = 7eaten 
4.FK535 = 7eaten 
5.FKA205 = 7eaten 
6.FK545 = 4eaten 
7.FKA229 = 7eaten 
Total = 46 
 
Kmowt AP 9 * 168 = Total = 1512 
FK503 = 0.0015mg*3 
FK504 = 0.0015mg*3 
FKA177 = 0.0015mg*4 
FKA179 = 0.0015mg*4 
FK536 = 0.0015mg*3 
FK537 = 0.0015mg*3 
FKA202 = 0.0015mg*3 
FK544 = 0.0015mg*3 
FKA230 = 0.0015mg*4 
Total = 0.045 mg 
0.045 x105 / 1512 = 
= 2.9761905 
FK503 = 7 eaten 
FK504 = 7 eaten 
FKA177 = 7 eaten 
FKA179 = 7 eaten 
FK536 = 7 eaten 
FK537 = 7 eaten 
FKA202 = 7 eaten 
FK544 = 0 eaten 
FKA230 = 6 eaten 
Total = 55 
 
Kmonull Sham 7 * 168 = Total = 1176 
1.K1180 = 0.0015mg*3 
2.K1216 = 0.0015mg*3 
3.K1223 = 0.0015mg*3 
4.K1224 = 0.0015mg*3 
5.K1247 = 0.0015mg*3 
6.K1263 = 0.0015mg*3 
7.K1264 = 0.0015mg*3 
Total = 0.0315 mg 
0.0315 x105 / 1176 = 
= 2.678571 
1.K1180 = 7eaten 
2.K1216 = 7eaten 
3.K1223 = 7eaten 
4.K1224 = 7eaten 
5.K1247 = 7eaten 
6.K1263 = 7eaten 
7.K1264 = 1eaten 
Total = 43 
 
Kmonull AP 
K1179 = 168 
K1181 = 168 
K1217 = 23.5 
K1222 = 168 
K1225 = 168 
K1246 = 168 
K1248 = 93.1 
K1261 = 168 
K1262 = 168 
Total = 1292.6  
K1179 = 0.0015mg*3 
K1181 = 0.0015mg*3 
K1217 = 0.0015mg*3 
K1222 = 0.0015mg*3 
K1225 = 0.0015mg*3 
K1246 = 0.0015mg*3 
K1248 = 0.0015mg*4 
K1261 = 0.0015mg*3 
K1262 = 0.0015mg*3 
Total = 0.042 mg 
0.042 x105 / 1292.6 = 
=3.249265 
K1179 = 7 eaten 
K1181= 7 eaten 
K1217 = 0 eaten 
K1222 = 6 eaten 
K1225 = 7 eaten 
K1246 = 7 eaten 
K1248 = 1 eaten 
K1261 = 1 eaten 
K1262 = 0 eaten 
Total = 36 
 
Kmoalb-cre Sham 7 * 168 = Total = 1176 
A227 = 0.0015mg*3 
A234 = 0.0015mg*3 
A243 = 0.0015mg*3 
A252 = 0.0015mg*3 
A253 = 0.0015mg*3 
A270 = 0.0015mg*3 
A282 = 0.0015mg*3 
Total = 0.0315 mg 
0.0315 x105 / 1176 = 
= 2.678571 
A227 = 7 eaten 
A234 = 6 eaten 
A243 = 7 eaten 
A252 = 7 eaten 
A253 = 7 eaten 
A270 = 7 eaten 
A282 = 7 eaten 
Total = 48  
 
Kmoalb-cre AP 
A226 = 52.9 
A235 = 46.5 
A238 = 168 
A241 = 168 
A244 = 168 
A246 = 48.0 
A265 = 22.8 
A272 = 47.9 
A280 = 168 
A281 = 29.2 
Total = 895.3  
A226 = 0.0015mg*4 
A235 = 0.0015mg*4 
A238 = 0.0015mg*3 
A241 = 0.0015mg*3 
A244 = 0.0015mg*3 
A246 = 0.0015mg*4 
A265 = 0.0015mg*3 
A272 = 0.0015mg*4 
A280 = 0.0015mg*3 
A281 = 0.0015mg*4 
Total = 0.0525 mg 
0.0525 x105 / 895.3 = 
= 5.8639562 
A226 = 0 eaten 
A235 = 0 eaten 
A238 = 7 eaten 
A241 = 6.3 eaten 
A244 = 7 eaten 
A246 = 1 eaten 
A265 = 0 eaten 
A272 = 0 eaten 
A280 = 7 eaten 
A281 = 0 eaten 
Total = 28.3 
 
Table 84. Analgesia given in AP experiment 3 - TOTAL 
Columns from left to right: ‘Mouse line’ denotes the mouse line. ‘Rx’ denotes treatment: Sham laparotomy or experimental acute 
pancreatitis (AP). ‘Total group time’ denotes the sum total number of hrs of experimented mice in the cohort (i.e. 168-hrs if survived 
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6.10. Appendix 10 – Supplementary data of 24h studies 





Kmowt FK461 FK (HOM) M 23/06/15 25/11/15 155 AP 29.56 WT  35 Histology + KP + cytokines 
Kmowt FK463 FK (HOM) M 23/06/15 25/11/15 155 Sham 31.21 WT  35 Histology + KP + cytokines 
Kmoalb-cre FKA143 Cre(-) M 02/07/15 07/12/15 158 AP 32.67 WT  31 Histology + KP + cytokines 
Kmoalb-cre FKA152 Cre(-) M 12/07/15 07/12/15 148 Sham 29.56 WT  32 Histology + KP + cytokines 
Kmowt FK474 FK (HOM) M 15/07/15 08/12/15 146 Sham 26.47 WT  31 Histology + KP + cytokines 
Kmowt FK475 FK (HOM) M 15/07/15 08/12/15 146 AP 28.84 WT  32 Histology + KP + cytokines 
Kmowt FK485 FK (HOM) M 20/08/15 07/01/16 140 Sham 28.98 WT  33 Histology + KP + cytokines 
Kmowt FK486 FK (HOM) M 20/08/15 07/01/16 140 AP 24.92 WT  33 Histology + KP + cytokines 
Kmowt FK487 FK (HOM) M 20/08/15 07/01/16 140 AP 28.62 WT  31 Histology + KP + cytokines 
Kmowt FK488 FK (HOM) M 20/08/15 07/01/16 140 Sham 24.71 WT  30 Histology + KP + cytokines 
Kmowt FK489 FK (HOM) M 20/08/15 10/01/16 143 Sham 27.46 WT  36 Histology + KP + cytokines 
Kmowt FK490 FK (HOM) M 20/08/15 10/01/16 143 AP 28.47 WT  35 Histo + KP + cytokines + RNAseq 
Kmowt FK495 FK (HOM) M 12/09/15 03/02/16 144 Sham 26.88 WT  32 Histology + KP + cytokines 
Kmowt FK496 FK (HOM) M 12/09/15 03/02/16 144 AP 24.22 WT  32 Histo + KP + cytokines + RNAseq 
Kmowt FK500 FK (HOM) M 20/09/15 08/02/16 141 Sham 29.15 WT  29 Histology + KP + cytokines 
Kmowt FK501 FK (HOM) M 20/09/15 08/02/16 141 AP 31.07 WT  31 Histo + KP + cytokines + RNAseq 
Kmoalb-cre FKA307 Cre(-) M 20/06/16 07/11/16 140 AP 30.86 WT  25 Flow pilot M03A 
Kmowt FK592 FK (HOM) M 13/06/16 07/11/16 147 Sham 29.60 WT  26 Flow pilot M04A 
Kmowt FK570 FK (HOM) M 16/04/16 14/11/16 212 Sham 36.98 WT  27 Flow pilot + cytokines 
Kmowt FK571 FK (HOM) M 16/04/16 14/11/16 212 AP 32.86 WT  29 Flow pilot + cytokines 
Kmowt FK572 FK (HOM) M 16/04/16 14/11/16 212 Sham 34.22 WT  32 Flow pilot + cytokines 
Kmowt FK573 FK (HOM) M 16/04/16 14/11/16 212 AP 31.84 WT  32 Flow pilot + cytokines 
Kmowt FK608 FK (HOM) M 05/08/16 06/12/16 123 Sham 27.29 WT  28 Flow 
Kmowt FK609 FK (HOM) M 05/08/16 06/12/16 123 AP 27.79 WT  25 Flow 
Kmowt FK616 FK (HOM) M 27/08/16 12/12/16 107 AP 26.87 WT  27 Flow + cytokines 
Kmowt FK617 FK (HOM) M 27/08/16 12/12/16 107 Sham 27.49 WT  27 Flow + cytokines 
Kmowt FK618 FK (HOM) M 27/08/16 19/12/16 114 AP 26.17 WT  26 Flow + cytokines 
Kmowt FK619 FK (HOM) M 27/08/16 19/12/16 114 Sham 25.97 WT  28 Flow + cytokines 
Kmowt FK622 FK (HOM) M 14/09/16 16/01/17 124 Sham 27.88 WT  27 Flow 
Kmowt FK624 FK (HOM) M 14/09/16 16/01/17 124 AP 28.08 WT  27 Flow 
Kmowt FK634 FK (HOM) M 13/09/16 31/01/17 140 AP 30.20 WT  27 Flow 
Kmowt FK635 FK (HOM) M 13/09/16 31/01/17 140 Sham 29.67 WT  27 Flow 
Kmoalb-cre FKA331 Cre(-) M 04/09/16 09/01/17 127 AP 24.91 WT 24 Flow 
Kmoalb-cre FKA332 Cre(-) M 04/09/16 09/01/17 127 Sham 27.24 WT 24 Flow 
           
Kmonull K1142 KMO (HOM) M 29/06/15 25/11/15 149 AP 30.07 Null 33 Histology + KP + cytokines 
Kmonull K1143 KMO (HOM) M 29/06/15 25/11/15 149 Sham 28.83 Null 34 Histology + KP + cytokines 
Kmonull K1151 KMO (HOM) M 17/08/15 07/01/16 143 Sham 28.27 Null 34 Histology + KP + cytokines 
Kmonull K1152 KMO (HOM) M 17/08/15 07/01/16 143 AP 32.30 Null 34 Histology + KP + cytokines 
Kmonull K1159 KMO (HOM) M 27/08/15 10/01/16 136 Sham 27.99 Null 31 Histology + KP + cytokines 
Kmonull K1160 KMO (HOM) M 27/08/15 10/01/16 136 AP 30.88 Null 32 Histology + KP + cytokines 
Kmonull K1161 KMO (HOM) M 27/08/15 10/01/16 136 AP 30.81 Null 31 Histology + KP + cytokines 
Kmonull K1162 KMO (HOM) M 27/08/15 10/01/16 136 Sham 29.04 Null 30 Histology + KP + cytokines 
Kmonull K1169 KMO (HOM) M 12/09/15 03/02/16 144 AP 30.25 Null 29 Histology + KP + cytokines 
Kmonull K1170 KMO (HOM) M 12/09/15 03/02/16 144 Sham 28.11 Null 29 Histology + KP + cytokines 
Kmonull K1174 KMO (HOM) M 01/10/15 16/02/16 138 Sham 29.99 Null 30 Histology + KP + cytokines 
Kmonull K1175 KMO (HOM) M 01/10/15 16/02/16 138 AP 31.39 Null 31 Histology + KP + cytokines 
Kmonull K1182 KMO (HOM) M 13/10/15 07/03/16 146 AP 32.52 Null 32 Histology + KP + cytokines 
Kmonull K1183 KMO (HOM) M 13/10/15 07/03/16  146 Sham 31.26 Null 30 Histology + KP + cytokines 
Kmonull K1193 KMO (HOM) M 15/10/15 07/03/16 144 AP 29.61 Null 31 Histology + KP + cytokines 
Kmonull K1194 KMO (HOM) M 15/10/15 07/03/16 144 Sham 28.56 Null 31 Histology + KP + cytokines 
Kmonull K1312 KMO (HOM) M 21/06/16 07/11/16 139 Sham 29.20 Null 28 Flow pilot (M02A) 
Kmonull K1313 KMO (HOM) M 21/06/16 07/11/16 139 AP 31.65 Null 28 Flow pilot (M01A) 
Kmonull K1278 KMO (HOM) M 27/04/16 16/11/16 203 AP 34.48 Null 28 Flow pilot + cytokines 
Kmonull K1279 KMO (HOM) M 27/04/16 16/11/16 203 Sham 30.84 Null 27 Flow pilot + cytokines 
Kmonull K1296 KMO (HOM) M 08/06/16 16/11/16 161 AP 30.81 Null 27 Flow + cytokines 
Kmonull K1297 KMO (HOM) M 08/06/16 16/11/16 161 Sham 31.29 Null 28 Flow + cytokines 
Kmonull K1341 KMO (HOM) M 28/07/16 06/12/16 131 AP 32.31 Null 27 Flow 
Kmonull K1342 KMO (HOM) M 28/07/16 06/12/16 131 Sham 31.71 Null 28 Flow 
Kmonull K1343 KMO (HOM) M 28/07/16 12/12/16 137 Sham 34.10 Null 30 Flow + cytokines 
Kmonull K1344 KMO (HOM) M 28/07/16 12/12/16 137 AP 31.73 Null 30 Flow + cytokines 
Kmonull K1350 KMO (HOM) M 06/08/16 19/12/16 135 AP 28.13 Null 27 Flow + cytokines 
Kmonull K1351 KMO (HOM) M 06/08/16 19/12/16 135 Sham 29.82 Null 30 Flow + cytokines 
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Kmonull K1369 KMO (HOM) M 11/09/16 09/01/17 120 AP 31.78 Null 26 Flow 
Kmonull K1370 KMO (HOM) M 11/09/16 09/01/17 120 Sham 33.51 Null 26 Flow 
Kmonull K1371 KMO (HOM) M 11/09/16 16/01/17 127 AP 29.04 Null 27 Flow 
Kmonull K1372 KMO (HOM) M 11/09/16 16/01/17 127 Sham 34.27 Null 27 Flow 
           
Kmoalb-cre A148 Cre(+) M 12/07/15 07/12/15 153 Sham 28.98 Alb-cre 36 Histology + KP + cytokines 
Kmoalb-cre A149 Cre(+) M 12/07/15 07/12/15 153 AP 30.21 Alb-cre 34 Histology + KP + cytokines 
Kmoalb-cre A150 Cre(+) M 12/07/15 08/12/15 154 AP 28.42 Alb-cre 32 Histology + KP + cytokines 
Kmoalb-cre A151 Cre(+) M 12/07/15 08/12/15 154 Sham 27.32 Alb-cre 33 Histology + KP + cytokines 
Kmoalb-cre A156 Cre(+) M 26/07/15 21/12/15 148 AP 31.50 Alb-cre 36 Histology + KP + cytokines 
Kmoalb-cre A157 Cre(+) M 26/07/15 21/12/15 148 Sham 32.51 Alb-cre 34 Histology + KP + cytokines 
Kmoalb-cre A163 Cre(+) M 05/09/15 20/01/16 137 Sham 29.11 Alb-cre 32 Histology + KP + cytokines 
Kmoalb-cre A164 Cre(+) M 05/09/15 20/01/16 137 AP 29.77 Alb-cre 30 Histology + KP + cytokines 
Kmoalb-cre A196 Cre(+) M 16/01/16 01/06/16 137 AP 30.64 Alb-cre 29 Histology + KP + cytokines 
Kmoalb-cre A197 Cre(+) M 16/01/16 01/06/16 137 Sham 29.83 Alb-cre 29 Histology + KP + cytokines 
Kmoalb-cre A201 Cre(+) M 28/01/16 06/06/16 130 AP 26.33 Alb-cre 31 Histology + KP + cytokines 
Kmoalb-cre A203 Cre(+) M 28/01/16 06/06/16 130 Sham 30.46 Alb-cre 28 Histology + KP + cytokines 
Kmoalb-cre A204 Cre(+) M 28/01/16 06/06/16 130 Sham 29.58 Alb-cre 30 Histology + KP + cytokines 
Kmoalb-cre A206 Cre(+) M 28/01/16 06/06/16 130 AP 26.81 Alb-cre 30 Histology + KP + cytokines 
Kmoalb-cre A313 Cre(+) M 20/07/16 06/12/16 139 Sham 29.82 Alb-cre 27 Flow + cytokines 
Kmoalb-cre A314 Cre(+) M 20/07/16 06/12/16 139 AP 28.40 Alb-cre 27 Flow + cytokines 
Kmoalb-cre A320 Cre(+) M 12/08/16 12/12/16 122 Sham 28.91 Alb-cre 27 Flow + cytokines 
Kmoalb-cre A322 Cre(+) M 12/08/16 12/12/16 122 AP 29.89 Alb-cre 28 Flow + cytokines 
Kmoalb-cre A327 Cre(+) M 12/08/16 19/12/16 129 AP 28.20 Alb-cre 30 Flow + cytokines 
Kmoalb-cre A328 Cre(+) M 12/08/16 19/12/16 129 Sham 31.53 Alb-cre 30 Flow + cytokines 
Kmoalb-cre A339 Cre(+) M 22/09/19 09/01/17 109 Sham 27.68 Alb-cre 27 Flow 
Kmoalb-cre A340 Cre(+) M 22/09/19 09/01/17 109 AP 25.03 Alb-cre 26 Flow 
Kmoalb-cre A341 Cre(+) M 22/09/19 16/01/17 116 Sham 27.29 Alb-cre 28 Flow 
Kmoalb-cre A342 Cre(+) M 22/09/19 16/01/17 116 AP 25.82 Alb-cre 28 Flow 
Kmoalb-cre A343 Cre(+) M 22/09/19 31/01/17 131 AP 30.03 Alb-cre 27 Flow + cytokines 
Kmoalb-cre A344 Cre(+) M 22/09/19 31/01/17 131 Sham 27.85 Alb-cre 27 Flow + cytokines 
Kmoalb-cre A345 Cre(+) M 22/09/19 31/01/17 131 AP 26.95 Alb-cre 23 Flow + cytokines 
Kmoalb-cre A346 Cre(+) M 22/09/19 31/01/17 131 Sham 29.18 Alb-cre 25 Flow + cytokines 
Table 85. 24h study subjects 
AP = 2.0% filtered, in PBS, 50ul, 5min, clamp (1d). Sham = laparotomy with inspection of duodenal loop. 
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6.10. Appendix 10 – Supplementary data of 24h studies. Cont. 
Line ID Rx Group Oedema Infiltrate Necrosis Total Comment Amylase (U/L) Log10 Amy 
Kmowt FK461 AP WT  2 2 0 4  40600 4.61 
Kmowt FK463 Sham WT  0 0 0 0  2160 3.33 
Kmoalb-cre FKA143 AP WT  1 1 1 3  6292 3.80 
Kmoalb-cre FKA152 Sham WT  0 0 0 0  2040 3.31 
Kmowt FK474 Sham WT  0 0 0 0 A (detail below) 2212 3.34 
Kmowt FK475 AP WT  3 2 2 7  6760 3.83 
Kmowt FK485 Sham WT  0 0 0 0  2260 3.35 
Kmowt FK486 AP WT  3 3 3 9  1940 3.29 
Kmowt FK487 AP WT  0 0 0 0  7632 3.88 
Kmowt FK488 Sham WT  1 3 0 4 B (detail below) 2256 3.35 
Kmowt FK489 Sham WT  0 1 0 1  2272 3.36 
Kmowt FK490 AP WT  2 2 3 7  9240 3.97 
Kmowt FK495 Sham WT  0 0 0 0  2252 3.35 
Kmowt FK496 AP WT  2 2 1 5  11680 4.07 
Kmowt FK500 Sham WT  0 0 0 0  2300 3.36 
Kmowt FK501 AP WT  3 3 3 9  7740 3.89 
    
Kmonull K1142 AP Null 2 1 1 4 C (detail below) 3660 3.56 
Kmonull K1143 Sham Null 0 1 0 1  2130 3.33 
Kmonull K1151 Sham Null 0 1 0 1  1852 3.27 
Kmonull K1152 AP Null 2 2 2 6 C (detail below) 7232 3.86 
Kmonull K1159 Sham Null 0 1 0 1  1740 3.24 
Kmonull K1160 AP Null 2 2 0 4  6080 3.78 
Kmonull K1161 AP Null 0 2 0 2 D (detail below) 7960 3.90 
Kmonull K1162 Sham Null 0 0 0 0  2152 3.33 
Kmonull K1169 AP Null 3 2 2 7  10140 4.01 
Kmonull K1170 Sham Null 0 0 0 0  2332 3.37 
Kmonull K1174 Sham Null 0 0 0 0  2452 3.39 
Kmonull K1175 AP Null 2 2 2 6 E (detail below) 6380 3.80 
Kmonull K1182 AP Null 2 1 1 4 C (detail below) 7060 3.85 
Kmonull K1183 Sham Null 0 0 0 0  2152 3.33 
Kmonull K1193 AP Null 2 1 1 4  43252 4.64 
Kmonull K1194 Sham Null 0 0 0 0  2600 3.41 
    
Kmoalb-cre A148 Sham Alb-cre 1 1 0 2  1980 3.30 
Kmoalb-cre A149 AP Alb-cre 3 2 2 7  7260 3.86 
Kmoalb-cre A150 AP Alb-cre 1 1 1 3  19332 4.29 
Kmoalb-cre A151 Sham Alb-cre 0 0 0 0  2392 3.38 
Kmoalb-cre A156 AP Alb-cre 3 2 2 7  20620 4.31 
Kmoalb-cre A157 Sham Alb-cre 0 0 0 0  2272 3.36 
Kmoalb-cre A163 Sham Alb-cre 1 1 0 2  2232 3.35 
Kmoalb-cre A164 AP Alb-cre 1 2 1 4  8600 3.93 
Kmoalb-cre A196 AP Alb-cre 3 3 3 9 F (detail below) 40496 4.61 
Kmoalb-cre A197 Sham Alb-cre 0 0 0 0  2344 3.37 
Kmoalb-cre A201 AP Alb-cre 3 3 2 8 C (detail below) 14304 4.16 
Kmoalb-cre A203 Sham Alb-cre 0 0 0 0  2256 3.35 
Kmoalb-cre A204 Sham Alb-cre 0 1 0 1  1576 3.20 
Kmoalb-cre A206 AP Alb-cre 2 1 1 4  95552 4.98 
Table 86. Pancreas injury histology score at 24h with plasma amylase level 
Oedema: 0 Absent; 1 focally increased between lobules; 2 diffusely increased between lobes; 3 acini disrupted and separated. 
Inflammatory cell infiltrate: 0 Absent; 1 in ducts (around ductal margins); 2 in the parenchyma (in <50% of the lobules); 3 in the 
parenchyma (in >50% of the lobules). 
Acinar necrosis: 0 Absent; 1 periductal necrosis (<= 5%*); 2 focal necrosis (5 to 20%*); 3 diffuse parenchymal necrosis (20-50%*). 
*Refers to approximate % of cells involved per examined field. 
Comments - A: Inflammatory infiltrate in omental fat rather than pancreas; B: Severe end-stage pancreas with loss of the majority of 
acinar tissue and retention of only residual ducts; C: With mild fat necrosis; D: Fat necrosis & inflame cell infiltrates but no acinar injury 
in section; E: With moderate fat necrosis; F: Cocco-bacillary bacteria present. 
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6.10. Appendix 10 – Supplementary data of 24h studies. Cont. 
Line ID Rx Group Weight End body weight (g) Weight loss (% start) Survived 24h 
Kmowt FK461 AP WT 29.56 28.70 2.909 Y 
Kmowt FK463 Sham WT 31.21 30.66 3.783 Y 
Kmoalb-cre FKA143 AP WT 32.67 32.43 0.735 Y 
Kmoalb-cre FKA152 Sham WT 29.56 28.91 2.199 Y 
Kmowt FK474 Sham WT 26.47 26.46 0.038 Y 
Kmowt FK475 AP WT 28.84 27.24 5.548 Y 
Kmowt FK485 Sham WT 28.98 28.56 1.449 Y 
Kmowt FK486 AP WT 24.92 24.19 2.929 Y 
Kmowt FK487 AP WT 28.62 27.42 4.193 Y 
Kmowt FK488 Sham WT 24.71 23.99 2.914 Y 
Kmowt FK489 Sham WT 27.46 26.52 3.423 Y 
Kmowt FK490 AP WT 28.47 27.49 3.442 Y 
Kmowt FK495 Sham WT 26.88 26.23 2.418 Y 
Kmowt FK496 AP WT 24.22 23.30 3.799 Y 
Kmowt FK500 Sham WT 29.15 28.53 2.127 Y 
Kmowt FK501 AP WT 31.07 30.14 2.993 Y 
Kmoalb-cre FKA307 AP WT 30.86 29.14 5.574 Y 
Kmowt FK592 Sham WT 29.60 28.34 4.257 Y 
Kmowt FK570 Sham WT 36.98 35.14 4.976 Y 
Kmowt FK571 AP WT 32.86 31.00 5.660 Y 
Kmowt FK572 Sham WT 34.22 32.85 4.004 Y 
Kmowt FK573 AP WT 31.84 31.11 2.293 Y 
Kmowt FK608 Sham WT 27.29 27.28 0.037 Y 
Kmowt FK609 AP WT 27.79 25.95 6.621 Y 
Kmowt FK616 AP WT 26.87 25.36 5.620 Y 
Kmowt FK617 Sham WT 27.49 26.45 3.783 Y 
Kmowt FK618 AP WT 26.17 24.83 5.120 Y 
Kmowt FK619 Sham WT 25.97 24.91 4.082 Y 
Kmowt FK622 Sham WT 27.88 27.53 1.255 Y 
Kmowt FK624 AP WT 28.08 26.74 4.772 Y 
Kmowt FK634 AP WT 30.20 MISSING MISSING Y 
Kmowt FK635 Sham WT 29.67 MISSING MISSING Y 
Kmoalb-cre FKA331 AP WT 24.91 23.28 6.544 Y 
Kmoalb-cre FKA332 Sham WT 27.24 25.40 6.755 Y 
        
Kmonull K1142 AP Null 30.07 29.48 1.962 Y 
Kmonull K1143 Sham Null 28.83 28.72 0.382 Y 
Kmonull K1151 Sham Null 28.27 27.41 3.042 Y 
Kmonull K1152 AP Null 32.30 30.99 3.967 Y 
Kmonull K1159 Sham Null 27.99 28.12 -0.46 Y 
Kmonull K1160 AP Null 30.88 30.88 2.234 Y 
Kmonull K1161 AP Null 30.81 30.53 0.909 Y 
Kmonull K1162 Sham Null 29.04 28.41 2.169 Y 
Kmonull K1169 AP Null 30.25 28.90 4.463 Y 
Kmonull K1170 Sham Null 28.11 28.11 4.411 Y 
Kmonull K1174 Sham Null 29.99 30.42 -1.43 Y 
Kmonull K1175 AP Null 31.39 29.68 5.448 Y 
Kmonull K1182 AP Null 32.52 30.84 5.166 Y 
Kmonull K1183 Sham Null 31.26 29.90 4.351 Y 
Kmonull K1193 AP Null 29.61 28.40 4.086 Y 
Kmonull K1194 Sham Null 28.56 27.59 3.396 Y 
Kmonull K1312 Sham Null 29.20 28.28 3.151 Y 
Kmonull K1313 AP Null 31.65 29.77 5.940 Y 
Kmonull K1278 AP Null 34.48 32.14 6.787 Y 
Kmonull K1279 Sham Null 30.84 29.79 3.405 Y 
Kmonull K1296 AP Null 30.81 30.35 1.493 Y 
Kmonull K1297 Sham Null 31.29 29.80 4.762 Y 
Kmonull K1341 AP Null 32.31 29.79 7.799 Y 
Kmonull K1342 Sham Null 31.71 29.85 5.866 Y 
Kmonull K1343 Sham Null 34.10 31.74 6.921 Y 
Kmonull K1344 AP Null 31.73 29.53 6.934 Y 
Kmonull K1350 AP Null 28.13 27.04 3.875 Y 
Kmonull K1351 Sham Null 29.82 28.75 3.588 Y 
Kmonull K1369 AP Null 31.78 29.59 6.891 Y 
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Kmonull K1370 Sham Null 33.51 31.03 7.401 Y 
Kmonull K1371 AP Null 29.04 27.33 5.888 Y 
Kmonull K1372 Sham Null 34.27 32.10 6.332 Y 
        
Kmoalb-cre A148 Sham Alb-cre 28.98 28.53 1.553 Y 
Kmoalb-cre A149 AP Alb-cre 30.21 29.82 1.291 Y 
Kmoalb-cre A150 AP Alb-cre 28.42 28.58 -0.56 Y 
Kmoalb-cre A151 Sham Alb-cre 27.32 26.85 1.720 Y 
Kmoalb-cre A156 AP Alb-cre 31.50 29.97 4.857 Y 
Kmoalb-cre A157 Sham Alb-cre 32.51 30.79 5.291 Y 
Kmoalb-cre A163 Sham Alb-cre 29.11 28.13 3.367 Y 
Kmoalb-cre A164 AP Alb-cre 29.77 28.78 3.325 Y 
Kmoalb-cre A196 AP Alb-cre 30.64 29.71 3.035 Y 
Kmoalb-cre A197 Sham Alb-cre 29.83 28.86 3.252 Y 
Kmoalb-cre A201 AP Alb-cre 26.33 26.86 -2.013 Y 
Kmoalb-cre A203 Sham Alb-cre 30.46 29.08 4.531 Y 
Kmoalb-cre A204 Sham Alb-cre 29.58 27.97 5.443 Y 
Kmoalb-cre A206 AP Alb-cre 26.81 26.36 1.678 Y 
Kmoalb-cre A313 Sham Alb-cre 29.82 28.78 3.488 Y 
Kmoalb-cre A314 AP Alb-cre 28.40 27.05 4.754 Y 
Kmoalb-cre A320 Sham Alb-cre 28.91 26.73 7.541 Y 
Kmoalb-cre A322 AP Alb-cre 29.89 28.96 3.111 Y 
Kmoalb-cre A327 AP Alb-cre 28.20 25.59 9.255 Y 
Kmoalb-cre A328 Sham Alb-cre 31.53 30.41 3.552 Y 
Kmoalb-cre A339 Sham Alb-cre 27.68 27.18 1.806 Y 
Kmoalb-cre A340 AP Alb-cre 25.03 23.79 4.954 Y 
Kmoalb-cre A341 Sham Alb-cre 27.29 25.76 5.606 Y 
Kmoalb-cre A342 AP Alb-cre 25.82 24.22 6.197 Y 
Kmoalb-cre A343 AP Alb-cre 30.03 MISSING MISSING Y 
Kmoalb-cre A344 Sham Alb-cre 27.85 MISSING MISSING Y 
Kmoalb-cre A345 AP Alb-cre 26.95 MISSING MISSING Y 
Kmoalb-cre A346 Sham Alb-cre 29.18 MISSING MISSING Y 
Table 87. 24-hr exp. Outcome of study subjects – experiment 4 (weight loss) 
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6.10. Appendix 10 – Supplementary data of 24h studies. Cont. 
















Kmowt FK461 AP WT  24.0 63 40600 4.608526 8 15.0 228 6.8 
Kmowt FK463 Sham WT 23.3 30 2160 3.334454 8 18.3 105 7.3 
Kmoalb-cre FKA143 AP WT 23.8 98 6292 3.798789 3 8.8 220 6.8 
Kmoalb-cre FKA152 Sham WT 26.3 35 2040 3.309630 3 16.8 120 5.0 
Kmowt FK474 Sham WT 26.8 78 2212 3.344785 5 17.8 328 8.0 
Kmowt FK475 AP WT 24.8 48 6760 3.829947 3 13.8 425 6.5 
Kmowt FK485 Sham WT 27.5 138 2260 3.354108 8 20.0 575 5.8 
Kmowt FK486 AP WT 25.3 90 1940 3.287802 3 10.8 193 6.3 
Kmowt FK487 AP WT 23.8 60 7632 3.882638 3 17.8 198 8.5 
Kmowt FK488 Sham WT  26.3 43 2256 3.353339 3 13.8 268 9.8 
Kmowt FK489 Sham WT 26.3 193 2272 3.356408 5 16.5 388 5.8 
Kmowt FK490 AP WT 26.5 93 9240 3.965672 8 12.8 300 6.5 
Kmowt FK495 Sham WT 23.8 63 2252 3.352568 5 9.0 168 5.8 
Kmowt FK496 AP WT 25.5 250 11680 4.067443 5 14.3 390 14.3 
Kmowt FK500 Sham WT 27.0 100 2300 3.361728 5 16.0 265 4.3 
Kmowt FK501 AP WT 24.0 93 7740 3.888741 5 14.0 225 5.3 
Kmowt FK570 Sham WT  30.4 138 2500 3.397940 NT 17.6 270 6.4 
Kmowt FK571 AP WT 25.8 210 19260 4.284656 NT 12.2 540 10.5 
Kmowt FK572 Sham WT 29.0 248 3000 3.477121 NT 19.4 284 4.9 
Kmowt FK573 AP WT 24.4 158 34100 4.532754 NT 14.6 262 4.8 
Kmowt FK608 Sham WT 27.2 140 3340 3.523746 NT 14.0 176 5.1 
Kmowt FK609 AP WT 22.4 100 18900 4.276462 NT 10.4 220 8.0 
Kmowt FK616 AP WT 25.6 78 2340 3.369216 NT 11.8 246 5.1 
Kmowt FK617 Sham WT 26.8 50 1880 3.274158 NT 17.2 170 6.1 
Kmowt FK618 AP WT 28.4 100 6820 3.833784 NT 15.4 178 5.2 
Kmowt FK619 Sham WT 31.0 134 2420 3.383815 NT 23.4 214 6.3 
Kmowt FK622 Sham WT 34.8 56 2540 3.404834 NT 22.4 270 8.0 
Kmowt FK624 AP WT 25.4 152 32440 4.511081 NT 6.4 1888 14.7 
Kmowt FK634 AP WT 25.6 138 6900 3.838849 NT 18.2 300 5.5 
Kmowt FK635 Sham WT 26.4 82 2380 3.376577 NT 17.4 180 6.3 
Kmoalb-cre FKA331 AP WT 30.0 141 19230 4.283979 NT 11.1 999 17.0 
Kmoalb-cre FKA332 Sham WT 25.2 246 2260 3.354108 NT 15.6 342 5.0 
            
Kmonull K1142 AP Null 23.0 70 3660 3.563481 3 16.0 195 6.8 
Kmonull K1143 Sham Null 26.5 28 2130 3.328380 5 16.0 143 6.3 
Kmonull K1151 Sham Null 25.0 25 1852 3.267641 5 18.5 138 5.5 
Kmonull K1152 AP Null 24.3 35 7232 3.859258 5 10.5 273 5.3 
Kmonull K1159 Sham Null 23.8 23 1740 3.240549 8 11.5 190 9.8 
Kmonull K1160 AP Null 26.5 55 6080 3.783904 3 17.3 273 7.0 
Kmonull K1161 AP Null 25.3 28 7960 3.900913 5 11.0 248 6.0 
Kmonull K1162 Sham Null 26.0 23 2152 3.332842 8 15.8 170 6.0 
Kmonull K1169 AP Null 25.0 30 10140 4.006038 10 10.0 210 6.5 
Kmonull K1170 Sham Null 26.8 23 2332 3.367729 8 15.8 130 4.5 
Kmonull K1174 Sham Null 25.5 450 2452 3.389520 8 16.8 190 10.5 
Kmonull K1175 AP Null 22.8 40 6380 3.804821 8 14.0 243 7.8 
Kmonull K1182 AP Null 27.0 45 7060 3.848805 10 18.0 218 6.8 
Kmonull K1183 Sham Null 26.5 25 2152 3.332842 10 19.3 230 6.5 
Kmonull K1193 AP Null 25.3 40 43252 4.636006 8 2.5 358 5.0 
Kmonull K1194 Sham Null 23.3 30 2600 3.414973 5 9.3 238 5.5 
Kmonull K1278 AP Null NT NT 4420 3.645422 NT NT NT NT 
Kmonull K1279 Sham Null NT NT 1920 3.283301 NT NT NT NT 
Kmonull K1296 AP Null 23.8 50 5080 3.705864 NT 17.2 176 4.0 
Kmonull K1297 Sham Null 26.0 54 1760 3.245513 NT 19.2 200 5.0 
Kmonull K1341 AP Null 30.4 62 51600 4.712650 NT 14.4 226 5.4 
Kmonull K1342 Sham Null 25.6 36 4920 3.691965 NT 19.0 140 5.1 
Kmonull K1343 Sham Null 26.6 44 2620 3.418301 NT 20.0 150 5.4 
Kmonull K1344 AP Null 25.4 118 20520 4.312177 NT 7.4 378 8.3 
Kmonull K1350 AP Null 24.0 146 40040 4.602494 NT 6.6 572 12.8 
Kmonull K1351 Sham Null 27.6 40 3180 3.502427 NT 19.0 144 5.0 
Kmonull K1369 AP Null 27.4 48 9200 3.963788 NT 19.2 186 4.8 
Kmonull K1370 Sham Null 30.4 30 1980 3.296665 NT 21.2 216 7.1 
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Kmonull K1371 AP Null 26.0 40 2280 3.357935 NT 16.2 158 5.1 
Kmonull K1372 Sham Null 28.3 30 2180 3.338456 NT 19.2 168 5.1 
            
Kmoalb-cre A148 Sham Alb-cre 26.3 40 1980 3.296665 8 15.0 220 4.8 
Kmoalb-cre A149 AP Alb-cre 23.5 50 7260 3.860937 10 7.5 313 5.5 
Kmoalb-cre A150 AP Alb-cre 24.0 165 19332 4.286277 23 11.8 1223 34.3 
Kmoalb-cre A151 Sham Alb-cre 27.3 65 2392 3.378761 5 17.0 273 7.0 
Kmoalb-cre A156 AP Alb-cre 23.3 123 20620 4.314289 5 15.0 310 6.3 
Kmoalb-cre A157 Sham Alb-cre 25.0 48 2272 3.356408 8 15.5 215 7.3 
Kmoalb-cre A163 Sham Alb-cre 23.8 33 2232 3.348694 5 16.8 128 7.3 
Kmoalb-cre A164 AP Alb-cre 24.0 60 8600 3.934498 5 7.3 190 7.0 
Kmoalb-cre A196 AP Alb-cre 20.6 42 40496 4.607412 NT 4.0 884 21.8 
Kmoalb-cre A197 Sham Alb-cre 25.6 42 2344 3.369958 NT 9.6 338 6.8 
Kmoalb-cre A201 AP Alb-cre 17.2 52 14304 4.155458 NT 5.6 566 5.0 
Kmoalb-cre A203 Sham Alb-cre 23.0 66 2256 3.353339 NT 14.4 286 3.8 
Kmoalb-cre A204 Sham Alb-cre 24.0 24 1576 3.197556 NT 10.8 250 5.4 
Kmoalb-cre A206 AP Alb-cre 19.6 230 95552 4.980240 NT 4.8 1724 31.2 
Kmoalb-cre A313 Sham Alb-cre 25.8 86 2220 3.346353 NT 18.2 160 5.6 
Kmoalb-cre A314 AP Alb-cre 30.8 270 42040 4.623663 NT 19.2 700 14.9 
Kmoalb-cre A320 Sham Alb-cre 25.8 96 3520 3.546543 NT 18.8 166 5.0 
Kmoalb-cre A322 AP Alb-cre 21.4 104 6100 3.785330 NT 24.6 138 5.5 
Kmoalb-cre A327 AP Alb-cre 27.6 82 16060 4.205746 NT 13.8 262 6.0 
Kmoalb-cre A328 Sham Alb-cre 24.8 48 2480 3.394452 NT 18.0 150 5.5 
Kmoalb-cre A339 Sham Alb-cre 23.6 30 1820 3.260071 NT 13.2 122 6.4 
Kmoalb-cre A340 AP Alb-cre 24.4 66 5360 3.729165 NT 17.4 150 4.7 
Kmoalb-cre A341 Sham Alb-cre 25.2 50 2420 3.383815 NT 16.4 136 6.5 
Kmoalb-cre A342 AP Alb-cre 22.2 90 37460 4.573568 NT 5.8 396 9.0 
Kmoalb-cre A343 AP Alb-cre 24.6 54 10520 4.022016 NT 9.6 204 5.6 
Kmoalb-cre A344 Sham Alb-cre 26.8 54 2660 3.424882 NT 18.2 152 6.5 
Kmoalb-cre A345 AP Alb-cre 24.6 106 4140 3.617000 NT 17.2 168 5.5 
Kmoalb-cre A346 Sham Alb-cre 24.8 90 2160 3.334454 NT 18.4 136 4.7 
Table 88. 24-hr exp. Outcome of study subjects – experiment 4 (biochemistry) 
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6.10. Appendix 10 – Supplementary data of 24h studies. Cont. 
 
 
Figure 50: Calibration curves of MSD cytokine plate with limits of detection 
From Plate A. 
 





















LOD A 0.063 0.140 0.350 0.127 0.115 1.264 0.795 22.682 0.320 0.147 
LOD B 0.290 0.253 1.519 0.254 1.158 10.545 0.757 47.170 0.335 0.630 
FK461 AP WT  A 0.550 2.149 1.996 0.450 66.442 64.207 18.404 36.386 44.454 25.687 Used 
FK463 Sham WT A 0.582 1.026 0.857 1.291 3.933 32.627 15.715 51.417 22.752 13.935 Used 
FKA143 AP WT A 0.647 1.998 2.111 0.240 54.260 107.394 17.124 <22.682 28.459 9.558 Used 
FKA152 Sham WT A 0.313 1.502 0.697 0.143 53.318 65.753 13.898 <22.682 26.094 8.319 Used 
FK474 Sham WT A 0.733 1.534 0.554 1.146 6.612 261.370 17.414 35.407 78.943 12.540 Used 
FK475 AP WT A 0.382 2.181 1.742 0.139 56.566 122.358 16.789 <22.682 63.789 8.277 Used 
FK485 Sham WT A 0.334 1.136 0.428 0.296 17.998 137.643 12.399 <22.682 60.125 5.970 Used 
FK486 AP WT A 2.009 3.740 4.581 0.772 19.135 334.182 20.096 <22.682 117.193 17.359 Used 
FK487 AP WT A 0.222 1.541 0.672 0.174 18.820 54.701 13.978 <22.682 52.269 6.373 Used 
FK488 Sham WT A 2.644 1.301 5.697 3.377 37.408 51.624 30.804 <22.682 49.243 17.433 Used 
FK489 Sham WT A 0.326 1.469 0.722 0.140 19.913 112.916 10.943 <22.682 47.986 7.420 Used 
FK490 AP WT A 0.288 3.903 1.246 0.136 37.932 244.068 17.544 <22.682 73.233 7.604 Used 
FK495 Sham WT A 0.285 2.892 0.554 0.344 77.286 125.816 10.173 31.407 47.752 6.862 Used 
FK496 AP WT A 0.311 2.341 1.251 <0.127 49.474 79.198 18.908 <22.682 39.677 7.321 Used 
FK500 Sham WT A 0.258 1.689 0.697 0.222 54.501 182.239 12.818 <22.682 73.407 6.293 Used 
FK501 AP WT A 1.299 5.511 2.011 0.216 41.835 327.471 16.667 <22.682 180.230 11.480 Used 
FK570 Sham WT B 0.762 1.795 <1.519 <0.254 134.986 115.692 16.137 54.662 20.236 7.964 Not used 
FK571 AP WT n/a I/S I/S I/S I/S I/S I/S I/S I/S I/S I/S I/S 
FK572 Sham WT B 0.811 1.194 2.181 0.325 30.959 65.742 19.736 80.618 35.451 9.824 Used 
FK573 AP WT B 0.294 5.100 <1.519 0.238 100.743 267.855 21.608 67.186 135.878 10.708 Used 
FK616 AP WT B 2.460 4.911 11.234 0.539 27.866 14034.698 70.950 305.011 1054.946 417.008 Used 
FK617 Sham WT B 2.199 1.763 3.403 1.337 95.114 129.800 19.645 210.425 52.321 11.625 Used 
FK618 AP WT B 0.332 2.907 1.558 0.584 58.296 126.112 21.229 <47.170 45.318 8.661 Used 
FK619 Sham WT B <0.290 1.370 4.181 0.520 36.317 71.495 15.643 <47.170 23.641 8.089 Used 
               
K1142 AP Null A 0.963 2.866 2.229 <0.127 22.293 76.808 16.988 <22.682 55.481 8.937 Used 
K1143 Sham Null A 1.144 1.634 2.263 <0.127 23.745 57.490 24.545 <22.682 34.651 9.919 Used 
K1151 Sham Null A 0.348 1.434 1.907 <0.127 14.724 43.604 18.607 <22.682 23.315 10.097 Used 
K1152 AP Null A 1.036 2.902 5.013 <0.127 26.735 155.033 17.019 <22.682 42.959 12.581 Used 
K1159 Sham Null A 0.467 1.240 1.220 0.170 84.190 65.379 22.723 <22.682 70.489 9.220 Used 
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K1160 AP Null A 0.276 2.710 2.045 <0.127 89.994 107.465 17.696 <22.682 57.900 10.273 Used 
K1161 AP Null A 0.472 2.681 0.818 <0.127 50.741 50.741 15.530 <22.682 20.466 6.813 Used 
K1162 Sham Null A 0.383 0.922 0.929 <0.127 24.535 32.604 16.174 <22.682 25.931 9.959 Used 
K1169 AP Null A 0.447 2.866 6.788 0.174 25.970 157.888 13.087 <22.682 47.260 12.534 Used 
K1170 Sham Null A 0.670 2.409 2.258 <0.127 25.695 60.263 16.871 <22.682 42.363 10.492 Used 
K1174 Sham Null A 0.367 2.438 0.974 <0.127 34.807 59.970 17.451 <22.682 37.844 9.803 Used 
K1175 AP Null A 0.392 1.892 1.825 <0.127 47.157 155.535 12.337 <22.682 63.410 8.060 Used 
K1182 AP Null A 0.248 1.789 1.001 <0.127 16.059 151.934 12.681 <22.682 65.962 7.606 Used 
K1183 Sham Null A 0.482 1.495 2.820 0.354 49.041 203.046 22.232 <22.682 37.937 13.493 Used 
K1193 AP Null A 1.030 13.360 4.893 1.432 25.210 1465.147 23.180 100.204 542.630 9.426 Used 
K1194 Sham Null A 1.467 1.682 3.509 0.584 52.402 87.133 16.625 45.266 56.112 13.283 Used 
K1278 AP Null B <0.290 2.199 3.103 0.272 118.829 256.296 30.616 54.230 72.175 13.143 Used 
K1279 Sham Null B 1.231 2.071 4.173 0.318 212.571 70.840 19.134 <47.170 25.189 12.097 Used 
K1296 AP Null B <0.290 2.856 3.023 <0.254 37.663 176.529 23.404 <47.170 41.727 16.461 Used 
K1297 Sham Null B <0.290 1.460 3.786 0.565 17.415 76.186 17.413 62.293 20.416 14.123 Used 
K1343 Sham Null B 0.586 2.206 <1.519 <0.254 92.963 66.768 19.777 <47.170 22.079 5.446 Used 
K1344 AP Null B 1.874 7.072 5.576 1.049 10.667 2330.471 36.678 129.890 86.539 17.245 Used 
K1350 AP Null B 0.534 8.903 4.812 0.660 22.356 1251.897 497.509 89.675 489.979 40.719 N/U-surplus 
K1351 Sham Null B 1.099 1.182 2.998 0.314 49.207 57.331 23.271 69.230 14.253 12.219 N/U-surplus 
               
A148 Sham Alb-cre B 1.163 1.428 3.812 0.417 62.394 96.925 18.544 82.586 47.998 11.274 Used 
A149 AP Alb-cre B 0.332 4.332 5.189 0.305 76.143 194.074 19.103 62.623 38.516 12.252 Used 
A150 AP Alb-cre B <0.290 4.937 6.381 <0.254 12.663 2436.790 150.709 107.406 212.329 33.507 Used 
A151 Sham Alb-cre B 0.720 1.434 1.678 0.349 23.104 108.912 14.876 64.089 36.775 9.552 Used 
A156 AP Alb-cre B 0.421 1.847 2.268 <0.254 49.631 111.187 10.034 <47.170 58.116 7.213 Used 
A157 Sham Alb-cre B <0.290 1.827 3.403 <0.254 44.209 101.364 15.807 55.761 48.387 9.116 Used 
A163 Sham Alb-cre B 0.776 1.659 5.007 0.404 58.056 63.728 26.383 51.086 33.896 11.495 Used 
A164 AP Alb-cre B 0.549 1.949 4.716 0.756 30.718 257.592 16.477 81.297 36.906 13.792 Used 
A196 AP Alb-cre B <0.290 22.362 4.265 <0.254 21.697 139276.387 1108.517 680.974 5477.826 238.829 Used 
A197 Sham Alb-cre B 0.613 1.337 <1.519 <0.254 32.271 51.675 12.187 <47.170 27.019 7.072 Used 
A201 AP Alb-cre B 1.278 3.384 5.483 0.331 45.496 528.060 19.237 92.981 211.932 12.202 Used 
A203 Sham Alb-cre B 1.938 1.260 4.494 0.520 22.441 129.424 19.531 96.043 42.702 12.163 Used 
A204 Sham Alb-cre B 0.310 1.615 1.640 <0.254 80.923 108.498 16.032 84.452 32.978 8.279 Used 
A206 AP Alb-cre B 0.578 22.255 8.868 1.321 69.233 43433.935 199.695 357.291 1859.783 39.014 Used 
A313 Sham Alb-cre B <0.290 1.712 1.666 1.498 38.779 102.685 16.419 118.745 28.534 11.233 Used 
A314 AP Alb-cre B 0.390 14.756 19.768 1.637 62.703 12180.191 199.750 225.793 887.832 45.804 Used 
A320 Sham Alb-cre B <0.290 1.357 3.160 0.517 63.735 36.492 15.642 <47.170 19.370 9.921 Used 
A322 AP Alb-cre B <0.290 3.206 <1.519 <0.254 20.911 129.797 19.942 52.969 34.195 10.062 Used 
A327 AP Alb-cre B 1.859 3.402 6.843 0.501 29.509 176.045 17.960 <47.170 61.211 12.501 Used 
A328 Sham Alb-cre B 0.980 1.376 3.065 <0.254 62.262 107.513 21.621 <47.170 32.282 12.446 Used 
A343 AP Alb-cre B <0.290 4.010 <1.519 0.265 16.527 864.951 29.314 <47.170 413.868 10.307 Used 
A344 Sham Alb-cre B 0.337 1.834 <1.519 <0.254 47.296 68.604 19.766 52.982 14.431 13.750 Used 
A345 AP Alb-cre B 0.762 2.429 1.829 <0.254 63.531 109.011 23.104 51.529 29.366 10.653 N/U-surplus 
A346 Sham Alb-cre B 0.565 0.9265 3.103 <0.254 112.432 94.100 22.126 74.916 14.404 11.470 N/U-surplus 
Table 89. 24-hr exp. Outcome of study subjects at 24h (cytokines) 
I/S: insufficient sample. LOD: limit of detection. N/U: not used 
 
 
ID Rx Group Plate IL6 (pg/ml) 
 
Log10 IL6 TNFα (pg/ml) Log10 TNFα 
LOD A 1.264  0.147  
LOD B 10.545  0.630  
FK461 AP WT  A 64.207 1.8076 25.687 1.4097 
FK463 Sham WT A 32.627 1.5136 13.935 1.1441 
FKA143 AP WT A 107.394 2.0310 9.558 0.9804 
FKA152 Sham WT A 65.753 1.8179 8.319 0.9201 
FK474 Sham WT A 261.370 2.4173 12.540 1.0983 
FK475 AP WT A 122.358 2.0876 8.277 0.9179 
FK485 Sham WT A 137.643 2.1388 5.970 0.7760 
FK486 AP WT A 334.182 2.5240 17.359 1.2395 
FK487 AP WT A 54.701 1.7380 6.373 0.8043 
FK488 Sham WT A 51.624 1.7129 17.433 1.2414 
FK489 Sham WT A 112.916 2.0528 7.420 0.8704 
FK490 AP WT A 244.068 2.3875 7.604 0.8810 
Metabolic regulators of inflammation in acute pancreatitis                                                         S0897427 
Alastair J Hayes 
  - 244 -  
 
FK495 Sham WT A 125.816 2.0997 6.862 0.8365 
FK496 AP WT A 79.198 1.8987 7.321 0.8646 
FK500 Sham WT A 182.239 2.2606 6.293 0.7989 
FK501 AP WT A 327.471 2.5152 11.480 1.0599 
FK570 Sham WT B 115.692 2.0633 7.964 0.9011 
FK571 AP WT n/a I/S  I/S  
FK572 Sham WT B 65.742 1.8178 9.824 0.9923 
FK573 AP WT B 267.855 2.4279 10.708 1.0297 
FK616 AP WT B 14034.698 4.1472 417.008 2.6201 
FK617 Sham WT B 129.800 2.1133 11.625 1.0654 
FK618 AP WT B 126.112 2.1008 8.661 0.9376 
FK619 Sham WT B 71.495 1.8543 8.089 0.9079 
        
K1142 AP Null A 76.808 1.8854 8.937 0.9512 
K1143 Sham Null A 57.490 1.7596 9.919 0.9965 
K1151 Sham Null A 43.604 1.6395 10.097 1.0042 
K1152 AP Null A 155.033 2.1904 12.581 1.0997 
K1159 Sham Null A 65.379 1.8154 9.220 0.9647 
K1160 AP Null A 107.465 2.0313 10.273 1.0117 
K1161 AP Null A 50.741 1.7054 6.813 0.8333 
K1162 Sham Null A 32.604 1.5133 9.959 0.9982 
K1169 AP Null A 157.888 2.1983 12.534 1.0981 
K1170 Sham Null A 60.263 1.7801 10.492 1.0209 
K1174 Sham Null A 59.970 1.7779 9.803 0.9914 
K1175 AP Null A 155.535 2.1918 8.060 0.9063 
K1182 AP Null A 151.934 2.1817 7.606 0.8812 
K1183 Sham Null A 203.046 2.3076 13.493 1.1301 
K1193 AP Null A 1465.147 3.1659 9.426 0.9743 
K1194 Sham Null A 87.133 1.9402 13.283 1.1233 
K1278 AP Null B 256.296 2.4087 13.143 1.1187 
K1279 Sham Null B 70.840 1.8503 12.097 1.0827 
K1296 AP Null B 176.529 2.2468 16.461 1.2165 
K1297 Sham Null B 76.186 1.8819 14.123 1.1499 
K1343 Sham Null B 66.768 1.8246 5.446 0.7361 
K1344 AP Null B 2330.471 3.3674 17.245 1.2367 
K1350 AP Null B 1251.897 3.0976 40.719 1.6098 
K1351 Sham Null B 57.331 1.7584 12.219 1.0870 
        
A148 Sham Alb-cre B 96.925 1.9864 11.274 1.0521 
A149 AP Alb-cre B 194.074 2.2880 12.252 1.0882 
A150 AP Alb-cre B 2436.790 3.3868 33.507 1.5251 
A151 Sham Alb-cre B 108.912 2.0371 9.552 0.9801 
A156 AP Alb-cre B 111.187 2.0461 7.213 0.8581 
A157 Sham Alb-cre B 101.364 2.0059 9.116 0.9598 
A163 Sham Alb-cre B 63.728 1.8043 11.495 1.0605 
A164 AP Alb-cre B 257.592 2.4109 13.792 1.1396 
A196 AP Alb-cre B 139276.387 5.1439 238.829 2.3781 
A197 Sham Alb-cre B 51.675 1.7133 7.072 0.8495 
A201 AP Alb-cre B 528.060 2.7227 12.202 1.0864 
A203 Sham Alb-cre B 129.424 2.1120 12.163 1.0850 
A204 Sham Alb-cre B 108.498 2.0354 8.279 0.9180 
A206 AP Alb-cre B 43433.935 4.6378 39.014 1.5912 
A313 Sham Alb-cre B 102.685 2.0115 11.233 1.0505 
A314 AP Alb-cre B 12180.191 4.0857 45.804 1.6609 
A320 Sham Alb-cre B 36.492 1.5622 9.921 0.9966 
A322 AP Alb-cre B 129.797 2.1133 10.062 1.0027 
A327 AP Alb-cre B 176.045 2.2456 12.501 1.0969 
A328 Sham Alb-cre B 107.513 2.0315 12.446 1.0950 
A343 AP Alb-cre B 864.951 2.9370 10.307 1.0131 
A344 Sham Alb-cre B 68.604 1.8363 13.750 1.1383 
A345 AP Alb-cre B 109.011 2.0375 10.653 1.0275 
A346 Sham Alb-cre B 94.100 1.9736 11.470 1.0596 
Table 90. 24-hr exp. Plasma cytokines – Log10 data transformation 
I/S: insufficient sample. LOD: limit of detection.  
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Line ID Rx Trp (μg/ml) 
LOD 20 μg/l 
Kyn (μg/l) 
LOD 10 μg/l 
KA (μg/l) 
LOD 5 μg/l 
AA (μg/l) 
LOD 1 μg/l 
3HK (μg/l) 
LOD 1 μg/l 
3HAA (μg/l) 
LOD 2 μg/l 
PA (μg/l) 
LOD 10 μg/l 
XA (μg/l) 
LOD 5 μg/l 
Kmowt FK461 AP 16950.18 115.867 <5 3.667 <1 2.340 <10 <5 
Kmowt FK463 Sham 18806.83 165.444 <5 4.356 8.356 <2 <10 <5 
Kmoalb-cre FKA143 AP 21168.13 334.200 <5 4.667 <1 <2 <10 <5 
Kmoalb-cre FKA152 Sham 26775.73 168.800 <5 1.667 <1 <2 <10 <5 
Kmowt FK474 Sham 20012.78 205.178 <5 4.222 6.311 <2 20.044 <5 
Kmowt FK475 AP 18108.83 216.266 <5 3.089 9.200 <2 <10 <5 
Kmowt FK485 Sham 23316.18 388.266 <5 4.378 26.067 <2 19.978 <5 
Kmowt FK486 AP 21022.86 1083.066 <5 2.556 52.689 <2 10.644 <5 
Kmowt FK487 AP 19951.80 175.822 <5 3.489 <1 <2 12.089 <5 
Kmowt FK488 Sham 18095.72 939.732 <5 4.111 19.578 <2 13.911 <5 
Kmowt FK489 Sham 24536.53 268.089 <5 4.756 <1 <2 15.844 <5 
Kmowt FK490 AP 25968.89 383.489 <5 5.867 8.422 <2 25.600 96.800 
Kmowt FK495 Sham 25489.06 540.399 7.178 8.489 30.844 21.15 21.800 286.000 
Kmowt FK496 AP 18640.06 237.422 <5 2.444 <1 <2 <10 <5 
Kmowt FK500 Sham 20932.93 165.400 <5 0.311 <1 <2 <10 <5 
Kmowt FK501 AP 16070.92 243.822 <5 0.978 <1 <2 <10 <5 
           
Kmonull K1142 AP 21996.69 4970.528 899.355 101.200 <1 11.644 <10 <5 
Kmonull K1143 Sham 18513.63 3783.996 514.288 81.533 <1 <2 <10 <5 
Kmonull K1151 Sham 18954.87 3132.930 329.755 78.533 <1 <2 <10 <5 
Kmonull K1152 AP 18438.89 3158.819 939.577 63.578 <1 <2 <10 <5 
Kmonull K1159 Sham 22555.67 8650.014 2213.731 264.733 <1 <2 <10 <5 
Kmonull K1160 AP 20962.27 5479.417 494.340 134.644 <1 <2 <10 <5 
Kmonull K1161 AP 31471.52 5904.372 880.266 147.555 <1 3.111 <10 <5 
Kmonull K1162 Sham 21037.69 4285.151 524.644 81.844 <1 <2 <10 <5 
Kmonull K1169 AP 18783.4 3472.530 897.110 75.222 <1 <2 <10 <5 
Kmonull K1170 Sham 18832.03 3187.841 233.155 61.244 <1 <2 <10 <5 
Kmonull K1174 Sham 16611.21 10724.523 995.488 213.778 <1 <2 <10 <5 
Kmonull K1175 AP 20334.62 6805.771 2276.220 202.244 <1 <2 <10 <5 
Kmonull K1182 AP 20581.91 7601.304 960.288 150.022 <1 <2 <10 <5 
Kmonull K1183 Sham 18396.76 2235.331 235.111 48.689 <1 <2 <10 <5 
Kmonull K1193 AP 23594.60 5953.661 837.577 120.822 <1 <2 <10 <5 
Kmonull K1194 Sham 16031.14 1731.132 437.422 43.978 <1 <2 <10 <5 
           
Kmoalb-cre A148 Sham 18668.09 1291.999 <5 53.689 4.111 <2 <10 <5 
Kmoalb-cre A149 AP 24984.62 2044.020 99.689 77.711 28.067 <2 <10 72.600 
Kmoalb-cre A150 AP 11718.74 5481.283 1101.666 114.178 1030.399 <2 176.556 2323.200 
Kmoalb-cre A151 Sham 28930.46 2728.997 165.155 113.844 <1 2.533 <10 63.800 
Kmoalb-cre A156 AP 19848.40 3088.530 322.355 137.667 45.578 <2 10.200 6.600 
Kmoalb-cre A157 Sham 20647.80 2793.886 433.044 124.400 88.822 <2 <10 1034.000 
Kmoalb-cre A163 Sham 20106.49 2660.642 284.777 105.400 75.755 <2 <10 217.800 
Kmoalb-cre A164 AP 22381.18 3408.797 310.933 173.666 72.022 <2 <10 134.200 
Kmoalb-cre A196 AP 8247.792 2455.709 386.577 64.400 447.155 <2 87.067 336.600 
Kmoalb-cre A197 Sham 28202.53 2500.553 219.088 143.733 96.000 <2 <10 644.600 
Kmoalb-cre A201 AP 21116.76 2436.598 113.067 78.689 122.355 <2 <10 114.400 
Kmoalb-cre A203 Sham 17890.18 731.866 <5 22.044 8.044 <2 <10 <5 
Kmoalb-cre A204 Sham 18527.56 1253.977 <5 61.022 1.156 <2 <10 <5 
Kmoalb-cre A206 AP 8722.236 2689.931 785.177 61.689 506.911 <2 206.200 587.400 
Table 91. Concentrations of kynurenine metabolites in AP and sham at 24h 
Columns indicate which mouse line mice were derived from, arbitrary ID, genotype, sex, body weight, age at cull, experimental group, 
and plasma concentration of analyte according to LC-MS/MS analysis. Abbreviations: 3HK: 3-hydroxykynurenine; AA: anthranilic acid; 
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Line ID Gene Sex Rx Group Flow Code DOB DOS Age (d) Exps 
Kmowt FK608 FK (HOM) M Sham WT M24 05/08/16 06/12/16 123 B,Lun,Liv 
Kmowt FK609 FK (HOM) M AP WT M23 05/08/16 06/12/16 123 B,Lun,Liv 
Kmowt FK616 FK (HOM) M AP WT M31 27/08/16 12/12/16 107 B,Lun,Liv 
Kmowt FK617 FK (HOM) M Sham WT M32 27/08/16 12/12/16 107 Lun,Liv 
Kmowt FK618 FK (HOM) M AP WT M45 27/08/16 19/12/16 114 B,Lun,Liv 
Kmowt FK619 FK (HOM) M Sham WT M46 27/08/16 19/12/16 114 B,Lun,Liv 
Kmowt FK622 FK (HOM) M Sham WT M64 14/09/16 16/01/17 124 B,Lun,Liv 
Kmowt FK624 FK (HOM) M AP WT M63 14/09/16 16/01/17 124 B,Lun,Liv 
Kmowt FK634 FK (HOM) M AP WT M73 13/09/16 31/01/17 140 B,Lun,Liv 
Kmowt FK635 FK (HOM) M Sham WT M74 13/09/16 31/01/17 140 B,Lun,Liv 
Kmoalb-cre FKA331 Cre(-) M AP WT M53 04/09/16 09/01/17 127 B,Lun,Liv 
Kmoalb-cre FKA332 Cre(-) M Sham WT M54 04/09/16 09/01/17 127 B,Lun,Liv 
           
Kmonull K1296 KMO (HOM) M AP Null M13 08/06/16 16/11/16 161 B,Lun,Liv 
Kmonull K1297 KMO (HOM) M Sham Null M14 08/06/16 16/11/16 161 B,Lun,Liv 
Kmonull K1341 KMO (HOM) M AP Null M21 28/07/16 06/12/16 131 B,Lun,Liv 
Kmonull K1342 KMO (HOM) M Sham Null M22 28/07/16 06/12/16 131 B,Lun,Liv 
Kmonull K1343 KMO (HOM) M Sham Null M36 28/07/16 12/12/16 137 B,Lun,Liv 
Kmonull K1344 KMO (HOM) M AP Null M35 28/07/16 12/12/16 137 B,Lun,Liv 
Kmonull K1350 KMO (HOM) M AP Null M43 06/08/16 19/12/16 135 B,Lun,Liv 
Kmonull K1351 KMO (HOM) M Sham Null M44 06/08/16 19/12/16 135 B,Lun,Liv 
Kmonull K1369 KMO (HOM) M AP Null M51 11/09/16 09/01/17 120 B,Lun,Liv 
Kmonull K1370 KMO (HOM) M Sham Null M52 11/09/16 09/01/17 120 B,Lun,Liv 
Kmonull K1371 KMO (HOM) M AP Null M65 11/09/16 16/01/17 127 B,Lun,Liv 
Kmonull K1372 KMO (HOM) M Sham Null M66 11/09/16 16/01/17 127 B,Lun,Liv 
           
Kmoalb-cre A313 Cre(+) M Sham Alb-cre M26 20/07/16 06/12/16 139 B,Lun,Liv 
Kmoalb-cre A314 Cre(+) M AP Alb-cre M25 20/07/16 06/12/16 139 B,Lun,Liv 
Kmoalb-cre A320 Cre(+) M Sham Alb-cre M34 12/08/16 12/12/16 122 B,Lun,Liv 
Kmoalb-cre A322 Cre(+) M AP Alb-cre M33 12/08/16 12/12/16 122 B,Lun,Liv 
Kmoalb-cre A327 Cre(+) M AP Alb-cre M41 12/08/16 19/12/16 129 B,Lun,Liv 
Kmoalb-cre A328 Cre(+) M Sham Alb-cre M48 12/08/16 19/12/16 129 B,Lun,Liv 
Kmoalb-cre A339 Cre(+) M Sham Alb-cre M56 22/09/16 09/01/17 109 B,Lun,Liv 
Kmoalb-cre A340 Cre(+) M AP Alb-cre M55 22/09/16 09/01/17 109 B,Lun,Liv 
Kmoalb-cre A341 Cre(+) M Sham Alb-cre M62 22/09/16 16/01/17 116 B,Lun,Liv 
Kmoalb-cre A342 Cre(+) M AP Alb-cre M61 22/09/16 16/01/17 116 Lun 
Kmoalb-cre A343 Cre(+) M AP Alb-cre M71 22/09/16 31/01/17 131 B,Lun,Liv 
Kmoalb-cre A344 Cre(+) M Sham Alb-cre M72 22/09/16 31/01/17 131 B,Lun,Liv 
Kmoalb-cre A345 Cre(+) M AP Alb-cre M75 22/09/16 31/01/17 131 B,Lun,Liv 
Kmoalb-cre A346 Cre(+) M Sham Alb-cre M76 22/09/16 31/01/17 131 B,Lun,Liv 
Table 92. 24-hr exp. Outcome of study subjects – experiment 4 (flow cytometry) 
WT = Sham (n = 7), AP (n = 7); KMO = Sham (n = 7), AP (n = 7); Alb-cre: Sham (n = 7), AP (n = 7). 
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  % Ly6hi monos Comment 
FK608 Sham WT M24 54463 1.46 16.0 55.8 4367 2142 49.0  
FK609 AP WT M23 32527 0.03 75.7 90.9 1183 538 45.5  
FK616 AP WT M31 56519  3.73 71.5 85.7 2649 2255 85.1  
FK617 Sham WT M32 6347 - - - - - - Excluded. A 
FK618 AP WT M45 32730 1.95 22.7 69.6 1491 404 27.1  
FK619 Sham WT M46 52755 2.68 14.9 61.2 1940 685 35.3  
FKA331 AP WT M53 10409 1.49 38.3 53.7 854 287 33.6  
FKA332 Sham WT M54 53009 2.13 18.0 63.1 2579 979 38.0  
FK622 Sham WT M64 52185 1.72 18.0 62.8 2775 953 34.3  
FK624 AP WT M63 53198 0.02 83.1 91.7 2911 1898 65.2  
FK634 AP WT M73 56990 2.46 34.3 81.1 1990 874 43.9  
FK635 Sham WT M74 58524 3.76 30.8 73.5 2786 1265 45.4  
            
K1296 AP Null M13 22089 2.54 36.6 79.4 758 232 30.6  
K1297 Sham Null M14 22071 5.08 24.4 63.3 1373 318 23.2  
K1341 AP Null M21 53933 0.30 49.4 78.2 4289 3422 79.8  
K1342 Sham Null M22 54677 0.41 14.1 70.1 1622 768 47.3  
K1343 Sham Null M36 53868 1.80 15.9 67.4 1753 617 35.2  
K1344 AP Null M35 59271 0.23 69.6 78.8 3747 2445 65.3  
K1350 AP Null M43 28233 0.14 47.2 78.0 2147 625 29.1  
K1351 Sham Null M44 54018 2.63 19.2 66.9 1678 678 40.4  
K1369 AP Null M51 52057 1.25 40.5 78.6 2151 479 22.3  
K1370 Sham Null M52 52708 2.72 21.7 66.1 2032 1067 52.5  
K1371 AP Null M65 52663 0.85 17.5 76.2 1337 382 28.6  
K1372 Sham Null M66 52470 2.09 17.9 64.6 2467 1099 44.5  
            
A313 Sham Alb-cre M26 56538 2.53 18.8 64.2 2502 1290 51.6  
A314 AP Alb-cre M25 27689 0.07 80.8 90.0 1631 1206 73.9  
A320 Sham Alb-cre M34 53755 6.67 12.4 59.6 2332 1157 49.6  
A322 AP Alb-cre M33 32078 2.56 25.4 72.4 1154 492 42.6  
A327 AP Alb-cre M41 30935 0.23 30.4 75.8 1966 407 20.7  
A328 Sham Alb-cre M42 52558 1.51 13.1 57.4 2723 453 16.6  
A339 Sham Alb-cre M56 53082 2.91 23.4 59.6 4110 1749 42.6  
A340 AP Alb-cre M55 39709 2.95 18.1 64.3 1513 671 44.3  
A341 Sham Alb-cre M62 52632 2.43 16.3 56.3 3310 1236 37.3  
A342 AP Alb-cre M61 5614 - - - - - - Excluded. B. 
A343 AP Alb-cre M71 11094 0.03 60.2 87.9 550 347 63.1  
A344 Sham Alb-cre M72 56549 3.52 17.6 61.1 3058 1501 49.1  
A345 AP Alb-cre M75 56391 3.39 22.2 71.1 2094 445 21.3  
A346 Sham Alb-cre M76 57200 2.23 20.7 72.1 2216 864 39.0  
Table 93. Blood flow cytometry  
Comments - A: sample put on dry ice rather than wet ice, in error (excluded); B: cytometer wasted sample (excluded). n.c.: not 
calculated. Data: Blood flow analysis_current xls. 
 
  
Metabolic regulators of inflammation in acute pancreatitis                                                         S0897427 
Alastair J Hayes 
  - 248 -  
 
6.10. Appendix 10 – Supplementary data of 24h studies. Cont. 
 









FK608 WT/Sham M24 16.0 1.46 8.018 49.0  
FK617 WT/Sham M32 Excluded Excluded Excluded Excluded Excluded. A 
FK619 WT/Sham M46 14.9 2.68 3.677 35.3  
FKA332 WT/Sham M54 18.0 2.13 4.865 38.0  
FK622 WT/Sham M64 18.0 1.72 5.318 34.3  
FK635 WT/Sham M74 30.8 3.76 4.760 45.4  
        
FK609 WT/AP M23 75.7 0.03 3.637 45.5  
FK616 WT/AP M31 71.5 3.73 4.687 85.1  
FK618 WT/AP M45 22.7 1.95 4.555 27.1  
FKA331 WT/AP M53 38.3 1.49 8.204 33.6  
FK624 WT/AP M63 83.1 0.02 5.472 65.2  
FK634 WT/AP M73 34.3 2.46 3.492 43.9  
        
A313 Acre/Sham M26 18.8 2.53 4.425 51.6  
A320 Acre/Sham M34 12.4 1.39 4.338 49.6  
A328 Acre/Sham M42 13.1 1.51 5.181 16.6  
A339 Acre/Sham M56 23.4 2.91 7.743 42.6  
A341 Acre/Sham M62 16.3 2.43 6.289 37.3  
A344 Acre/Sham M72 17.6 3.52 5.408 49.1  
A346 Acre/Sham M76 20.7 2.23 3.874 39.0  
        
A314 Acre/AP M25 80.8 0.069 5.890 73.9  
A322 Acre/AP M33 25.4 2.560 3.597 42.6  
A327 Acre/AP M41 30.4 0.230 6.355 20.7  
A340 Acre/AP M55 18.1 2.950 3.810 44.3  
A342 Acre/AP M61 (71.5) Excluded Excluded Excluded Excluded. B 
A343 Acre/AP M71 60.2 0.027 4.958 63.1  
A345 Acre/AP M75 22.2 3.390 3.713 21.3  
        
K1297 Null/Sham M14 24.4 5.08 6.221 23.2  
K1342 Null/Sham M22 14.1 0.41 2.967 47.3  
K1343 Null/Sham M36 15.9 1.80 3.254 35.2  
K1351 Null/Sham M44 19.2 2.63 3.106 40.4  
K1370 Null/Sham M52 21.7 2.72 3.855 52.5  
K1372 Null/Sham M66 17.9 2.09 4.702 44.5  
        
K1296 Null/AP M13 36.6 2.54 3.432 30.6  
K1341 Null/AP M21 49.4 0.30 7.952 79.8  
K1344 Null/AP M35 69.6 0.23 6.322 65.3  
K1350 Null/AP M43 47.2 0.14 7.605 29.1  
K1369 Null/AP M51 40.5 1.25 4.132 22.3  
K1371 Null/AP M65 17.5 0.85 2.539 28.6  
Table 94. Blood flow cytometry calculations 
Comments - A: sample put on dry ice rather than wet ice, in error (excluded); B: cytometer wasted sample (excluded). 
n.c.: not calculated. Data: Blood flow analysis_current xls. 
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FK608 Sham WT M24 558718 242785 166449 63831 16290 3916 12256 9.79 21925 8079 6764  
FK609 AP WT M23 1110914 475434 277997 220870 143522 242 29209 51.60 30653 11139 9324  
FK616 AP WT M31 824957 410522 323117 192293 100262 13130 118945 31.0 38212 11477 9497  
FK617 Sham WT M32 657567 291811 229957 86186 30553 5189 14466 13.3 23188 9083 5813  
FK618 AP WT M45 486749 172592 133117 54137 15421 4827 13907 8.93 13722 3135 4191  
FK619 Sham WT M46 389115 170488 133859 45628 10895 5585 11139 8.14 12412 2834 3826  
FK622 Sham WT M64 285485 95892 71541 19016 5120 2316 3727 7.16 5269 1272 1134  
FK624 AP WT M63 143336 42059 24566 19868 12088 25 1602 49.20 4215 1833 584  
FK634 AP WT M73 606427 216954 146666 40890 11507 6218 5341 7.85 11164 2276 3117  
FK635 Sham WT M74 580486 194366 148375 33833 7548 5505 4175 5.09 11947 1801 2083  
FKA331 AP WT M53 829987 279097 143662 85166 25792 4949 16671 18.00 24451 6663 7141  
FKA332 Sham WT M54 457005 198121 142499 33162 6299 6287 4947 4.42 11849 2079 2441  
                
K1296 AP Null M13 304547 132419 97041 36474 15497 3898 3264 16.00 7382 1414  1532  
K1297 Sham Null M14 481390 152097 99197 34948 8300 6235 4714 8.37 10890 
check 
1789  2025 
check 
 
K1312 Sham Null M02A 315199 132064 95388 26127 11655 1973 3438 12.2 6837 1853  1395  
K1313 AP Null M01A 548255 158891 96164 67457 39874 62 10487 41.5 12242 6801  2409  
K1341 AP Null M21 587271 292416 163185 90663 49507 728 14769 30.30 18035 10888  5270  
K1342 Sham Null M22 583224 240679 165000 49093 14545 1216 11783 8.82 15293 4492  4373  
K1343 Sham Null M36 647757 294662 210793 76223 18919 6989 14251 8.98 26789 7263 4695  
K1344 AP Null M35 2113229 672023 400738 329634 165456 158 38628 41.3 74572 20268  8407  
K1350 AP Null M43 549507 205537 135123 91035 42820 246 13394 31.7 25253 7401 5953  
K1351 Sham Null M44 374139 173342 132464 54395 15048 5818 13930 11.4 13405 2910 3732  
K1369 AP Null M51 557687 224047 143709 50703 22025 3037 10242 15.30 10158 1641 3596  
K1370 Sham Null M52 462645 209295 142780 43904 12051 9895 8846 8.44 9164 2181  2742  
K1371 AP Null M65 614019 209805 145614 33843 9811 3355 7268 6.74 8265 1751  2736  
K1372 Sham Null M66 543002 196689 145571 35712 8242 6720 6259 5.66 10228 2711  2086  
                
A313 Sham Alb-cre M26 682448 271858 15882 60902 17252 6888 9219 10.90 20184 7318  4747  
A314 AP Alb-cre M25 449091 238271 171452 147260 108516 405 10389 63.30 19277 11325  4467  
A320 Sham Alb-cre M34 739932 291390 212366 64014 15129 6127 10390 7.12 23961 9468  5536  
A322 AP Alb-cre M33 849278 304504 221297 74956 17820 7047 14066 8.05 17820 7337 5807  
A327 AP Alb-cre M41 542331 195636 106972 55285 21672 311 14196 20.3 12199 2633  4287  
A328 Sham Alb-cre M42 398911 192631 132271 45834 8826 3858 10649 6.67 15727 2493  4580  
A339 Sham Alb-cre M56 397996 151473 111161 31973 6584 4295 7822 5.92 8762 2109  2712  
A340 AP Alb-cre M55 487527 204654 145336 43955 8747 8118 10761 6.02 10954 2144  2892  
A341 Sham Alb-cre M62 610217 219598 145294 42908 10085 6599 8133 6.94 12216 3758  2851  
A342 AP Alb-cre M61 836330 268087 145505 118950 73842 242 10872 50.7 23087 11845  3108  
A343 AP Alb-cre M71 1395958 258104 150391 91085 32638 154 15188 21.7 29479 9364  5263  
A344 Sham Alb-cre M72 457488 175658 148385 32499 6697 7713 3694 4.51 9775 2147 1851  
A345 AP Alb-cre M75 624278 196758 151233 41441 8644 6872 6915 5.72 12761 1578  2492  
A346 Sham Alb-cre M76 549217 194242 150346 40066 8390 7232 5829 5.58 12223 2450  2484  
Table 95. Lung flow cytometry 
File: lung flow analysis_current 
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%Monos - Lung 
Comments 
FK608 WT/Sham M24 9.79 2.3527 13.172 36.848  
FK617 WT/Sham M32 13.3 2.2565 10.084 39.171  
FK619 WT/Sham M46 8.14 4.1723 9.272 22.833  
FKA332 WT/Sham M54 4.42 4.4120 8.315 17.546  
FK622 WT/Sham M64 7.16 3.2373 7.365 24.141  
FK635 WT/Sham M74 5.09 3.7102 8.052 15.075  
        
FK609 WT/AP M23 51.60 0.0871 11.026 36.339  
FK616 WT/AP M31 31.03 4.0635 11.826 30.035  
FK618 WT/AP M45 8.93 3.6261 10.308 22.847  
FKA331 WT/AP M53 18.00 3.4449 17.020 27.250  
FK624 WT/AP M63 49.20 0.1018 17.158 43.488  
FK634 WT/AP M73 7.85 4.2396 7.612 20.387  
        
A313 Acre/Sham M26 10.90 4.3370 12.709 36.256  
A320 Acre/Sham M34 7.12 2.8851 11.283 39.514  
A328 Acre/Sham M42 6.67 2.9167 11.890 15.852  
A339 Acre/Sham M56 5.92 3.8638 7.882 24.070  
A341 Acre/Sham M62 6.94 4.5418 8.408 30.763  
A344 Acre/Sham M72 4.51 5.1980 6.588 21.964  
A346 Acre/Sham M76 5.58 4.8102 8.130 20.044  
        
A314 Acre/AP M25 63.30 0.2362 11.243 58.749  
A322 Acre/AP M33 8.05 3.1844 12.080 41.173  
A327 Acre/AP M41 20.26 0.2907 11.404 21.584  
A340 Acre/AP M55 6.02 5.5857 7.537 19.573  
A342 Acre/AP M61 50.70 0.1663 15.867 51.306  
A343 Acre/AP M71 21.70 0.1024 19.602 31.765  
A345 Acre/AP M75 5.72 4.5440 8.438 12.366  
        
K1297 Null/Sham M14 8.37 6.2855 10.978 16.428  
K1342 Null/Sham M22 8.82 0.7370 9.268 29.373  
K1343 Null/Sham M36 8.98 3.3156 12.709 27.112  
K1351 Null/Sham M44 11.40 4.3921 10.120 21.708  
K1370 Null/Sham M52 8.44 6.9302 6.418 23.800  
K1372 Null/Sham M66 5.66 4.6163 7.026 26.506  
        
K1296 Null/AP M13 16.00 4.0169 7.607 19.155  
K1341 Null/AP M21 30.30 0.4461 11.052 60.371  
K1344 Null/AP M35 41.30 0.0394 18.609 27.179  
K1350 Null/AP M43 31.70 0.1821 18.689 29.307  
K1369 Null/AP M51 15.30 2.1133 7.068 16.155  
K1371 Null/AP M65 6.74 2.3040 5.676 21.186  
Table 96. Lung flow cytometry calculations 
File: lung flow analysis_current 
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NonDC Ly6Chi        
infilt monos 
%Ly6Chi        
infilt monos 
Notes 
FKA307 AP WT  M03A 355551 134834 42882 27665 9376 451 4492 5541 4624 1785 38.6  
FK592 Sham WT M04A 358210 152298 43813 15021 2072 1726 2629 2967 2510 982 39.1  
FK608 Sham WT M24 350214 162624 64609 24832 4031 2508 2687 8086 6243 2788 44.7  
FK609 AP WT M23 334562 170965 65828 27540 7017 718 5468 6722 5389 1853 34.4  
FK616 AP WT M31 249449 158614 113339 55057 32708 4737 953 6307 4188 1923 45.9  
FK617 Sham WT M32 506741 250841 124635 35239 10144 3104 2732 8628 6349 2937 46.3  
FK618 AP WT M45 414836 205948 82874 53094 5687 2499 13630 11912 9801 3432 35.0  
FK619 Sham WT M46 517256 242776 87185 48593 8137 4350 7676 13215 10645 2869 27.0  
FK622 Sham WT M64 674442 199401 72117 40210 4355 3881 13413 7403 6438 2903 45.1  
FK624 AP WT M63 307184 130810 94006 67030 25973 1719 1384 12664 10526 2981 28.3  
FK634 AP WT M73 860622 190234 76960 37873 12404 2030 9755 6720 5576 2062 37.0  
FK635 Sham WT M74 862496 191338 81518 34255 7573 3889 7521 8105 6956 2838 40.8  
FKA331 AP WT M53 2087156 162290 93915 65081 18990 1725 14186 17356 15062 3402 22.6  
FKA332 Sham WT M54 1804763 147207 70112 33779 4714 4314 9449 5016 4141 1013 24.5  
                
K1296 AP Null M13 720839 170349 86629 38728 11401 3145 7137 8423 7348 4125 56.1  
K1297 Sham Null M14 1004767 199449 76831 31699 5056 4150 6844 7728 5971 2701 45.2  
K1312 Sham Null M02A 647283 193144 41934 15175 1892 1139 3185 3886 3165 1032 32.6  
K1313 AP Null M01A 452003 163750 40681 21104 4564 148 3994 5602 4890 1562 31.9  
K1341 AP Null M21 327068 154996 68808 32276 7002 656 5161 9706 8414 4491 53.4  
K1342 Sham Null M22 402076 201027 77955 34882 6915 1368 5169 10108 8077 3663 45.4  
K1343 Sham Null M36 2195200 244377 96781 28038 9191 3961 806 6933 5260 1407 26.7  
K1344 AP Null M35 775897 377763 161227 71289 32679 618 2163 9230 8363 4286 51.2  
K1350 AP Null M43 479626 226509 83876 69937 21863 360 12524 10284 8609 3173 36.9  
K1351 Sham Null M44 976326 188248 84071 40620 4446 2145 9854 6374 5306 1855 35.0  
K1369 AP Null M51 616855 142550 77124 41046 10004 1065 10262 12188 10241 4340 42.4  
K1370 Sham Null M52 691771 192712 95401 38061 8124 5022 4478 11305 9061 3167 35.0  
K1371 AP Null M65 145121 53787 22320 10961 1838 532 2741 3015 2661 895 33.6  
K1372 Sham Null M66 108026 49039 21944 8307 1715 1153 683 2731 2292 778 33.9  
                
A313 Sham Alb-cre M26 318264 140377 55490 22635 5796 1912 2871 6005 4726 2033 43.0  
A314 AP Alb-cre M25 387452 193481 81990 41853 14861 2155 4296 10004 8185 3542 43.3  
A320 Sham Alb-cre M34 1410767 314482 108115 38365 11775 6893 1836 9052 6489 2725 42.0  
A322 AP Alb-cre M33 1046319 355058 165157 37240 12737 2492 2141 10402 7997 3665 45.8  
A327 AP Alb-cre M41 511355 250719 89679 67372 8928 704 22310 9196 7606 1931 25.4  
A328 Sham Alb-cre M42 693340 230502 89580 57479 3690 1979 16806 7255 5656 1833 32.4  
A339 Sham Alb-cre M56 451959 136867 83750 42271 5421 6171  6812 10881 8595 2580 30.0  
A340 AP Alb-cre M55 287749 78382 40684 20661 3365 1510 7121 3668 2821 961 34.1  
A341 Sham Alb-cre M62 533704 159075 51866 31373 3567 2974 9369 5228 4643 1983 42.7  
A342 AP Alb-cre M61 19237 523 91 - - - - - - - - Excluded. 
A343 AP Alb-cre M71 845302 236074 75300 49842 12450 746 13576 14057 12206 2880 23.6  
A344 Sham Alb-cre M72 894484 226732 69424 37439 5001 5210 12606 5918 5170 1859 36.0  
A345 AP Alb-cre M75 694537 165695 80734 47357 11269 3383 7568 16806 14884 7187 48.3  
A346 Sham Alb-cre M76 809360 214213 85212 33452 9399 6603 2506 6916 5693 1777 31.2  
Table 97. Liver flow cytometry 
Comment: Cytometer wasted sample and remainder insufficient (A342). 
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%Monos - Liver 
Comments 
FK608 WT/Sham M24 6.24 3.88 12.52 44.66  
FK617 WT/Sham M32 8.14 2.49 6.92 46.26  
FK619 WT/Sham M46 9.33 4.99 15.16 26.95  
FKA332 WT/Sham M54 6.72 6.15 7.15 24.46  
FK622 WT/Sham M64 6.04 5.38 10.27 45.09  
FK635 WT/Sham M74 9.29 4.77 9.94 40.80  
        
FK609 WT/AP M23 10.66 1.09 10.21 34.38  
FK616 WT/AP M31 28.86 4.18 5.56 45.92  
FK618 WT/AP M45 6.86 3.02 14.37 35.02  
FKA331 WT/AP M53 20.22 1.84 18.48 22.59  
FK624 WT/AP M63 27.63 1.83 13.47 28.32  
FK634 WT/AP M73 16.12 2.64 8.73 36.98  
        
A313 Acre/Sham M26 10.45 3.45 10.82 43.02  
A320 Acre/Sham M34 10.89 6.38 8.37 41.99  
A328 Acre/Sham M42 4.12 2.21 8.10 32.41  
A339 Acre/Sham M56 6.47 7.37 12.99 30.02  
A341 Acre/Sham M62 6.88 5.73 10.08 42.71  
A344 Acre/Sham M72 7.20 7.50 8.52 35.96  
A346 Acre/Sham M76 11.03 7.75 8.12 31.21  
        
A314 Acre/AP M25 18.13 2.63 12.20 43.27  
A322 Acre/AP M33 7.71 1.51 6.30 45.83  
A327 Acre/AP M41 9.96 0.79 10.25 25.39  
A340 Acre/AP M55 8.27 3.71 9.02 34.07  
A342 Acre/AP M61   Cytometer wasted  sample Excluded. A 
A343 Acre/AP M71 16.53 0.99 18.67 23.59  
A345 Acre/AP M75 13.96 4.19 20.82 48.29  
        
K1297 Null/Sham M14 6.58 5.40 10.06 45.24  
K1342 Null/Sham M22 8.87 1.75 12.97 45.35  
K1343 Null/Sham M36 9.50 4.09 7.16 26.75  
K1351 Null/Sham M44 5.29 2.55 7.58 34.96  
K1370 Null/Sham M52 8.52 5.26 11.85 34.95  
K1372 Null/Sham M66 7.82 5.25 12.45 33.94  
        
K1296 Null/AP M13 13.16 3.63 9.72 56.14  
K1341 Null/AP M21 10.18 0.95 14.11 53.38  
K1344 Null/AP M35 20.27 0.38 5.72 51.25  
K1350 Null/AP M43 26.07 0.43 12.26 36.86  
K1369 Null/AP M51 12.97 1.38 15.80 42.38  
K1371 Null/AP M65 8.23 2.38 13.51 33.63  
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Group [3HK] uM 
A367 – 0.25mg/ml oral 0.084998 
A368 – 0.25mg/ml oral 0.054414 
A403 – 0.25mg/ml oral 0.084958 
A405 – 0.25mg/ml oral  0.045746 
A369 – Vehicle/ drinking water 0.715227 
A370 – Vehicle/ drinking water 0.407366 
A404 – Vehicle/ drinking water 0.179525 
A406 – Vehicle/ drinking water 0.464352 
KMOG11- 967 / drinking water 0.044601 (LOD) 
KMOG11-997/ drinking water 0.044601 (LOD) 
KMOG11-1027/ drinking water 0.044601 (LOD) 
KMOG11-1057/ drinking water 0.044601 (LOD) 
Table 99. Pilot work testing lower dose of GSK898 (0.25 mg/ml drinking water) 
 
 
Line ID Sex Weight DOB Age (d) Telem Gene Start  Surgery Date Finish  Rx 
Kmoalb-cre A369 M 30.82 10/11/16 151 n/a Cre(+) 10/04/17 n/a 14/04/17 Vehicle w. 
Kmoalb-cre A370 M 31.52 10/11/16 151 n/a Cre(+) 10/04/17 n/a 14/04/17 Vehicle w. 
Kmoalb-cre A404 M 26.40 13/01/17 91 n/a Cre(+) 10/04/17 n/a 14/04/17 Vehicle w. 
Kmoalb-cre A406 M 26.48 13/01/17 91 n/a Cre(+) 10/04/17 n/a 14/04/17 Vehicle w. 
Kmoalb-cre A395 M 27.40 04/12/16 152 n/a Cre(+) 05/05/17 n/a 09/05/17 0.5mg/ml w. (4d) 
Kmoalb-cre A396 M 27.32 04/12/16 152 n/a Cre(+) 05/05/17 n/a 09/05/17 0.5mg/ml w. (4d) 
Kmoalb-cre A428 M 25.75 18/01/17 107 n/a Cre(+) 05/05/17 n/a 09/05/17 0.5mg/ml w. (4d) 
Kmoalb-cre A429 M 26.70 18/01/17 107 n/a Cre(+) 05/05/17 n/a 09/05/17 0.5mg/ml w. (4d) 
            Kmoalb-cre A381 M 26.15 30/11/16 147 EM-21 Cre(+) 22/04/17 26/04/17 03/05/17 AP + 0.5mg/ml w. 
Kmoalb-cre A383 M 28.71 30/11/16 147 EM-22 Cre(+) 22/04/17 26/04/17 01/05/17 AP + 0.5mg/ml w. 
Kmoalb-cre A384 M 29.50 30/11/16 147 EM-24 Cre(+) 22/04/17 26/04/17 03/05/17 AP + 0.5mg/ml w. 
Kmoalb-cre A388 M 29.41 30/11/16 148 EM-28 Cre(+) 23/04/17 27/04/17 02/05/17 AP + 0.5mg/ml w. 
Kmoalb-cre A390 M 27.77 04/12/16 144 EM-25 Cre(+) 23/04/17 27/04/17 04/05/17 AP + 0.5mg/ml w. 
Kmoalb-cre A391 M 27.44 04/12/16 144 EM-27 Cre(+) 23/04/17 27/04/17 01/05/17 AP + 0.5mg/ml w. 
Kmoalb-cre A392 M 29.43 04/12/16 151 EM-21 Cre(+) 30/04/17 04/05/17 05/05/17 AP + 0.5mg/ml w. 
Kmoalb-cre A393 M 29.41 04/12/16 151 EM-24 Cre(+) 30/04/17 04/05/17 10/05/17 AP + 0.5mg/ml w. 
            Kmoalb-cre A382 M 29.20 30/11/16 147 EM-23 Cre(+) 22/04/17 26/04/17 03/05/17 AP + vehicle w. 
Kmoalb-cre A386 M 30.42 30/11/16 148 EM-26 Cre(+) 23/04/17 27/04/17 28/04/17 AP + vehicle w. 
Kmoalb-cre A394 M 26.63 04/12/16 151 EM-23 Cre(+) 30/04/17 04/05/17 11/05/17 AP + vehicle w. 
Kmoalb-cre A226 M 26.59 28/02/16 155 EM-22 Cre(+) 28/07/17 01/08/16 03/08/16 AP + vehicle w. 
Kmoalb-cre A235 M 29.76 21/03/16 134 EM-25 Cre(+) 29/07/17 02/08/16 04/08/16 AP + vehicle w. 
Kmoalb-cre A238 M 31.41 04/04/16 134 EM-22 Cre(+) 12/08/17 16/08/16 23/08/16 AP + vehicle w. 
Kmoalb-cre A241 M 29.89 06/04/16 132 EM-23 Cre(+) 12/08/17 16/08/16 23/08/16 AP + vehicle w. 
Kmoalb-cre A244 M 28.43 06/04/16 133 EM-24 Cre(+) 13/08/17 17/08/16 24/08/16 AP + vehicle w. 
Kmoalb-cre A246 M 28.01 06/04/16 133 EM-26 Cre(+) 13/08/17 17/08/16 19/08/16 AP + vehicle w. 
Kmoalb-cre A272 M 28.85 16/04/16 136 EM-23 Cre(+) 26/08/17 30/08/16 01/09/16 AP + vehicle w. 
Kmoalb-cre A265 M 27.25 16/04/16 136 EM-22 Cre(+) 26/08/17 30/08/16 31/08/16 AP + vehicle w. 
Kmoalb-cre A280 M 29.00 29/04/16 130 EM-23 Cre(+) 02/08/17 06/09/16 13/09/16 AP + vehicle w. 
Kmoalb-cre A281 M 28.72 29/04/16 130 EM-22 Cre(+) 02/08/17 06/09/16 07/09/16 AP + vehicle w. 
            Kmoalb-cre A227 M 27.36 28/02/16 155 EM-23 Cre(+) 28/07/17 01/08/16 08/08/16 Sham + vehicle w. 
Kmoalb-cre A234 M 30.55 21/03/16 134 EM-28 Cre(+) 29/07/17 02/08/16 09/08/16 Sham + vehicle w. 
Kmoalb-cre A243 M 27.60 06/04/16 132 EM-21 Cre(+) 12/08/17 16/08/16 23/08/16 Sham + vehicle w. 
Kmoalb-cre A252 M 27.37 09/04/16 130 EM-25 Cre(+) 13/08/17 17/08/16 24/08/16 Sham + vehicle w. 
Kmoalb-cre A253 M 28.00 09/04/16 143 EM-24 Cre(+) 26/08/17 30/08/16 06/09/16 Sham + vehicle w. 
Kmoalb-cre A270 M 27.93 16/04/16 136 EM-21 Cre(+) 26/07/17 30/08/16 06/09/16 Sham + vehicle w. 
Kmoalb-cre A282 M 29.54 29/04/16 130 EM-23 Cre(+) 02/08/17 06/09/16 13/09/16 Sham + vehicle w. 
Table 100. Drinking water drug study subjects 
Experiment 5. Oral drug. 0.5mg/ml 898 drinking. Same scales instrument for all weight measurements. 
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Line ID Weight Age (d) Rx Survival (h) End weight (g) Weight loss (%) 
        Kmoalb-cre A381 26.15 147 AP + 0.5mg/ml w. 168.0 26.77 -2.37 
Kmoalb-cre A383 28.71 147 AP + 0.5mg/ml w. 122.6 23.74 17.31 
Kmoalb-cre A384 29.50 147 AP + 0.5mg/ml w. 168.0 24.77 16.03 
Kmoalb-cre A388 29.41 148 AP + 0.5mg/ml w. 122.6 23.74 19.28 
Kmoalb-cre A390 27.77 144 AP + 0.5mg/ml w. 168.0 23.51 15.34 
Kmoalb-cre A391 27.44 144 AP + 0.5mg/ml w. 101.5 25.23 8.05 
Kmoalb-cre A392 29.43 151 AP + 0.5mg/ml w. 31.3 28.64 2.68 
Kmoalb-cre A393 29.41 151 AP + 0.5mg/ml w. 115.8 23.64 19.62 
        Kmoalb-cre A382 29.20 147 AP + vehicle w. 168.0 25.70 11.99 
Kmoalb-cre A386 30.42 148 AP + vehicle w. 20.5 29.75 2.20 
Kmoalb-cre A394 26.63 151 AP + vehicle w. 168.0 25.92 2.67 
Kmoalb-cre A226 26.59 155 AP + vehicle w. 52.9 24.67  7.22 
Kmoalb-cre A235 29.76 134 AP + vehicle w. 46.5 27.92  6.18 
Kmoalb-cre A238 31.41 134 AP + vehicle w. 168.0 22.98  26.84 
Kmoalb-cre A241 29.89 132 AP + vehicle w. 168.0 28.47  4.75 
Kmoalb-cre A244 28.43 133 AP + vehicle w. 168.0 24.10  15.23 
Kmoalb-cre A246 28.01 133 AP + vehicle w. 48.0 25.11  10.35 
Kmoalb-cre A272 28.85 136 AP + vehicle w. 47.8 25.44 11.820 
Kmoalb-cre A265 27.25 136 AP + vehicle w. 23.4 27.68 Gain 1.578 
Kmoalb-cre A280 29.00 130 AP + vehicle w. 168.0 27.22 6.138 
Kmoalb-cre A281 28.72 130 AP + vehicle w. 29.2 28.97 Gain 0.870 
        Kmoalb-cre A227 27.36 155 Sham + vehicle w. 168.0 26.16 4.386 
Kmoalb-cre A234 30.55 134 Sham + vehicle w. 168.0 27.19 10.998 
Kmoalb-cre A243 27.60 132 Sham + vehicle w. 168.0 26.66 3.406 
Kmoalb-cre A252 27.37 130 Sham + vehicle w. 168.0 25.32 7.490 
Kmoalb-cre A253 28.00 143 Sham + vehicle w. 168.0 26.75 4.464 
Kmoalb-cre A270 27.93 136 Sham + vehicle w. 168.0 25.07 10.240 
Kmoalb-cre A282 29.54 130 Sham + vehicle w. 168.0 27.94 5.416 
Table 101. Outcome of drinking water drug study subjects (survival and weight loss) 
Experiment 5. Oral drug. 0.5mg/ml 898 drinking. Same scales instrument for all weight measurements. 
 
 






Activity / hr  
Kmoalb-cre A381 AP + 0.5mg/ml w. EM-21 168.0 No 168.00 76879 457.6 
Kmoalb-cre A383 AP + 0.5mg/ml w. EM-22  Yes 122.55 49177 401.3 
Kmoalb-cre A384 AP + 0.5mg/ml w. EM-24 168.0 No 168.00 111941 666.3 
Kmoalb-cre A388 AP + 0.5mg/ml w. EM-28  Yes 122.58 57635 470.2 
Kmoalb-cre A390 AP + 0.5mg/ml w. EM-25 168.0 No 168.00 102015 607.2 
Kmoalb-cre A391 AP + 0.5mg/ml w. EM-27  Yes 101.42 39841 392.8 
Kmoalb-cre A392 AP + 0.5mg/ml w. EM-21  Yes 29.50 33106 1122.2 
Kmoalb-cre A393 AP + 0.5mg/ml w. EM-24  Yes 115.50 80817 699.7 
         Kmoalb-cre A382 AP + vehicle w. EM-23 168.0 No 168.00 85083 506.4 
Kmoalb-cre A386 AP + vehicle w. EM-26  Yes 20.30 4341 213.8 
Kmoalb-cre A394 AP + vehicle w. EM-23 168.0 No 168.00 124634 741.9 
Kmoalb-cre A226 AP + vehicle w. EM-22  Yes 50.12 13136 262.1 
Kmoalb-cre A235 AP + vehicle w. EM-25  Yes 44.33 17651 398.2 
Kmoalb-cre A238 AP + vehicle w. EM-22 168.0 No 168.00 117908 701.8 
Kmoalb-cre A241 AP + vehicle w. EM-23 168.0 No 168.00 103024 613.2 
Kmoalb-cre A244 AP + vehicle w. EM-24 168.0 No 168.00 68024 404.9 
Kmoalb-cre A246 AP + vehicle w. EM-26  Yes 46.75 39641 847.9 
Kmoalb-cre A272 AP + vehicle w. EM-23  Yes 45.53 42421 931.7 
Kmoalb-cre A265 AP + vehicle w. EM-22  Yes 22.38 5089 227.4 
Kmoalb-cre A280 AP + vehicle w. EM-23 168.0 No 168.00 117205 697.6 
Kmoalb-cre A281 AP + vehicle w. EM-22  Yes 28.22 13095 464.0 
         Kmoalb-cre A227 Sham + vehicle w. EM-23 168.0 No 168.00 155445 925.3 
Kmoalb-cre A234 Sham + vehicle w. EM-28 168.0 No 168.00 105159 625.9 
Kmoalb-cre A243 Sham + vehicle w. EM-21 168.0 No 168.00 160670 956.4 
Kmoalb-cre A252 Sham + vehicle w. EM-25 168.0 No 168.00 178645 1063.4 
Kmoalb-cre A253 Sham + vehicle w. EM-24 168.0 No 168.00 142455 847.9 
Kmoalb-cre A270 Sham + vehicle w. EM-21 168.0 No 168.00 147469 877.8 
Kmoalb-cre A282 Sham + vehicle w. EM-23 168.0 No 168.00 166382 990.4 
Table 102. Outcome of drinking water drug study subjects (telemetry) 
Experiment 5. Oral drug. 0.5mg/ml 898 drinking. Same scales instrument for all weight measurements. 
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Line ID Gene Sex DOB Pump Pump 
insert 





Kmoalb-cre A407 Cre(+) M 13/01/17 A (898) 30/05/17 n/a 02/06/17 137 Drug 31.10 na Acre/ Drug 
Kmoalb-cre A408 Cre(+) M 13/01/17 B (V) 30/05/17 n/a 02/06/17 137 Vehicle 30.12 na Acre/ Vehicle 
Kmoalb-cre A409 Cre(+) M 13/01/17 C (898) 30/05/17 n/a 02/06/17 137 Drug 26.19 na Acre/ Drug 
Kmoalb-cre A433 Cre(+) M 18/01/17 L (V) 09/06/17 n/a 12/06/17 132 Vehicle 26.02 na Acre/ Vehicle 
              Kmoalb-cre A411 Cre(+) M 13/01/17 D (898) 30/05/17 02/06/17 09/06/17 140 AP + Drug 29.63 EM-25 Acre/ AP/ Drug 
Kmoalb-cre A420 Cre(+) M 16/01/17 F (898) 30/05/17 02/06/17 09/06/17 137 AP + Drug 30.39 EM-28 Acre/ AP/ Drug 
Kmoalb-cre A430 Cre(+) M 18/01/17 H (898) 02/06/17 05/06/17 12/06/17 138 AP + Drug 26.23 EM-24 Acre/ AP/ Drug 
Kmoalb-cre A431 Cre(+) M 18/01/17 J (898) 02/06/17 05/06/17 12/06/17 138 AP + Drug 26.67 EM-21 Acre/ AP/ Drug 
Kmoalb-cre A436 Cre(+) M 03/03/17 M (898) 16/06/17 19/06/17 26/06/17 108 AP + Drug 26.82 EM-23 Acre/ AP/ Drug 
Kmoalb-cre A438 Cre(+) M 03/03/17 O (898) 16/06/17 19/06/17 26/06/17 108 AP + Drug 28.35 EM-24 Acre/ AP/ Drug 
Kmoalb-cre A452 Cre(+) M 27/04/17 X (898) 24/06/17 27/06/17 04/07/17 61 AP + Drug 21.88 EM-24 Acre/ AP/ Drug 
              Kmoalb-cre A415 Cre(+) M 13/01/17 E (V) 30/05/17 02/06/17 03/06/17 140 AP + V 30.12 EM-26 Acre/ AP/ Vehicle 
Kmoalb-cre A416 Cre(+) M 13/01/17 G (V) 30/05/17 02/06/17 09/06/17 140 AP + V 29.12 EM-27 Acre/ AP/ Vehicle 
Kmoalb-cre A421 Cre(+) M 16/01/17 I (V) 02/06/17 05/06/17 12/06/17 140 AP + V 30.05 EM-22 Acre/ AP/ Vehicle 
Kmoalb-cre A432 Cre(+) M 18/01/17 K (V) 02/06/17 05/06/17 12/06/17 138 AP + V 26.88 EM-23 Acre/ AP/ Vehicle 
Kmoalb-cre A439 Cre(+) M 03/03/17 P (V) 16/06/17 19/06/17 26/06/17 105 AP + V 25.59 EM-21 Acre/ AP/ Vehicle 
Kmoalb-cre A422 Cre(+) M 16/01/17 S (V) 17/06/17 20/06/17 27/06/17 155 AP + V 29.92 EM-27 Acre/ AP/ Vehicle 
Kmoalb-cre A440 Cre(+) M 03/03/17 Q (V) 17/06/17 20/06/17 27/06/17 109 AP + V 26.37 EM-26 Acre/ AP/ Vehicle 
Kmoalb-cre A449 Cre(+) M 27/04/17 Y (V) 24/06/17 27/06/17 04/07/17 61 AP + V 24.76 EM-23 Acre/ AP/ Vehicle 
Kmoalb-cre A450 Cre(+) M 27/04/17 Z (V) 24/06/17 27/06/17 28/06/17 61 AP + V 24.21 EM-21 Acre/ AP/ Vehicle 
Kmoalb-cre A451 Cre(+) M 27/04/17 A2 (V) 24/06/17 27/06/17 04/07/17 61 AP + V 23.11 EM-22 Acre/ AP/ Vehicle 
Table 103. Minipump drug study subjects 
Drug: KMO inhibitor GSK898 250mg/ml in 50:50 DMSO:PEG; Vehicle: 50:50 DMSO:PEG, no drug. 
Nb. A445 (pump R, 898) excluded due to operative failure and underwent schedule 1 cull (20/06/17). 
 
 
Line ID Pump Group Weight (g) End weight (g) Weight loss (%) Survival 
Kmoalb-cre A411 D (898) Acre/ AP/ Drug 29.63 27.54 7.05 168.0 
Kmoalb-cre A420 F (898) Acre/ AP/ Drug 30.39 29.96 1.41 168.0 
Kmoalb-cre A430 H (898) Acre/ AP/ Drug 26.23 26.49 Gain 0.99  168.0 
Kmoalb-cre A431 J (898) Acre/ AP/ Drug 26.67 24.35 8.70 168.0 
Kmoalb-cre A436 M (898) Acre/ AP/ Drug 26.82 22.19 17.26 166.8 
Kmoalb-cre A438 O (898) Acre/ AP/ Drug 28.35 28.04 1.09 168.0 
Kmoalb-cre A452 X (898) Acre/ AP/ Drug 21.88 19.83 9.37 168.0 
        Kmoalb-cre A415 E (V) Acre/ AP/ Vehicle 30.12 28.96 3.85 23.5 
Kmoalb-cre A416 G (V) Acre/ AP/ Vehicle 29.12 25.05 13.98 168.0 
Kmoalb-cre A421 I (V) Acre/ AP/ Vehicle 30.05 28.57 4.93 168.0 
Kmoalb-cre A432 K (V) Acre/ AP/ Vehicle 26.88 25.30 5.88 168.0 
Kmoalb-cre A439 P (V) Acre/ AP/ Vehicle 25.59 22.20 13.25 168.0 
Kmoalb-cre A422 S (V) Acre/ AP/ Vehicle 29.92 23.95 19.95 168.0 
Kmoalb-cre A440 Q (V) Acre/ AP/ Vehicle 26.37 23.17 12.14 168.0 
Kmoalb-cre A449 Y (V) Acre/ AP/ Vehicle 24.76 22.40 9.53 168.0 
Kmoalb-cre A450 Z (V) Acre/ AP/ Vehicle 24.21 22.32 7.81 28.9 
Kmoalb-cre A451 A2 (V) Acre/ AP/ Vehicle 23.11 18.71 19.04 168.0 
Table 104. Outcome of minipump drug study subjects (survival and weight loss) 
Drug: KMO inhibitor GSK898 250mg/ml in 50:50 DMSO:PEG; Vehicle: 50:50 DMSO:PEG, no drug. 
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6.11. Appendix 11 – Supplementary data of experiment 5 (drug studies). Cont. 
 
Line ID Pump Group Telem Survival Humane 
endpoint 
Telemetry time Activity Total Activity / hr  
Kmoalb-cre A411 D (898) Acre/ AP/ Drug EM-25 168.0 No 168.00 149803 891.7 
Kmoalb-cre A420 F (898) Acre/ AP/ Drug EM-28 168.0 No 168.00 125734 748.4 
Kmoalb-cre A430 H (898) Acre/ AP/ Drug EM-24 168.0 No 168.00 111544 664.0 
Kmoalb-cre A431 J (898) Acre/ AP/ Drug EM-21 168.0 No 168.00 61034 363.3 
Kmoalb-cre A436 M (898) Acre/ AP/ Drug EM-23 166.8 Yes 165.17 81721 494.8 
Kmoalb-cre A438 O (898) Acre/ AP/ Drug EM-24 168.0 No 168.00 112290 668.4 
Kmoalb-cre A452 X (898) Acre/ AP/ Drug EM-24 168.0 No 168.00 63091 375.5 
          Kmoalb-cre A415 E (V) Acre/ AP/ Vehicle EM-26 23.5 Yes  21.43 5974 278.8 
Kmoalb-cre A416 G (V) Acre/ AP/ Vehicle EM-27 168.0 No 168.00 65485 389.8 
Kmoalb-cre A421 I (V) Acre/ AP/ Vehicle EM-22 168.0 No 168.00 123059 732.5 
Kmoalb-cre A432 K (V) Acre/ AP/ Vehicle EM-23 168.0 No 168.00 106879 636.2 
Kmoalb-cre A439 P (V) Acre/ AP/ Vehicle EM-21 168.0 No 168.00 120473 717.1 
Kmoalb-cre A422 S (V) Acre/ AP/ Vehicle EM-27 168.0 No 168.00 74368 442.7 
Kmoalb-cre A440 Q (V) Acre/ AP/ Vehicle EM-26 168.0 No 168.00 81593 485.7 
Kmoalb-cre A449 Y (V) Acre/ AP/ Vehicle EM-23 168.0 No 168.00 77597 461.9 
Kmoalb-cre A450 Z (V) Acre/ AP/ Vehicle EM-21 28.9 Yes 26.91 11086 426.4 
Kmoalb-cre A451 A2 (V) Acre/ AP/ Vehicle EM-22 168.0 No 168.00 26542 158.0 
Table 105. Outcome of minipump drug study subjects (telemetry) 
Drug: KMO inhibitor GSK898 250mg/ml in 50:50 DMSO:PEG; Vehicle: 50:50 DMSO:PEG, no drug 
 
 











Kmoalb-cre A411 D (898) Acre/ AP/ Drug 168.0 0.2715 3224.24 34206.1 88.47 BLQ  
Kmoalb-cre A420 F (898) Acre/ AP/ Drug 168.0 0.2009 6206.58 46279.9 185.61 0.87 
Kmoalb-cre A430 H (898) Acre/ AP/ Drug 168.0 0.3775 3830.42 87936.1 156.65 2.14 
Kmoalb-cre A431 J (898) Acre/ AP/ Drug 168.0 0.2822 5884.33 35532.6 41.30 BLQ  
Kmoalb-cre A436 M (898) Acre/ AP/ Drug 166.8 0.0297 14008.72 3827.2 85.99 25.13 
Kmoalb-cre A438 O (898) Acre/ AP/ Drug 168.0 0.3336 6931.66 32148.5 47.89 0.87 
Kmoalb-cre A452 X (898) Acre/ AP/ Drug 168.0 0.2866 3463.10 111982.4 130.64 13.48 
          Kmoalb-cre A415 E (V) Acre/ AP/ Vehicle 23.5 19.0379 4989.31 73.3 30.56 41.72 
Kmoalb-cre A416 G (V) Acre/ AP/ Vehicle 168.0 5.0223 2667.72 50.9 27.81 30.29 
Kmoalb-cre A421 I (V) Acre/ AP/ Vehicle 168.0 4.2415 5604.92 306.2 45.42 176.22 
Kmoalb-cre A432 K (V) Acre/ AP/ Vehicle 168.0 4.8599 3185.37 140.4 26.21 109.71 
Kmoalb-cre A439 P (V) Acre/ AP/ Vehicle 168.0 3.1421 3362.73 231.2 25.41 137.91 
Kmoalb-cre A422 S (V) Acre/ AP/ Vehicle 168.0 1.6650 5776.76 101.6 48.4 36.2 
Kmoalb-cre A440 Q (V) Acre/ AP/ Vehicle 168.0 5.0913 1174.14 125.5 21.72 21.93 
Kmoalb-cre A449 Y (V) Acre/ AP/ Vehicle 168.0 1.3855 1877.31 86.8 10 58.77 
Kmoalb-cre A450 Z (V) Acre/ AP/ Vehicle 28.9 16.2600 2005.70 145.3 53.51 11.92 
Kmoalb-cre A451 A2 (V) Acre/ AP/ Vehicle 168.0 0.9752 3458.32 90.0 26.15 22.27 
Table 106. Outcome of minipump drug study subjects (3HK levels and drug levels) 
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6.12. Appendix 12 – Supplementary data of experiment 6 (invitro studies) 
Interleukin-1β Caspase 3/7 activity / Luminescence (x105) 
Controls Metabolite 
[Metabolite] [Cytokine] Cytokine +ve. 
Stauro. 

















































100 μM 0  
pg/ml 
4.52084 13.78157 3.58971 0.00007 3.16975 3.71743 4.76679 2.85021 2.17355 2.92596 3.54205 14.02375 
4.13316 11.65738 3.79708 0.00070 4.16655 3.62444 3.92738 3.23780 2.48706 4.58372 4.23459 13.18513 
3.33285 13.16687 Error* 0.00049 3.91954 3.44549 3.41860 2.74952 3.33698 3.78585 4.01575 15.26739 
100 μM 1 
pg/ml 
3.72346 
As above  
3.44454 3.11726 2.99124 2.74328 2.46221 2.75512 3.86202 
4.27233 
3.13239 3.03451 3.64647 3.79803 3.17261 3.85693 3.06752 
3.95949 
3.31009 3.37742 3.41638 2.49636 3.66511 3.77515 4.84858 
100 μM 10 
pg/ml 
4.43283 
As above  
4.78843 3.71266 3.10181 3.23441 1.93265 2.73270 3.63376 
4.45128 4.39572 4.51193 4.47545 4.16686 2.81943 4.19463 4.55265 
4.31155 4.80572 3.94645 4.51023 3.61385 2.86270 4.24551 4.43527 
100 μM 100 
pg/ml 
10.21961 
As above  
5.24249 5.08636 4.85346 4.06290 3.56704 3.41966 5.99530 
6.52227 
5.34770 6.92992 5.91316 5.48743 4.11546 5.54658 4.15998 
6.52642 
6.73819 5.71832 6.64607 5.52757 4.77803 5.76857 7.14841 
         
500 μM 0 
pg/ml 
4.52084 
As above  
4.02666 3.39076 3.78702 1.30586 1.31768 2.79024 3.54205 
4.13316 4.04478 3.40050 4.21085 1.10663 1.93656 4.45393 4.23459 
3.33285 
3.97750 3.72198 4.38820 1.61654 1.31019 3.59489 4.01575 
500 μM 1 
pg/ml 
3.72346 
As above  
3.73670 3.82197 4.12373 2.04960 1.78012 2.98785 3.86202 
4.27233 
5.08244 4.02719 5.14803 3.67496 1.82406 4.32427 3.06752 
3.95949 
4.46899 4.12045 4.59708 1.54749 1.68085 4.07011 4.84858 
500 μM 10 
pg/ml 
4.43283 
As above  
5.57546 3.64308 4.29660 13.29273 2.31496 3.18012 3.63376 
4.45128 
3.45513 7.02186 5.15471 18.43147 3.25505 4.88688 4.55265 
4.31155 4.92433 4.30773 4.29088 15.01336 2.51909 4.61130 4.43527 
500 μM 100 
pg/ml 
10.21961 
As above  
5.87821 4.70092 8.54789 18.69304 4.75989 4.04891 5.99530 
6.52227 
6.96195 6.28324 7.59733 17.87523 7.29842 6.25252 4.15998 
6.52642 7.11467 5.55263 7.28606 16.47507 4.57057 6.00402 7.14841 
         
Table 107. Endothelial cell caspase 3/7 study – interleukin 1 beta 
17th May 2017. 6000 cells per well HMVEC-L. EBM-2. Read at 90mins 
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6.12. Appendix 12 – Supplementary data of experiment 7. Cont. 
 
IL6 Caspase 3/7 activity / Luminescence (x105) 
Controls Metabolite 











































100 μM 0  
ng/ml 
1.45951 6.11164 1.41043 0.00014 1.29548 1.44843 1.86533 1.56973 1.19997 1.60943 
1.18422 6.98263 1.11637 0.00010 1.25091 1.41314 1.52177 1.47215 0.98227 1.29450 
1.20240 7.03619 1.13740 -0.00007 1.25158 1.26066 1.38773 1.44231 0.97883 1.20314 
100 μM 100 
ng/ml 
1.30245 
As above As above As above 
1.23807 1.20071 1.75907 1.61936 1.11355 1.62422 
1.62154 1.25809 1.36754 1.34157 1.29555 0.94778 1.34147 
1.23227 1.19269 1.40536 1.21116 1.40198 0.94507 1.14247 
         
500 μM 0  
ng/ml 
1.45951 
As above As above As above 
1.82984 1.39396 1.33475 2.94793 1.32535 1.56984 
1.18422 1.37598 1.44966 1.12185 2.20497 1.05591 1.17240 
1.20240 1.37222 1.48105 1.45962 2.25986 1. 64428 1.07568 
500 μM 100 
ng/ml 
1.30245 
As above As above As above 
1.38340 1.88518 1.55738 1.62760 1.68145 1.36314 
1.62154 1.35846 1.14982 1.28088 1.69102 1.04758 1.22854 
1.23227 1.45994 1.51737 1.34351 1.91349 1.64534 1.08422 
         
Table 108. Endothelial cell caspase 3/7 study – interleukin 6 
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6.12. Appendix 12 – Supplementary data of experiment 7. Cont. 
 
IL10 Caspase 3/7 activity / Luminescence (x105) 
Controls Metabolite 











































100 μM 0 
ng/ml 
1.45951 6.11164 1.41043 0.00014 1.29548 1.44843 1.86533 1.56973 1.19997 1.60943 
1.18422 6.98263 1.11637 0.00010 1.25091 1.41314 1.52177 1.47215 0.98227 1.29450 
1.20240 7.03619 1.13740 -0.00007 1.25158 1.26066 1.38773 1.44231 0.97883 1.20314 
100 μM 100 
ng/ml 
1.53215 
As above As above As above 
1.48327 1.43523 1.79836 1.63900 1.32176 1.59740 
1.19456 1.38569 1.31803 1.33914 1.31265 1.26431 1.12407 
1.30182 1.28408 1.36905 1.25063 1.44970 0.90562 1.26572 
         
500 μM 0 
ng/ml 
1.45951 
As above As above As above 
1.82984 1.39396 1.33475 2.94793 1.32535 1.56984 
1.18422 1.37598 1.44966 1.12185 2.20497 1.05591 1.17240 
1.20240 1.37222 1.48105 1.45962 2.25986 1. 64428 1.07568 
500 μM 100 
ng/ml 
1.53215 
As above As above As above 
1.38668 1.36155 1.41497 1.68525 1.60162 1.53838 
1.19456 1.45768 1.40068 1.70539 1.86011 1.01055 1.15900 
1.30182 1.47567 1.58399 1.68472 1.71915 1.23237 1.10838 
         
Table 109. Endothelial cell caspase 3/7 study – interleukin 10 
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6.12. Appendix 12 – Supplementary data of experiment 7. Cont. 




Linear (R=12) Count % Caspase of 
Controls 
TRP 500 TRP 500 μM 0 611164 14 y = 6111.5x +14 182984 29.9386403 
TRP 100 TRP 100 μM 0 611164 14 y = 6111.5x +14 129548 21.1951239 
TRP 500 + 100 ng/ml IL6 TRP 500 μM 100 ng/ml IL6 611164 14 y = 6111.5x +14 138340 22.6337233 
TRP 100 + 100 ng/ml IL6 TRP 100 μM 100 ng/ml IL6 611164 14 y = 6111.5x +14 123807 20.2557474 
TRP 500 + 100 ng/ml IL10 TRP 500 μM 100 ng/ml IL10 611164 14 y = 6111.5x +14 138668 22.6873926 
TRP 100 + 100 ng/ml IL10 TRP 100 μM 100 ng/ml IL10 611164 14 y = 6111.5x +14 148327 24.2678557 
        
KYN 500 KYN 500 μM 0 611164 14 y = 6111.5x +14 139396 22.8065123 
KYN 100 KYN 100 μM 0 611164 14 y = 6111.5x +14 144843 23.6977829 
KYN 500 + 100 ng/ml IL6 KYN 500 μM 100 ng/ml IL6 611164 14 y = 6111.5x +14 188518 30.8441463 
KYN 100 + 100 ng/ml IL6 KYN 100 μM 100 ng/ml IL6 611164 14 y = 6111.5x +14 120071 19.6444408 
KYN 500 + 100 ng/ml IL10 KYN 500 μM 100 ng/ml IL10 611164 14 y = 6111.5x +14 136155 22.2762006 
KYN 100 + 100 ng/ml IL10 KYN 100 μM 100 ng/ml IL10 611164 14 y = 6111.5x +14 143523 23.4817966 
        
KA 500 KA 500 μM 0 611164 14 y = 6111.5x +14 133475 21.8376831 
KA 100 KA 100 μM 0 611164 14 y = 6111.5x +14 186533 30.5193488 
KA 500 + 100 ng/ml IL6 KA 500 μM 100 ng/ml IL6 611164 14 y = 6111.5x +14 155738 25.4804876 
KA 100 + 100 ng/ml IL6 KA 100 μM 100 ng/ml IL6 611164 14 y = 6111.5x +14 175907 28.7806594 
KA 500 + 100 ng/ml IL10 KA 500 μM 100 ng/ml IL10 611164 14 y = 6111.5x +14 141497 23.1502904 
KA 100 + 100 ng/ml IL10 KA 100 μM 100 ng/ml IL10 611164 14 y = 6111.5x +14 179836 29.4235458 
        3HK 500 3HK 500 μM 0 611164 14 y = 6111.5x +14 294793 48.2334942 
3HK 100 3HK 100 μM 0 611164 14 y = 6111.5x +14 156973 25.6825657 
3HK 500 + 100 ng/ml IL6 3HK 500 μM 100 ng/ml IL6 611164 14 y = 6111.5x +14 162760 26.6294690 
3HK 100 + 100 ng/ml IL6 3HK 100 μM 100 ng/ml IL6 611164 14 y = 6111.5x +14 161936 26.4946413 
3HK 500 + 100 ng/ml IL10 3HK 500 μM 100 ng/ml IL10 611164 14 y = 6111.5x +14 168525 27.5727726 
3HK 100 + 100 ng/ml IL10 3HK 100 μM 100 ng/ml IL10 611164 14 y = 6111.5x +14 163900 26.8160026 
        3HAA 500 3HAA 500 μM 0 611164 14 y = 6111.5x +14 132535 21.6838747 
3HAA 100 3HAA 100 μM 0 611164 14 y = 6111.5x +14 119997 19.6323325 
3HAA 500 + 100 ng/ml IL6 3HAA 500 μM 100 ng/ml IL6 611164 14 y = 6111.5x +14 168145 27.5105948 
3HAA 100 + 100 ng/ml IL6 3HAA 100 μM 100 ng/ml IL6 611164 14 y = 6111.5x +14 111355 18.2182770 
3HAA 500 + 100 ng/ml IL10 3HAA 500 μM 100 ng/ml IL10 611164 14 y = 6111.5x +14 160162 26.2043688 
3HAA 100 + 100 ng/ml IL10 3HAA 100 μM 100 ng/ml IL10 611164 14 y = 6111.5x +14 132176 21.6251329 
        XA 500 XA 500 μM 0 611164 14 y = 6111.5x +14 156984 25.6843655 
XA 100 XA 100 μM 0 611164 14 y = 6111.5x +14 160943 26.3321607 
XA 500 + 100 ng/ml IL6 XA 500 μM 100 ng/ml IL6 611164 14 y = 6111.5x +14 136314 22.3022171 
XA 100 + 100 ng/ml IL6 XA 100 μM 100 ng/ml IL6 611164 14 y = 6111.5x +14 162422 26.5741635 
XA 500 + 100 ng/ml IL10 XA 500 μM 100 ng/ml IL10 611164 14 y = 6111.5x +14 153838 25.1695983 
XA 100 + 100 ng/ml IL10 XA 100 μM 100 ng/ml IL10 611164 14 y = 6111.5x +14 159740 26.1353187 
        TRP 500 TRP 500 μM 0 698263 10 y = 6982.5x +10 137598 19.704690 
TRP 100 TRP 100 μM 0 698263 10 y = 6982.5x +10 125091 17.913498 
TRP 500 + 100 ng/ml IL6 TRP 500 μM 100 ng/ml IL6 698263 10 y = 6982.5x +10 135846 19.453777 
TRP 100 + 100 ng/ml IL6 TRP 100 μM 100 ng/ml IL6 698263 10 y = 6982.5x +10 125809 18.016327 
TRP 500 + 100 ng/ml IL10 TRP 500 μM 100 ng/ml IL10 698263 10 y = 6982.5x +10 145768 20.874758 
TRP 100 + 100 ng/ml IL10 TRP 100 μM 100 ng/ml IL10 698263 10 y = 6982.5x +10 138569 19.843752 
        KYN 500 KYN 500 μM 0 698263 10 y = 6982.5x +10 144966 20.759900 
KYN 100 KYN 100 μM 0 698263 10 y = 6982.5x +10 141314 20.236878 
KYN 500 + 100 ng/ml IL6 KYN 500 μM 100 ng/ml IL6 698263 10 y = 6982.5x +10 114982 16.465736 
KYN 100 + 100 ng/ml IL6 KYN 100 μM 100 ng/ml IL6 698263 10 y = 6982.5x +10 136754 19.058432 
KYN 500 + 100 ng/ml IL10 KYN 500 μM 100 ng/ml IL10 698263 10 y = 6982.5x +10 140068 20.068432 
KYN 100 + 100 ng/ml IL10 KYN 100 μM 100 ng/ml IL10 698263 10 y = 6982.5x +10 131803 18.874758 
        KA 500 KA 500 μM 0 698263 10 y = 6982.5x +10 112185 16.065163 
KA 100 KA 100 μM 0 698263 10 y = 6982.5x +10 152177 21.792624 
KA 500 + 100 ng/ml IL6 KA 500 μM 100 ng/ml IL6 698263 10 y = 6982.5x +10 128088 18.342714 
KA 100 + 100 ng/ml IL6 KA 100 μM 100 ng/ml IL6 698263 10 y = 6982.5x +10 134157 19.211887 
KA 500 + 100 ng/ml IL10 KA 500 μM 100 ng/ml IL10 698263 10 y = 6982.5x +10 170539 24.422342 
KA 100 + 100 ng/ml IL10 KA 100 μM 100 ng/ml IL10 698263 10 y = 6982.5x +10 133914 19.177086 
        3HK 500 3HK 500 μM 0 698263 10 y = 6982.5x +10 220497 31.577086 
3HK 100 3HK 100 μM 0 698263 10 y = 6982.5x +10 147215 21.081991 
3HK 500 + 100 ng/ml IL6 3HK 500 μM 100 ng/ml IL6 698263 10 y = 6982.5x +10 169102 24.216541 
3HK 100 + 100 ng/ml IL6 3HK 100 μM 100 ng/ml IL6 698263 10 y = 6982.5x +10 129555 18.552811 
3HK 500 + 100 ng/ml IL10 3HK 500 μM 100 ng/ml IL10 698263 10 y = 6982.5x +10 186011 26.638167 
3HK 100 + 100 ng/ml IL10 3HK 100 μM 100 ng/ml IL10 698263 10 y = 6982.5x +10 131265 18.797709 
        3HAA 500 3HAA 500 μM 0 698263 10 y = 6982.5x +10 105591 15.120802 
3HAA 100 3HAA 100 μM 0 698263 10 y = 6982.5x +10 098227 14.066165 
3HAA 500 + 100 ng/ml IL6 3HAA 500 μM 100 ng/ml IL6 698263 10 y = 6982.5x +10 104758 15.001504 
3HAA 100 + 100 ng/ml IL6 3HAA 100 μM 100 ng/ml IL6 698263 10 y = 6982.5x +10 094778 13.572216 
3HAA 500 + 100 ng/ml IL10 3HAA 500 μM 100 ng/ml IL10 698263 10 y = 6982.5x +10 101055 14.471178 
3HAA 100 + 100 ng/ml IL10 3HAA 100 μM 100 ng/ml IL10 698263 10 y = 6982.5x +10 126431 18.105406 
        XA 500 XA 500 μM 0 698263 10 y = 6982.5x +10 117240 16.789116 
XA 100 XA 100 μM 0 698263 10 y = 6982.5x +10 129450 18.537773 
XA 500 + 100 ng/ml IL6 XA 500 μM 100 ng/ml IL6 698263 10 y = 6982.5x +10 122854 17.593126 
XA 100 + 100 ng/ml IL6 XA 100 μM 100 ng/ml IL6 698263 10 y = 6982.5x +10 134147 19.210455 
XA 500 + 100 ng/ml IL10 XA 500 μM 100 ng/ml IL10 698263 10 y = 6982.5x +10 115900 16.597207 
XA 100 + 100 ng/ml IL10 XA 100 μM 100 ng/ml IL10 698263 10 y = 6982.5x +10 112407 16.096957 
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TRP 500 TRP 500 μM 0 703619 -7 y = 7036.3x - 7 137222 19.5030058 
TRP 100 TRP 100 μM 0 703619 -7 y = 7036.3x - 7 125158 17.7884684 
TRP 500 + 100 ng/ml IL6 TRP 500 μM 100 ng/ml IL6 703619 -7 y = 7036.3x - 7 145994 20.7496838 
TRP 100 + 100 ng/ml IL6 TRP 100 μM 100 ng/ml IL6 703619 -7 y = 7036.3x - 7 119269 16.9515228 
TRP 500 + 100 ng/ml IL10 TRP 500 μM 100 ng/ml IL10 703619 -7 y = 7036.3x - 7 147567 20.9732388 
TRP 100 + 100 ng/ml IL10 TRP 100 μM 100 ng/ml IL10 703619 -7 y = 7036.3x - 7 128408 18.2503589 
        KYN 500 KYN 500 μM 0 703619 -7 y = 7036.3x - 7 148105 21.0496994 
KYN 100 KYN 100 μM 0 703619 -7 y = 7036.3x - 7 126066 17.9175135 
KYN 500 + 100 ng/ml IL6 KYN 500 μM 100 ng/ml IL6 703619 -7 y = 7036.3x - 7 151737 21.5658798 
KYN 100 + 100 ng/ml IL6 KYN 100 μM 100 ng/ml IL6 703619 -7 y = 7036.3x - 7 140536 19.9739920 
KYN 500 + 100 ng/ml IL10 KYN 500 μM 100 ng/ml IL10 703619 -7 y = 7036.3x - 7 158399 22.5126842 
KYN 100 + 100 ng/ml IL10 KYN 100 μM 100 ng/ml IL10 703619 -7 y = 7036.3x - 7 136905 19.4579538 
        KA 500 KA 500 μM 0 703619 -7 y = 7036.3x - 7 145962 20.7451359 
KA 100 KA 100 μM 0 703619 -7 y = 7036.3x - 7 138773 19.7234342 
KA 500 + 100 ng/ml IL6 KA 500 μM 100 ng/ml IL6 703619 -7 y = 7036.3x - 7 134351 19.0949789 
KA 100 + 100 ng/ml IL6 KA 100 μM 100 ng/ml IL6 703619 -7 y = 7036.3x - 7 121116 17.2140187 
KA 500 + 100 ng/ml IL10 KA 500 μM 100 ng/ml IL10 703619 -7 y = 7036.3x - 7 168472 23.9442605 
KA 100 + 100 ng/ml IL10 KA 100 μM 100 ng/ml IL10 703619 -7 y = 7036.3x - 7 125063 17.7749670 
        3HK 500 3HK 500 μM 0 703619 -7 y = 7036.3x - 7 225986 32.1181587 
3HK 100 3HK 100 μM 0 703619 -7 y = 7036.3x - 7 144231 20.4991260 
3HK 500 + 100 ng/ml IL6 3HK 500 μM 100 ng/ml IL6 703619 -7 y = 7036.3x - 7 191349 27.1955431 
3HK 100 + 100 ng/ml IL6 3HK 100 μM 100 ng/ml IL6 703619 -7 y = 7036.3x - 7 140198 19.9259554 
3HK 500 + 100 ng/ml IL10 3HK 500 μM 100 ng/ml IL10 703619 -7 y = 7036.3x - 7 171915 24.4335801 
3HK 100 + 100 ng/ml IL10 3HK 100 μM 100 ng/ml IL10 703619 -7 y = 7036.3x - 7 144970 20.6041528 
        3HAA 500 3HAA 500 μM 0 703619 -7 y = 7036.3x - 7 164428 23.3695266 
3HAA 100 3HAA 100 μM 0 703619 -7 y = 7036.3x - 7 097883 13.9121413 
3HAA 500 + 100 ng/ml IL6 3HAA 500 μM 100 ng/ml IL6 703619 -7 y = 7036.3x - 7 164534 23.3845913 
3HAA 100 + 100 ng/ml IL6 3HAA 100 μM 100 ng/ml IL6 703619 -7 y = 7036.3x - 7 094507 13.4323437 
3HAA 500 + 100 ng/ml IL10 3HAA 500 μM 100 ng/ml IL10 703619 -7 y = 7036.3x - 7 123237 17.5154556 
3HAA 100 + 100 ng/ml IL10 3HAA 100 μM 100 ng/ml IL10 703619 -7 y = 7036.3x - 7 090562 12.8716797 
        XA 500 XA 500 μM 0 703619 -7 y = 7036.3x - 7 107568 15.2885750 
XA 100 XA 100 μM 0 703619 -7 y = 7036.3x - 7 120314 17.1000384 
XA 500 + 100 ng/ml IL6 XA 500 μM 100 ng/ml IL6 703619 -7 y = 7036.3x - 7 108422 15.4099456 
XA 100 + 100 ng/ml IL6 XA 100 μM 100 ng/ml IL6 703619 -7 y = 7036.3x - 7 114247 16.2377954 
XA 500 + 100 ng/ml IL10 XA 500 μM 100 ng/ml IL10 703619 -7 y = 7036.3x - 7 110838 15.7533078 
XA 100 + 100 ng/ml IL10 XA 100 μM 100 ng/ml IL10 703619 -7 y = 7036.3x – 7 126572 17.9894263 
        TRP 500 TRP 500 μM 0 1348335 7 y = 13483x + 7 402666 29.8641994 
TRP 100 TRP 100 μM 0 1348335 7 y = 13483x + 7 316975 23.5087147 
TRP 500 + 10 pg/ml IL1β TRP 500 μM 10 IL1β 1348335 7 y = 13483x + 7 557546 41.3512571 
TRP 100 + 10 pg/ml IL1β TRP 100 μM 10 IL1β 1348335 7 y = 13483x + 7 478843 35.5140547 
TRP 500 + 100 pg/ml IL1β TRP 500 μM 100 IL1β 1348335 7 y = 13483x + 7 587821 43.5966773 
TRP 100 + 100 pg/ml IL1β TRP 100 μM 100 IL1β 1348335 7 y = 13483x + 7 524249 38.8817029 
        KYN 500 KYN 500 μM 0 1348335 7 y = 13483x + 7 339076 25.1478899 
KYN 100 KYN 100 μM 0 1348335 7 y = 13483x + 7 371743 27.5707187 
KYN 500 + 10 pg/ml IL1β KYN 500 μM 10 pg/ml IL1β 1348335 7 y = 13483x + 7 364308 27.0192835 
KYN 100 + 10 pg/ml IL1β KYN 100 μM 10 pg/ml IL1β 1348335 7 y = 13483x + 7 371266 27.5353408 
KYN 500 + 100 pg/ml IL1β KYN 500 μM 100 pg/ml IL1β 1348335 7 y = 13483x + 7 470092 34.8650152 
KYN 100 + 100 pg/ml IL1β KYN 100 μM 100 pg/ml IL1β 1348335 7 y = 13483x + 7 508636 37.7237262 
        KA 500 KA 500 μM 0 1348335 7 y = 13483x + 7 378702 28.0868501 
KA 100 KA 100 μM 0 1348335 7 y = 13483x + 7 476679 35.3535563 
KA 500 + 10 pg/ml IL1β KA 500 μM 10 pg/ml IL1β 1348335 7 y = 13483x + 7 429660 31.8662761 
KA 100 + 10 pg/ml IL1β KA 100 μM 10 pg/ml IL1β 1348335 7 y = 13483x + 7 310181 23.0048209 
KA 500 + 100 pg/ml IL1β KA 500 μM 100 pg/ml IL1β 1348335 7 y = 13483x + 7 854789 63.3970185 
KA 100 + 100 pg/ml IL1β KA 100 μM 100 pg/ml IL1β 1348335 7 y = 13483x + 7 485346 35.9963658 
        3HK 500 3HK 500 μM 0 1348335 7 y = 13483x + 7 130586 9.68471408 
3HK 100 3HK 100 μM 0 1348335 7 y = 13483x + 7 285021 21.1387673 
3HK 500 + 10 pg/ml IL1β 3HK 500 μM 10 pg/ml IL1β 1348335 7 y = 13483x + 7 1329273 98.5882964 
3HK 100 + 10 pg/ml IL1β 3HK 100 μM 10 pg/ml IL1β 1348335 7 y = 13483x + 7 323441 23.9882815 
3HK 500 + 100 pg/ml IL1β 3HK 500 μM 100 pg/ml IL1β 1348335 7 y = 13483x + 7 1869304 138.641029 
3HK 100 + 100 pg/ml IL1β 3HK 100 μM 100 pg/ml IL1β 1348335 7 y = 13483x + 7 406290 30.1329823 
        3HAA 500 3HAA 500 μM 0 1348335 7 y = 13483x + 7 131768 9.77238003 
3HAA 100 3HAA 100 μM 0 1348335 7 y = 13483x + 7 217355 16.1201513 
3HAA 500 + 10 pg/ml IL1β 3HAA 500 μM 10 pg/ml IL1β 1348335 7 y = 13483x + 7 231496 17.1689535 
3HAA 100 + 10 pg/ml IL1β 3HAA 100 μM 10 pg/ml IL1β 1348335 7 y = 13483x + 7 193265 14.3334569 
3HAA 500 + 100 pg/ml IL1β 3HAA 500 μM 100 pg/ml IL1β 1348335 7 y = 13483x + 7 475989 35.3023808 
3HAA 100 + 100 pg/ml IL1β 3HAA 100 μM 100 pg/ml IL1β 1348335 7 y = 13483x + 7 356704 26.4553141 
        XA 500 XA 500 μM 0 1348335 7 y = 13483x + 7 279024 20.6939850 
XA 100 XA 100 μM 0 1348335 7 y = 13483x + 7 292596 21.7005859 
XA 500 + 10 pg/ml IL1β XA 500 μM 10 pg/ml IL1β 1348335 7 y = 13483x + 7 318012 23.5856263 
XA 100 + 10 pg/ml IL1β XA 100 μM 10 pg/ml IL1β 1348335 7 y = 13483x + 7 273270 20.2672254 
XA 500 + 100 pg/ml IL1β XA 500 μM 100 pg/ml IL1β 1348335 7 y = 13483x + 7 404891 30.0292220 
XA 100 + 100 pg/ml IL1β XA 100 μM 100 pg/ml IL1β 1348335 7 y = 13483x + 7 341966 25.3622339 
        TRP 500 TRP 500 μM 0 1359531 70 y = 13595x + 70 404478 29.7468187 
TRP 100 TRP 100 μM 0 1359531 70 y = 13595x + 70 416655 30.6425156 
TRP 500 + 10 pg/ml IL1β TRP 500 μM 10 pg/ml IL1β 1359531 70 y = 13595x + 70 345513 25.4095623 
TRP 100 + 10 pg/ml IL1β TRP 100 μM 10 pg/ml IL1β 1359531 70 y = 13595x + 70 439572 32.3282089 
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TRP 500 + 100 pg/ml IL1β TRP 500 μM 100 pg/ml IL1β 1359531 70 y = 13595x + 70 696195 51.2044869 
TRP 100 + 100 pg/ml IL1β TRP 100 μM 100 pg/ml IL1β 1359531 70 y = 13595x + 70 534770 39.3306363 
        KYN 500 KYN 500 μM 0 1359531 70 y = 13595x + 70 340050 25.0077234 
KYN 100 KYN 100 μM 0 1359531 70 y = 13595x + 70 362444 26.6549467 
KYN 500 + 10 pg/ml IL1β KYN 500 μM 10 pg/ml IL1β 1359531 70 y = 13595x + 70 702186 51.6451637 
KYN 100 + 10 pg/ml IL1β KYN 100 μM 10 pg/ml IL1β 1359531 70 y = 13595x + 70 451193 33.1830085 
KYN 500 + 100 pg/ml IL1β KYN 500 μM 100 pg/ml IL1β 1359531 70 y = 13595x + 70 628324 46.2121368 
KYN 100 + 100 pg/ml IL1β KYN 100 μM 100 pg/ml IL1β 1359531 70 y = 13595x + 70 692992 50.9688856 
        KA 500 KA 500 μM 0 1359531 70 y = 13595x + 70 421085 30.9683707 
KA 100 KA 100 μM 0 1359531 70 y = 13595x + 70 392738 28.8832659 
KA 500 + 10 pg/ml IL1β KA 500 μM 10 pg/ml IL1β 1359531 70 y = 13595x + 70 515471 37.9110702 
KA 100 + 10 pg/ml IL1β KA 100 μM 10 pg/ml IL1β 1359531 70 y = 13595x + 70 447545 32.9146745 
KA 500 + 100 pg/ml IL1β KA 500 μM 100 pg/ml IL1β 1359531 70 y = 13595x + 70 759733 55.8781170 
KA 100 + 100 pg/ml IL1β KA 100 μM 100 pg/ml IL1β 1359531 70 y = 13595x + 70 591316 43.4899595 
        3HK 500 3HK 500 μM 0 1359531 70 y = 13595x + 70 110663 8.13482898 
3HK 100 3HK 100 μM 0 1359531 70 y = 13595x + 70 323780 23.8109599 
3HK 500 + 10 pg/ml IL1β 3HK 500 μM 10 pg/ml IL1β 1359531 70 y = 13595x + 70 1843147 135.5702100 
3HK 100 + 10 pg/ml IL1β 3HK 100 μM 10 pg/ml IL1β 1359531 70 y = 13595x + 70 416686 30.6447959 
3HK 500 + 100 pg/ml IL1β 3HK 500 μM 100 pg/ml IL1β 1359531 70 y = 13595x + 70 1787523 131.4787050 
3HK 100 + 100 pg/ml IL1β 3HK 100 μM 100 pg/ml IL1β 1359531 70 y = 13595x + 70 548743 40.3584406 
        3HAA 500 3HAA 500 μM 0 1359531 70 y = 13595x + 70 193656 14.2394998 
3HAA 100 3HAA 100 μM 0 1359531 70 y = 13595x + 70 248706 18.2887826 
3HAA 500 + 10 pg/ml IL1β 3HAA 500 μM 10 pg/ml IL1β 1359531 70 y = 13595x + 70 325505 23.9378448 
3HAA 100 + 10 pg/ml IL1β 3HAA 100 μM 10 pg/ml IL1β 1359531 70 y = 13595x + 70 281943 20.7335785 
3HAA 500 + 100 pg/ml IL1β 3HAA 500 μM 100 pg/ml IL1β 1359531 70 y = 13595x + 70 729841 53.6793674 
3HAA 100 + 100 pg/ml IL1β 3HAA 100 μM 100 pg/ml IL1β 1359531 70 y = 13595x + 70 411546 30.2667157 
        XA 500 XA 500 μM 0 1359531 70 y = 13595x + 70 445393 32.7563810 
XA 100 XA 100 μM 0 1359531 70 y = 13595x + 70 458372 33.7110702 
XA 500 + 10 pg/ml IL1β XA 500 μM 10 pg/ml IL1β 1359531 70 y = 13595x + 70 488688 35.9410077 
XA 100 + 10 pg/ml IL1β XA 100 μM 10 pg/ml IL1β 1359531 70 y = 13595x + 70 419463 30.8490622 
XA 500 + 100 pg/ml IL1β XA 500 μM 100 pg/ml IL1β 1359531 70 y = 13595x + 70 625252 45.9861714 
XA 100 + 100 pg/ml IL1β XA 100 μM 100 pg/ml IL1β 1359531 70 y = 13595x + 70 554658 40.793527 
        TRP 500 TRP 500 μM 0 1346238.5 49 y = 13462x + 49 397750 29.5424900 
TRP 100 TRP 100 μM 0 1346238.5 49 y = 13462x + 49 391954 29.1119447 
TRP 500 + 10 pg/ml IL1β TRP 500 μM 10 pg/ml IL1β 1346238.5 49 y = 13462x + 49 492433 36.5758431 
TRP 100 + 10 pg/ml IL1β TRP 100 μM 10 pg/ml IL1β 1346238.5 49 y = 13462x + 49 480572 35.6947705 
TRP 500 + 100 pg/ml IL1β TRP 500 μM 100 pg/ml IL1β 1346238.5 49 y = 13462x + 49 711467 52.8463824 
TRP 100 + 100 pg/ml IL1β TRP 100 μM 100 pg/ml IL1β 1346238.5 49 y = 13462x + 49 673819 50.0497697 
        KYN 500 KYN 500 μM 0 1346238.5 49 y = 13462x + 49 372198 27.6444065 
KYN 100 KYN 100 μM 0 1346238.5 49 y = 13462x + 49 344549 25.5905512 
KYN 500 + 10 pg/ml IL1β KYN 500 μM 10 pg/ml IL1β 1346238.5 49 y = 13462x + 49 430773 31.995543 
KYN 100 + 10 pg/ml IL1β KYN 100 μM 10 pg/ml IL1β 1346238.5 49 y = 13462x + 49 394645 29.3118407 
KYN 500 + 100 pg/ml IL1β KYN 500 μM 100 pg/ml IL1β 1346238.5 49 y = 13462x + 49 555263 41.2430545 
KYN 100 + 100 pg/ml IL1β KYN 100 μM 100 pg/ml IL1β 1346238.5 49 y = 13462x + 49 571832 42.4738523 
        KA 500 KA 500 μM 0 1346238.5 49 y = 13462x + 49 438820 32.5932997 
KA 100 KA 100 μM 0 1346238.5 49 y = 13462x + 49 341860 25.3908037 
KA 500 + 10 pg/ml IL1β KA 500 μM 10 pg/ml IL1β 1346238.5 49 y = 13462x + 49 429088 31.8703759 
KA 100 + 10 pg/ml IL1β KA 100 μM 10 pg/ml IL1β 1346238.5 49 y = 13462x + 49 451023 33.4997772 
KA 500 + 100 pg/ml IL1β KA 500 μM 100 pg/ml IL1β 1346238.5 49 y = 13462x + 49 728606 54.1195216 
KA 100 + 100 pg/ml IL1β KA 100 μM 100 pg/ml IL1β 1346238.5 49 y = 13462x + 49 664607 49.3654732 
        3HK 500 3HK 500 μM 0 1346238.5 49 y = 13462x + 49 161654 12.0045313 
3HK 100 3HK 100 μM 0 1346238.5 49 y = 13462x + 49 274952 20.4206656 
3HK 500 + 10 pg/ml IL1β 3HK 500 μM 10 pg/ml IL1β 1346238.5 49 y = 13462x + 49 1501336 111.520354 
3HK 100 + 10 pg/ml IL1β 3HK 100 μM 10 pg/ml IL1β 1346238.5 49 y = 13462x + 49 361385 26.8411826 
3HK 500 + 100 pg/ml IL1β 3HK 500 μM 100 pg/ml IL1β 1346238.5 49 y = 13462x + 49 1647507 122.378398 
3HK 100 + 100 pg/ml IL1β 3HK 100 μM 100 pg/ml IL1β 1346238.5 49 y = 13462x + 49 552757 41.0569009 
        3HAA 500 3HAA 500 μM 0 1346238.5 49 y = 13462x + 49 131019 9.72886644 
3HAA 100 3HAA 100 μM 0 1346238.5 49 y = 13462x + 49 333698 24.7845045 
3HAA 500 + 10 pg/ml IL1β 3HAA 500 μM 10 pg/ml IL1β 1346238.5 49 y = 13462x + 49 251909 18.7089585 
3HAA 100 + 10 pg/ml IL1β 3HAA 100 μM 10 pg/ml IL1β 1346238.5 49 y = 13462x + 49 286270 21.2614025 
3HAA 500 + 100 pg/ml IL1β 3HAA 500 μM 100 pg/ml IL1β 1346238.5 49 y = 13462x + 49 457057 33.9480018 
3HAA 100 + 100 pg/ml IL1β 3HAA 100 μM 100 pg/ml IL1β 1346238.5 49 y = 13462x + 49 477803 35.4890804 
        XA 500 XA 500 μM 0 1346238.5 49 y = 13462x + 49 359489 26.7003417 
XA 100 XA 100 μM 0 1346238.5 49 y = 13462x + 49 378585 28.1188531 
XA 500 + 10 pg/ml IL1β XA 500 μM 10 pg/ml IL1β 1346238.5 49 y = 13462x + 49 461130 34.2505571 
XA 100 + 10 pg/ml IL1β XA 100 μM 10 pg/ml IL1β 1346238.5 49 y = 13462x + 49 424551 31.5333531 
XA 500 + 100 pg/ml IL1β XA 500 μM 100 pg/ml IL1β 1346238.5 49 y = 13462x + 49 600402 44.5961224 
XA 100 + 100 pg/ml IL1β XA 100 μM 100 pg/ml IL1β 1346238.5 49 y = 13462x + 49 576857 42.8471252 
        
Table 110. Endothelial cell caspase 3/7 study – data conversion to relative percentage of controls 
Staurosporin 10 μM was used for positive control for caspase 3/7 activation. Negative control to gauge absence of 
luminescence was a ‘no caspase reagent’ reading of wells containing cells, medium and DMSO. 
 
Staurosporin 10 μM was used for positive control for caspase 3/7 activation. 
 
 
